{"29cfb4937683fda69196fa3505530a572ce40333": [["increasing number of recovered patients discharged from hospital by regular follow-up and medical observation, some medical professionals were found to be positive for COVID-19 after hospital discharge [5] , and more attention should be paid to the follow-up of non-medical patients.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 274, 282], ["COVID", "TEST", 168, 173]]]], "50c1c7e04ad2bc4d6bea24917e2d82a0f8950e30": [["IntroductionDeep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively known as venous thromboembolism (VTE).", [["IntroductionDeep vein", "ANATOMY", 0, 21], ["pulmonary", "ANATOMY", 43, 52], ["venous", "ANATOMY", 93, 99], ["IntroductionDeep vein thrombosis", "DISEASE", 0, 32], ["DVT", "DISEASE", 34, 37], ["pulmonary embolism", "DISEASE", 43, 61], ["PE", "DISEASE", 63, 65], ["venous thromboembolism", "DISEASE", 93, 115], ["VTE", "DISEASE", 117, 120], ["IntroductionDeep vein", "MULTI-TISSUE_STRUCTURE", 0, 21], ["pulmonary", "ORGAN", 43, 52], ["venous", "MULTI-TISSUE_STRUCTURE", 93, 99], ["IntroductionDeep vein thrombosis", "PROBLEM", 0, 32], ["DVT)", "PROBLEM", 34, 38], ["pulmonary embolism", "PROBLEM", 43, 61], ["PE", "PROBLEM", 63, 65], ["venous thromboembolism (VTE", "PROBLEM", 93, 120], ["vein", "ANATOMY", 17, 21], ["thrombosis", "OBSERVATION", 22, 32], ["DVT", "OBSERVATION", 34, 37], ["pulmonary", "ANATOMY", 43, 52], ["embolism", "OBSERVATION", 53, 61], ["PE", "OBSERVATION", 63, 65], ["venous", "ANATOMY", 93, 99], ["thromboembolism", "OBSERVATION", 100, 115]]], ["PE is categorized as acute pulmonary embolism (APE) and chronic thromboembolic pulmonary hypertension (CTEPH).", [["pulmonary", "ANATOMY", 27, 36], ["pulmonary", "ANATOMY", 79, 88], ["PE", "DISEASE", 0, 2], ["acute pulmonary embolism", "DISEASE", 21, 45], ["APE", "DISEASE", 47, 50], ["chronic thromboembolic pulmonary hypertension", "DISEASE", 56, 101], ["CTEPH", "DISEASE", 103, 108], ["pulmonary", "ORGAN", 27, 36], ["pulmonary", "ORGAN", 79, 88], ["PE", "PROBLEM", 0, 2], ["acute pulmonary embolism", "PROBLEM", 21, 45], ["chronic thromboembolic pulmonary hypertension", "PROBLEM", 56, 101], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["pulmonary", "ANATOMY", 27, 36], ["embolism", "OBSERVATION", 37, 45], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["thromboembolic", "OBSERVATION", 64, 78], ["pulmonary", "ANATOMY", 79, 88], ["hypertension", "OBSERVATION", 89, 101], ["CTEPH", "OBSERVATION", 103, 108]]], ["PE is a major health problem, with a high incidence, mortality, misdiagnosis and miss diagnosis rate [1] .", [["PE", "DISEASE", 0, 2], ["PE", "PROBLEM", 0, 2]]], ["VTE risk factors can be classified as either acquired or inherited, and most of them are acquired.", [["VTE", "DISEASE", 0, 3], ["VTE risk factors", "PROBLEM", 0, 16]]], ["The American College of Chest Physicians (ACCP) has published guidelines for the prevention, diagnosis, and treatment of VTE in surgical patients since 1995 [2] .", [["VTE", "DISEASE", 121, 124], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["VTE", "PROBLEM", 121, 124], ["Chest", "ANATOMY", 24, 29]]], ["However, the incidence of symptomatic VTE was increasing instead of reducing [4] , probably because the pathogenesis of VTE is still unclear.IntroductionSmeeth et al. [5] have reported that acute infections were associated with an increased risk of VTE.", [["VTE", "DISEASE", 38, 41], ["VTE", "DISEASE", 120, 123], ["acute infections", "DISEASE", 190, 206], ["VTE", "DISEASE", 249, 252], ["symptomatic VTE", "PROBLEM", 26, 41], ["VTE", "PROBLEM", 120, 123], ["acute infections", "PROBLEM", 190, 206], ["VTE", "PROBLEM", 249, 252], ["symptomatic", "OBSERVATION_MODIFIER", 26, 37], ["VTE", "OBSERVATION", 38, 41], ["VTE", "OBSERVATION", 120, 123], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["infections", "OBSERVATION", 196, 206], ["increased", "OBSERVATION_MODIFIER", 231, 240], ["VTE", "OBSERVATION", 249, 252]]], ["Previously, we reported that VTE was found in multiple organs including the lungs, spleen, pancreas, kidneys, and adrenal glands from a patient who died of severe acute respiratory syndrome [6] .", [["organs", "ANATOMY", 55, 61], ["lungs", "ANATOMY", 76, 81], ["spleen", "ANATOMY", 83, 89], ["pancreas", "ANATOMY", 91, 99], ["kidneys", "ANATOMY", 101, 108], ["adrenal glands", "ANATOMY", 114, 128], ["VTE", "DISEASE", 29, 32], ["acute respiratory syndrome", "DISEASE", 163, 189], ["organs", "ORGAN", 55, 61], ["lungs", "ORGAN", 76, 81], ["spleen", "ORGAN", 83, 89], ["pancreas", "ORGAN", 91, 99], ["kidneys", "ORGAN", 101, 108], ["adrenal glands", "ORGAN", 114, 128], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["VTE", "PROBLEM", 29, 32], ["multiple organs including the lungs, spleen, pancreas, kidneys, and adrenal glands", "PROBLEM", 46, 128], ["severe acute respiratory syndrome", "PROBLEM", 156, 189], ["VTE", "OBSERVATION", 29, 32], ["lungs", "ANATOMY", 76, 81], ["spleen", "ANATOMY", 83, 89], ["pancreas", "ANATOMY", 91, 99], ["kidneys", "ANATOMY", 101, 108], ["adrenal glands", "ANATOMY", 114, 128], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory syndrome", "OBSERVATION", 169, 189]]], ["In addition, our previous study showed significantly down-regulated mRNA expression of genes associated with natural killer (NK) cells and T cells in patients with symptomatic PE [7] , and declined cellular immune function in patients with acute PE and CTEPH respectively [8, 9] .", [["natural killer (NK) cells", "ANATOMY", 109, 134], ["T cells", "ANATOMY", 139, 146], ["cellular", "ANATOMY", 198, 206], ["PE", "DISEASE", 176, 178], ["PE", "DISEASE", 246, 248], ["CTEPH", "DISEASE", 253, 258], ["natural killer (NK) cells", "CELL", 109, 134], ["T cells", "CELL", 139, 146], ["patients", "ORGANISM", 150, 158], ["cellular", "CELL", 198, 206], ["patients", "ORGANISM", 226, 234], ["natural killer (NK) cells", "CELL_TYPE", 109, 134], ["T cells", "CELL_TYPE", 139, 146], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 226, 234], ["our previous study", "TEST", 13, 31], ["significantly down-regulated mRNA expression of genes", "PROBLEM", 39, 92], ["T cells", "PROBLEM", 139, 146], ["symptomatic PE", "PROBLEM", 164, 178], ["acute PE", "PROBLEM", 240, 248], ["CTEPH", "TEST", 253, 258], ["symptomatic", "OBSERVATION_MODIFIER", 164, 175], ["PE", "OBSERVATION", 176, 178], ["immune function", "OBSERVATION", 207, 222], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["PE", "OBSERVATION", 246, 248]]], ["These previous studies indicate that the occurrence and progress of symptomatic PE are closely associated with both the innate and adaptive immunity.IntroductionThe complement system plays an important role in both the innate and adaptive immune systems to defense against pathogens [10] .", [["PE", "DISEASE", 80, 82], ["These previous studies", "TEST", 0, 22], ["symptomatic PE", "PROBLEM", 68, 82], ["adaptive immune systems", "TREATMENT", 230, 253], ["pathogens", "PROBLEM", 273, 282], ["symptomatic", "OBSERVATION_MODIFIER", 68, 79], ["PE", "OBSERVATION", 80, 82]]], ["It is composed of more than 30 different proteins, including complement components, receptors and regulators.", [["complement components", "PROTEIN", 61, 82], ["receptors and regulators", "PROTEIN", 84, 108]]], ["Therefore, in the present study, human microarray analysis was used to examine the mRNA expression of the complement components, receptors and regulators in PBMCs isolated Thrombosis Research 132 (2013) e54-e57 from symptomatic PE patients and controls.", [["PBMCs", "ANATOMY", 157, 162], ["Thrombosis", "DISEASE", 172, 182], ["PE", "DISEASE", 228, 230], ["human", "ORGANISM", 33, 38], ["PBMCs", "CELL", 157, 162], ["patients", "ORGANISM", 231, 239], ["complement components", "PROTEIN", 106, 127], ["PBMCs", "CELL_TYPE", 157, 162], ["human", "SPECIES", 33, 38], ["patients", "SPECIES", 231, 239], ["human", "SPECIES", 33, 38], ["human microarray analysis", "TEST", 33, 58], ["PBMCs", "TEST", 157, 162], ["Thrombosis Research", "TEST", 172, 191], ["symptomatic PE patients and controls", "PROBLEM", 216, 252], ["Thrombosis", "OBSERVATION", 172, 182], ["symptomatic", "OBSERVATION_MODIFIER", 216, 227], ["PE", "OBSERVATION", 228, 230]]], ["We designed this in vitro study to investigate the changes in the function of the complement system in patients with symptomatic PE.PatientsTwenty patients with PE were recruited from Tongji Hospital of Tongji University from 2007 to 2008.", [["PE", "DISEASE", 129, 131], ["PE", "DISEASE", 161, 163], ["patients", "ORGANISM", 103, 111], ["Patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 103, 111], ["Patients", "SPECIES", 132, 140], ["patients", "SPECIES", 147, 155], ["vitro study", "TEST", 20, 31], ["the changes", "PROBLEM", 47, 58], ["symptomatic PE", "PROBLEM", 117, 131], ["PE", "PROBLEM", 161, 163], ["symptomatic", "OBSERVATION_MODIFIER", 117, 128], ["PE", "OBSERVATION", 129, 131], ["PE", "OBSERVATION", 161, 163]]], ["A diagnosis of PE required any two of the following three criteria: 1) Selectivity pulmonary angiography shows pulmonary artery obstruction or filling defect; 2) Lung ventilation/perfusion scan shows single or multiple blood perfusion defect, normal or abnormal ventilation, and V/Q does not match.", [["pulmonary", "ANATOMY", 83, 92], ["pulmonary artery", "ANATOMY", 111, 127], ["Lung", "ANATOMY", 162, 166], ["blood", "ANATOMY", 219, 224], ["PE", "DISEASE", 15, 17], ["pulmonary artery obstruction", "DISEASE", 111, 139], ["pulmonary", "ORGAN", 83, 92], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 111, 127], ["Lung", "ORGAN", 162, 166], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["PE", "PROBLEM", 15, 17], ["Selectivity pulmonary angiography", "TEST", 71, 104], ["pulmonary artery obstruction", "PROBLEM", 111, 139], ["filling defect", "PROBLEM", 143, 157], ["Lung ventilation/perfusion scan", "TEST", 162, 193], ["single or multiple blood perfusion defect", "PROBLEM", 200, 241], ["abnormal ventilation", "PROBLEM", 253, 273], ["PE", "OBSERVATION", 15, 17], ["pulmonary", "ANATOMY", 83, 92], ["pulmonary artery", "ANATOMY", 111, 127], ["obstruction", "OBSERVATION", 128, 139], ["filling defect", "OBSERVATION", 143, 157], ["Lung", "ANATOMY", 162, 166], ["ventilation", "OBSERVATION", 167, 178], ["multiple", "OBSERVATION_MODIFIER", 210, 218], ["blood perfusion defect", "OBSERVATION", 219, 241], ["normal", "OBSERVATION", 243, 249], ["abnormal ventilation", "OBSERVATION", 253, 273]]], ["3) Clinical diagnosis: there are risk factors for PE and other cardiovascular diseases can be excluded by clinical performance, electrocardiogram and chest film, arterial blood gas analysis suggests hypoxemia and hypocapnia, and D-dimer detection, echocardiography, chest computed tomography support PE diagnosis.", [["cardiovascular", "ANATOMY", 63, 77], ["arterial blood", "ANATOMY", 162, 176], ["PE", "DISEASE", 50, 52], ["cardiovascular diseases", "DISEASE", 63, 86], ["hypoxemia", "DISEASE", 199, 208], ["hypocapnia", "DISEASE", 213, 223], ["arterial", "MULTI-TISSUE_STRUCTURE", 162, 170], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["D-dimer", "SIMPLE_CHEMICAL", 229, 236], ["risk factors", "PROBLEM", 33, 45], ["PE", "PROBLEM", 50, 52], ["other cardiovascular diseases", "PROBLEM", 57, 86], ["clinical performance", "TEST", 106, 126], ["electrocardiogram", "TEST", 128, 145], ["chest film", "TEST", 150, 160], ["arterial blood gas analysis", "TEST", 162, 189], ["hypoxemia", "PROBLEM", 199, 208], ["hypocapnia", "PROBLEM", 213, 223], ["D-dimer detection", "TEST", 229, 246], ["echocardiography", "TEST", 248, 264], ["chest computed tomography", "TEST", 266, 291], ["PE", "OBSERVATION", 50, 52], ["cardiovascular", "ANATOMY", 63, 77], ["diseases", "OBSERVATION", 78, 86], ["chest", "ANATOMY", 150, 155], ["hypoxemia", "OBSERVATION", 199, 208], ["hypocapnia", "OBSERVATION", 213, 223], ["chest", "ANATOMY", 266, 271], ["PE", "OBSERVATION", 300, 302]]], ["We chose twenty patients admitted in our department of cardiology at the same time as control in the study.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["the study", "TEST", 97, 106]]], ["The patients were divided into two groups: 1) PE patient group: 20 patients (11 males and 9 females), with a mean age of 70 \u00b1 14 (44~89) yr, include 3 cases of CTEPH; 2) Control group: 20 patients (11 males and 9 females) without PE, DVT, arterial thrombosis, and congenital coagulation abnormality, mean age with a mean age of 72 \u00b1 14(44~91) yr, which were matched in sex and age with the PE group.", [["arterial", "ANATOMY", 239, 247], ["CTEPH", "DISEASE", 160, 165], ["PE", "DISEASE", 230, 232], ["DVT", "DISEASE", 234, 237], ["arterial thrombosis", "DISEASE", 239, 258], ["congenital coagulation abnormality", "DISEASE", 264, 298], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 49, 56], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 188, 196], ["arterial", "MULTI-TISSUE_STRUCTURE", 239, 247], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 49, 56], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 188, 196], ["CTEPH", "PROBLEM", 160, 165], ["PE", "PROBLEM", 230, 232], ["DVT", "PROBLEM", 234, 237], ["arterial thrombosis", "PROBLEM", 239, 258], ["congenital coagulation abnormality", "PROBLEM", 264, 298], ["the PE group", "PROBLEM", 386, 398], ["PE", "OBSERVATION", 46, 48], ["without", "UNCERTAINTY", 222, 229], ["PE", "OBSERVATION", 230, 232], ["DVT", "OBSERVATION", 234, 237], ["arterial", "ANATOMY", 239, 247], ["thrombosis", "OBSERVATION", 248, 258], ["congenital", "OBSERVATION_MODIFIER", 264, 274], ["coagulation", "OBSERVATION", 275, 286], ["PE", "OBSERVATION", 390, 392]]], ["There was no significant statistical difference between the age of the two groups (P > 0.05).", [["P", "TEST", 83, 84], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["statistical", "OBSERVATION_MODIFIER", 25, 36], ["difference", "OBSERVATION", 37, 47]]], ["The clinical trial has been approved by the Ethics Committee of Tongji University, and informed consent form was also obtained.Gene Expression ProfilingAgilent G4112A Whole Human Genome Oligo Microarrays were purchased from Agilent (USA).", [["Human", "ORGANISM", 173, 178], ["Human", "SPECIES", 173, 178], ["Human", "SPECIES", 173, 178], ["Whole Human Genome Oligo Microarrays", "TREATMENT", 167, 203]]], ["A microarray is composed of 44,290 spots including 41675 genes or transcripts, 314 negative control spots, 1924 positive control spots and 359 blank spots.", [["41675 genes", "DNA", 51, 62], ["A microarray", "TEST", 0, 12], ["blank spots", "TEST", 143, 154], ["blank spots", "OBSERVATION", 143, 154]]], ["All patients were subjected to microarray analysis.Gene Expression ProfilingTotal RNA Isolation 5 ml of peripheral blood samples anti-coagulated with EDTA were drawn from patients suspected with PE immediately after admitting to the hospital and from those patients without PE, respectively.", [["peripheral blood samples", "ANATOMY", 104, 128], ["PE", "DISEASE", 274, 276], ["EDTA", "CHEMICAL", 150, 154], ["patients", "ORGANISM", 4, 12], ["peripheral blood samples", "ORGANISM_SUBSTANCE", 104, 128], ["EDTA", "SIMPLE_CHEMICAL", 150, 154], ["patients", "ORGANISM", 171, 179], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 171, 179], ["patients", "SPECIES", 257, 265], ["microarray analysis", "TEST", 31, 50], ["Gene Expression ProfilingTotal RNA Isolation", "TREATMENT", 51, 95], ["peripheral blood samples", "TEST", 104, 128], ["EDTA", "TREATMENT", 150, 154], ["PE", "PROBLEM", 195, 197], ["PE", "PROBLEM", 274, 276], ["PE", "OBSERVATION", 195, 197], ["PE", "OBSERVATION", 274, 276]]], ["Mononuclear cells were obtained through density gradient centrifugation with Ficoll solution and remaining red blood cells were destroyed with erythrocyte lysis buffer (Qiagen, Hilden, Germany).", [["Mononuclear cells", "ANATOMY", 0, 17], ["red blood cells", "ANATOMY", 107, 122], ["erythrocyte", "ANATOMY", 143, 154], ["Mononuclear cells", "CELL", 0, 17], ["red blood cells", "CELL", 107, 122], ["erythrocyte", "CELL", 143, 154], ["Mononuclear cells", "CELL_TYPE", 0, 17], ["red blood cells", "CELL_TYPE", 107, 122], ["Mononuclear cells", "TEST", 0, 17], ["density gradient centrifugation", "TREATMENT", 40, 71], ["Ficoll solution", "TREATMENT", 77, 92], ["remaining red blood cells", "TREATMENT", 97, 122], ["erythrocyte lysis buffer", "TREATMENT", 143, 167], ["erythrocyte lysis", "OBSERVATION", 143, 160]]], ["Total mononuclear cell RNA was extracted with TRIzol(Invitrogen, Carlsbad, USA) and purified with Qiagen RNeasy column (Qiagen, Hilden, Germany) according to the manufacturer's instructions.", [["mononuclear cell", "ANATOMY", 6, 22], ["mononuclear cell", "CELL", 6, 22], ["mononuclear cell RNA", "RNA", 6, 26], ["Total mononuclear cell RNA", "TEST", 0, 26], ["TRIzol", "TREATMENT", 46, 52], ["Invitrogen", "TREATMENT", 53, 63], ["Qiagen RNeasy column", "TREATMENT", 98, 118], ["mononuclear cell RNA", "OBSERVATION", 6, 26]]], ["Isolated total RNA was testified and quantified by means of Nanodrop ND-1000 spectrophotometer (Nanodrop Technology, Cambrige, UK).Detection of Gene ExpressionAbout 1 \u03bcg of total RNA was reversely transcribed into double strand cDNA.", [["total RNA", "RNA", 173, 182], ["double strand cDNA", "DNA", 214, 232], ["Isolated total RNA", "PROBLEM", 0, 18], ["Nanodrop ND", "TREATMENT", 60, 71], ["Gene ExpressionAbout", "PROBLEM", 144, 164], ["total RNA", "TREATMENT", 173, 182], ["total RNA", "OBSERVATION", 9, 18]]], ["After purification, in vitro amplification was performed with Agilent Low RNA Input Linear Amplification Kit (Agilent, Pal alto, USA) and modified UTP [aaUTP, 5-(3-aminoally1)-UTP] was used to replace UTP.", [["UTP", "CHEMICAL", 147, 150], ["aaUTP, 5-(3-aminoally1)-UTP", "CHEMICAL", 152, 179], ["UTP", "CHEMICAL", 201, 204], ["UTP", "CHEMICAL", 147, 150], ["aaUTP", "CHEMICAL", 152, 157], ["5-(3-aminoally1)-UTP", "CHEMICAL", 159, 179], ["UTP", "CHEMICAL", 201, 204], ["UTP", "SIMPLE_CHEMICAL", 147, 150], ["aaUTP", "SIMPLE_CHEMICAL", 152, 157], ["5-(3-aminoally1)-UTP", "SIMPLE_CHEMICAL", 159, 179], ["UTP", "SIMPLE_CHEMICAL", 201, 204], ["aaUTP", "TEST", 152, 157], ["UTP", "TEST", 201, 204]]], ["The integrated aaUTP can interact with Cy3 NHS ester forming fluorescent products which are then used for hybridization.", [["aaUTP", "CHEMICAL", 15, 20], ["Cy3 NHS ester", "CHEMICAL", 39, 52], ["Cy3 NHS ester", "CHEMICAL", 39, 52], ["aaUTP", "SIMPLE_CHEMICAL", 15, 20], ["Cy3 NHS ester", "SIMPLE_CHEMICAL", 39, 52], ["aaUTP", "PROTEIN", 15, 20], ["Cy3 NHS ester forming fluorescent products", "TREATMENT", 39, 81], ["hybridization", "PROBLEM", 106, 119]]], ["The integration rate of fluorescence can be determined with a NanodropND-1000 spectrophotometer.", [["a NanodropND-1000 spectrophotometer", "TREATMENT", 60, 95]]], ["Then, hybridization mixture was prepared with Agilent oligonucleotide microarray in situ hybridization plus kit.", [["hybridization mixture", "TREATMENT", 6, 27], ["Agilent oligonucleotide microarray", "TREATMENT", 46, 80]]], ["About 750 ng of fluorescent products were fragmented at 60\u00b0C and hybridization was conducted in Human Whole-Genome 60-mer oligo-chips (G4112F, Agilent Technologies) at 60\u00b0C for 17 h at 10 rpm.", [["C", "GENE_OR_GENE_PRODUCT", 59, 60], ["Human", "ORGANISM", 96, 101], ["Human", "SPECIES", 96, 101], ["Human", "SPECIES", 96, 101], ["fluorescent products", "TREATMENT", 16, 36], ["hybridization", "TREATMENT", 65, 78], ["mer oligo-chips", "TREATMENT", 118, 133], ["Agilent Technologies", "TREATMENT", 143, 163]]], ["After hybridization, the chips were washed with Agilent Gene Expression Wash Buffer according to manufacturer's instructions.", [["hybridization", "TREATMENT", 6, 19], ["the chips", "TREATMENT", 21, 30], ["Agilent Gene Expression Wash Buffer", "TREATMENT", 48, 83]]], ["The standardization of original signals was carried out with RMA standardized method and standardized signal values were used for screening of differentially expressed genes.RT-PCRThree differential genes in the microarray were selected and their expressions were confirmed by RT-PCR.", [["differentially expressed genes", "DNA", 143, 173], ["RT-PCRThree differential genes", "DNA", 174, 204], ["RMA standardized method", "TEST", 61, 84], ["standardized signal values", "TEST", 89, 115], ["screening", "TEST", 130, 139], ["the microarray", "TEST", 208, 222], ["RT", "TEST", 277, 279], ["PCR", "TEST", 280, 283]]], ["Among genes with differential expressions, 3 genes were randomly selected and these genes and house keeping gene (GAPDH) were subjected to RT-PCR.", [["house keeping gene", "GENE_OR_GENE_PRODUCT", 94, 112], ["GAPDH", "GENE_OR_GENE_PRODUCT", 114, 119], ["house keeping gene", "DNA", 94, 112], ["GAPDH", "DNA", 114, 119], ["PCR", "TEST", 142, 145]]], ["The relative expressions were expressed as the expressions of target genes normalized by that of GAPDH (2 -\u25b3\u25b3Ct ).", [["GAPDH", "GENE_OR_GENE_PRODUCT", 97, 102], ["2 -\u25b3\u25b3Ct", "GENE_OR_GENE_PRODUCT", 104, 111], ["target genes", "DNA", 62, 74], ["GAPDH", "PROTEIN", 97, 102]]], ["Melting curve and 2 -\u25b3\u25b3Ct method were used to compare the difference in the expressions between control group and PE group.", [["Melting curve", "TEST", 0, 13], ["Ct method", "TEST", 23, 32], ["control group and PE group", "TREATMENT", 96, 122], ["PE", "OBSERVATION", 114, 116]]], ["Results from RT-PCR were consistent with microarray analysis.Statistical AnalysisIndependent-Samples T Test was used to compare mRNA levels in samples from PE patients and controls.", [["samples", "ANATOMY", 143, 150], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["RT-PCR", "TEST", 13, 19], ["microarray analysis", "TEST", 41, 60], ["Samples T Test", "TEST", 93, 107], ["mRNA levels", "TEST", 128, 139], ["PE patients", "TEST", 156, 167], ["consistent with", "UNCERTAINTY", 25, 40], ["PE", "OBSERVATION", 156, 158]]], ["Statistical tests were performed using SPSS 17.0, and p values b0.05 were considered significant.", [["Statistical tests", "TEST", 0, 17], ["SPSS", "TEST", 39, 43], ["p values b0.05", "TEST", 54, 68]]], ["Before t test, test for equality of variances was performed, if variances were not equal, t test result would be corrected.Gene Expression of Complement ComponentsThe results showed that mRNA expressions of complement early components including C1q\u03b1, C1q\u03b2, C1q\u03b3, C1r, C1s, C2, C3, C4b, Factor B, Factor D, Factor P, MBL, MASP1 and MASP2 in PBMCs from patients with PE and controls were detected (Fig. 1A) .", [["PBMCs", "ANATOMY", 340, 345], ["C1q\u03b1", "GENE_OR_GENE_PRODUCT", 245, 249], ["C1q\u03b2", "GENE_OR_GENE_PRODUCT", 251, 255], ["C1q\u03b3", "GENE_OR_GENE_PRODUCT", 257, 261], ["C1r", "GENE_OR_GENE_PRODUCT", 263, 266], ["C1s", "GENE_OR_GENE_PRODUCT", 268, 271], ["C2", "GENE_OR_GENE_PRODUCT", 273, 275], ["C3", "GENE_OR_GENE_PRODUCT", 277, 279], ["C4b", "GENE_OR_GENE_PRODUCT", 281, 284], ["Factor B", "GENE_OR_GENE_PRODUCT", 286, 294], ["Factor D", "GENE_OR_GENE_PRODUCT", 296, 304], ["Factor P", "GENE_OR_GENE_PRODUCT", 306, 314], ["MBL", "GENE_OR_GENE_PRODUCT", 316, 319], ["MASP1", "GENE_OR_GENE_PRODUCT", 321, 326], ["MASP2", "GENE_OR_GENE_PRODUCT", 331, 336], ["PBMCs", "CELL", 340, 345], ["patients", "ORGANISM", 351, 359], ["Complement Components", "PROTEIN", 142, 163], ["complement early components", "PROTEIN", 207, 234], ["C1q\u03b1", "PROTEIN", 245, 249], ["C1q\u03b2", "PROTEIN", 251, 255], ["C1q\u03b3", "PROTEIN", 257, 261], ["C1r", "PROTEIN", 263, 266], ["C1s", "PROTEIN", 268, 271], ["C2", "PROTEIN", 273, 275], ["C3", "PROTEIN", 277, 279], ["C4b", "PROTEIN", 281, 284], ["Factor B", "PROTEIN", 286, 294], ["Factor D", "PROTEIN", 296, 304], ["Factor P", "PROTEIN", 306, 314], ["MBL", "PROTEIN", 316, 319], ["MASP1", "PROTEIN", 321, 326], ["MASP2", "PROTEIN", 331, 336], ["PBMCs", "CELL_TYPE", 340, 345], ["patients", "SPECIES", 351, 359], ["t test", "TEST", 7, 13], ["test", "TEST", 15, 19], ["t test", "TEST", 90, 96], ["Complement Components", "TEST", 142, 163], ["mRNA expressions of complement early components", "PROBLEM", 187, 234], ["C1q\u03b1", "TEST", 245, 249], ["C1q\u03b2", "TEST", 251, 255], ["C1r", "TEST", 263, 266], ["C1s", "TEST", 268, 271], ["C2", "TEST", 273, 275], ["C3", "TEST", 277, 279], ["C4b", "TEST", 281, 284], ["Factor B", "TEST", 286, 294], ["Factor P", "TEST", 306, 314], ["MBL", "TEST", 316, 319], ["MASP1", "TEST", 321, 326], ["MASP2", "TEST", 331, 336], ["PBMCs", "TEST", 340, 345], ["PE", "PROBLEM", 365, 367], ["C1s", "ANATOMY", 268, 271], ["C2", "ANATOMY", 273, 275], ["PE", "OBSERVATION", 365, 367]]], ["In PBMCs from PE patients, expression of the genes encoding C1q\u03b1, C1q\u03b2, C4b and Factor P was significantly greater (P b 0.01) than that in controls.", [["PBMCs", "ANATOMY", 3, 8], ["PBMCs", "CELL", 3, 8], ["patients", "ORGANISM", 17, 25], ["C1q\u03b1", "GENE_OR_GENE_PRODUCT", 60, 64], ["C1q\u03b2", "GENE_OR_GENE_PRODUCT", 66, 70], ["C4b", "GENE_OR_GENE_PRODUCT", 72, 75], ["Factor P", "GENE_OR_GENE_PRODUCT", 80, 88], ["PBMCs", "CELL_TYPE", 3, 8], ["C1q\u03b1", "PROTEIN", 60, 64], ["C1q\u03b2", "PROTEIN", 66, 70], ["C4b", "PROTEIN", 72, 75], ["Factor P", "PROTEIN", 80, 88], ["patients", "SPECIES", 17, 25], ["PE", "PROBLEM", 14, 16], ["Factor P", "TEST", 80, 88], ["PE", "OBSERVATION", 14, 16]]], ["Gene expression of MBL and MASP1 was lower (P b 0.05) in PBMCs from PE patients compared with controls.Gene Expression of Complement ComponentsGene expressions of complement late components including C5, C6, C7, C8\u03b1, C8\u03b2, C8\u03b3 and C9 in PBMCs from PE patients and controls were also detected (Fig. 1B) .", [["PBMCs", "ANATOMY", 57, 62], ["PBMCs", "ANATOMY", 236, 241], ["MBL", "GENE_OR_GENE_PRODUCT", 19, 22], ["MASP1", "GENE_OR_GENE_PRODUCT", 27, 32], ["PBMCs", "CELL", 57, 62], ["patients", "ORGANISM", 71, 79], ["C5", "GENE_OR_GENE_PRODUCT", 200, 202], ["C7", "GENE_OR_GENE_PRODUCT", 208, 210], ["C8\u03b1", "GENE_OR_GENE_PRODUCT", 212, 215], ["C8\u03b2", "GENE_OR_GENE_PRODUCT", 217, 220], ["C8\u03b3", "GENE_OR_GENE_PRODUCT", 222, 225], ["C9", "GENE_OR_GENE_PRODUCT", 230, 232], ["PBMCs", "CELL", 236, 241], ["patients", "ORGANISM", 250, 258], ["MBL", "PROTEIN", 19, 22], ["MASP1", "PROTEIN", 27, 32], ["PBMCs", "CELL_TYPE", 57, 62], ["complement late components", "PROTEIN", 163, 189], ["C5", "PROTEIN", 200, 202], ["C6", "PROTEIN", 204, 206], ["C7", "PROTEIN", 208, 210], ["C8\u03b1", "PROTEIN", 212, 215], ["C8\u03b2", "PROTEIN", 217, 220], ["C8\u03b3", "PROTEIN", 222, 225], ["C9", "PROTEIN", 230, 232], ["PBMCs", "CELL_TYPE", 236, 241], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 250, 258], ["MBL", "TEST", 19, 22], ["MASP1", "TEST", 27, 32], ["PBMCs", "PROBLEM", 57, 62], ["PE", "PROBLEM", 68, 70], ["complement late components including C5, C6, C7, C8\u03b1, C8\u03b2, C8\u03b3 and C9 in PBMCs", "PROBLEM", 163, 241], ["MBL", "OBSERVATION", 19, 22], ["PE", "OBSERVATION", 68, 70], ["C5", "ANATOMY_MODIFIER", 200, 202], ["C6", "ANATOMY_MODIFIER", 204, 206], ["C7", "ANATOMY_MODIFIER", 208, 210], ["C8", "ANATOMY_MODIFIER", 217, 219], ["C8", "ANATOMY_MODIFIER", 222, 224], ["PE", "OBSERVATION", 247, 249]]], ["In PE patients, mRNA expression of C5 was significantly up-regulated (P b 0.05), whereas C6, C7 and C9 were significantly down-regulated (P b 0.05) compared with controls.Gene Expression of Complement ReceptorsThe results showed that mRNA expressions of complement receptors including CR1, CR2, C3aR, integrin \u03b1M, integrin \u03b1X, integrin \u03b22 and C5aR in PBMCs from PE patients and controls were examined ( Fig. 2A) .", [["PBMCs", "ANATOMY", 351, 356], ["patients", "ORGANISM", 6, 14], ["C5", "GENE_OR_GENE_PRODUCT", 35, 37], ["C7", "GENE_OR_GENE_PRODUCT", 93, 95], ["C9", "GENE_OR_GENE_PRODUCT", 100, 102], ["Complement Receptors", "GENE_OR_GENE_PRODUCT", 190, 210], ["complement receptors", "GENE_OR_GENE_PRODUCT", 254, 274], ["CR1", "GENE_OR_GENE_PRODUCT", 285, 288], ["CR2", "GENE_OR_GENE_PRODUCT", 290, 293], ["C3aR", "GENE_OR_GENE_PRODUCT", 295, 299], ["integrin \u03b1M", "GENE_OR_GENE_PRODUCT", 301, 312], ["integrin \u03b1X", "GENE_OR_GENE_PRODUCT", 314, 325], ["integrin \u03b22", "GENE_OR_GENE_PRODUCT", 327, 338], ["C5aR", "GENE_OR_GENE_PRODUCT", 343, 347], ["PBMCs", "CELL", 351, 356], ["patients", "ORGANISM", 365, 373], ["C5", "PROTEIN", 35, 37], ["Complement Receptors", "PROTEIN", 190, 210], ["complement receptors", "PROTEIN", 254, 274], ["CR1", "PROTEIN", 285, 288], ["CR2", "PROTEIN", 290, 293], ["C3aR", "PROTEIN", 295, 299], ["integrin \u03b1M", "PROTEIN", 301, 312], ["integrin \u03b1X", "PROTEIN", 314, 325], ["integrin \u03b22", "PROTEIN", 327, 338], ["C5aR", "PROTEIN", 343, 347], ["PBMCs", "CELL_TYPE", 351, 356], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 365, 373], ["mRNA expression of C5", "PROBLEM", 16, 37], ["Complement Receptors", "TEST", 190, 210], ["complement receptors", "TEST", 254, 274], ["CR1", "TEST", 285, 288], ["CR2", "TEST", 290, 293], ["C3aR", "TEST", 295, 299], ["integrin \u03b1X", "TREATMENT", 314, 325], ["integrin \u03b22", "TREATMENT", 327, 338], ["C5aR in PBMCs", "TREATMENT", 343, 356], ["PE", "PROBLEM", 362, 364], ["PE", "OBSERVATION", 3, 5], ["C5", "ANATOMY", 35, 37], ["C7", "ANATOMY", 93, 95], ["C9", "ANATOMY", 100, 102], ["PE", "OBSERVATION", 362, 364]]], ["CR3 consists of integrin \u03b1M and integrin \u03b22, and CR4 comprises integrin \u03b1X and integrin \u03b22.", [["CR3", "GENE_OR_GENE_PRODUCT", 0, 3], ["integrin \u03b1M", "GENE_OR_GENE_PRODUCT", 16, 27], ["integrin \u03b22", "GENE_OR_GENE_PRODUCT", 32, 43], ["CR4", "GENE_OR_GENE_PRODUCT", 49, 52], ["integrin \u03b1X", "GENE_OR_GENE_PRODUCT", 63, 74], ["integrin \u03b22", "GENE_OR_GENE_PRODUCT", 79, 90], ["CR3", "PROTEIN", 0, 3], ["integrin \u03b1M", "PROTEIN", 16, 27], ["integrin \u03b22", "PROTEIN", 32, 43], ["CR4", "PROTEIN", 49, 52], ["integrin \u03b1X", "PROTEIN", 63, 74], ["integrin \u03b22", "PROTEIN", 79, 90], ["CR3", "TEST", 0, 3], ["integrin", "TEST", 16, 24], ["integrin", "TEST", 32, 40], ["CR4", "TEST", 49, 52], ["integrin \u03b1X", "TREATMENT", 63, 74], ["integrin \u03b2", "TREATMENT", 79, 89]]], ["In PE patients, expressions of all the seven genes mRNAs were up-regulated, and mRNA expressions of CR1, integrin \u03b1M, integrin \u03b1X and C5aR were significantly up-regulated (P b 0.01) compared with controls.Gene Expression of Complement RegulatorsGene expressions of complement regulators C4b binding protein, \u03b1 (C4BP\u03b1), C4b binding protein, \u03b2 (C4BP\u03b2), Factor H, Factor I, CD59, CD55 and CD46 in PBMCs from PE patients and controls were detected (Fig. 2B ).", [["PBMCs", "ANATOMY", 394, 399], ["patients", "ORGANISM", 6, 14], ["CR1", "GENE_OR_GENE_PRODUCT", 100, 103], ["integrin \u03b1M", "GENE_OR_GENE_PRODUCT", 105, 116], ["integrin \u03b1X", "GENE_OR_GENE_PRODUCT", 118, 129], ["C5aR", "GENE_OR_GENE_PRODUCT", 134, 138], ["C4b binding protein", "GENE_OR_GENE_PRODUCT", 287, 306], ["\u03b1 (C4BP\u03b1", "GENE_OR_GENE_PRODUCT", 308, 316], ["C4b binding protein", "GENE_OR_GENE_PRODUCT", 319, 338], ["\u03b2", "GENE_OR_GENE_PRODUCT", 340, 341], ["C4BP\u03b2", "GENE_OR_GENE_PRODUCT", 343, 348], ["Factor H", "GENE_OR_GENE_PRODUCT", 351, 359], ["Factor I", "GENE_OR_GENE_PRODUCT", 361, 369], ["CD59", "GENE_OR_GENE_PRODUCT", 371, 375], ["CD55", "GENE_OR_GENE_PRODUCT", 377, 381], ["CD46", "GENE_OR_GENE_PRODUCT", 386, 390], ["PBMCs", "CELL", 394, 399], ["patients", "ORGANISM", 408, 416], ["mRNAs", "RNA", 51, 56], ["CR1", "PROTEIN", 100, 103], ["integrin \u03b1M", "PROTEIN", 105, 116], ["integrin \u03b1X", "PROTEIN", 118, 129], ["C5aR", "PROTEIN", 134, 138], ["Complement Regulators", "PROTEIN", 224, 245], ["complement regulators", "PROTEIN", 265, 286], ["C4b binding protein", "PROTEIN", 287, 306], ["\u03b1", "PROTEIN", 308, 309], ["C4BP\u03b1", "PROTEIN", 311, 316], ["C4b binding protein", "PROTEIN", 319, 338], ["\u03b2", "PROTEIN", 340, 341], ["C4BP\u03b2", "PROTEIN", 343, 348], ["Factor H", "PROTEIN", 351, 359], ["Factor I", "PROTEIN", 361, 369], ["CD59", "PROTEIN", 371, 375], ["CD55", "PROTEIN", 377, 381], ["CD46", "PROTEIN", 386, 390], ["PBMCs", "CELL_TYPE", 394, 399], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 408, 416], ["all the seven genes mRNAs", "PROBLEM", 31, 56], ["CR1", "TEST", 100, 103], ["integrin \u03b1X", "TREATMENT", 118, 129], ["C5aR", "TEST", 134, 138], ["Complement Regulators", "TEST", 224, 245], ["complement regulators", "TEST", 265, 286], ["C4b binding protein", "TEST", 287, 306], ["\u03b1 (C4BP\u03b1", "TEST", 308, 316], ["C4b binding protein", "TEST", 319, 338], ["C4BP", "TEST", 343, 347], ["Factor H", "TEST", 351, 359], ["Factor I", "TEST", 361, 369], ["CD59", "TEST", 371, 375], ["CD55", "TEST", 377, 381], ["CD46", "TEST", 386, 390], ["PBMCs", "TEST", 394, 399], ["PE", "TEST", 405, 407], ["PE", "OBSERVATION", 3, 5], ["PE", "OBSERVATION", 405, 407]]], ["CD59 and CD55 mRNAs were both significantly up-regulated (P b 0.05), while Factor I mRNA was significantly down-regulated (P b 0.05) in PBMCs from PE patients than controls.DiscussionThe complement system is an important component of the innate immunity, however, it also plays an important role in the adaptive immune system to defend against pathogens [10] .", [["PBMCs", "ANATOMY", 136, 141], ["immune system", "ANATOMY", 312, 325], ["CD59", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD55", "GENE_OR_GENE_PRODUCT", 9, 13], ["Factor I", "GENE_OR_GENE_PRODUCT", 75, 83], ["PBMCs", "CELL", 136, 141], ["patients", "ORGANISM", 150, 158], ["CD59 and CD55 mRNAs", "RNA", 0, 19], ["Factor I mRNA", "RNA", 75, 88], ["PBMCs", "CELL_TYPE", 136, 141], ["patients", "SPECIES", 150, 158], ["CD59", "TEST", 0, 4], ["CD55 mRNAs", "TEST", 9, 19], ["Factor I mRNA", "TEST", 75, 88], ["PE", "PROBLEM", 147, 149], ["the adaptive immune system", "TREATMENT", 299, 325], ["pathogens", "PROBLEM", 344, 353], ["PE", "OBSERVATION", 147, 149]]], ["Three distinct pathways activate the complement system: the classical, lectin, and alternative pathways.", [["lectin", "GENE_OR_GENE_PRODUCT", 71, 77], ["lectin", "PROTEIN", 71, 77]]], ["All of them share a common terminal pathway which leads to the formation of membrane attack complex (MAC) which forms a transmembrane pore in the target cells' membrane that causes cell lysis and death [11] .DiscussionWe detected the early complement components of three complement pathways in the two groups, and we found that C1q\u03b1, C1q\u03b2, C4b and Factor P mRNAs were significantly up-regulated, while MBL and MASP1 mRNAs were significantly down-regulated in PE patients compared with controls (Fig. 1) .", [["membrane", "ANATOMY", 76, 84], ["transmembrane pore", "ANATOMY", 120, 138], ["cells", "ANATOMY", 153, 158], ["membrane", "ANATOMY", 160, 168], ["cell", "ANATOMY", 181, 185], ["death", "DISEASE", 196, 201], ["membrane attack complex", "GENE_OR_GENE_PRODUCT", 76, 99], ["cells", "CELL", 153, 158], ["' membrane", "CELLULAR_COMPONENT", 158, 168], ["cell", "CELL", 181, 185], ["C1q\u03b1", "GENE_OR_GENE_PRODUCT", 328, 332], ["C1q\u03b2", "GENE_OR_GENE_PRODUCT", 334, 338], ["C4b", "GENE_OR_GENE_PRODUCT", 340, 343], ["Factor P", "GENE_OR_GENE_PRODUCT", 348, 356], ["MBL", "GENE_OR_GENE_PRODUCT", 402, 405], ["MASP1", "GENE_OR_GENE_PRODUCT", 410, 415], ["patients", "ORGANISM", 462, 470], ["membrane attack complex", "PROTEIN", 76, 99], ["MAC", "PROTEIN", 101, 104], ["C1q\u03b1, C1q\u03b2, C4b and Factor P mRNAs", "RNA", 328, 362], ["MBL and MASP1 mRNAs", "RNA", 402, 421], ["patients", "SPECIES", 462, 470], ["membrane attack complex", "PROBLEM", 76, 99], ["a transmembrane pore", "PROBLEM", 118, 138], ["cell lysis", "PROBLEM", 181, 191], ["death", "PROBLEM", 196, 201], ["C1q\u03b1", "TEST", 328, 332], ["Factor P mRNAs", "TEST", 348, 362], ["MBL", "TEST", 402, 405], ["MASP1 mRNAs", "TEST", 410, 421], ["PE", "PROBLEM", 459, 461], ["membrane attack", "OBSERVATION", 76, 91], ["transmembrane pore", "OBSERVATION_MODIFIER", 120, 138], ["cell lysis", "OBSERVATION", 181, 191], ["PE", "OBSERVATION", 459, 461]]], ["The up-regulation of C1q\u03b1, C1q\u03b2 and C4b mRNAs in PE patients suggests that there exists pathogen invasion, leading to the activation of the classical pathway.", [["C1q\u03b1", "GENE_OR_GENE_PRODUCT", 21, 25], ["C1q\u03b2", "GENE_OR_GENE_PRODUCT", 27, 31], ["C4b", "GENE_OR_GENE_PRODUCT", 36, 39], ["patients", "ORGANISM", 52, 60], ["C1q\u03b1, C1q\u03b2 and C4b mRNAs", "RNA", 21, 45], ["patients", "SPECIES", 52, 60], ["C1q\u03b1", "TEST", 21, 25], ["pathogen invasion", "PROBLEM", 88, 105], ["up-regulation", "OBSERVATION_MODIFIER", 4, 17], ["PE", "OBSERVATION", 49, 51], ["pathogen", "OBSERVATION_MODIFIER", 88, 96], ["invasion", "OBSERVATION", 97, 105]]], ["When mannose-bind lectin (MBL) or Ficolin bind to carbohydrate on the surface of pathogens, the MBL-associated serine proteases (MASPs) are activated, then the lectin pathway is activated [12] .", [["surface", "ANATOMY", 70, 77], ["mannose", "CHEMICAL", 5, 12], ["Ficolin", "CHEMICAL", 34, 41], ["mannose", "CHEMICAL", 5, 12], ["carbohydrate", "CHEMICAL", 50, 62], ["serine", "CHEMICAL", 111, 117], ["mannose-bind lectin", "GENE_OR_GENE_PRODUCT", 5, 24], ["MBL", "GENE_OR_GENE_PRODUCT", 26, 29], ["Ficolin", "GENE_OR_GENE_PRODUCT", 34, 41], ["surface", "CELLULAR_COMPONENT", 70, 77], ["MBL-associated serine proteases", "GENE_OR_GENE_PRODUCT", 96, 127], ["MASPs", "GENE_OR_GENE_PRODUCT", 129, 134], ["lectin", "GENE_OR_GENE_PRODUCT", 160, 166], ["mannose-bind lectin", "PROTEIN", 5, 24], ["MBL", "PROTEIN", 26, 29], ["Ficolin", "PROTEIN", 34, 41], ["MBL", "PROTEIN", 96, 99], ["serine proteases", "PROTEIN", 111, 127], ["MASPs", "PROTEIN", 129, 134], ["lectin", "PROTEIN", 160, 166], ["mannose-bind lectin (MBL)", "TREATMENT", 5, 30], ["Ficolin bind", "TREATMENT", 34, 46], ["pathogens", "PROBLEM", 81, 90], ["the MBL", "TEST", 92, 99], ["serine proteases", "TREATMENT", 111, 127]]], ["Previous studies have shown that people with MBL deficiency are susceptible to a variety of infections, especially when their adaptive immunity is immature [13] [14] [15] .", [["MBL deficiency", "DISEASE", 45, 59], ["infections", "DISEASE", 92, 102], ["people", "ORGANISM", 33, 39], ["MBL", "GENE_OR_GENE_PRODUCT", 45, 48], ["MBL", "PROTEIN", 45, 48], ["people", "SPECIES", 33, 39], ["Previous studies", "TEST", 0, 16], ["MBL deficiency", "PROBLEM", 45, 59], ["infections", "PROBLEM", 92, 102], ["infections", "OBSERVATION", 92, 102]]], ["Therefore, the down-regulation of MBL and MASP1 mRNAs in PE patients indicates deficiency or decline of the lectin pathway function in PE patients.DiscussionC5b initiates the formation of MAC, which consists of C5b, C6, C7, C8, and multiple molecules of C9 [10] .", [["DiscussionC5b", "CHEMICAL", 147, 160], ["C5b", "CHEMICAL", 211, 214], ["C7", "CHEMICAL", 220, 222], ["C8", "CHEMICAL", 224, 226], ["MBL", "GENE_OR_GENE_PRODUCT", 34, 37], ["MASP1", "GENE_OR_GENE_PRODUCT", 42, 47], ["patients", "ORGANISM", 60, 68], ["lectin", "GENE_OR_GENE_PRODUCT", 108, 114], ["patients", "ORGANISM", 138, 146], ["DiscussionC5b", "SIMPLE_CHEMICAL", 147, 160], ["C5b", "GENE_OR_GENE_PRODUCT", 211, 214], ["MBL and MASP1 mRNAs", "RNA", 34, 53], ["lectin", "PROTEIN", 108, 114], ["DiscussionC5b", "PROTEIN", 147, 160], ["C5b", "PROTEIN", 211, 214], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 138, 146], ["MBL", "PROBLEM", 34, 37], ["MASP1 mRNAs", "PROBLEM", 42, 53], ["PE", "PROBLEM", 57, 59], ["deficiency", "PROBLEM", 79, 89], ["PE", "OBSERVATION", 57, 59], ["deficiency", "OBSERVATION", 79, 89], ["PE", "OBSERVATION", 135, 137], ["C6", "ANATOMY_MODIFIER", 216, 218], ["C7", "ANATOMY_MODIFIER", 220, 222], ["C8", "ANATOMY_MODIFIER", 224, 226]]], ["Recent research has shown that C5, C6, C7, C8 or C9 deficiencies increase susceptibility to infections [16] .", [["infections", "DISEASE", 92, 102], ["C5", "GENE_OR_GENE_PRODUCT", 31, 33], ["C9", "GENE_OR_GENE_PRODUCT", 49, 51], ["C5, C6, C7, C8", "PROBLEM", 31, 45], ["C9 deficiencies", "PROBLEM", 49, 64], ["susceptibility to infections", "PROBLEM", 74, 102], ["C5", "ANATOMY_MODIFIER", 31, 33], ["C6", "ANATOMY_MODIFIER", 35, 37], ["C7", "ANATOMY_MODIFIER", 39, 41], ["C8", "ANATOMY_MODIFIER", 43, 45], ["C9", "ANATOMY", 49, 51], ["infections", "OBSERVATION", 92, 102]]], ["Our results showed lower mRNA expression of C6, C7 and C9 in PE patients, suggesting decreased MAC-mediated cell lysis of infected cells in PE patients.DiscussionWe detected the gene expression of complement receptors ( Fig. 2A) , and our results showed that CR1, integrin \u03b1M, integrin \u03b1X and C5aR mRNAs were significantly up-regulated in PE patients.", [["cell", "ANATOMY", 108, 112], ["cells", "ANATOMY", 131, 136], ["C7", "GENE_OR_GENE_PRODUCT", 48, 50], ["C9", "GENE_OR_GENE_PRODUCT", 55, 57], ["patients", "ORGANISM", 64, 72], ["MAC", "SIMPLE_CHEMICAL", 95, 98], ["cell", "CELL", 108, 112], ["cells", "CELL", 131, 136], ["patients", "ORGANISM", 143, 151], ["complement receptors", "GENE_OR_GENE_PRODUCT", 197, 217], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 220, 227], ["CR1", "GENE_OR_GENE_PRODUCT", 259, 262], ["integrin \u03b1M", "GENE_OR_GENE_PRODUCT", 264, 275], ["integrin \u03b1X", "GENE_OR_GENE_PRODUCT", 277, 288], ["C5aR", "GENE_OR_GENE_PRODUCT", 293, 297], ["patients", "ORGANISM", 342, 350], ["infected cells", "CELL_TYPE", 122, 136], ["complement receptors", "PROTEIN", 197, 217], ["Fig. 2A", "PROTEIN", 220, 227], ["CR1, integrin \u03b1M, integrin \u03b1X and C5aR mRNAs", "RNA", 259, 303], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 342, 350], ["lower mRNA expression of C6, C7 and C9 in PE", "PROBLEM", 19, 63], ["decreased MAC", "PROBLEM", 85, 98], ["mediated cell lysis", "TREATMENT", 99, 118], ["infected cells", "PROBLEM", 122, 136], ["PE", "PROBLEM", 140, 142], ["CR1", "TEST", 259, 262], ["integrin \u03b1X", "TEST", 277, 288], ["C5aR mRNAs", "TEST", 293, 303], ["lower", "ANATOMY_MODIFIER", 19, 24], ["mRNA expression", "OBSERVATION", 25, 40], ["C6", "ANATOMY_MODIFIER", 44, 46], ["C7", "ANATOMY", 48, 50], ["C9", "ANATOMY", 55, 57], ["PE", "OBSERVATION", 61, 63], ["suggesting", "UNCERTAINTY", 74, 84], ["decreased", "OBSERVATION_MODIFIER", 85, 94], ["MAC", "OBSERVATION", 95, 98], ["cell lysis", "OBSERVATION", 108, 118], ["infected cells", "OBSERVATION", 122, 136], ["PE", "OBSERVATION", 140, 142], ["PE", "OBSERVATION", 339, 341]]], ["Thus, the interactions between some complement effector molecules (C3b, iC3b, C5a) and their receptors were enhanced.DiscussionGene expressions of several complement regulators were also examined in the present study (Fig. 2B) .", [["complement effector molecules", "GENE_OR_GENE_PRODUCT", 36, 65], ["C3b", "GENE_OR_GENE_PRODUCT", 67, 70], ["iC3b", "GENE_OR_GENE_PRODUCT", 72, 76], ["C5a", "GENE_OR_GENE_PRODUCT", 78, 81], ["complement effector molecules", "PROTEIN", 36, 65], ["C3b", "PROTEIN", 67, 70], ["iC3b", "PROTEIN", 72, 76], ["C5a", "PROTEIN", 78, 81], ["complement regulators", "PROTEIN", 155, 176]]], ["Our results showed that the mRNA expression of CD59 and CD55 which is also known as decay acceleration factor (DAF) was significantly increased, however, mRNA expression of Factor I was significantly decreased.", [["CD59", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD55", "GENE_OR_GENE_PRODUCT", 56, 60], ["decay acceleration factor", "GENE_OR_GENE_PRODUCT", 84, 109], ["DAF", "GENE_OR_GENE_PRODUCT", 111, 114], ["Factor I", "GENE_OR_GENE_PRODUCT", 173, 181], ["CD59", "PROTEIN", 47, 51], ["CD55", "PROTEIN", 56, 60], ["decay acceleration factor", "PROTEIN", 84, 109], ["DAF", "PROTEIN", 111, 114], ["Factor I", "PROTEIN", 173, 181], ["CD59", "TEST", 47, 51], ["CD55", "TEST", 56, 60], ["acceleration factor", "PROBLEM", 90, 109], ["Factor I", "TEST", 173, 181], ["significantly", "OBSERVATION_MODIFIER", 120, 133], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["decreased", "OBSERVATION_MODIFIER", 200, 209]]], ["CD55, C4BP and Factor H can regulate the complement activation through inhibiting the activity of C3 convertase [10] .", [["CD55", "GENE_OR_GENE_PRODUCT", 0, 4], ["C4BP", "GENE_OR_GENE_PRODUCT", 6, 10], ["Factor H", "GENE_OR_GENE_PRODUCT", 15, 23], ["C3 convertase", "GENE_OR_GENE_PRODUCT", 98, 111], ["CD55", "PROTEIN", 0, 4], ["C4BP", "PROTEIN", 6, 10], ["Factor H", "PROTEIN", 15, 23], ["C3 convertase", "PROTEIN", 98, 111], ["CD55", "TEST", 0, 4], ["C4BP", "TEST", 6, 10], ["the activity of C3 convertase", "TREATMENT", 82, 111]]], ["CD59 can bind to C8 (\u03b1 chain) and C9 during MAC complex formation and protects host cells from MAC-mediated lysis [17] .", [["cells", "ANATOMY", 84, 89], ["CD59", "GENE_OR_GENE_PRODUCT", 0, 4], ["C8", "GENE_OR_GENE_PRODUCT", 17, 19], ["\u03b1 chain", "GENE_OR_GENE_PRODUCT", 21, 28], ["C9", "GENE_OR_GENE_PRODUCT", 34, 36], ["MAC complex", "GENE_OR_GENE_PRODUCT", 44, 55], ["host cells", "CELL", 79, 89], ["MAC", "SIMPLE_CHEMICAL", 95, 98], ["CD59", "PROTEIN", 0, 4], ["C8", "PROTEIN", 17, 19], ["\u03b1 chain", "PROTEIN", 21, 28], ["C9", "PROTEIN", 34, 36], ["MAC complex", "PROTEIN", 44, 55], ["host cells", "CELL_TYPE", 79, 89], ["CD59", "TEST", 0, 4], ["MAC-mediated lysis", "TREATMENT", 95, 113], ["C8", "ANATOMY_MODIFIER", 17, 19], ["host cells", "OBSERVATION", 79, 89]]], ["Thus, the up-regulation of CD59 and CD55 mRNAs suggests inhibition of MAC-mediated lysis in PE patients.", [["PE", "DISEASE", 92, 94], ["CD59", "GENE_OR_GENE_PRODUCT", 27, 31], ["CD55", "GENE_OR_GENE_PRODUCT", 36, 40], ["MAC", "GENE_OR_GENE_PRODUCT", 70, 73], ["patients", "ORGANISM", 95, 103], ["CD59 and CD55 mRNAs", "RNA", 27, 46], ["patients", "SPECIES", 95, 103], ["CD59", "TEST", 27, 31], ["CD55 mRNAs", "TEST", 36, 46], ["MAC-mediated lysis", "TREATMENT", 70, 88], ["PE", "PROBLEM", 92, 94], ["lysis", "OBSERVATION", 83, 88], ["PE", "OBSERVATION", 92, 94]]], ["However, in our present study, it is unclear whether the cause of the up-regulation of CD55 and CD59 mRNAs is inherited or acquired.", [["CD55", "GENE_OR_GENE_PRODUCT", 87, 91], ["CD59", "GENE_OR_GENE_PRODUCT", 96, 100], ["CD55 and CD59 mRNAs", "RNA", 87, 106], ["our present study", "TEST", 12, 29], ["CD55", "TEST", 87, 91], ["CD59 mRNAs", "TEST", 96, 106]]], ["It has been reported that Factor I deficiency was associated with recurrent bacterial infections [18] .", [["Factor I deficiency", "DISEASE", 26, 45], ["bacterial infections", "DISEASE", 76, 96], ["Factor I", "GENE_OR_GENE_PRODUCT", 26, 34], ["Factor I", "PROTEIN", 26, 34], ["Factor I deficiency", "PROBLEM", 26, 45], ["recurrent bacterial infections", "PROBLEM", 66, 96], ["associated with", "UNCERTAINTY", 50, 65], ["recurrent", "OBSERVATION_MODIFIER", 66, 75], ["bacterial", "OBSERVATION_MODIFIER", 76, 85], ["infections", "OBSERVATION", 86, 96]]], ["In our present study, Factor I mRNA expression was down-regulated in PE patients compared with controls, suggesting that PE patients are susceptible to bacterial infections.DiscussionOur results showed that mRNA expression of various components, receptors and regulators of the complement pathways were unbalanced in PE patients, indicating that the function of some segments were enhanced and some were reduced or deficiency in the complement activation.", [["bacterial infections", "DISEASE", 152, 172], ["Factor I", "GENE_OR_GENE_PRODUCT", 22, 30], ["patients", "ORGANISM", 72, 80], ["PE", "ORGANISM", 121, 123], ["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 320, 328], ["Factor I mRNA", "RNA", 22, 35], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 320, 328], ["our present study", "TEST", 3, 20], ["Factor I mRNA expression", "PROBLEM", 22, 46], ["PE", "PROBLEM", 69, 71], ["PE", "PROBLEM", 121, 123], ["bacterial infections", "PROBLEM", 152, 172], ["mRNA expression of various components", "PROBLEM", 207, 244], ["the complement pathways", "TEST", 274, 297], ["PE", "PROBLEM", 317, 319], ["deficiency", "PROBLEM", 415, 425], ["PE", "OBSERVATION", 69, 71], ["PE", "OBSERVATION", 121, 123], ["bacterial", "OBSERVATION_MODIFIER", 152, 161], ["infections", "OBSERVATION", 162, 172], ["PE", "OBSERVATION", 317, 319], ["reduced", "OBSERVATION_MODIFIER", 404, 411]]], ["To defend against pathogens, the innate immune system mainly comprises the complement proteins, phagocytes, and NK cells, whereas the adaptive immune system consists of T cells and B cells which produce antibodies when stimulated.", [["phagocytes", "ANATOMY", 96, 106], ["NK cells", "ANATOMY", 112, 120], ["immune system", "ANATOMY", 143, 156], ["T cells", "ANATOMY", 169, 176], ["B cells", "ANATOMY", 181, 188], ["phagocytes", "CELL", 96, 106], ["NK cells", "CELL", 112, 120], ["T cells", "CELL", 169, 176], ["B cells", "CELL", 181, 188], ["complement proteins", "PROTEIN", 75, 94], ["phagocytes", "CELL_TYPE", 96, 106], ["NK cells", "CELL_TYPE", 112, 120], ["T cells", "CELL_TYPE", 169, 176], ["B cells", "CELL_TYPE", 181, 188], ["antibodies", "PROTEIN", 203, 213], ["pathogens", "PROBLEM", 18, 27], ["the complement proteins", "TEST", 71, 94], ["phagocytes", "TEST", 96, 106], ["NK cells", "PROBLEM", 112, 120], ["T cells", "PROBLEM", 169, 176], ["B cells", "PROBLEM", 181, 188], ["NK cells", "OBSERVATION", 112, 120]]], ["Previously, we have reported that mRNA expression of genes associated with NK and T cells was down-regulated in PE patients [7] .", [["NK", "ANATOMY", 75, 77], ["T cells", "ANATOMY", 82, 89], ["NK", "CELL", 75, 77], ["T cells", "CELL", 82, 89], ["patients", "ORGANISM", 115, 123], ["NK and T cells", "CELL_TYPE", 75, 89], ["patients", "SPECIES", 115, 123], ["mRNA expression of genes", "PROBLEM", 34, 58], ["NK and T cells", "PROBLEM", 75, 89], ["PE", "OBSERVATION", 112, 114]]], ["We also reported that transmission electron microscopy showed rod-like bacteria in a patient with recurrent PE/DVT, indicating phagocyte deficiency in PE patients [19] .", [["phagocyte", "ANATOMY", 127, 136], ["PE", "DISEASE", 108, 110], ["DVT", "DISEASE", 111, 114], ["PE", "DISEASE", 151, 153], ["patient", "ORGANISM", 85, 92], ["DVT", "PATHOLOGICAL_FORMATION", 111, 114], ["phagocyte", "CELL", 127, 136], ["patients", "ORGANISM", 154, 162], ["patient", "SPECIES", 85, 92], ["patients", "SPECIES", 154, 162], ["transmission electron microscopy", "TEST", 22, 54], ["rod-like bacteria", "PROBLEM", 62, 79], ["recurrent PE", "PROBLEM", 98, 110], ["DVT", "PROBLEM", 111, 114], ["phagocyte deficiency", "PROBLEM", 127, 147], ["PE", "PROBLEM", 151, 153], ["rod-like", "OBSERVATION_MODIFIER", 62, 70], ["bacteria", "OBSERVATION", 71, 79], ["recurrent", "OBSERVATION_MODIFIER", 98, 107], ["PE", "OBSERVATION", 108, 110], ["DVT", "OBSERVATION", 111, 114], ["phagocyte deficiency", "OBSERVATION", 127, 147], ["PE", "OBSERVATION", 151, 153]]], ["In addition, our previous studies showed decreased number of CD 3 + T cells and CD 8 + T cells, and an imbalance in the CD 4 + /CD 8 + ratio in patients with acute PE and CTEPH respectively [8, 9] .", [["CD 3 + T cells", "ANATOMY", 61, 75], ["CD 8 + T cells", "ANATOMY", 80, 94], ["PE", "DISEASE", 164, 166], ["CTEPH", "DISEASE", 171, 176], ["CD 3", "GENE_OR_GENE_PRODUCT", 61, 65], ["CD 8", "GENE_OR_GENE_PRODUCT", 80, 84], ["CD 4", "GENE_OR_GENE_PRODUCT", 120, 124], ["CD 8", "GENE_OR_GENE_PRODUCT", 128, 132], ["patients", "ORGANISM", 144, 152], ["T cells", "CELL_TYPE", 68, 75], ["T cells", "CELL_TYPE", 87, 94], ["patients", "SPECIES", 144, 152], ["our previous studies", "TEST", 13, 33], ["CD 3 + T cells", "PROBLEM", 61, 75], ["CD", "TEST", 80, 82], ["T cells", "PROBLEM", 87, 94], ["an imbalance", "PROBLEM", 100, 112], ["the CD", "TEST", 116, 122], ["acute PE", "PROBLEM", 158, 166], ["CTEPH", "TEST", 171, 176], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["imbalance", "OBSERVATION", 103, 112], ["acute", "OBSERVATION_MODIFIER", 158, 163], ["PE", "OBSERVATION", 164, 166], ["CTEPH", "OBSERVATION", 171, 176]]], ["In our present study, several complement early components of the classical pathway and the alternative pathway and complement receptors mRNAs were significantly up-regulated, suggesting complement activation in PE patients.", [["complement receptors", "GENE_OR_GENE_PRODUCT", 115, 135], ["patients", "ORGANISM", 214, 222], ["complement receptors mRNAs", "RNA", 115, 141], ["patients", "SPECIES", 214, 222], ["our present study", "TEST", 3, 20], ["complement receptors mRNAs", "TEST", 115, 141], ["complement activation in PE patients", "PROBLEM", 186, 222], ["PE", "OBSERVATION", 211, 213]]], ["However, mRNA expression of several components of MBL pathway and the formation of MAC were significantly down-regulated, suggesting defective or reduced complement function in PE patients.DiscussionIn conclusion, we speculate that when there exist deficiencies in both the innate and adaptive immunity, the pathogens can not be prevented or eliminated once they invade and circulate in the blood.", [["blood", "ANATOMY", 391, 396], ["MBL", "GENE_OR_GENE_PRODUCT", 50, 53], ["MAC", "GENE_OR_GENE_PRODUCT", 83, 86], ["patients", "ORGANISM", 180, 188], ["blood", "ORGANISM_SUBSTANCE", 391, 396], ["MBL", "PROTEIN", 50, 53], ["MAC", "PROTEIN", 83, 86], ["patients", "SPECIES", 180, 188], ["MBL pathway", "PROBLEM", 50, 61], ["MAC", "PROBLEM", 83, 86], ["defective or reduced complement function in PE patients", "PROBLEM", 133, 188], ["deficiencies", "PROBLEM", 249, 261], ["the pathogens", "PROBLEM", 304, 317], ["MAC", "ANATOMY", 83, 86], ["suggesting", "UNCERTAINTY", 122, 132], ["defective", "OBSERVATION", 133, 142], ["reduced", "OBSERVATION_MODIFIER", 146, 153], ["PE", "OBSERVATION", 177, 179], ["blood", "ANATOMY", 391, 396]]], ["The pathogens then activate the coagulation system directly or with the inflammation indirectly, leading to the occurrence of symptomatic VTE finally.", [["inflammation", "DISEASE", 72, 84], ["VTE", "DISEASE", 138, 141], ["The pathogens", "PROBLEM", 0, 13], ["the coagulation system", "TEST", 28, 50], ["the inflammation", "PROBLEM", 68, 84], ["symptomatic VTE", "PROBLEM", 126, 141], ["inflammation", "OBSERVATION", 72, 84], ["symptomatic", "OBSERVATION_MODIFIER", 126, 137], ["VTE", "OBSERVATION", 138, 141]]], ["The occurrence of symptomatic VTE may be associated with infections under the condition of immune deficiency.Conflict of Interest StatementNone of the authors declare that there exist any conflicts of interest.", [["VTE", "DISEASE", 30, 33], ["infections", "DISEASE", 57, 67], ["immune deficiency", "DISEASE", 91, 108], ["symptomatic VTE", "PROBLEM", 18, 33], ["infections", "PROBLEM", 57, 67], ["immune deficiency", "PROBLEM", 91, 108], ["symptomatic", "OBSERVATION_MODIFIER", 18, 29], ["VTE", "OBSERVATION", 30, 33], ["may be associated with", "UNCERTAINTY", 34, 56], ["infections", "OBSERVATION", 57, 67], ["immune deficiency", "OBSERVATION", 91, 108]]]], "PMC7152260": [["Increased Synovial Volume ::: Radiographic Signs of Joint DiseaseAny moderate increase in joint capsular or intracapsular soft tissue volume may be detected on good-quality radiographs.", [["Synovial", "ANATOMY", 10, 18], ["joint capsular", "ANATOMY", 90, 104], ["soft tissue", "ANATOMY", 122, 133], ["Joint Disease", "DISEASE", 52, 65], ["Synovial", "TISSUE", 10, 18], ["joint capsular", "TISSUE", 90, 104], ["intracapsular soft tissue", "TISSUE", 108, 133], ["Joint Disease", "PROBLEM", 52, 65], ["Any moderate increase in joint capsular or intracapsular soft tissue volume", "PROBLEM", 65, 140], ["Synovial Volume", "OBSERVATION", 10, 25], ["Joint", "ANATOMY", 52, 57], ["Disease", "OBSERVATION", 58, 65], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["joint", "ANATOMY", 90, 95], ["capsular", "ANATOMY_MODIFIER", 96, 104], ["intracapsular", "ANATOMY_MODIFIER", 108, 121], ["soft tissue", "ANATOMY", 122, 133], ["volume", "OBSERVATION", 134, 140]]], ["The joint cartilage, synovial fluid, synovial membrane, and joint capsule cannot be differentiated, because they are all of soft tissue opacity and therefore silhouette with one another.", [["joint cartilage", "ANATOMY", 4, 19], ["synovial fluid", "ANATOMY", 21, 35], ["synovial membrane", "ANATOMY", 37, 54], ["joint capsule", "ANATOMY", 60, 73], ["tissue", "ANATOMY", 129, 135], ["joint cartilage", "TISSUE", 4, 19], ["synovial fluid", "TISSUE", 21, 35], ["synovial membrane", "MULTI-TISSUE_STRUCTURE", 37, 54], ["joint capsule", "CANCER", 60, 73], ["soft tissue", "TISSUE", 124, 135], ["synovial fluid, synovial membrane, and joint capsule", "PROBLEM", 21, 73], ["soft tissue opacity", "PROBLEM", 124, 143], ["joint cartilage", "ANATOMY", 4, 19], ["synovial", "ANATOMY", 21, 29], ["fluid", "OBSERVATION", 30, 35], ["synovial membrane", "OBSERVATION", 37, 54], ["joint", "ANATOMY", 60, 65], ["capsule", "ANATOMY_MODIFIER", 66, 73], ["soft tissue", "OBSERVATION_MODIFIER", 124, 135], ["opacity", "OBSERVATION", 136, 143], ["silhouette", "OBSERVATION_MODIFIER", 158, 168]]], ["In most joints, an increase in synovial mass appears as periarticular soft tissue swelling, which is identified radiographically by the increased opacity of affected soft tissues.Increased Synovial Volume ::: Radiographic Signs of Joint DiseaseIn the stifle, the infrapatellar fat pad sign may be used to evaluate synovial volume.", [["joints", "ANATOMY", 8, 14], ["synovial mass", "ANATOMY", 31, 44], ["periarticular soft tissue", "ANATOMY", 56, 81], ["soft tissues", "ANATOMY", 166, 178], ["Synovial", "ANATOMY", 189, 197], ["infrapatellar fat pad", "ANATOMY", 263, 284], ["synovial", "ANATOMY", 314, 322], ["swelling", "DISEASE", 82, 90], ["joints", "MULTI-TISSUE_STRUCTURE", 8, 14], ["synovial", "TISSUE", 31, 39], ["periarticular soft tissue", "TISSUE", 56, 81], ["soft tissues", "TISSUE", 166, 178], ["Synovial", "TISSUE", 189, 197], ["infrapatellar fat pad", "TISSUE", 263, 284], ["synovial", "TISSUE", 314, 322], ["an increase in synovial mass", "PROBLEM", 16, 44], ["periarticular soft tissue swelling", "PROBLEM", 56, 90], ["the increased opacity of affected soft tissues", "PROBLEM", 132, 178], ["Radiographic Signs", "TEST", 209, 227], ["Joint DiseaseIn the stifle", "PROBLEM", 231, 257], ["the infrapatellar fat pad sign", "TEST", 259, 289], ["synovial volume", "TEST", 314, 329], ["most", "ANATOMY_MODIFIER", 3, 7], ["joints", "ANATOMY", 8, 14], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["synovial", "ANATOMY", 31, 39], ["mass", "OBSERVATION", 40, 44], ["periarticular", "ANATOMY_MODIFIER", 56, 69], ["soft tissue", "ANATOMY", 70, 81], ["swelling", "OBSERVATION", 82, 90], ["radiographically", "OBSERVATION_MODIFIER", 112, 128], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["opacity", "OBSERVATION", 146, 153], ["affected", "OBSERVATION_MODIFIER", 157, 165], ["soft tissues", "ANATOMY", 166, 178], ["Synovial Volume", "OBSERVATION", 189, 204], ["Joint", "ANATOMY", 231, 236], ["stifle", "OBSERVATION", 251, 257], ["infrapatellar", "ANATOMY", 263, 276]]], ["The normal infrapatellar fat pad is identified readily on lateral stifle radiographs as a relatively radiolucent triangular region immediately caudal to the patellar ligament (Fig. 21.2).", [["infrapatellar fat pad", "ANATOMY", 11, 32], ["caudal", "ANATOMY", 143, 149], ["patellar ligament", "ANATOMY", 157, 174], ["infrapatellar fat pad", "TISSUE", 11, 32], ["patellar ligament", "TISSUE", 157, 174], ["lateral stifle radiographs", "TEST", 58, 84], ["a relatively radiolucent triangular region", "PROBLEM", 88, 130], ["normal", "OBSERVATION_MODIFIER", 4, 10], ["infrapatellar", "ANATOMY", 11, 24], ["fat pad", "OBSERVATION", 25, 32], ["relatively", "OBSERVATION_MODIFIER", 90, 100], ["radiolucent", "OBSERVATION_MODIFIER", 101, 112], ["triangular", "OBSERVATION_MODIFIER", 113, 123], ["region", "ANATOMY_MODIFIER", 124, 130], ["caudal", "ANATOMY_MODIFIER", 143, 149], ["patellar ligament", "ANATOMY", 157, 174]]], ["When stifle synovial mass increases, either from increased synovial fluid or soft tissue, a combination of inflammatory response and effusion causes the shape of the fat pad to be altered and the fat pad to become less visible.Altered Thickness of the Joint Space ::: Radiographic Signs of Joint DiseaseThe joint space is the region of soft tissue opacity between subchondral bone surfaces of opposing weight-bearing surfaces of a joint.", [["stifle synovial mass", "ANATOMY", 5, 25], ["synovial fluid", "ANATOMY", 59, 73], ["soft tissue", "ANATOMY", 77, 88], ["fat pad", "ANATOMY", 166, 173], ["fat", "ANATOMY", 196, 199], ["joint space", "ANATOMY", 307, 318], ["soft tissue", "ANATOMY", 336, 347], ["subchondral bone", "ANATOMY", 364, 380], ["joint", "ANATOMY", 431, 436], ["effusion", "DISEASE", 133, 141], ["Joint Disease", "DISEASE", 290, 303], ["stifle synovial", "MULTI-TISSUE_STRUCTURE", 5, 20], ["synovial fluid", "TISSUE", 59, 73], ["soft tissue", "TISSUE", 77, 88], ["fat pad", "TISSUE", 166, 173], ["fat pad", "TISSUE", 196, 203], ["joint space", "MULTI-TISSUE_STRUCTURE", 307, 318], ["soft tissue", "TISSUE", 336, 347], ["subchondral bone", "TISSUE", 364, 380], ["joint", "MULTI-TISSUE_STRUCTURE", 431, 436], ["stifle synovial mass", "PROBLEM", 5, 25], ["increased synovial fluid", "PROBLEM", 49, 73], ["soft tissue", "PROBLEM", 77, 88], ["inflammatory response", "PROBLEM", 107, 128], ["effusion", "PROBLEM", 133, 141], ["the fat pad", "PROBLEM", 162, 173], ["the fat pad", "PROBLEM", 192, 203], ["Joint Disease", "PROBLEM", 290, 303], ["soft tissue opacity", "PROBLEM", 336, 355], ["synovial", "ANATOMY", 12, 20], ["mass", "OBSERVATION", 21, 25], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["synovial", "ANATOMY", 59, 67], ["fluid", "OBSERVATION", 68, 73], ["soft tissue", "OBSERVATION_MODIFIER", 77, 88], ["inflammatory", "OBSERVATION_MODIFIER", 107, 119], ["effusion", "OBSERVATION", 133, 141], ["shape", "OBSERVATION_MODIFIER", 153, 158], ["fat pad", "OBSERVATION", 166, 173], ["altered", "OBSERVATION_MODIFIER", 180, 187], ["fat pad", "OBSERVATION", 196, 203], ["less visible", "OBSERVATION_MODIFIER", 214, 226], ["Thickness", "OBSERVATION_MODIFIER", 235, 244], ["Joint", "ANATOMY", 252, 257], ["Joint", "ANATOMY", 290, 295], ["Disease", "OBSERVATION", 296, 303], ["joint", "ANATOMY", 307, 312], ["space", "ANATOMY_MODIFIER", 313, 318], ["soft tissue", "ANATOMY", 336, 347], ["opacity", "OBSERVATION", 348, 355], ["subchondral", "ANATOMY_MODIFIER", 364, 375], ["bone", "ANATOMY", 376, 380], ["surfaces", "OBSERVATION_MODIFIER", 381, 389], ["opposing weight", "OBSERVATION", 393, 408], ["bearing", "OBSERVATION_MODIFIER", 409, 416], ["surfaces", "OBSERVATION_MODIFIER", 417, 425], ["joint", "ANATOMY", 431, 436]]], ["This space consists of two layers of articular cartilage separated by a microfilm of synovial fluid.", [["articular cartilage", "ANATOMY", 37, 56], ["synovial fluid", "ANATOMY", 85, 99], ["layers", "TISSUE", 27, 33], ["articular cartilage", "TISSUE", 37, 56], ["synovial fluid", "ORGANISM_SUBSTANCE", 85, 99], ["articular cartilage", "PROBLEM", 37, 56], ["synovial fluid", "PROBLEM", 85, 99], ["two", "OBSERVATION_MODIFIER", 23, 26], ["layers", "OBSERVATION_MODIFIER", 27, 33], ["articular cartilage", "ANATOMY", 37, 56], ["synovial", "ANATOMY", 85, 93], ["fluid", "OBSERVATION", 94, 99]]], ["In early joint disease, synovial effusion may cause widening of the joint space.", [["joint", "ANATOMY", 9, 14], ["synovial effusion", "ANATOMY", 24, 41], ["joint space", "ANATOMY", 68, 79], ["synovial effusion", "DISEASE", 24, 41], ["joint", "MULTI-TISSUE_STRUCTURE", 9, 14], ["synovial", "PATHOLOGICAL_FORMATION", 24, 32], ["joint space", "MULTI-TISSUE_STRUCTURE", 68, 79], ["early joint disease", "PROBLEM", 3, 22], ["synovial effusion", "PROBLEM", 24, 41], ["widening of the joint space", "PROBLEM", 52, 79], ["early", "OBSERVATION_MODIFIER", 3, 8], ["joint", "ANATOMY", 9, 14], ["disease", "OBSERVATION", 15, 22], ["synovial", "ANATOMY", 24, 32], ["effusion", "OBSERVATION", 33, 41], ["widening", "OBSERVATION_MODIFIER", 52, 60], ["joint space", "ANATOMY", 68, 79]]], ["As joint disease progresses, attrition of articular cartilage results in decreased width of the joint space (Fig. 21.3).", [["joint", "ANATOMY", 3, 8], ["articular cartilage", "ANATOMY", 42, 61], ["joint", "ANATOMY", 96, 101], ["joint", "MULTI-TISSUE_STRUCTURE", 3, 8], ["articular cartilage", "TISSUE", 42, 61], ["joint", "MULTI-TISSUE_STRUCTURE", 96, 101], ["joint disease", "PROBLEM", 3, 16], ["attrition of articular cartilage", "PROBLEM", 29, 61], ["decreased width of the joint space", "PROBLEM", 73, 107], ["joint", "ANATOMY", 3, 8], ["disease", "OBSERVATION", 9, 16], ["articular cartilage", "ANATOMY", 42, 61], ["decreased", "OBSERVATION_MODIFIER", 73, 82], ["width", "OBSERVATION_MODIFIER", 83, 88], ["joint", "ANATOMY", 96, 101]]], ["These changes in joint space width are rarely diagnosed radiographically as a result of small animal patients not being radiographed while bearing weight and also because of inconsistency between the orientation of the primary x-ray beam and joint space.Decreased Subchondral Bone Opacity and Bone Cyst ::: Radiographic Signs of Joint DiseaseSubchondral bone is separated from the synovial fluid by an intact layer of articular cartilage.", [["joint space", "ANATOMY", 17, 28], ["joint", "ANATOMY", 242, 247], ["Bone", "ANATOMY", 276, 280], ["Bone", "ANATOMY", 293, 297], ["Joint DiseaseSubchondral bone", "ANATOMY", 329, 358], ["synovial fluid", "ANATOMY", 381, 395], ["articular cartilage", "ANATOMY", 418, 437], ["joint space", "MULTI-TISSUE_STRUCTURE", 17, 28], ["patients", "ORGANISM", 101, 109], ["joint space", "MULTI-TISSUE_STRUCTURE", 242, 253], ["Subchondral Bone", "TISSUE", 264, 280], ["Bone", "TISSUE", 293, 297], ["bone", "TISSUE", 354, 358], ["synovial fluid", "ORGANISM_SUBSTANCE", 381, 395], ["articular cartilage", "TISSUE", 418, 437], ["patients", "SPECIES", 101, 109], ["These changes in joint space width", "PROBLEM", 0, 34], ["Decreased Subchondral Bone Opacity", "PROBLEM", 254, 288], ["Radiographic Signs", "TEST", 307, 325], ["Joint DiseaseSubchondral bone", "PROBLEM", 329, 358], ["the synovial fluid", "TEST", 377, 395], ["joint", "ANATOMY", 17, 22], ["width", "OBSERVATION_MODIFIER", 29, 34], ["small", "OBSERVATION_MODIFIER", 88, 93], ["joint", "ANATOMY", 242, 247], ["Subchondral", "ANATOMY_MODIFIER", 264, 275], ["Bone", "ANATOMY", 276, 280], ["Opacity", "OBSERVATION", 281, 288], ["Bone", "ANATOMY", 293, 297], ["Cyst", "OBSERVATION", 298, 302], ["Joint", "ANATOMY", 329, 334], ["DiseaseSubchondral", "ANATOMY_MODIFIER", 335, 353], ["bone", "ANATOMY", 354, 358], ["synovial", "ANATOMY", 381, 389], ["fluid", "OBSERVATION", 390, 395], ["intact", "OBSERVATION_MODIFIER", 402, 408], ["layer", "OBSERVATION_MODIFIER", 409, 414], ["articular cartilage", "ANATOMY", 418, 437]]], ["Any disease that changes the character of synovial fluid, causing the articular cartilage to erode, potentially threatens the integrity of subchondral bone.", [["synovial fluid", "ANATOMY", 42, 56], ["articular cartilage", "ANATOMY", 70, 89], ["subchondral bone", "ANATOMY", 139, 155], ["synovial fluid", "TISSUE", 42, 56], ["articular cartilage", "TISSUE", 70, 89], ["subchondral bone", "MULTI-TISSUE_STRUCTURE", 139, 155], ["Any disease", "PROBLEM", 0, 11], ["synovial fluid", "PROBLEM", 42, 56], ["the articular cartilage", "PROBLEM", 66, 89], ["disease", "OBSERVATION", 4, 11], ["synovial", "ANATOMY", 42, 50], ["fluid", "OBSERVATION", 51, 56], ["articular cartilage", "ANATOMY", 70, 89], ["integrity", "OBSERVATION_MODIFIER", 126, 135], ["subchondral", "ANATOMY_MODIFIER", 139, 150], ["bone", "ANATOMY", 151, 155]]], ["In inflammatory joint disease, inflammatory exudates may cause pronounced subchondral bone loss.", [["joint", "ANATOMY", 16, 21], ["subchondral bone", "ANATOMY", 74, 90], ["inflammatory joint disease", "DISEASE", 3, 29], ["subchondral bone loss", "DISEASE", 74, 95], ["joint", "MULTI-TISSUE_STRUCTURE", 16, 21], ["subchondral", "MULTI-TISSUE_STRUCTURE", 74, 85], ["bone", "TISSUE", 86, 90], ["inflammatory joint disease", "PROBLEM", 3, 29], ["inflammatory exudates", "PROBLEM", 31, 52], ["pronounced subchondral bone loss", "PROBLEM", 63, 95], ["inflammatory", "OBSERVATION_MODIFIER", 3, 15], ["joint", "ANATOMY", 16, 21], ["disease", "OBSERVATION", 22, 29], ["inflammatory", "OBSERVATION_MODIFIER", 31, 43], ["may cause", "UNCERTAINTY", 53, 62], ["pronounced", "OBSERVATION_MODIFIER", 63, 73], ["subchondral", "ANATOMY_MODIFIER", 74, 85], ["bone", "ANATOMY", 86, 90], ["loss", "OBSERVATION", 91, 95]]], ["Infectious arthritis may extend into subchondral bone.", [["subchondral bone", "ANATOMY", 37, 53], ["Infectious arthritis", "DISEASE", 0, 20], ["subchondral bone", "MULTI-TISSUE_STRUCTURE", 37, 53], ["Infectious arthritis", "PROBLEM", 0, 20], ["arthritis", "OBSERVATION", 11, 20], ["subchondral", "ANATOMY_MODIFIER", 37, 48], ["bone", "ANATOMY", 49, 53]]], ["Subchondral bone loss appears initially as a ragged margin of subchondral bone, but it may extend to cause marked destruction of bone (Fig. 21.4).", [["bone", "ANATOMY", 12, 16], ["subchondral bone", "ANATOMY", 62, 78], ["bone", "ANATOMY", 129, 133], ["bone loss", "DISEASE", 12, 21], ["bone", "TISSUE", 12, 16], ["subchondral bone", "TISSUE", 62, 78], ["bone", "TISSUE", 129, 133], ["Subchondral bone loss", "PROBLEM", 0, 21], ["marked destruction of bone", "PROBLEM", 107, 133], ["bone", "ANATOMY", 12, 16], ["loss", "OBSERVATION", 17, 21], ["ragged", "OBSERVATION_MODIFIER", 45, 51], ["margin", "OBSERVATION_MODIFIER", 52, 58], ["subchondral", "ANATOMY_MODIFIER", 62, 73], ["bone", "ANATOMY", 74, 78], ["marked", "OBSERVATION_MODIFIER", 107, 113], ["destruction", "OBSERVATION", 114, 125], ["bone", "ANATOMY", 129, 133]]], ["When bone loss affects smaller carpal and tarsal bones, these small cuboidal bones may be dramatically reduced in mass.Increased Subchondral Bone Opacity ::: Radiographic Signs of Joint DiseaseIn benign joint disease, such as degenerative joint disease, subchondral bone may be more opaque than normal because of stress remodeling (see Fig. 21.3).", [["bone", "ANATOMY", 5, 9], ["carpal", "ANATOMY", 31, 37], ["tarsal bones", "ANATOMY", 42, 54], ["cuboidal bones", "ANATOMY", 68, 82], ["Bone", "ANATOMY", 141, 145], ["joint", "ANATOMY", 203, 208], ["joint", "ANATOMY", 239, 244], ["subchondral bone", "ANATOMY", 254, 270], ["bone loss", "DISEASE", 5, 14], ["benign joint disease", "DISEASE", 196, 216], ["degenerative joint disease", "DISEASE", 226, 252], ["bone", "TISSUE", 5, 9], ["carpal", "MULTI-TISSUE_STRUCTURE", 31, 37], ["tarsal bones", "MULTI-TISSUE_STRUCTURE", 42, 54], ["cuboidal bones", "TISSUE", 68, 82], ["Bone", "TISSUE", 141, 145], ["joint", "MULTI-TISSUE_STRUCTURE", 203, 208], ["joint", "MULTI-TISSUE_STRUCTURE", 239, 244], ["subchondral bone", "MULTI-TISSUE_STRUCTURE", 254, 270], ["bone loss affects smaller carpal and tarsal bones", "PROBLEM", 5, 54], ["these small cuboidal bones", "PROBLEM", 56, 82], ["mass", "PROBLEM", 114, 118], ["Increased Subchondral Bone Opacity", "PROBLEM", 119, 153], ["Radiographic Signs", "TEST", 158, 176], ["Joint DiseaseIn benign joint disease", "PROBLEM", 180, 216], ["degenerative joint disease", "PROBLEM", 226, 252], ["subchondral bone", "PROBLEM", 254, 270], ["stress remodeling", "PROBLEM", 313, 330], ["bone", "ANATOMY", 5, 9], ["loss", "OBSERVATION", 10, 14], ["smaller", "OBSERVATION_MODIFIER", 23, 30], ["carpal", "ANATOMY", 31, 37], ["tarsal bones", "ANATOMY", 42, 54], ["small", "OBSERVATION_MODIFIER", 62, 67], ["cuboidal", "ANATOMY_MODIFIER", 68, 76], ["bones", "ANATOMY", 77, 82], ["may be", "UNCERTAINTY", 83, 89], ["dramatically", "OBSERVATION_MODIFIER", 90, 102], ["reduced", "OBSERVATION_MODIFIER", 103, 110], ["mass", "OBSERVATION", 114, 118], ["Subchondral", "ANATOMY_MODIFIER", 129, 140], ["Bone", "ANATOMY", 141, 145], ["Opacity", "OBSERVATION", 146, 153], ["Joint", "ANATOMY", 180, 185], ["benign", "OBSERVATION_MODIFIER", 196, 202], ["joint disease", "OBSERVATION", 203, 216], ["degenerative", "OBSERVATION_MODIFIER", 226, 238], ["joint", "ANATOMY", 239, 244], ["disease", "OBSERVATION", 245, 252], ["subchondral", "ANATOMY_MODIFIER", 254, 265], ["bone", "ANATOMY", 266, 270]]], ["Increased subchondral bone opacity usually appears as a subchondral zone of increased opacity 1 to 2 mm wide.Altered Perichondral Bone Opacity ::: Radiographic Signs of Joint DiseaseArticular cartilage merges with the synovial membrane at the chondrosynovial junction.", [["subchondral bone", "ANATOMY", 10, 26], ["subchondral zone", "ANATOMY", 56, 72], ["Bone", "ANATOMY", 130, 134], ["Joint DiseaseArticular cartilage", "ANATOMY", 169, 201], ["synovial membrane", "ANATOMY", 218, 235], ["chondrosynovial junction", "ANATOMY", 243, 267], ["opacity", "DISEASE", 86, 93], ["subchondral bone", "TISSUE", 10, 26], ["Perichondral Bone", "TISSUE", 117, 134], ["cartilage", "TISSUE", 192, 201], ["synovial membrane", "MULTI-TISSUE_STRUCTURE", 218, 235], ["chondrosynovial junction", "MULTI-TISSUE_STRUCTURE", 243, 267], ["Increased subchondral bone opacity", "PROBLEM", 0, 34], ["a subchondral zone of increased opacity", "PROBLEM", 54, 93], ["Altered Perichondral Bone Opacity", "PROBLEM", 109, 142], ["Radiographic Signs", "TEST", 147, 165], ["Joint DiseaseArticular cartilage merges", "PROBLEM", 169, 208], ["the synovial membrane at the chondrosynovial junction", "TREATMENT", 214, 267], ["subchondral", "ANATOMY_MODIFIER", 10, 21], ["bone", "ANATOMY", 22, 26], ["opacity", "OBSERVATION", 27, 34], ["subchondral", "OBSERVATION_MODIFIER", 56, 67], ["zone", "OBSERVATION_MODIFIER", 68, 72], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["opacity", "OBSERVATION", 86, 93], ["1 to 2 mm", "OBSERVATION_MODIFIER", 94, 103], ["wide", "OBSERVATION_MODIFIER", 104, 108], ["Perichondral", "ANATOMY_MODIFIER", 117, 129], ["Bone", "ANATOMY", 130, 134], ["Opacity", "OBSERVATION", 135, 142], ["Joint", "ANATOMY", 169, 174], ["DiseaseArticular cartilage", "OBSERVATION", 175, 201], ["synovial membrane", "OBSERVATION", 218, 235], ["chondrosynovial junction", "ANATOMY", 243, 267]]], ["This highly vascular membrane is sensitive to inflammation.", [["vascular membrane", "ANATOMY", 12, 29], ["inflammation", "DISEASE", 46, 58], ["vascular membrane", "MULTI-TISSUE_STRUCTURE", 12, 29], ["inflammation", "PROBLEM", 46, 58], ["vascular membrane", "ANATOMY", 12, 29], ["inflammation", "OBSERVATION", 46, 58]]], ["Synovial inflammation, or hypertrophy, may result in erosion of bone adjacent to the synovium.", [["Synovial", "ANATOMY", 0, 8], ["bone", "ANATOMY", 64, 68], ["synovium", "ANATOMY", 85, 93], ["Synovial inflammation", "DISEASE", 0, 21], ["hypertrophy", "DISEASE", 26, 37], ["Synovial", "TISSUE", 0, 8], ["bone", "TISSUE", 64, 68], ["synovium", "TISSUE", 85, 93], ["Synovial inflammation", "PROBLEM", 0, 21], ["hypertrophy", "PROBLEM", 26, 37], ["erosion of bone", "PROBLEM", 53, 68], ["inflammation", "OBSERVATION", 9, 21], ["hypertrophy", "OBSERVATION", 26, 37], ["erosion", "OBSERVATION", 53, 60], ["bone", "ANATOMY", 64, 68], ["synovium", "ANATOMY", 85, 93]]], ["Early inflammation causes adjacent bone to appear ragged and spiculated.", [["bone", "ANATOMY", 35, 39], ["inflammation", "DISEASE", 6, 18], ["bone", "TISSUE", 35, 39], ["Early inflammation", "PROBLEM", 0, 18], ["adjacent bone", "PROBLEM", 26, 39], ["inflammation", "OBSERVATION", 6, 18], ["bone", "ANATOMY", 35, 39], ["ragged", "OBSERVATION_MODIFIER", 50, 56], ["spiculated", "OBSERVATION_MODIFIER", 61, 71]]], ["Longstanding or severe synovial inflammation or hypertrophy may cause pronounced bone erosion (Fig. 21.5).Articular Soft Tissue Mineralization ::: Radiographic Signs of Joint DiseaseMineralization may occur within the joint capsule, synovial membrane, or synovial fluid as a consequence of chronic joint disease.", [["synovial", "ANATOMY", 23, 31], ["bone", "ANATOMY", 81, 85], ["Articular", "ANATOMY", 106, 115], ["joint capsule", "ANATOMY", 218, 231], ["synovial membrane", "ANATOMY", 233, 250], ["synovial fluid", "ANATOMY", 255, 269], ["joint", "ANATOMY", 298, 303], ["inflammation", "DISEASE", 32, 44], ["hypertrophy", "DISEASE", 48, 59], ["bone erosion", "DISEASE", 81, 93], ["chronic joint disease", "DISEASE", 290, 311], ["synovial", "TISSUE", 23, 31], ["bone", "TISSUE", 81, 85], ["Articular Soft Tissue", "TISSUE", 106, 127], ["joint capsule", "TISSUE", 218, 231], ["synovial membrane", "MULTI-TISSUE_STRUCTURE", 233, 250], ["synovial fluid", "ORGANISM_SUBSTANCE", 255, 269], ["joint", "ORGAN", 298, 303], ["Longstanding or severe synovial inflammation", "PROBLEM", 0, 44], ["hypertrophy", "PROBLEM", 48, 59], ["pronounced bone erosion", "PROBLEM", 70, 93], ["Radiographic Signs", "TEST", 147, 165], ["Joint DiseaseMineralization", "PROBLEM", 169, 196], ["synovial membrane", "PROBLEM", 233, 250], ["synovial fluid", "PROBLEM", 255, 269], ["chronic joint disease", "PROBLEM", 290, 311], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["synovial", "ANATOMY", 23, 31], ["inflammation", "OBSERVATION", 32, 44], ["hypertrophy", "OBSERVATION", 48, 59], ["may cause", "UNCERTAINTY", 60, 69], ["pronounced", "OBSERVATION_MODIFIER", 70, 80], ["bone", "ANATOMY", 81, 85], ["erosion", "OBSERVATION", 86, 93], ["Soft Tissue", "ANATOMY", 116, 127], ["Mineralization", "OBSERVATION", 128, 142], ["Joint", "ANATOMY", 169, 174], ["DiseaseMineralization", "OBSERVATION", 175, 196], ["joint", "ANATOMY", 218, 223], ["capsule", "ANATOMY_MODIFIER", 224, 231], ["synovial membrane", "ANATOMY", 233, 250], ["synovial", "ANATOMY", 255, 263], ["fluid", "OBSERVATION", 264, 269], ["chronic", "OBSERVATION_MODIFIER", 290, 297], ["joint", "ANATOMY", 298, 303], ["disease", "OBSERVATION", 304, 311]]], ["Occasionally, large accumulations of articular or periarticular calcific material may be observed.", [["articular", "ANATOMY", 37, 46], ["periarticular calcific material", "ANATOMY", 50, 81], ["articular", "TISSUE", 37, 46], ["large accumulations of articular or periarticular calcific material", "PROBLEM", 14, 81], ["large", "OBSERVATION_MODIFIER", 14, 19], ["accumulations", "OBSERVATION_MODIFIER", 20, 33], ["articular", "ANATOMY", 37, 46], ["periarticular", "ANATOMY", 50, 63], ["calcific", "OBSERVATION", 64, 72], ["may be observed", "UNCERTAINTY", 82, 97]]], ["Large osteochondromas have been reported within the joints of dogs and cats, and intrameniscal calcification and ossification have been observed in the stifle joints of cats.1 Pseudogout, or calcium pyrophosphate deposition disease, also causes mineralization of articular and periarticular soft tissues and has been reported in dogs.Intraarticular Calcified Bodies ::: Radiographic Signs of Joint DiseaseSmall, well-defined articular and periarticular calcific opacities are occasionally observed in dogs and cats.", [["osteochondromas", "ANATOMY", 6, 21], ["joints", "ANATOMY", 52, 58], ["stifle joints", "ANATOMY", 152, 165], ["articular", "ANATOMY", 263, 272], ["periarticular soft tissues", "ANATOMY", 277, 303], ["articular", "ANATOMY", 425, 434], ["periarticular calcific opacities", "ANATOMY", 439, 471], ["osteochondromas", "DISEASE", 6, 21], ["calcification", "DISEASE", 95, 108], ["ossification", "DISEASE", 113, 125], ["calcium pyrophosphate", "CHEMICAL", 191, 212], ["opacities", "DISEASE", 462, 471], ["calcium pyrophosphate", "CHEMICAL", 191, 212], ["osteochondromas", "CANCER", 6, 21], ["joints", "MULTI-TISSUE_STRUCTURE", 52, 58], ["dogs", "ORGANISM", 62, 66], ["cats", "ORGANISM", 71, 75], ["stifle joints", "MULTI-TISSUE_STRUCTURE", 152, 165], ["cats", "ORGANISM", 169, 173], ["calcium pyrophosphate", "SIMPLE_CHEMICAL", 191, 212], ["articular", "TISSUE", 263, 272], ["periarticular soft tissues", "TISSUE", 277, 303], ["dogs", "ORGANISM", 329, 333], ["articular", "TISSUE", 425, 434], ["periarticular calcific opacities", "PATHOLOGICAL_FORMATION", 439, 471], ["dogs", "ORGANISM", 501, 505], ["cats", "ORGANISM", 510, 514], ["dogs", "SPECIES", 62, 66], ["cats", "SPECIES", 71, 75], ["cats", "SPECIES", 169, 173], ["dogs", "SPECIES", 329, 333], ["dogs", "SPECIES", 501, 505], ["cats", "SPECIES", 510, 514], ["Large osteochondromas", "PROBLEM", 0, 21], ["intrameniscal calcification", "PROBLEM", 81, 108], ["ossification", "PROBLEM", 113, 125], ["1 Pseudogout", "PROBLEM", 174, 186], ["calcium pyrophosphate deposition disease", "PROBLEM", 191, 231], ["mineralization of articular and periarticular soft tissues", "PROBLEM", 245, 303], ["Radiographic Signs", "TEST", 370, 388], ["Joint DiseaseSmall", "PROBLEM", 392, 410], ["well-defined articular and periarticular calcific opacities", "PROBLEM", 412, 471], ["osteochondromas", "OBSERVATION", 6, 21], ["joints", "ANATOMY", 52, 58], ["intrameniscal", "OBSERVATION_MODIFIER", 81, 94], ["calcification", "OBSERVATION", 95, 108], ["ossification", "OBSERVATION", 113, 125], ["stifle", "ANATOMY_MODIFIER", 152, 158], ["joints", "ANATOMY", 159, 165], ["Pseudogout", "OBSERVATION", 176, 186], ["calcium pyrophosphate deposition disease", "OBSERVATION", 191, 231], ["mineralization", "OBSERVATION_MODIFIER", 245, 259], ["articular", "ANATOMY", 263, 272], ["periarticular", "ANATOMY_MODIFIER", 277, 290], ["soft tissues", "ANATOMY", 291, 303], ["Calcified", "OBSERVATION_MODIFIER", 349, 358], ["Bodies", "OBSERVATION", 359, 365], ["Joint", "ANATOMY", 392, 397], ["DiseaseSmall", "OBSERVATION", 398, 410], ["well-defined", "OBSERVATION_MODIFIER", 412, 424], ["articular", "OBSERVATION_MODIFIER", 425, 434], ["periarticular", "ANATOMY", 439, 452], ["calcific", "OBSERVATION_MODIFIER", 453, 461], ["opacities", "OBSERVATION", 462, 471]]], ["Such mineralized fragments are sometimes called joint mice.", [["fragments", "ANATOMY", 17, 26], ["mice", "ORGANISM", 54, 58], ["mice", "SPECIES", 54, 58], ["Such mineralized fragments", "PROBLEM", 0, 26], ["mineralized", "OBSERVATION_MODIFIER", 5, 16], ["fragments", "OBSERVATION", 17, 26], ["joint", "ANATOMY", 48, 53]]], ["Not all such fragments are free within the joint, although they may appear free radiographically; fragments may become adhered to the joint capsule.", [["fragments", "ANATOMY", 13, 22], ["joint", "ANATOMY", 43, 48], ["fragments", "ANATOMY", 98, 107], ["joint capsule", "ANATOMY", 134, 147], ["joint", "MULTI-TISSUE_STRUCTURE", 43, 48], ["joint capsule", "CANCER", 134, 147], ["all such fragments", "PROBLEM", 4, 22], ["fragments", "PROBLEM", 98, 107], ["all", "OBSERVATION_MODIFIER", 4, 7], ["such fragments", "OBSERVATION", 8, 22], ["free", "OBSERVATION_MODIFIER", 27, 31], ["joint", "ANATOMY", 43, 48], ["fragments", "OBSERVATION", 98, 107], ["joint", "ANATOMY", 134, 139], ["capsule", "ANATOMY_MODIFIER", 140, 147]]], ["Articular calcified bodies usually fall into three fairly distinct categories: (1) avulsed fragments of articular or periarticular bone, (2) osteochondral components of a disintegrating joint surface, or (3) small synovial osteochondromas (Table 21.1).2 They must be differentiated from sesamoid bones.Joint Displacement or Incongruency ::: Radiographic Signs of Joint DiseaseWhen the normal spatial relation between components of a joint is disturbed, some type of displacement has occurred.", [["Articular calcified bodies", "ANATOMY", 0, 26], ["fragments", "ANATOMY", 91, 100], ["articular", "ANATOMY", 104, 113], ["periarticular bone", "ANATOMY", 117, 135], ["osteochondral components", "ANATOMY", 141, 165], ["joint surface", "ANATOMY", 186, 199], ["synovial osteochondromas", "ANATOMY", 214, 238], ["sesamoid bones", "ANATOMY", 287, 301], ["joint", "ANATOMY", 433, 438], ["synovial osteochondromas", "DISEASE", 214, 238], ["articular", "TISSUE", 104, 113], ["periarticular bone", "TISSUE", 117, 135], ["joint surface", "CELLULAR_COMPONENT", 186, 199], ["synovial osteochondromas", "CANCER", 214, 238], ["sesamoid bones", "MULTI-TISSUE_STRUCTURE", 287, 301], ["Joint", "MULTI-TISSUE_STRUCTURE", 302, 307], ["joint", "MULTI-TISSUE_STRUCTURE", 433, 438], ["Articular calcified bodies", "PROBLEM", 0, 26], ["avulsed fragments of articular or periarticular bone", "PROBLEM", 83, 135], ["a disintegrating joint surface", "PROBLEM", 169, 199], ["small synovial osteochondromas", "PROBLEM", 208, 238], ["Joint Displacement", "PROBLEM", 302, 320], ["Radiographic Signs", "TEST", 341, 359], ["Joint DiseaseWhen", "PROBLEM", 363, 380], ["displacement", "PROBLEM", 466, 478], ["calcified", "OBSERVATION_MODIFIER", 10, 19], ["bodies", "OBSERVATION", 20, 26], ["fairly", "OBSERVATION_MODIFIER", 51, 57], ["distinct", "OBSERVATION_MODIFIER", 58, 66], ["categories", "OBSERVATION", 67, 77], ["avulsed", "OBSERVATION_MODIFIER", 83, 90], ["fragments", "OBSERVATION", 91, 100], ["articular", "ANATOMY", 104, 113], ["periarticular bone", "ANATOMY", 117, 135], ["osteochondral", "ANATOMY", 141, 154], ["joint", "ANATOMY", 186, 191], ["small", "OBSERVATION_MODIFIER", 208, 213], ["synovial", "ANATOMY", 214, 222], ["osteochondromas", "OBSERVATION", 223, 238], ["sesamoid bones", "ANATOMY", 287, 301], ["Displacement", "OBSERVATION", 308, 320], ["Joint", "ANATOMY", 363, 368], ["normal", "OBSERVATION", 385, 391], ["spatial", "OBSERVATION_MODIFIER", 392, 399], ["joint", "ANATOMY", 433, 438], ["disturbed", "OBSERVATION_MODIFIER", 442, 451], ["displacement", "OBSERVATION_MODIFIER", 466, 478]]], ["A good example is a luxated coxofemoral joint.", [["coxofemoral joint", "ANATOMY", 28, 45], ["coxofemoral joint", "MULTI-TISSUE_STRUCTURE", 28, 45], ["a luxated coxofemoral joint", "PROBLEM", 18, 45], ["good", "OBSERVATION_MODIFIER", 2, 6], ["coxofemoral joint", "ANATOMY", 28, 45]]], ["Other less obvious incongruities, such as the cranial drawer sign in a stifle with a ruptured cranial cruciate ligament and minor elbow incongruity in dogs with elbow dysplasia, can be difficult to see radiographically.3", [["cranial", "ANATOMY", 46, 53], ["cranial cruciate ligament", "ANATOMY", 94, 119], ["elbow", "ANATOMY", 130, 135], ["elbow dysplasia", "ANATOMY", 161, 176], ["elbow dysplasia", "DISEASE", 161, 176], ["stifle", "ORGANISM_SUBDIVISION", 71, 77], ["cranial cruciate ligament", "TISSUE", 94, 119], ["elbow", "ORGANISM_SUBDIVISION", 130, 135], ["elbow", "ORGANISM_SUBDIVISION", 161, 166], ["dysplasia", "PATHOLOGICAL_FORMATION", 167, 176], ["dogs", "SPECIES", 151, 155], ["Other less obvious incongruities", "PROBLEM", 0, 32], ["the cranial drawer sign", "TEST", 42, 65], ["a ruptured cranial cruciate ligament", "PROBLEM", 83, 119], ["minor elbow incongruity in dogs", "PROBLEM", 124, 155], ["elbow dysplasia", "PROBLEM", 161, 176], ["less", "OBSERVATION_MODIFIER", 6, 10], ["obvious", "OBSERVATION_MODIFIER", 11, 18], ["incongruities", "OBSERVATION", 19, 32], ["cranial", "ANATOMY", 46, 53], ["ruptured", "OBSERVATION", 85, 93], ["cranial", "ANATOMY_MODIFIER", 94, 101], ["cruciate ligament", "ANATOMY", 102, 119], ["elbow", "ANATOMY", 130, 135], ["incongruity", "OBSERVATION", 136, 147], ["elbow", "ANATOMY", 161, 166], ["dysplasia", "OBSERVATION", 167, 176]]]], "PMC7377504": [["Employment perspectives ::: IntroductionAmong EU countries, Italy is known for high and persistent youth unemployment.", [["persistent", "OBSERVATION_MODIFIER", 88, 98]]], ["In the age group of 15\u201329 yr of age, Italians not in education, employment, or training account for 23.4% compared to the EU figure of 12.9%.", [["the EU figure", "TEST", 118, 131]]], ["Ten years after graduation, Italian graduates, defined as people who have been in the educational system for \u226516 yr, have lower unemployment rates (12.3%) compared to those people with 13 yr of education (23.2% unemployment rate).", [["people", "ORGANISM", 58, 64], ["people", "ORGANISM", 173, 179], ["people", "SPECIES", 58, 64], ["people", "SPECIES", 173, 179], ["lower unemployment rates", "PROBLEM", 122, 146]]], ["Primary school graduates or those people with 8 yr of education have an unemployment rate of 41.6% (Istat, 2019).", [["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["an unemployment rate", "TEST", 69, 89]]], ["Five years after graduation, first-level university graduates in agriculture and veterinary sciences (bachelor\u2019s level) have an employment index of 84%, which is lower than the average of their contemporary graduates 88.6% (Figure 1).", [["an employment index", "TEST", 125, 144]]], ["Wage disparity still exists among the sexes with males, first-level or second-level graduates, earning 100 euros/mo more than their female counterparts in agriculture and veterinary sciences (Almalaurea, 2019).Employment perspectives ::: IntroductionRegarding the job market, the Italian perspective is not affected by the other EU countries as a result of the free movement of professions guaranteed by the community agreements.", [["Wage disparity", "PROBLEM", 0, 14]]], ["The 3-yr, first cycle degree course in animal production is currently offered at 14 universities, which are distributed in most regions of Italy (Figure 2).", [["degree", "OBSERVATION_MODIFIER", 22, 28], ["course", "OBSERVATION_MODIFIER", 29, 35], ["most regions", "OBSERVATION_MODIFIER", 123, 135]]], ["At a large university campus, a programmed number of students is expected.", [["large", "OBSERVATION_MODIFIER", 5, 10]]], ["In open-access smaller academies, an initial verification is conducted to ascertain the student\u2019s level of preparation for university classes and any formative deficiencies that will impact their performance.", [["an initial verification", "TEST", 34, 57], ["any formative deficiencies", "PROBLEM", 146, 172]]], ["This course of study is usually named \u201csciences and technologies of animal production\u201d and offers a very broad introduction to agro-technical systems to create the knowledge base for the management of livestock farms.", [["agro-technical systems", "TREATMENT", 127, 149], ["livestock farms", "OBSERVATION", 201, 216]]], ["The courses in animal production include large educational spaces dedicated to practical aspects and internships\u2014both in university experimental farms and in private agricultural, livestock, processing, marketing, and consulting companies (Figure 3).Italian higher education system in animal science ::: IntroductionThe degree thesis usually includes discussion of a project combined with a training internship.", [["a training internship", "TREATMENT", 389, 410], ["large", "OBSERVATION_MODIFIER", 41, 46]]], ["After obtaining the 3-yr qualification, a percentage of students (almost 50%) abandon their studies and look for a job.", [["their studies", "TEST", 86, 99]]], ["The natural and prevalent continuation of studies is the master\u2019s degree in animal and production sciences.Italian higher education system in animal science ::: IntroductionThe second cycle of animal science studies is represented by 16, 2-yr master programs that are currently offered by 15 universities.", [["studies", "TEST", 42, 49], ["animal science studies", "TEST", 193, 215]]], ["Courses are managed by departments of agricultural sciences or veterinary medicine or jointly by both departments.", [["veterinary medicine", "TREATMENT", 63, 82]]], ["There is a wide range of programs at each university.", [["wide", "OBSERVATION_MODIFIER", 11, 15]]], ["Seven out of sixteen master\u2019s programs have a title of \u201cAnimal Science\u201d (or similar) and they are aimed at producing students with a broad range of training that covers several fields of the animal sciences.", [["a broad range of training", "TREATMENT", 131, 156]]], ["Some courses offer a double-degree program.", [["a double-degree program", "TREATMENT", 19, 42]]], ["During the master\u2019s program, the student must develop an experimental project that is usually carried out in an internal traineeship at the same university or in a foreign country with the support of the Erasmus program or other international grants.", [["the Erasmus program", "TREATMENT", 200, 219]]], ["Five years after graduation, about 75% of the students are employed in a field connected to their qualifications.Italian higher education system in animal science ::: IntroductionAll departments are composed of different research units, covering most disciplinary competencies.", [["different research units", "TREATMENT", 211, 235]]], ["These disciplines are animal genetics, animal nutrition, applied animal science, aquaculture, poultry, and zooculture.Italian higher education system in animal science ::: IntroductionThe highest degree of education is the PhD. In 2016, in Italy, there were 12 PhD programs that can be clearly classified as animal science.", [["animal nutrition", "TREATMENT", 39, 55], ["aquaculture", "TREATMENT", 81, 92], ["poultry", "TREATMENT", 94, 101]]], ["In the same year, a total of 45 positions in animal science were available to graduates with a PhD. On average, every year, a total of 35 students finish their PhD. In recent years, however, there has been a tendency for a reduced number of positions in animal science that require a PhD. The reduced number of available positions that require a PhD is due mainly to the high costs (about 60,000 euros) for opening a PhD position and the decrease of scholarships available from public funding.Research and innovation investment ::: IntroductionIn Italy, the investment in research and innovation is 1.35% of the GDP (1.97% in Europe) with a slow increase that is essentially driven by a progressive increase of private/business investments and a decrease in public investments.", [["GDP", "CHEMICAL", 612, 615], ["a PhD position", "TREATMENT", 415, 429], ["public funding", "TREATMENT", 478, 492], ["the GDP", "TEST", 608, 615], ["a slow increase", "PROBLEM", 639, 654], ["private/business investments", "TREATMENT", 711, 739], ["a decrease in public investments", "PROBLEM", 744, 776], ["tendency", "OBSERVATION_MODIFIER", 208, 216], ["reduced", "OBSERVATION_MODIFIER", 293, 300], ["number", "OBSERVATION_MODIFIER", 301, 307], ["decrease", "OBSERVATION_MODIFIER", 438, 446], ["slow", "OBSERVATION_MODIFIER", 641, 645], ["increase", "OBSERVATION", 646, 654], ["progressive", "OBSERVATION_MODIFIER", 687, 698], ["increase", "OBSERVATION_MODIFIER", 699, 707], ["decrease", "OBSERVATION_MODIFIER", 746, 754]]], ["The financial resources allocated by the Italian government for research and development, rather than actual expenditures reported by research and development indicators (OECD, 2019), has decreased by 20% over the past 10 yr.", [["decreased", "OBSERVATION_MODIFIER", 188, 197]]], ["Despite limited public engagement in supporting research, Italian scientists are quite active in European scenarios in a variety of different fields, including agriculture and animal science.", [["active", "OBSERVATION_MODIFIER", 87, 93]]], ["Italian scientists produce a significant number of high-quality publications (as determined by IF and citation indexes) in the area of agricultural and veterinary science that covers about 7.6% of the total number of Italian researchers.Research and innovation investment ::: IntroductionResearch and innovation policy are formed both at the national and regional level through the preparation of planning documents and the management of dedicated funds.", [["significant", "OBSERVATION_MODIFIER", 29, 40], ["agricultural", "OBSERVATION_MODIFIER", 135, 147], ["veterinary science", "OBSERVATION", 152, 170]]], ["In December 2019, the Italian government included in the 2020 budget funding for a new national agency for research as an independent body for the coordination of research funding.Research and innovation investment ::: IntroductionStrategic plans for innovation and research in the food and forestry agricultural sector (RDP 2014\u20132020) supported the following topics:Research and innovation investment ::: IntroductionAt the regional level, agricultural research is regulated by specific rules, regarding innovation development and transfer services.", [["body", "ANATOMY", 134, 138], ["body", "ORGANISM_SUBDIVISION", 134, 138], ["research funding", "TREATMENT", 163, 179], ["innovation", "TREATMENT", 251, 261]]], ["Regional administrations have full autonomy of action.", [["Regional administrations", "TREATMENT", 0, 24]]], ["At the regional level, the investments in zootechnical research is about 25% of the total investment in agricultural research (Macr\u00ec, 2017; research financed by the regions 2017).", [["investments", "OBSERVATION_MODIFIER", 27, 38]]], ["If the main issues supported at a territorial level in recent years are examined, the most frequently pursued objective has been that of developing new products and processes for improving product quality.", [["the main issues", "PROBLEM", 3, 18], ["main", "OBSERVATION_MODIFIER", 7, 11], ["new", "OBSERVATION_MODIFIER", 148, 151], ["products", "OBSERVATION", 152, 160]]], ["A further goal has been the achievement of innovations aimed at decreasing production costs, management of natural resources, and enhancing biodiversity and the health and well-being of farm animals (with particular focus on alternatives to antimicrobials).Research and innovation investment ::: IntroductionIn order to strengthen the area of research and innovation, the Ministry of Research and University, since 2012, has supported the creation of a national cluster of agrifood, a recognized association of companies, universities, research centers, and territorial representations, for the development and enhancement of national technology in the agrifood area and the promotion of life-long learning initiatives.Research and innovation investment ::: IntroductionIn a perspective that aligns with the 2030 Agenda on sustainability goals, new challenges in the field of research and innovation in animal science must support sustainable competitiveness and encourage the development of healthy and safe breeding systems to secure food safety (goal 2).", [["agrifood", "DISEASE", 473, 481], ["natural resources", "TREATMENT", 107, 124], ["antimicrobials", "TREATMENT", 241, 255], ["safe breeding systems", "TREATMENT", 1004, 1025], ["enhancing", "OBSERVATION_MODIFIER", 130, 139], ["biodiversity", "OBSERVATION_MODIFIER", 140, 152], ["territorial representations", "OBSERVATION", 558, 585]]], ["Interventions aimed at encouraging the supply of environmental services by livestock production systems, reduction of greenhouse gas emissions, definition of integrated strategies for disease prevention, and control activities (goal 15) are priorities.", [["Interventions", "TREATMENT", 0, 13], ["greenhouse gas emissions", "TREATMENT", 118, 142], ["disease prevention", "TREATMENT", 184, 202]]], ["Animal scientists will be asked to repurpose food waste not intended for human consumption for feed use (goal 13).", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78]]], ["Innovation must consider not only technical-production elements but must also favor improvement of the organizational and management components of livestock production (Figure 4).", [["livestock production", "PROBLEM", 147, 167]]], ["Precision farming and feeding technologies, as well as new techniques in animal breeding and reproduction, are increasingly essential to compete effectively in the global market of agrifood products.Future ConsiderationsThe direction and types of training needed for graduates in animal science are difficult to forecast.", [["feeding technologies", "TREATMENT", 22, 42], ["agrifood products", "TREATMENT", 181, 198], ["training", "TREATMENT", 247, 255]]], ["To adapt to a dynamic environment, the human capital in livestock applied science and basic disciplines, as well as soft skills, will be reinforced in animal science graduate courses.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44]]], ["The future animal science educational programs should change not only in terms of innovative content but also in terms of teaching methods.", [["animal science educational programs", "TREATMENT", 11, 46], ["teaching methods", "TREATMENT", 122, 138]]], ["In this direction, the new generation of animal science courses must use new technological innovations and change their approaches in defining the curriculum content.", [["animal science courses", "TREATMENT", 41, 63], ["new technological innovations", "TREATMENT", 73, 102], ["new", "OBSERVATION_MODIFIER", 23, 26]]], ["Short continuous massive open online courses will be continuously generated for the maintenance and improvement of the graduates\u2019 skills necessary for continuous transformation of animal production chains.", [["Short continuous massive open online courses", "TREATMENT", 0, 44], ["animal production chains", "TREATMENT", 180, 204], ["massive", "OBSERVATION_MODIFIER", 17, 24], ["open", "OBSERVATION", 25, 29]]], ["Only this integrated approach will allow students to develop a modern range of knowledge related to the livestock value chain and to build confidence in the subject and in themselves.Future ConsiderationsThis scenario has undergone an incredible acceleration due to the COVID-19 pandemic.", [["an incredible acceleration", "PROBLEM", 232, 258], ["the COVID", "TEST", 266, 275], ["pandemic", "PROBLEM", 279, 287]]], ["This paper was written before the SARS-CoV-2 coronavirus reached Italy and Europe in full force in early 2020.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2 coronavirus", "ORGANISM", 34, 56], ["SARS-CoV-2 coronavirus", "SPECIES", 34, 56]]], ["During recent months, universities adapted quickly and developed distance learning solutions for education and training programs to meet social distancing requirements in an attempt to slow the spread of the virus and minimize the impact on the health care system.", [["distance learning solutions", "TREATMENT", 65, 92], ["education and training programs", "TREATMENT", 97, 128], ["social distancing requirements", "TREATMENT", 137, 167], ["the virus", "PROBLEM", 204, 213]]], ["This experience makes it clear that nothing will return as before once the crisis has been overcome.", [["the crisis", "PROBLEM", 71, 81]]], ["The impact of the COVID-19 pandemic on the Italian zootechnical system and the food supply chain will be a major topic of debate among scientists, professionals, and stakeholders for many months to come.", [["the COVID", "TREATMENT", 14, 23], ["the Italian zootechnical system", "TREATMENT", 39, 70]]], ["Analysis of the short-and medium-term effects of the pandemic on the food production system must be given high priority among the many challenges animal scientists must face in the near future.", [["Analysis", "TEST", 0, 8], ["the short-and medium-term effects", "PROBLEM", 12, 45], ["short", "OBSERVATION_MODIFIER", 16, 21]]], ["Additionally, the increased demand for sustainable animal products with the increasing availability of nonconventional foods and the need for sustainable feed production systems creates a challenge for the animal scientist.", [["the increased demand", "PROBLEM", 14, 34], ["sustainable animal products", "TREATMENT", 39, 66], ["nonconventional foods", "TREATMENT", 103, 124], ["sustainable feed production systems", "TREATMENT", 142, 177], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["demand", "OBSERVATION_MODIFIER", 28, 34]]], ["Food accessibility and economical production must be balanced with the emerging interest by consumers of animal products to ensure ethical animal production systems.ConclusionsThe future of research and training programs in animal science departments in Italy is as much of a challenge as animal scientists have ever experienced.", [["economical production", "PROBLEM", 23, 44], ["animal products", "TREATMENT", 105, 120], ["ethical animal production systems", "PROBLEM", 131, 164], ["research and training programs", "TREATMENT", 190, 220]]], ["The limitations in free movement of people and products caused by the SARS-CoV-2 pandemic will have a long-lasting impact on animal production and animal science.", [["SARS", "DISEASE", 70, 74], ["people", "ORGANISM", 36, 42], ["SARS-CoV-2", "ORGANISM", 70, 80], ["people", "SPECIES", 36, 42], ["SARS-CoV", "SPECIES", 70, 78], ["the SARS", "PROBLEM", 66, 74]]], ["Given the growing demand for ethical food production systems by the millennial generation, animal science graduates must be nimble and flexible enough to rapidly design and implement new strategies for the production of animal-sourced foods.", [["foods", "ORGANISM_SUBDIVISION", 235, 240], ["ethical food production systems", "TREATMENT", 29, 60], ["new strategies", "TREATMENT", 183, 197]]], ["We must prepare future animal scientists with as much of a broad and diverse background of knowledge and skills as possible that will enable them to establish cross-disciplinary approaches among animal, human, and environmental health in a \u201cone-health\u201d approach.", [["human", "ORGANISM", 203, 208], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 203, 208]]], ["In addition, future animal scientists will need to be equipped with new models of animal production systems, coupled with smart working skills and information and technology tools, efficient and safe use of resources, and robust communication capabilities to meet societal demands for animal-sourced foods.", [["foods", "ORGANISM_SUBDIVISION", 300, 305]]]], "60d0249804cbf3e01db9e6eda2e5cd83db23d15f": [["IntroductionAmantadine and its dimethyl derivative memantine, are two low-affinity, uncompetitive NMDAR antagonists, clinically used to treat Parkinson's and Alzheimer's diseases, respectively.", [["IntroductionAmantadine", "CHEMICAL", 0, 22], ["memantine", "CHEMICAL", 51, 60], ["Parkinson's and Alzheimer's diseases", "DISEASE", 142, 178], ["IntroductionAmantadine", "CHEMICAL", 0, 22], ["dimethyl", "CHEMICAL", 31, 39], ["memantine", "CHEMICAL", 51, 60], ["IntroductionAmantadine", "SIMPLE_CHEMICAL", 0, 22], ["dimethyl derivative", "SIMPLE_CHEMICAL", 31, 50], ["memantine", "SIMPLE_CHEMICAL", 51, 60], ["NMDAR", "SIMPLE_CHEMICAL", 98, 103], ["IntroductionAmantadine", "TREATMENT", 0, 22], ["its dimethyl derivative memantine", "TREATMENT", 27, 60], ["uncompetitive NMDAR antagonists", "TREATMENT", 84, 115], ["Parkinson's", "PROBLEM", 142, 153], ["Alzheimer's diseases", "PROBLEM", 158, 178]]], ["1 Amantadine and its analogue rimantadine also target the M2 ion-channel protein of the influenza A virus, having prophylactic and therapeutic activities in influenza A virus infections.", [["Amantadine", "CHEMICAL", 2, 12], ["rimantadine", "CHEMICAL", 30, 41], ["influenza A virus infections", "DISEASE", 157, 185], ["Amantadine", "CHEMICAL", 2, 12], ["rimantadine", "CHEMICAL", 30, 41], ["Amantadine", "SIMPLE_CHEMICAL", 2, 12], ["rimantadine", "SIMPLE_CHEMICAL", 30, 41], ["influenza A virus", "ORGANISM", 88, 105], ["influenza A virus", "ORGANISM", 157, 174], ["M2 ion-channel protein", "PROTEIN", 58, 80], ["influenza A virus", "SPECIES", 88, 105], ["influenza A virus", "SPECIES", 157, 174], ["influenza A virus", "SPECIES", 88, 105], ["influenza A virus", "SPECIES", 157, 174], ["Amantadine", "TREATMENT", 2, 12], ["its analogue rimantadine", "TREATMENT", 17, 41], ["the influenza A virus", "PROBLEM", 84, 105], ["prophylactic", "TREATMENT", 114, 126], ["influenza A virus infections", "PROBLEM", 157, 185]]], ["However, many influenza virus strains have developed resistance to amantadine and rimantadine.", [["amantadine", "CHEMICAL", 67, 77], ["rimantadine", "CHEMICAL", 82, 93], ["amantadine", "CHEMICAL", 67, 77], ["rimantadine", "CHEMICAL", 82, 93], ["influenza virus", "ORGANISM", 14, 29], ["amantadine", "SIMPLE_CHEMICAL", 67, 77], ["rimantadine", "SIMPLE_CHEMICAL", 82, 93], ["many influenza virus strains", "PROBLEM", 9, 37], ["amantadine", "TREATMENT", 67, 77], ["rimantadine", "TREATMENT", 82, 93], ["influenza virus", "OBSERVATION", 14, 29]]], ["2 Finally, amantadine, rimantadine and related polycyclic amines possess trypanocidal properties (Fig. 1) .", [["amantadine", "CHEMICAL", 11, 21], ["rimantadine", "CHEMICAL", 23, 34], ["polycyclic amines", "CHEMICAL", 47, 64], ["amantadine", "CHEMICAL", 11, 21], ["rimantadine", "CHEMICAL", 23, 34], ["polycyclic amines", "CHEMICAL", 47, 64], ["amantadine", "SIMPLE_CHEMICAL", 11, 21], ["rimantadine", "SIMPLE_CHEMICAL", 23, 34], ["related polycyclic amines", "SIMPLE_CHEMICAL", 39, 64], ["amantadine", "TREATMENT", 11, 21], ["rimantadine", "TREATMENT", 23, 34], ["related polycyclic amines possess trypanocidal properties", "TREATMENT", 39, 96], ["trypanocidal properties", "OBSERVATION", 73, 96]]], ["3 Considering the interesting pharmacological profile of amantadine, rimantadine and memantine, these compounds are ideal leads in the development of new agents to treat excitotoxic NMDAR channel mediated neurodegenerative diseases, influenza infections or African trypanosomiasis.IntroductionRecently, we started a research project directed to the synthesis and pharmacological evaluation of new analogs of amantadine, memantine and rimantadine.", [["amantadine", "CHEMICAL", 57, 67], ["rimantadine", "CHEMICAL", 69, 80], ["memantine", "CHEMICAL", 85, 94], ["neurodegenerative diseases", "DISEASE", 205, 231], ["influenza infections", "DISEASE", 233, 253], ["trypanosomiasis", "DISEASE", 265, 280], ["amantadine", "CHEMICAL", 408, 418], ["memantine", "CHEMICAL", 420, 429], ["rimantadine", "CHEMICAL", 434, 445], ["amantadine", "CHEMICAL", 57, 67], ["rimantadine", "CHEMICAL", 69, 80], ["memantine", "CHEMICAL", 85, 94], ["amantadine", "CHEMICAL", 408, 418], ["memantine", "CHEMICAL", 420, 429], ["rimantadine", "CHEMICAL", 434, 445], ["amantadine", "SIMPLE_CHEMICAL", 57, 67], ["rimantadine", "SIMPLE_CHEMICAL", 69, 80], ["memantine", "SIMPLE_CHEMICAL", 85, 94], ["amantadine", "SIMPLE_CHEMICAL", 408, 418], ["memantine", "SIMPLE_CHEMICAL", 420, 429], ["rimantadine", "SIMPLE_CHEMICAL", 434, 445], ["amantadine", "TREATMENT", 57, 67], ["rimantadine", "TREATMENT", 69, 80], ["memantine", "TREATMENT", 85, 94], ["new agents", "TREATMENT", 150, 160], ["excitotoxic NMDAR channel mediated neurodegenerative diseases", "PROBLEM", 170, 231], ["influenza infections", "PROBLEM", 233, 253], ["African trypanosomiasis", "PROBLEM", 257, 280], ["a research project", "TREATMENT", 314, 332], ["the synthesis", "TREATMENT", 345, 358], ["pharmacological evaluation", "TEST", 363, 389], ["amantadine", "TREATMENT", 408, 418], ["memantine", "TREATMENT", 420, 429], ["rimantadine", "TREATMENT", 434, 445], ["neurodegenerative", "OBSERVATION_MODIFIER", 205, 222], ["diseases", "OBSERVATION", 223, 231]]], ["So far, we have synthesized ring-contracted analogs of these drugs and found that they showed NMDA receptor antagonism, many of them being more potent than amantadine but less potent than memantine.", [["NMDA", "CHEMICAL", 94, 98], ["amantadine", "CHEMICAL", 156, 166], ["memantine", "CHEMICAL", 188, 197], ["NMDA", "CHEMICAL", 94, 98], ["amantadine", "CHEMICAL", 156, 166], ["memantine", "CHEMICAL", 188, 197], ["NMDA", "SIMPLE_CHEMICAL", 94, 98], ["amantadine", "SIMPLE_CHEMICAL", 156, 166], ["memantine", "SIMPLE_CHEMICAL", 188, 197], ["these drugs", "TREATMENT", 55, 66], ["NMDA receptor antagonism", "PROBLEM", 94, 118], ["amantadine", "TREATMENT", 156, 166], ["memantine", "TREATMENT", 188, 197]]], ["4 Moreover, several of these compounds displayed an anti-influenza activity very similar to that of amantadine.", [["amantadine", "CHEMICAL", 100, 110], ["amantadine", "CHEMICAL", 100, 110], ["amantadine", "SIMPLE_CHEMICAL", 100, 110], ["an anti-influenza activity", "PROBLEM", 49, 75], ["amantadine", "TREATMENT", 100, 110], ["anti-influenza activity", "OBSERVATION", 52, 75]]], ["5 We also found that oxapolycyclic amines such as 3-alkyl(2-oxadamantyl)-1-amines and 1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4-benzoxonin-3-amines of general structures 1 and 2, respectively, were also active as NMDA receptor antagonists.", [["amines", "CHEMICAL", 35, 41], ["3-alkyl(2-oxadamantyl)-1-amines", "CHEMICAL", 50, 81], ["1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4-benzoxonin-3-amines", "CHEMICAL", 86, 147], ["NMDA", "CHEMICAL", 213, 217], ["oxapolycyclic amines", "CHEMICAL", 21, 41], ["3-alkyl(2-oxadamantyl)-1-amines", "CHEMICAL", 50, 81], ["1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4-benzoxonin-3-amines", "CHEMICAL", 86, 147], ["NMDA", "CHEMICAL", 213, 217], ["oxapolycyclic amines", "SIMPLE_CHEMICAL", 21, 41], ["3-alkyl(2-oxadamantyl)-1-amines", "SIMPLE_CHEMICAL", 50, 81], ["1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4-benzoxonin-3-amines", "SIMPLE_CHEMICAL", 86, 147], ["NMDA", "SIMPLE_CHEMICAL", 213, 217], ["oxapolycyclic amines", "TREATMENT", 21, 41], ["amines", "TEST", 75, 81], ["hexahydro", "TEST", 98, 107], ["dimethano", "TREATMENT", 116, 125], ["NMDA receptor antagonists", "TREATMENT", 213, 238]]], ["While these compounds lacked anti-influenza activity, several of them displayed trypanocidal activity (Fig. 2) .", [["anti-influenza activity", "TREATMENT", 29, 52], ["anti-influenza activity", "OBSERVATION", 29, 52], ["trypanocidal activity", "OBSERVATION", 80, 101]]], ["6 Although several 1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4benzoxonin-3-amines, 2, displayed low micromolar activity as NMDA receptor antagonists, the presence of an hemiaminal subunit in these compounds may raise serious concerns about their stability and thus of their further development as therapeutical agents.", [["1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4benzoxonin-3-amines", "CHEMICAL", 19, 79], ["NMDA", "CHEMICAL", 121, 125], ["1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4benzoxonin-3-amines", "CHEMICAL", 19, 79], ["NMDA", "CHEMICAL", 121, 125], ["1,2,3,5,6,7-hexahydro-1,5:3,7-dimethano-4benzoxonin-3-amines", "SIMPLE_CHEMICAL", 19, 79], ["NMDA", "SIMPLE_CHEMICAL", 121, 125], ["hemiaminal subunit", "PROTEIN", 167, 185], ["hexahydro", "TEST", 31, 40], ["dimethano-4benzoxonin", "TREATMENT", 49, 70], ["NMDA receptor antagonists", "TREATMENT", 121, 146], ["an hemiaminal subunit", "TREATMENT", 164, 185], ["therapeutical agents", "TREATMENT", 295, 315]]], ["In fact, it is known that NGP1-01, a micromolar NMDA receptor antagonist containing an hemiaminal unit, 7 decomposes easily in aqueous medium.", [["NGP1-01", "CHEMICAL", 26, 33], ["NMDA", "CHEMICAL", 48, 52], ["NGP1-01", "CHEMICAL", 26, 33], ["NMDA", "CHEMICAL", 48, 52], ["NGP1-01", "GENE_OR_GENE_PRODUCT", 26, 33], ["NMDA", "SIMPLE_CHEMICAL", 48, 52], ["NGP1", "TEST", 26, 30], ["a micromolar NMDA receptor antagonist", "TREATMENT", 35, 72], ["an hemiaminal unit", "TREATMENT", 84, 102], ["aqueous medium", "OBSERVATION", 127, 141]]], ["In this Letter we wish to report the synthesis and pharmacological evaluation of several benzopolycyclic amines derived from 3 (Fig. 2) .", [["benzopolycyclic amines", "CHEMICAL", 89, 111], ["benzopolycyclic amines", "CHEMICAL", 89, 111], ["benzopolycyclic amines", "SIMPLE_CHEMICAL", 89, 111], ["the synthesis", "TEST", 33, 46], ["pharmacological evaluation", "TEST", 51, 77], ["several benzopolycyclic amines", "TREATMENT", 81, 111]]], ["Several of these derivatives, that are devoid of the hemiaminal unit, show low micromolar NMDA receptor antagonist activity, although with higher IC 50 than the previously described oxa-analogues.", [["NMDA", "CHEMICAL", 90, 94], ["hemiaminal", "CHEMICAL", 53, 63], ["NMDA", "CHEMICAL", 90, 94], ["NMDA", "SIMPLE_CHEMICAL", 90, 94], ["oxa-analogues", "SIMPLE_CHEMICAL", 182, 195], ["these derivatives", "TREATMENT", 11, 28], ["low micromolar NMDA receptor antagonist activity", "PROBLEM", 75, 123], ["derivatives", "OBSERVATION", 17, 28], ["low micromolar", "OBSERVATION_MODIFIER", 75, 89]]], ["Interestingly, several of the new derivatives are endowed with low micromolar trypanocidal activity while only one compound has anti-influenza activity.SynthesisInspired by the work of Bishop et al., we prepared amine 3 from known diene 4.", [["amine", "CHEMICAL", 212, 217], ["diene", "CHEMICAL", 231, 236], ["amine", "CHEMICAL", 212, 217], ["diene", "CHEMICAL", 231, 236], ["amine 3", "SIMPLE_CHEMICAL", 212, 219], ["diene 4", "SIMPLE_CHEMICAL", 231, 238], ["the new derivatives", "PROBLEM", 26, 45], ["low micromolar trypanocidal activity", "PROBLEM", 63, 99], ["anti-influenza activity", "TREATMENT", 128, 151], ["new", "OBSERVATION_MODIFIER", 30, 33], ["derivatives", "OBSERVATION_MODIFIER", 34, 45], ["low micromolar", "OBSERVATION_MODIFIER", 63, 77], ["trypanocidal activity", "OBSERVATION", 78, 99], ["anti-influenza activity", "OBSERVATION", 128, 151]]], ["9 Thus, Ritter-type transannular cyclization with chloroacetonitrile in acidic medium, 10 and subsequent cleavage of the chloroacetyl group in the resulting chloroacetamide 5 with thiourea led to amine 3 in medium overall yield.", [["chloroacetonitrile", "CHEMICAL", 50, 68], ["chloroacetyl", "CHEMICAL", 121, 133], ["chloroacetamide 5", "CHEMICAL", 157, 174], ["thiourea", "CHEMICAL", 180, 188], ["amine 3", "CHEMICAL", 196, 203], ["chloroacetonitrile", "CHEMICAL", 50, 68], ["chloroacetyl", "CHEMICAL", 121, 133], ["chloroacetamide", "CHEMICAL", 157, 172], ["thiourea", "CHEMICAL", 180, 188], ["amine", "CHEMICAL", 196, 201], ["chloroacetonitrile", "SIMPLE_CHEMICAL", 50, 68], ["chloroacetyl", "SIMPLE_CHEMICAL", 121, 133], ["chloroacetamide 5", "SIMPLE_CHEMICAL", 157, 174], ["thiourea", "SIMPLE_CHEMICAL", 180, 188], ["amine 3", "SIMPLE_CHEMICAL", 196, 203], ["Ritter-type transannular cyclization", "TREATMENT", 8, 44], ["chloroacetonitrile in acidic medium", "TREATMENT", 50, 85], ["the chloroacetyl group", "TREATMENT", 117, 139], ["the resulting chloroacetamide", "TREATMENT", 143, 172], ["thiourea", "TREATMENT", 180, 188]]], ["11 Starting from amine 3 we have prepared several secondary and tertiary amines using classical methods in amine chemistry.", [["amine", "CHEMICAL", 17, 22], ["amines", "CHEMICAL", 73, 79], ["amine", "CHEMICAL", 107, 112], ["amine", "CHEMICAL", 17, 22], ["secondary and tertiary amines", "CHEMICAL", 50, 79], ["amine", "CHEMICAL", 107, 112], ["amine", "SIMPLE_CHEMICAL", 107, 112], ["tertiary amines", "TREATMENT", 64, 79]]], ["Briefly, reductive alkylation of 3 with benzaldehyde and NaBH 3 CN led to 6 in 59% while reductive alkylation of 3 and 6 with formaldehyde and NaBH 3 CN furnished 7 and 11 in 55% and 75% yield, respectively.", [["benzaldehyde", "CHEMICAL", 40, 52], ["NaBH", "CHEMICAL", 57, 61], ["formaldehyde", "CHEMICAL", 126, 138], ["NaBH", "CHEMICAL", 143, 147], ["benzaldehyde", "CHEMICAL", 40, 52], ["NaBH 3 CN", "CHEMICAL", 57, 66], ["formaldehyde", "CHEMICAL", 126, 138], ["NaBH 3 CN", "CHEMICAL", 143, 152], ["benzaldehyde", "SIMPLE_CHEMICAL", 40, 52], ["NaBH 3 CN", "SIMPLE_CHEMICAL", 57, 66], ["formaldehyde", "SIMPLE_CHEMICAL", 126, 138], ["NaBH 3 CN", "SIMPLE_CHEMICAL", 143, 152], ["reductive alkylation", "TREATMENT", 9, 29], ["reductive alkylation", "TREATMENT", 89, 109], ["reductive alkylation", "OBSERVATION", 9, 29]]], ["Hydrogenolysis of amine 7 led to secondary amine 8 in 74% yield.", [["amine", "CHEMICAL", 18, 23], ["amine", "CHEMICAL", 43, 48], ["amine", "CHEMICAL", 18, 23], ["amine", "CHEMICAL", 43, 48], ["amine 7", "SIMPLE_CHEMICAL", 18, 25], ["secondary amine 8", "SIMPLE_CHEMICAL", 33, 50], ["Hydrogenolysis of amine", "TREATMENT", 0, 23]]], ["Alternatively, 8 was obtained by reaction of 3 with methyl chloroformate followed by LiAlH 4 -mediated reduction of the intermediate carbamate, in 28% overall yield.", [["methyl chloroformate", "CHEMICAL", 52, 72], ["LiAlH 4", "CHEMICAL", 85, 92], ["carbamate", "CHEMICAL", 133, 142], ["methyl chloroformate", "CHEMICAL", 52, 72], ["LiAlH", "CHEMICAL", 85, 90], ["carbamate", "CHEMICAL", 133, 142], ["methyl chloroformate", "SIMPLE_CHEMICAL", 52, 72], ["LiAlH 4", "SIMPLE_CHEMICAL", 85, 92], ["intermediate carbamate", "SIMPLE_CHEMICAL", 120, 142], ["methyl chloroformate", "TREATMENT", 52, 72], ["LiAlH 4 -mediated reduction", "TREATMENT", 85, 112], ["the intermediate carbamate", "TREATMENT", 116, 142]]], ["Alkylation of 3 with propargyl bromide led to a mixture of 9 and 10 that were separated by column chromatography.", [["propargyl bromide", "CHEMICAL", 21, 38], ["propargyl bromide", "CHEMICAL", 21, 38], ["propargyl bromide", "SIMPLE_CHEMICAL", 21, 38], ["Alkylation", "TREATMENT", 0, 10], ["propargyl bromide", "TREATMENT", 21, 38]]], ["Finally, alkylation of 3 with 1,5-dibromopentane gave the piperidine derivative 12 in 35% yield (Scheme 1).NMDA receptor antagonist activityTo evaluate if the synthesized compounds were able to antagonize NMDA receptors, we have measured its effect on the increase in intracellular calcium evoked by glutamate or NMDA (both 100 lM, in the presence of 10 lM of glycine) on rat cultured cerebellar granule neurons.", [["intracellular", "ANATOMY", 268, 281], ["cerebellar granule neurons", "ANATOMY", 385, 411], ["1,5-dibromopentane", "CHEMICAL", 30, 48], ["piperidine", "CHEMICAL", 58, 68], ["NMDA", "CHEMICAL", 107, 111], ["NMDA", "CHEMICAL", 205, 209], ["calcium", "CHEMICAL", 282, 289], ["glutamate", "CHEMICAL", 300, 309], ["NMDA", "CHEMICAL", 313, 317], ["glycine", "CHEMICAL", 360, 367], ["1,5-dibromopentane", "CHEMICAL", 30, 48], ["piperidine", "CHEMICAL", 58, 68], ["NMDA", "CHEMICAL", 107, 111], ["NMDA", "CHEMICAL", 205, 209], ["calcium", "CHEMICAL", 282, 289], ["glutamate", "CHEMICAL", 300, 309], ["NMDA", "CHEMICAL", 313, 317], ["glycine", "CHEMICAL", 360, 367], ["1,5-dibromopentane", "SIMPLE_CHEMICAL", 30, 48], ["piperidine", "SIMPLE_CHEMICAL", 58, 68], ["NMDA receptor antagonist", "GENE_OR_GENE_PRODUCT", 107, 131], ["NMDA", "SIMPLE_CHEMICAL", 205, 209], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 268, 281], ["calcium", "SIMPLE_CHEMICAL", 282, 289], ["glutamate", "SIMPLE_CHEMICAL", 300, 309], ["NMDA", "SIMPLE_CHEMICAL", 313, 317], ["glycine", "SIMPLE_CHEMICAL", 360, 367], ["rat", "ORGANISM", 372, 375], ["cerebellar granule neurons", "CELL", 385, 411], ["NMDA receptor", "PROTEIN", 107, 120], ["NMDA receptors", "PROTEIN", 205, 219], ["rat cultured cerebellar granule neurons", "CELL_LINE", 372, 411], ["rat", "SPECIES", 372, 375], ["alkylation", "TREATMENT", 9, 19], ["dibromopentane", "TREATMENT", 34, 48], ["the piperidine derivative", "TREATMENT", 54, 79], ["NMDA receptor antagonist activity", "TREATMENT", 107, 140], ["the synthesized compounds", "PROBLEM", 155, 180], ["intracellular calcium", "TREATMENT", 268, 289], ["glutamate or NMDA", "TREATMENT", 300, 317], ["increase", "OBSERVATION_MODIFIER", 256, 264], ["cerebellar", "ANATOMY", 385, 395], ["granule neurons", "OBSERVATION", 396, 411]]], ["12 Inspection of the results shown in Table 1 reveals that piperidine derivative 12 had a value of IC 50 (NMDA) very similar to that of amantadine, while compounds 3, 8, 9 and 11 had values of IC 50 (NMDA) that were in the micromolar order, lower than amantadine but higher than memantine (Table 1) .NMDA receptor antagonist activityBenzyl derivatives 6 and 7 were devoid of activity, in agreement with our previous results with derivatives of general structures 1 and 2, 6 but in striking contrast with NGP1-01, a low micromolar 6,7,8,9,10,11-hexahydro-5,7:9,11- NMDA receptor antagonist that features a benzyl group in its structure.", [["piperidine", "CHEMICAL", 59, 69], ["NMDA", "CHEMICAL", 106, 110], ["amantadine", "CHEMICAL", 136, 146], ["compounds 3, 8, 9 and 11", "CHEMICAL", 154, 178], ["NMDA", "CHEMICAL", 200, 204], ["amantadine", "CHEMICAL", 252, 262], ["memantine", "CHEMICAL", 279, 288], ["NMDA", "CHEMICAL", 300, 304], ["Benzyl", "CHEMICAL", 333, 339], ["NGP1-01", "CHEMICAL", 504, 511], ["6,7,8,9,10,11-hexahydro-5,7:9,11-", "CHEMICAL", 530, 563], ["NMDA", "CHEMICAL", 564, 568], ["benzyl", "CHEMICAL", 605, 611], ["piperidine", "CHEMICAL", 59, 69], ["NMDA", "CHEMICAL", 106, 110], ["amantadine", "CHEMICAL", 136, 146], ["NMDA", "CHEMICAL", 200, 204], ["amantadine", "CHEMICAL", 252, 262], ["memantine", "CHEMICAL", 279, 288], ["NMDA", "CHEMICAL", 300, 304], ["Benzyl", "CHEMICAL", 333, 339], ["NGP1-01", "CHEMICAL", 504, 511], ["6,7,8,9,10,11-hexahydro-5,7:9,11- NMDA", "CHEMICAL", 530, 568], ["benzyl", "CHEMICAL", 605, 611], ["piperidine derivative 12", "SIMPLE_CHEMICAL", 59, 83], ["IC 50", "SIMPLE_CHEMICAL", 99, 104], ["NMDA", "SIMPLE_CHEMICAL", 106, 110], ["amantadine", "SIMPLE_CHEMICAL", 136, 146], ["NMDA", "SIMPLE_CHEMICAL", 200, 204], ["amantadine", "SIMPLE_CHEMICAL", 252, 262], ["memantine", "SIMPLE_CHEMICAL", 279, 288], ["NMDA receptor antagonist", "GENE_OR_GENE_PRODUCT", 300, 324], ["Benzyl", "SIMPLE_CHEMICAL", 333, 339], ["7", "SIMPLE_CHEMICAL", 358, 359], ["NGP1-01", "SIMPLE_CHEMICAL", 504, 511], ["6,7,8,9,10,11-hexahydro-5,7:9,11- NMDA", "SIMPLE_CHEMICAL", 530, 568], ["benzyl", "SIMPLE_CHEMICAL", 605, 611], ["NMDA receptor", "PROTEIN", 300, 313], ["piperidine derivative", "TREATMENT", 59, 80], ["amantadine", "TREATMENT", 136, 146], ["IC", "TEST", 193, 195], ["amantadine", "TREATMENT", 252, 262], ["NMDA receptor antagonist activity", "TREATMENT", 300, 333], ["Benzyl derivatives", "TREATMENT", 333, 351], ["NGP1", "TEST", 504, 508], ["a low micromolar", "TEST", 513, 529], ["hexahydro", "TEST", 544, 553]]], ["7 In our previous work with amines of general structure 2 we found that the NMDA receptor antagonist activity increased in going from the primary amine to the tertiary lower alkyl amine (R 1 2 3 ; IC 50 = 35 lM; R 1 3 , R 2 3 ; IC 50 = 6 lM; R 1 2 3 , R 3 ; IC 50 = 6 lM).", [["amines", "CHEMICAL", 28, 34], ["NMDA", "CHEMICAL", 76, 80], ["amine", "CHEMICAL", 146, 151], ["alkyl amine", "CHEMICAL", 174, 185], ["amines", "CHEMICAL", 28, 34], ["NMDA", "CHEMICAL", 76, 80], ["primary amine", "CHEMICAL", 138, 151], ["alkyl amine", "CHEMICAL", 174, 185], ["NMDA", "SIMPLE_CHEMICAL", 76, 80], ["amine", "SIMPLE_CHEMICAL", 146, 151], ["alkyl amine", "SIMPLE_CHEMICAL", 174, 185], ["NMDA receptor", "PROTEIN", 76, 89], ["the NMDA receptor antagonist activity", "TREATMENT", 72, 109], ["the tertiary lower alkyl amine", "TREATMENT", 155, 185], ["IC", "TEST", 197, 199], ["R", "TEST", 212, 213], ["R", "TEST", 220, 221], ["IC", "TEST", 228, 230], ["lM", "TEST", 238, 240], ["R", "TEST", 252, 253], ["IC", "TEST", 258, 260]]], ["However, the activity did not improved in going from 3 to 8 and 11.NMDA receptor antagonist activityWe had previously found that the replacement of the methylene unit of C-2 in amantadine by an oxygen atom, as in compound 1 (R 1 2 3 ), led to less potent NMDA receptor antagonists.", [["NMDA", "CHEMICAL", 67, 71], ["methylene", "CHEMICAL", 152, 161], ["C-2", "CHEMICAL", 170, 173], ["amantadine", "CHEMICAL", 177, 187], ["oxygen", "CHEMICAL", 194, 200], ["NMDA", "CHEMICAL", 255, 259], ["NMDA", "CHEMICAL", 67, 71], ["methylene", "CHEMICAL", 152, 161], ["amantadine", "CHEMICAL", 177, 187], ["oxygen", "CHEMICAL", 194, 200], ["NMDA", "CHEMICAL", 255, 259], ["NMDA receptor antagonist", "GENE_OR_GENE_PRODUCT", 67, 91], ["methylene", "SIMPLE_CHEMICAL", 152, 161], ["C-2", "SIMPLE_CHEMICAL", 170, 173], ["amantadine", "SIMPLE_CHEMICAL", 177, 187], ["oxygen", "SIMPLE_CHEMICAL", 194, 200], ["R 1 2 3", "SIMPLE_CHEMICAL", 225, 232], ["NMDA", "SIMPLE_CHEMICAL", 255, 259], ["NMDA receptor", "PROTEIN", 67, 80], ["NMDA receptor antagonist activity", "TREATMENT", 67, 100], ["the methylene unit of C", "TREATMENT", 148, 171], ["amantadine", "TREATMENT", 177, 187], ["an oxygen atom", "TREATMENT", 191, 205], ["less potent NMDA receptor antagonists", "TREATMENT", 243, 280], ["improved", "OBSERVATION_MODIFIER", 30, 38], ["oxygen atom", "OBSERVATION", 194, 205]]], ["6a Taking into account the good activity of several of our oxapolycyclic amines of general structure 2, we expected that the replacement of the oxygen atom on these derivatives by a methylene unit, as in the newer derivatives herein reported, would lead to more potent NMDA receptor antagonists.", [["amines", "CHEMICAL", 73, 79], ["oxygen", "CHEMICAL", 144, 150], ["methylene", "CHEMICAL", 182, 191], ["NMDA", "CHEMICAL", 269, 273], ["oxapolycyclic amines", "CHEMICAL", 59, 79], ["oxygen", "CHEMICAL", 144, 150], ["methylene", "CHEMICAL", 182, 191], ["NMDA", "CHEMICAL", 269, 273], ["oxapolycyclic amines", "SIMPLE_CHEMICAL", 59, 79], ["oxygen", "SIMPLE_CHEMICAL", 144, 150], ["methylene", "SIMPLE_CHEMICAL", 182, 191], ["NMDA", "SIMPLE_CHEMICAL", 269, 273], ["our oxapolycyclic amines", "TREATMENT", 55, 79], ["the replacement of the oxygen atom", "TREATMENT", 121, 155], ["these derivatives", "TREATMENT", 159, 176], ["a methylene unit", "TREATMENT", 180, 196], ["potent NMDA receptor antagonists", "TREATMENT", 262, 294]]], ["In fact, amine 3 (IC 50 = 13.6 lM) is much more potent than the previously described amine 2 (R 1 2 , R 3 3 ; IC 50 = 98 lM).", [["amine 3", "CHEMICAL", 9, 16], ["amine", "CHEMICAL", 85, 90], ["amine", "CHEMICAL", 9, 14], ["amine", "CHEMICAL", 85, 90], ["amine 3", "SIMPLE_CHEMICAL", 9, 16], ["amine 2", "SIMPLE_CHEMICAL", 85, 92], ["IC", "TEST", 110, 112], ["more potent", "OBSERVATION_MODIFIER", 43, 54]]], ["However, this trend is not general, and, for example, amine 11 is 3 times less potent (IC 50 = 12 lM) than tertiary amine 2 (R 1 2 3 3 ; IC 50 = 4 lM).NMDA receptor antagonist activityWorthy of note, the IC 50 of compound 8 as NMDA receptor antagonist is more than 20 times lower than its IC 50 as glutamate receptor antagonist, in a similar manner than has been found for memantine.Trypanocidal activityHuman African trypanosomiasis (HAT) is caused by infection with protozoan parasites of the Trypanosoma brucei species complex.", [["amine", "CHEMICAL", 54, 59], ["NMDA", "CHEMICAL", 151, 155], ["NMDA", "CHEMICAL", 227, 231], ["glutamate", "CHEMICAL", 298, 307], ["memantine", "CHEMICAL", 373, 382], ["African trypanosomiasis", "DISEASE", 410, 433], ["HAT", "DISEASE", 435, 438], ["infection", "DISEASE", 453, 462], ["protozoan parasites", "DISEASE", 468, 487], ["amine", "CHEMICAL", 54, 59], ["tertiary amine", "CHEMICAL", 107, 121], ["NMDA", "CHEMICAL", 151, 155], ["NMDA", "CHEMICAL", 227, 231], ["glutamate", "CHEMICAL", 298, 307], ["memantine", "CHEMICAL", 373, 382], ["amine 11", "SIMPLE_CHEMICAL", 54, 62], ["NMDA", "SIMPLE_CHEMICAL", 151, 155], ["NMDA", "SIMPLE_CHEMICAL", 227, 231], ["glutamate receptor antagonist", "GENE_OR_GENE_PRODUCT", 298, 327], ["memantine", "SIMPLE_CHEMICAL", 373, 382], ["Trypanocidal activityHuman African trypanosomiasis", "ORGANISM", 383, 433], ["Trypanosoma brucei species", "ORGANISM", 495, 521], ["NMDA receptor", "PROTEIN", 151, 164], ["Trypanosoma brucei species complex", "PROTEIN", 495, 529], ["Trypanosoma brucei", "SPECIES", 495, 513], ["Trypanosoma brucei", "SPECIES", 495, 513], ["tertiary amine", "TEST", 107, 121], ["IC", "TEST", 137, 139], ["the IC", "TREATMENT", 200, 206], ["NMDA receptor antagonist", "TREATMENT", 227, 251], ["glutamate receptor antagonist", "TREATMENT", 298, 327], ["memantine", "TREATMENT", 373, 382], ["Trypanocidal activityHuman African trypanosomiasis (HAT", "TREATMENT", 383, 438], ["infection", "PROBLEM", 453, 462], ["protozoan parasites", "PROBLEM", 468, 487], ["the Trypanosoma brucei species complex", "PROBLEM", 491, 529], ["infection", "OBSERVATION", 453, 462], ["protozoan parasites", "OBSERVATION", 468, 487], ["Trypanosoma brucei species", "OBSERVATION", 495, 521]]], ["The disease is endemic in many parts of sub-Saharan Africa, with upwards of 60 million people at risk.", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["The disease", "PROBLEM", 0, 11], ["endemic", "PROBLEM", 15, 22], ["disease", "OBSERVATION", 4, 11], ["endemic", "OBSERVATION_MODIFIER", 15, 22], ["many", "OBSERVATION_MODIFIER", 26, 30], ["parts", "OBSERVATION_MODIFIER", 31, 36], ["sub", "OBSERVATION_MODIFIER", 40, 43], ["Saharan Africa", "OBSERVATION", 44, 58], ["upwards", "OBSERVATION_MODIFIER", 65, 72]]], ["A process of antigenic variation prevents elimination of the parasite by the immune system, and the prospects of developing a vaccine are thought to be remote.", [["immune system", "ANATOMY", 77, 90], ["antigenic variation", "PROBLEM", 13, 32], ["the parasite", "PROBLEM", 57, 69], ["a vaccine", "TREATMENT", 124, 133], ["antigenic variation", "OBSERVATION", 13, 32]]], ["New drugs against HAT are therefore a major priority.", [["HAT", "DISEASE", 18, 21], ["New drugs", "TREATMENT", 0, 9]]], ["Drugs currently available against HAT are characterized by problems including toxicity, limited efficacy, cost and the need to administer under medical supervision.Trypanocidal activityThe anti-influenza virus drug rimantadine has been shown to be active in vitro against bloodstream form T. brucei and other adamantane derivatives have even greater activity.", [["bloodstream", "ANATOMY", 272, 283], ["toxicity", "DISEASE", 78, 86], ["rimantadine", "CHEMICAL", 215, 226], ["adamantane", "CHEMICAL", 309, 319], ["rimantadine", "CHEMICAL", 215, 226], ["adamantane", "CHEMICAL", 309, 319], ["anti-influenza virus", "ORGANISM", 189, 209], ["rimantadine", "SIMPLE_CHEMICAL", 215, 226], ["T. brucei", "ORGANISM", 289, 298], ["adamantane derivatives", "SIMPLE_CHEMICAL", 309, 331], ["T. brucei", "SPECIES", 289, 298], ["anti-influenza virus", "SPECIES", 189, 209], ["T. brucei", "SPECIES", 289, 298], ["Drugs", "TREATMENT", 0, 5], ["toxicity", "PROBLEM", 78, 86], ["Trypanocidal activity", "TREATMENT", 164, 185], ["The anti-influenza virus drug rimantadine", "TREATMENT", 185, 226], ["T. brucei", "PROBLEM", 289, 298], ["other adamantane derivatives", "TREATMENT", 303, 331], ["anti-influenza virus", "OBSERVATION", 189, 209], ["brucei", "OBSERVATION", 292, 298]]], ["3,4,13 Moreover, very recently, we found that several derivatives of general structures 1 and 2 showed significant activity against bloodstream form T. brucei.", [["bloodstream", "ANATOMY", 132, 143], ["T. brucei", "ORGANISM", 149, 158], ["T. brucei", "SPECIES", 149, 158], ["T. brucei", "SPECIES", 149, 158], ["general structures", "TEST", 69, 87], ["significant activity against bloodstream form T. brucei", "PROBLEM", 103, 158], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["activity", "OBSERVATION", 115, 123], ["T. brucei", "OBSERVATION", 149, 158]]], ["6 We therefore investigated if the newly synthesized polycyclic cage amines reported here also displayed significant activity against this parasite.Trypanocidal activityA total of 7 compounds were tested.", [["amines", "CHEMICAL", 69, 75], ["polycyclic cage amines", "CHEMICAL", 53, 75], ["polycyclic cage amines", "SIMPLE_CHEMICAL", 53, 75], ["the newly synthesized polycyclic cage amines", "PROBLEM", 31, 75], ["this parasite", "PROBLEM", 134, 147], ["Trypanocidal activityA", "TEST", 148, 170]]], ["Of these, 11 displayed little or no inhibitory activity against cultured bloodstream form T. brucei at 5 lg mL \u00c01 (15-20 lM).", [["T. brucei", "ORGANISM", 90, 99], ["T. brucei", "SPECIES", 90, 99], ["T. brucei", "SPECIES", 90, 99], ["cultured bloodstream", "TEST", 64, 84], ["T. brucei", "TEST", 90, 99], ["brucei", "OBSERVATION_MODIFIER", 93, 99]]], ["However, compound 10 inhibited parasite growth, at a level comparable to memantine.", [["compound 10", "CHEMICAL", 9, 20], ["memantine", "CHEMICAL", 73, 82], ["memantine", "CHEMICAL", 73, 82], ["parasite", "CELL", 31, 39], ["memantine", "SIMPLE_CHEMICAL", 73, 82], ["compound 10 inhibited parasite growth", "PROBLEM", 9, 46], ["memantine", "TREATMENT", 73, 82], ["10 inhibited", "OBSERVATION_MODIFIER", 18, 30], ["parasite", "OBSERVATION_MODIFIER", 31, 39], ["growth", "OBSERVATION_MODIFIER", 40, 46]]], ["More interestingly, compounds 3, 6, 7, 8 and 9 significantly inhibited parasite growth, at levels lower than rimantadine and memantine ( Table 2 ).", [["compounds 3, 6, 7, 8 and 9", "CHEMICAL", 20, 46], ["rimantadine", "CHEMICAL", 109, 120], ["memantine", "CHEMICAL", 125, 134], ["rimantadine", "CHEMICAL", 109, 120], ["memantine", "CHEMICAL", 125, 134], ["rimantadine", "SIMPLE_CHEMICAL", 109, 120], ["memantine", "SIMPLE_CHEMICAL", 125, 134], ["parasite growth", "PROBLEM", 71, 86], ["rimantadine", "TREATMENT", 109, 120], ["memantine", "TREATMENT", 125, 134], ["growth", "OBSERVATION_MODIFIER", 80, 86]]], ["The IC 90 of the more active compound, 9, was more than 4 times lower than that of rimantadine.", [["rimantadine", "CHEMICAL", 83, 94], ["rimantadine", "CHEMICAL", 83, 94], ["rimantadine", "SIMPLE_CHEMICAL", 83, 94], ["rimantadine", "TREATMENT", 83, 94], ["active", "OBSERVATION_MODIFIER", 22, 28], ["compound", "OBSERVATION", 29, 37]]], ["Inspection of the results shown in Table 2 reveals that secondary amines 6, 8 and 9 were more potent than tertiary amines 7, 10 and 11.Antiviral activityNone of the synthesized compounds was found to have antiviral activity against the enveloped DNA viruses herpes simplex virus (type 1 or type 2) or vaccinia virus; the enveloped RNA viruses feline coronavirus, parainfluenza-3 virus, respiratory syncytial virus, sindbis virus or Punta Toro virus; or the non-enveloped RNA viruses Coxsackievirus B4 and Reovirus-1.Antiviral activityCompound 10 was active against vesicular stomatitis virus (VSV) in HeLa cells, with an EC 50 (50% antiviral effective concentration) of 4 lM and a selectivity index (ratio of cytotoxic to antiviral concentration) of 25.", [["HeLa cells", "ANATOMY", 601, 611], ["EC", "ANATOMY", 621, 623], ["amines 6, 8 and 9", "CHEMICAL", 66, 83], ["amines", "CHEMICAL", 115, 121], ["herpes simplex virus", "DISEASE", 258, 278], ["feline coronavirus", "DISEASE", 343, 361], ["respiratory syncytial virus", "DISEASE", 386, 413], ["vesicular stomatitis", "DISEASE", 565, 585], ["secondary amines", "CHEMICAL", 56, 72], ["tertiary amines", "CHEMICAL", 106, 121], ["enveloped", "ORGANISM", 236, 245], ["DNA viruses", "ORGANISM", 246, 257], ["herpes simplex virus", "ORGANISM", 258, 278], ["type 1", "ORGANISM", 280, 286], ["type 2", "ORGANISM", 290, 296], ["vaccinia virus", "ORGANISM", 301, 315], ["enveloped", "ORGANISM", 321, 330], ["RNA viruses", "ORGANISM", 331, 342], ["feline coronavirus", "ORGANISM", 343, 361], ["parainfluenza-3 virus", "ORGANISM", 363, 384], ["respiratory syncytial virus", "ORGANISM", 386, 413], ["sindbis virus", "ORGANISM", 415, 428], ["Punta Toro virus", "ORGANISM", 432, 448], ["Coxsackievirus B4", "ORGANISM", 483, 500], ["Reovirus-1", "ORGANISM", 505, 515], ["vesicular stomatitis virus", "ORGANISM", 565, 591], ["VSV", "ORGANISM", 593, 596], ["HeLa cells", "CELL", 601, 611], ["EC", "CELL", 621, 623], ["HeLa cells", "CELL_LINE", 601, 611], ["herpes simplex virus", "SPECIES", 258, 278], ["vaccinia virus", "SPECIES", 301, 315], ["feline coronavirus", "SPECIES", 343, 361], ["parainfluenza-3 virus", "SPECIES", 363, 384], ["respiratory syncytial virus", "SPECIES", 386, 413], ["sindbis virus", "SPECIES", 415, 428], ["Punta Toro virus", "SPECIES", 432, 448], ["Coxsackievirus B4", "SPECIES", 483, 500], ["vesicular stomatitis virus", "SPECIES", 565, 591], ["herpes simplex virus", "SPECIES", 258, 278], ["vaccinia virus", "SPECIES", 301, 315], ["feline coronavirus", "SPECIES", 343, 361], ["parainfluenza-3 virus", "SPECIES", 363, 384], ["respiratory syncytial virus", "SPECIES", 386, 413], ["sindbis virus", "SPECIES", 415, 428], ["Punta Toro virus", "SPECIES", 432, 448], ["Coxsackievirus B4", "SPECIES", 483, 500], ["Reovirus-1", "SPECIES", 505, 515], ["vesicular stomatitis virus", "SPECIES", 565, 591], ["VSV", "SPECIES", 593, 596], ["secondary amines", "TEST", 56, 72], ["Antiviral activity", "TREATMENT", 135, 153], ["the synthesized compounds", "PROBLEM", 161, 186], ["antiviral activity", "TREATMENT", 205, 223], ["the enveloped DNA viruses herpes simplex virus", "PROBLEM", 232, 278], ["vaccinia virus", "PROBLEM", 301, 315], ["the enveloped RNA viruses feline coronavirus", "PROBLEM", 317, 361], ["parainfluenza", "PROBLEM", 363, 376], ["virus", "PROBLEM", 379, 384], ["respiratory syncytial virus", "PROBLEM", 386, 413], ["sindbis virus", "PROBLEM", 415, 428], ["Punta Toro virus", "PROBLEM", 432, 448], ["the non-enveloped RNA viruses Coxsackievirus B4", "PROBLEM", 453, 500], ["Reovirus", "PROBLEM", 505, 513], ["Antiviral activityCompound", "TREATMENT", 516, 542], ["vesicular stomatitis virus", "PROBLEM", 565, 591], ["an EC", "TEST", 618, 623], ["a selectivity index", "TEST", 679, 698], ["antiviral concentration", "TEST", 722, 745], ["syncytial virus", "OBSERVATION", 398, 413], ["HeLa cells", "ANATOMY", 601, 611]]], ["Another compound, 12, was only weakly active (EC 50 = 54 lM).", [["EC", "TEST", 46, 48], ["weakly", "OBSERVATION_MODIFIER", 31, 37], ["active", "OBSERVATION_MODIFIER", 38, 44]]], ["The antiviral data obtained by microscopy were confirmed by a colorimetric cell viability assay.", [["cell", "ANATOMY", 75, 79], ["cell", "CELL", 75, 79], ["The antiviral data", "TEST", 0, 18], ["a colorimetric cell viability assay", "TEST", 60, 95]]], ["However, both compounds were not active against VSV in HEL cells, which suggest that the anti-VSV activity may be cell type-dependent.Antiviral activityIn the influenza virus assays, all compounds proved to be inactive against the A/H3N2 subtype and influenza B virus.", [["HEL cells", "ANATOMY", 55, 64], ["cell", "ANATOMY", 114, 118], ["influenza virus", "DISEASE", 159, 174], ["influenza B", "DISEASE", 250, 261], ["VSV", "ORGANISM", 48, 51], ["HEL cells", "CELL", 55, 64], ["anti-VSV", "GENE_OR_GENE_PRODUCT", 89, 97], ["cell", "CELL", 114, 118], ["A/H3N2 subtype", "ORGANISM", 231, 245], ["influenza B virus", "ORGANISM", 250, 267], ["HEL cells", "CELL_LINE", 55, 64], ["anti-VSV", "PROTEIN", 89, 97], ["influenza B virus", "SPECIES", 250, 267], ["VSV", "SPECIES", 48, 51], ["influenza virus", "SPECIES", 159, 174], ["A/H3N2", "SPECIES", 231, 237], ["influenza B virus", "SPECIES", 250, 267], ["VSV in HEL cells", "PROBLEM", 48, 64], ["cell type-dependent", "PROBLEM", 114, 133], ["Antiviral activity", "TREATMENT", 134, 152], ["the influenza virus assays", "TEST", 155, 181], ["the A/H3N2 subtype", "PROBLEM", 227, 245], ["influenza B virus", "PROBLEM", 250, 267], ["HEL cells", "OBSERVATION", 55, 64], ["influenza virus", "OBSERVATION", 159, 174]]], ["Interestingly, benzyl derivative 6 displayed reasonable activity against the influenza A/H1N1 subtype (antiviral EC 50 = 10 lM).", [["benzyl derivative 6", "CHEMICAL", 15, 34], ["benzyl", "CHEMICAL", 15, 21], ["benzyl derivative 6", "SIMPLE_CHEMICAL", 15, 34], ["influenza A/H1N1 subtype", "ORGANISM", 77, 101], ["benzyl derivative", "TREATMENT", 15, 32], ["the influenza A/H1N1 subtype", "PROBLEM", 73, 101], ["antiviral EC", "TREATMENT", 103, 115]]], ["N CH 3 R' R Addition of the benzene ring to the adamantane nucleusis compatible with anti-trypanosoma and NMD Areceptor antagonist activities but detrimental for anti-influenza activity.Antiviral activityA benzyl substituent is compatible with anti-trypanosoma activity but detrimental for NMDA antagonism.Antiviral activityNMDA receptor antagonist activity is better when R=R'=H and R=R'=CH 3 .Antiviral activityIntroduction of this methylene unit instead of the oxygen atom previously studied, improves the anti-trypanosoma activity.", [["benzene", "CHEMICAL", 28, 35], ["adamantane", "CHEMICAL", 48, 58], ["benzyl substituent", "CHEMICAL", 206, 224], ["NMDA", "CHEMICAL", 290, 294], ["methylene", "CHEMICAL", 434, 443], ["oxygen", "CHEMICAL", 464, 470], ["N CH 3 R' R", "CHEMICAL", 0, 11], ["benzene", "CHEMICAL", 28, 35], ["adamantane", "CHEMICAL", 48, 58], ["benzyl", "CHEMICAL", 206, 212], ["NMDA", "CHEMICAL", 290, 294], ["methylene", "CHEMICAL", 434, 443], ["oxygen", "CHEMICAL", 464, 470], ["benzene", "SIMPLE_CHEMICAL", 28, 35], ["adamantane nucleusis", "SIMPLE_CHEMICAL", 48, 68], ["anti-trypanosoma", "SIMPLE_CHEMICAL", 85, 101], ["NMD Areceptor antagonist", "GENE_OR_GENE_PRODUCT", 106, 130], ["activityA benzyl substituent", "SIMPLE_CHEMICAL", 196, 224], ["anti-trypanosoma", "SIMPLE_CHEMICAL", 244, 260], ["NMDA", "SIMPLE_CHEMICAL", 290, 294], ["methylene", "SIMPLE_CHEMICAL", 434, 443], ["oxygen", "SIMPLE_CHEMICAL", 464, 470], ["anti-trypanosoma", "CANCER", 509, 525], ["Antiviral activityNMDA receptor", "PROTEIN", 306, 337], ["the benzene ring", "TREATMENT", 24, 40], ["the adamantane nucleusis", "PROBLEM", 44, 68], ["anti-trypanosoma", "TREATMENT", 85, 101], ["NMD Areceptor antagonist activities", "TREATMENT", 106, 141], ["anti-influenza activity", "TREATMENT", 162, 185], ["Antiviral activityA benzyl substituent", "TREATMENT", 186, 224], ["anti-trypanosoma activity", "PROBLEM", 244, 269], ["NMDA antagonism", "PROBLEM", 290, 305], ["Antiviral activityNMDA receptor antagonist activity", "TREATMENT", 306, 357], ["R", "TEST", 373, 374], ["Antiviral activity", "TREATMENT", 395, 413], ["this methylene unit", "TREATMENT", 429, 448], ["the oxygen atom", "TREATMENT", 460, 475], ["benzene ring", "OBSERVATION", 28, 40], ["benzyl substituent", "OBSERVATION", 206, 224], ["compatible with", "UNCERTAINTY", 228, 243]]], ["(IC 50 = 11.8 \u00b1 3.1 lM), and 9, the most potent compound as trypanocidal (IC 50 = 1.99 \u00b1 0.46 lM; IC 90 = 3.14 \u00b1 0.10 lM).", [["trypanocidal", "SIMPLE_CHEMICAL", 60, 72], ["IC", "TEST", 1, 3], ["IC", "TEST", 74, 76], ["IC", "TEST", 98, 100]]], ["It is well-known that the target of amantadine and rimantadine is the influenza A virus M2 channel protein and that a single S31N mutation in M2 renders the virus resistant to both drugs.", [["amantadine", "CHEMICAL", 36, 46], ["rimantadine", "CHEMICAL", 51, 62], ["amantadine", "CHEMICAL", 36, 46], ["rimantadine", "CHEMICAL", 51, 62], ["amantadine", "SIMPLE_CHEMICAL", 36, 46], ["rimantadine", "SIMPLE_CHEMICAL", 51, 62], ["influenza A virus", "ORGANISM", 70, 87], ["M2", "ORGANISM", 88, 90], ["S31N", "GENE_OR_GENE_PRODUCT", 125, 129], ["M2", "GENE_OR_GENE_PRODUCT", 142, 144], ["influenza A virus M2 channel protein", "PROTEIN", 70, 106], ["M2", "PROTEIN", 142, 144], ["influenza A virus", "SPECIES", 70, 87], ["influenza A virus", "SPECIES", 70, 87], ["amantadine", "TREATMENT", 36, 46], ["rimantadine", "TREATMENT", 51, 62], ["the influenza A virus M2 channel protein", "TREATMENT", 66, 106], ["a single S31N mutation", "TREATMENT", 116, 138], ["the virus", "PROBLEM", 153, 162], ["both drugs", "TREATMENT", 176, 186]]], ["2, 14 As most of the currently circulating subtypes of influenza A virus, A/H3N2 and A/H1N1, carry the S31N mutation in M2, there is an urgent need for the development of novel anti-influenza drugs that are effective against the most common amantadine-resistant mutants.", [["influenza A", "DISEASE", 55, 66], ["amantadine", "CHEMICAL", 241, 251], ["amantadine", "CHEMICAL", 241, 251], ["influenza A virus", "ORGANISM", 55, 72], ["A/H3N2", "ORGANISM", 74, 80], ["A/H1N1", "ORGANISM", 85, 91], ["S31N", "GENE_OR_GENE_PRODUCT", 103, 107], ["amantadine", "SIMPLE_CHEMICAL", 241, 251], ["influenza A virus", "SPECIES", 55, 72], ["influenza A virus", "SPECIES", 55, 72], ["A/H3N2", "SPECIES", 74, 80], ["A/H1N1", "SPECIES", 85, 91], ["influenza A virus", "PROBLEM", 55, 72], ["H3N2", "PROBLEM", 76, 80], ["H1N1", "PROBLEM", 87, 91], ["the S31N mutation", "PROBLEM", 99, 116], ["novel anti-influenza drugs", "TREATMENT", 171, 197], ["resistant mutants", "PROBLEM", 252, 269], ["influenza", "OBSERVATION", 55, 64], ["anti-influenza drugs", "OBSERVATION", 177, 197]]], ["15 The influenza A/PuertoRico/8/34 strain used for testing the activity of amine 6 has an M2 channel carrying two substituions associated with amantadine resistance, that is S31N and V27T.", [["amine", "CHEMICAL", 75, 80], ["amantadine", "CHEMICAL", 143, 153], ["amine", "CHEMICAL", 75, 80], ["amantadine", "CHEMICAL", 143, 153], ["influenza A/", "ORGANISM", 7, 19], ["PuertoRico/8/34 strain", "ORGANISM", 19, 41], ["amine 6", "SIMPLE_CHEMICAL", 75, 82], ["M2", "GENE_OR_GENE_PRODUCT", 90, 92], ["amantadine", "SIMPLE_CHEMICAL", 143, 153], ["S31N", "GENE_OR_GENE_PRODUCT", 174, 178], ["M2 channel", "PROTEIN", 90, 100], ["S31N", "PROTEIN", 174, 178], ["V27T", "PROTEIN", 183, 187], ["A/PuertoRico/8/34 strain", "SPECIES", 17, 41], ["The influenza A", "PROBLEM", 3, 18], ["PuertoRico/8/34 strain", "TREATMENT", 19, 41], ["amantadine resistance", "TREATMENT", 143, 164], ["amantadine resistance", "OBSERVATION", 143, 164]]], ["In order to assess if the target of 6 was the M2 protein, the inhibitory activity of 6 was tested on A/M2 channels expressed in Xenopus oocytes using the two-electrode voltage clamps (TEV) technique.", [["Xenopus oocytes", "ANATOMY", 128, 143], ["M2", "GENE_OR_GENE_PRODUCT", 46, 48], ["A/M2", "GENE_OR_GENE_PRODUCT", 101, 105], ["Xenopus", "ORGANISM", 128, 135], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 136, 143], ["M2 protein", "PROTEIN", 46, 56], ["M2 channels", "PROTEIN", 103, 114], ["A/M2 channels", "TREATMENT", 101, 114], ["Xenopus oocytes", "TREATMENT", 128, 143], ["the two-electrode voltage clamps", "TREATMENT", 150, 182], ["Xenopus oocytes", "OBSERVATION", 128, 143]]], ["Amine 6, at 100 lM, was unable to inhibit the activity of the wild-type (amantadine-sensitive) and the S31N and the V27A (amantadine-resistant) mutants, thus suggesting that 6 interacts with a different target in the virus.", [["Amine 6", "CHEMICAL", 0, 7], ["amantadine", "CHEMICAL", 73, 83], ["amantadine", "CHEMICAL", 122, 132], ["Amine", "CHEMICAL", 0, 5], ["amantadine", "CHEMICAL", 73, 83], ["amantadine", "CHEMICAL", 122, 132], ["Amine 6", "SIMPLE_CHEMICAL", 0, 7], ["amantadine", "SIMPLE_CHEMICAL", 73, 83], ["amantadine", "SIMPLE_CHEMICAL", 122, 132], ["Amine", "TREATMENT", 0, 5], ["amantadine", "TREATMENT", 73, 83], ["amantadine", "TREATMENT", 122, 132], ["a different target in the virus", "PROBLEM", 191, 222], ["lM", "ANATOMY", 16, 18]]], ["Neither 3 nor 11 were able to inhibit the activity of the wild-type and the S31N and the V27A mutants.ConclusionsIn summary, we have synthesized and fully characterized several benzopolycyclic amines.", [["benzopolycyclic amines", "CHEMICAL", 177, 199], ["benzopolycyclic amines", "CHEMICAL", 177, 199], ["S31N", "GENE_OR_GENE_PRODUCT", 76, 80], ["V27A", "GENE_OR_GENE_PRODUCT", 89, 93], ["benzopolycyclic amines", "SIMPLE_CHEMICAL", 177, 199], ["S31N", "PROTEIN", 76, 80], ["V27A mutants", "PROTEIN", 89, 101], ["several benzopolycyclic amines", "TREATMENT", 169, 199]]], ["Several of the derivatives were more potent than amantadine against NMDA-induced calcium increase in cerebellar granule neurons, although they were less potent than memantine.", [["cerebellar granule neurons", "ANATOMY", 101, 127], ["amantadine", "CHEMICAL", 49, 59], ["NMDA", "CHEMICAL", 68, 72], ["calcium", "CHEMICAL", 81, 88], ["memantine", "CHEMICAL", 165, 174], ["amantadine", "CHEMICAL", 49, 59], ["NMDA", "CHEMICAL", 68, 72], ["calcium", "CHEMICAL", 81, 88], ["memantine", "CHEMICAL", 165, 174], ["amantadine", "SIMPLE_CHEMICAL", 49, 59], ["NMDA", "SIMPLE_CHEMICAL", 68, 72], ["calcium", "SIMPLE_CHEMICAL", 81, 88], ["cerebellar granule neurons", "CELL", 101, 127], ["memantine", "SIMPLE_CHEMICAL", 165, 174], ["cerebellar granule neurons", "CELL_TYPE", 101, 127], ["the derivatives", "PROBLEM", 11, 26], ["amantadine", "TREATMENT", 49, 59], ["NMDA", "PROBLEM", 68, 72], ["calcium increase in cerebellar granule neurons", "PROBLEM", 81, 127], ["memantine", "TREATMENT", 165, 174], ["calcium increase", "OBSERVATION", 81, 97], ["cerebellar", "ANATOMY", 101, 111], ["granule neurons", "OBSERVATION", 112, 127]]], ["Several amines displayed a significant level of trypanocidal activity, being up to four times more potent than rimantadine.", [["amines", "CHEMICAL", 8, 14], ["rimantadine", "CHEMICAL", 111, 122], ["amines", "CHEMICAL", 8, 14], ["rimantadine", "CHEMICAL", 111, 122], ["amines", "SIMPLE_CHEMICAL", 8, 14], ["rimantadine", "SIMPLE_CHEMICAL", 111, 122], ["trypanocidal activity", "PROBLEM", 48, 69], ["rimantadine", "TREATMENT", 111, 122], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["trypanocidal activity", "OBSERVATION", 48, 69]]], ["Figure 3 summarizes the main features of the SAR of these new compounds, including the most potent compounds.ConclusionsRegarding antiviral activity, compound 10 displayed anti-VSV activity in HeLa cells, but not in HEL cells, suggesting that its antiviral activity can be cell type-dependent.", [["HeLa cells", "ANATOMY", 193, 203], ["HEL cells", "ANATOMY", 216, 225], ["cell", "ANATOMY", 273, 277], ["anti-VSV", "CANCER", 172, 180], ["HeLa cells", "CELL", 193, 203], ["HEL cells", "CELL", 216, 225], ["cell", "CELL", 273, 277], ["anti-VSV", "PROTEIN", 172, 180], ["HeLa cells", "CELL_LINE", 193, 203], ["HEL cells", "CELL_LINE", 216, 225], ["antiviral activity", "PROBLEM", 130, 148], ["anti-VSV activity in HeLa cells", "PROBLEM", 172, 203], ["HEL cells", "PROBLEM", 216, 225], ["cell type-dependent", "PROBLEM", 273, 292], ["main", "OBSERVATION_MODIFIER", 24, 28], ["new", "OBSERVATION_MODIFIER", 58, 61], ["compounds", "OBSERVATION", 62, 71], ["most potent", "OBSERVATION_MODIFIER", 87, 98], ["antiviral activity", "OBSERVATION", 130, 148], ["HeLa cells", "OBSERVATION", 193, 203]]], ["Finally, benzyl derivative 6, that is not active as NMDA receptor antagonist, is a low micromolar inhibitor of the influenza A/H1N1 subtype.", [["benzyl derivative 6", "CHEMICAL", 9, 28], ["NMDA", "CHEMICAL", 52, 56], ["benzyl", "CHEMICAL", 9, 15], ["NMDA", "CHEMICAL", 52, 56], ["benzyl derivative 6", "SIMPLE_CHEMICAL", 9, 28], ["NMDA", "SIMPLE_CHEMICAL", 52, 56], ["influenza A/H1N1 subtype", "ORGANISM", 115, 139], ["benzyl derivative", "TREATMENT", 9, 26], ["NMDA receptor antagonist", "TREATMENT", 52, 76], ["a low micromolar inhibitor", "TREATMENT", 81, 107], ["the influenza A/H1N1 subtype", "PROBLEM", 111, 139], ["low micromolar", "OBSERVATION_MODIFIER", 83, 97], ["influenza", "OBSERVATION", 115, 124]]], ["Interestingly, this anti-viral activity is not mediated by M2 channel blocking.ConclusionsThe synthesis and pharmacological evaluation of more polycyclic cage amines are in progress.GeneralMelting points were determined in open capillary tubes.", [["capillary tubes", "ANATOMY", 228, 243], ["amines", "CHEMICAL", 159, 165], ["polycyclic cage amines", "CHEMICAL", 143, 165], ["M2", "GENE_OR_GENE_PRODUCT", 59, 61], ["polycyclic cage amines", "SIMPLE_CHEMICAL", 143, 165], ["capillary tubes", "TISSUE", 228, 243], ["M2 channel", "PROTEIN", 59, 69], ["The synthesis", "TREATMENT", 90, 103], ["pharmacological evaluation", "TEST", 108, 134], ["more polycyclic cage amines", "TREATMENT", 138, 165], ["open capillary tubes", "TREATMENT", 223, 243], ["capillary tubes", "OBSERVATION", 228, 243]]], ["Unless otherwise stated, NMR spectra were recorded in CD 3 OD in the following spectrometers: 1 H NMR (500 MHz), 13 C NMR (100.6 MHz).", [["H", "CHEMICAL", 96, 97], ["NMR spectra", "TEST", 25, 36], ["NMR", "TEST", 98, 101], ["MHz", "TEST", 107, 110], ["NMR", "TEST", 118, 121], ["MHz", "TEST", 129, 132]]], ["Chemical shits (d) are reported in ppm related to internal tetramethylsilane (TMS).", [["tetramethylsilane", "CHEMICAL", 59, 76], ["tetramethylsilane", "CHEMICAL", 59, 76], ["TMS", "CHEMICAL", 78, 81], ["tetramethylsilane", "SIMPLE_CHEMICAL", 59, 76], ["internal tetramethylsilane (TMS", "TREATMENT", 50, 81]]], ["Assignments given for the NMR spectra are based on DEPT, COSY 1 H/ 1 H, HETCOR 1 H/ 13 C (HSQC and HMBC sequences for one bond and long range 1 H/ 13 C heterocorrelations, respectively) and NOESY experiments for selected compounds.", [["H", "CHEMICAL", 64, 65], ["H", "CHEMICAL", 69, 70], ["the NMR spectra", "TEST", 22, 37], ["HETCOR", "TEST", 72, 78], ["HSQC", "TEST", 90, 94], ["HMBC sequences", "TEST", 99, 113], ["heterocorrelations", "TEST", 152, 170]]], ["For the MS and GC/MS analyses the sample was introduced directly or through a gas chromatograph.", [["sample", "ANATOMY", 34, 40], ["the MS", "TEST", 4, 10], ["GC/MS analyses", "TEST", 15, 29], ["a gas chromatograph", "TEST", 76, 95]]], ["For GC/MS analyses a 30-meter column [5% diphenyl-95% dimethylpolysiloxane, conditions: 10 psi, initial temperature: 35\u00b0C (2 min), then heating at a range of 8\u00b0C/min till 300\u00b0C, then isothermic at 300\u00b0C] was used.", [["diphenyl-95% dimethylpolysiloxane", "CHEMICAL", 41, 74], ["diphenyl", "CHEMICAL", 41, 49], ["dimethylpolysiloxane", "CHEMICAL", 54, 74], ["diphenyl-95%", "SIMPLE_CHEMICAL", 41, 53], ["dimethylpolysiloxane", "SIMPLE_CHEMICAL", 54, 74], ["GC/MS analyses", "TEST", 4, 18], ["diphenyl", "TREATMENT", 41, 49], ["initial temperature", "TEST", 96, 115]]], ["The electron impact (70 eV) or chemical ionization (CH 4 ) techniques were used.", [["electron", "SIMPLE_CHEMICAL", 4, 12], ["chemical ionization (CH 4 ) techniques", "TREATMENT", 31, 69]]], ["Only significant ions are given: those with higher relative ratio, except for the ions with higher m/z values.", [["the ions", "PROBLEM", 78, 86], ["higher m/z values", "PROBLEM", 92, 109], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["ions", "OBSERVATION", 17, 21]]], ["Accurate mass measurements were obtained using ESI technic.", [["Accurate mass measurements", "TEST", 0, 26], ["ESI technic", "TREATMENT", 47, 58], ["mass", "OBSERVATION", 9, 13]]], ["Absorption values in the IR spectra (KBr) are given as wave-numbers (cm \u00c01 ).", [["Absorption values", "TEST", 0, 17]]], ["Only the more intense bands are given.", [["the more intense bands", "PROBLEM", 5, 27], ["more", "OBSERVATION_MODIFIER", 9, 13], ["intense", "OBSERVATION_MODIFIER", 14, 21], ["bands", "OBSERVATION", 22, 27]]], ["Column chromatography was performed on silica gel 60 \u00c5 (35-70 mesh).", [["silica", "CHEMICAL", 39, 45], ["Column chromatography", "TEST", 0, 21], ["silica gel", "TEST", 39, 49]]], ["For the thin layer chromatography (TLC) aluminum-backed sheets with silica gel 60 F 254 were used and spots were visualized with UV light and/or 1% aqueous solution of KMnO [4] [5] [6] 7, 8, 9, 10, 7:9,chloroacetamide, 5A suspension of diene 4 (5.3 g, 25.2 mmol), chloroacetonitrile (6.5 mL) and acetic acid (17 mL) was cooled to 0\u00b0C and concentrated H 2 SO 4 (8.2 mL, 151.2 mmol) was added dropwise (T < 10\u00b0C).", [["aluminum", "CHEMICAL", 40, 48], ["silica gel", "CHEMICAL", 68, 78], ["KMnO [4] [5] [6] 7, 8, 9, 10, 7:9,chloroacetamide, 5A suspension of diene 4", "CHEMICAL", 168, 243], ["chloroacetonitrile", "CHEMICAL", 264, 282], ["acetic acid", "CHEMICAL", 296, 307], ["H 2 SO 4", "CHEMICAL", 351, 359], ["aluminum", "CHEMICAL", 40, 48], ["silica", "CHEMICAL", 68, 74], ["KMnO [4] [5] [6]", "CHEMICAL", 168, 184], ["chloroacetamide", "CHEMICAL", 202, 217], ["diene", "CHEMICAL", 236, 241], ["chloroacetonitrile", "CHEMICAL", 264, 282], ["acetic acid", "CHEMICAL", 296, 307], ["H 2 SO 4", "CHEMICAL", 351, 359], ["KMnO [4] [5] [6] 7", "SIMPLE_CHEMICAL", 168, 186], ["chloroacetamide", "SIMPLE_CHEMICAL", 202, 217], ["diene 4", "SIMPLE_CHEMICAL", 236, 243], ["chloroacetonitrile", "SIMPLE_CHEMICAL", 264, 282], ["acetic acid", "SIMPLE_CHEMICAL", 296, 307], ["C", "SIMPLE_CHEMICAL", 332, 333], ["H 2 SO 4", "SIMPLE_CHEMICAL", 351, 359], ["the thin layer chromatography (TLC) aluminum-backed sheets with silica gel", "TREATMENT", 4, 78], ["UV light", "TREATMENT", 129, 137], ["chloroacetamide", "TREATMENT", 202, 217], ["diene", "TREATMENT", 236, 241], ["chloroacetonitrile", "TREATMENT", 264, 282], ["acetic acid", "TREATMENT", 296, 307]]], ["The suspension was added to ice (120 g) and a yellow solid precipitated.", [["The suspension", "TREATMENT", 0, 14], ["a yellow solid precipitated", "PROBLEM", 44, 71], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["The precipitate was filtered and solved in dichloromethane (100 mL).", [["dichloromethane", "CHEMICAL", 43, 58], ["dichloromethane", "SIMPLE_CHEMICAL", 43, 58], ["dichloromethane", "TREATMENT", 43, 58]]], ["The organic phase was dried with anhyd Na 2 SO 4 , filtered and concentrated in vacuo to give 5 as a yellow solid (5.44 g, 71% yield) .", [["anhyd Na 2 SO 4", "CHEMICAL", 33, 48], ["Na 2 SO 4", "CHEMICAL", 39, 48], ["The organic phase", "TEST", 0, 17], ["anhyd Na", "TREATMENT", 33, 41], ["organic phase", "OBSERVATION_MODIFIER", 4, 17]]], ["The analytical sample of 5 was obtained by crystallization from CH 2 Cl 2 , mp 166\u00c0168\u00b0C. IR 3320, 3301, 3062, 2949 IR 3320, 3301, 3062, , 2910 IR 3320, 3301, 3062, , 2861 IR 3320, 3301, 3062, , 1659 IR 3320, 3301, 3062, , 1651 IR 3320, 3301, 3062, , 1540 IR 3320, 3301, 3062, , 1492 IR 3320, 3301, 3062, , 1451 IR 3320, 3301, 3062, , 1431 IR 3320, 3301, 3062, , 1361 IR 3320, 3301, 3062, , 1328 IR 3320, 3301, 3062, , 1312 IR 3320, 3301, 3062, , 1210 IR 3320, 3301, 3062, , 1145 IR 3320, 3301, 3062, , 1091 IR 3320, 3301, 3062, , 1009 (15), 167 (11), 156 (15), 155 (82), 154 (20), 143 (14), 142 (13), 141 (20), 129 (19) , 128 (23), 115 (17) .", [["CH 2 Cl 2 , mp 166\u00c0168\u00b0C", "CHEMICAL", 64, 88], ["CH 2 Cl 2", "CHEMICAL", 64, 73], ["The analytical sample", "TEST", 0, 21], ["mp", "TEST", 76, 78], ["IR", "TEST", 90, 92], ["IR", "TEST", 116, 118], ["IR", "TEST", 144, 146], ["IR", "TEST", 172, 174], ["IR", "TEST", 200, 202], ["IR", "TEST", 228, 230], ["IR", "TEST", 256, 258], ["IR", "TEST", 284, 286], ["IR", "TEST", 312, 314], ["IR", "TEST", 340, 342], ["IR", "TEST", 368, 370], ["IR", "TEST", 396, 398], ["IR", "TEST", 424, 426], ["IR", "TEST", 452, 454], ["IR", "TEST", 480, 482], ["IR", "TEST", 508, 510]]], ["Anal.", [["Anal", "ANATOMY", 0, 4]]], ["Calcd. for C 18 H 22 ClNO (303.83): C 71.16, H 7.30, N 4.61, Cl 11.67.", [["C 18 H 22 ClNO", "CHEMICAL", 11, 25], ["C 18 H 22 ClNO (303.83)", "CHEMICAL", 11, 34], ["C", "CHEMICAL", 36, 37], ["H", "CHEMICAL", 45, 46], ["N", "CHEMICAL", 53, 54], ["Cl", "CHEMICAL", 61, 63], ["Calcd", "GENE_OR_GENE_PRODUCT", 0, 5], ["Calcd", "PROTEIN", 0, 5], ["C", "TEST", 11, 12], ["ClNO", "TEST", 21, 25], ["C", "TEST", 36, 37], ["H", "TEST", 45, 46], ["N", "TEST", 53, 54], ["Cl", "TEST", 61, 63]]], ["Found C 71.07, H 7.28, N 4.50, Cl 11.44.", [["C", "CHEMICAL", 6, 7], ["H", "CHEMICAL", 15, 16], ["N", "CHEMICAL", 23, 24], ["Cl", "CHEMICAL", 31, 33], ["C", "TEST", 6, 7], ["H", "TEST", 15, 16], ["N", "TEST", 23, 24], ["Cl", "TEST", 31, 33]]], ["6, 7, 8, 9, 10, 7:9, 3\u00c1HCl A mixture of chloroacetamide 5 (7.21 g, 23.7 mml), thiourea (2.16 g, 28.44 mmol), acetic acid (8.7 mL) in ethanol (44 mL) was stirred under reflux for 18 h.", [["chloroacetamide 5", "CHEMICAL", 40, 57], ["thiourea", "CHEMICAL", 78, 86], ["acetic acid", "CHEMICAL", 109, 120], ["ethanol", "CHEMICAL", 133, 140], ["reflux", "DISEASE", 167, 173], ["chloroacetamide", "CHEMICAL", 40, 55], ["thiourea", "CHEMICAL", 78, 86], ["acetic acid", "CHEMICAL", 109, 120], ["ethanol", "CHEMICAL", 133, 140], ["chloroacetamide 5", "SIMPLE_CHEMICAL", 40, 57], ["thiourea", "SIMPLE_CHEMICAL", 78, 86], ["acetic acid", "SIMPLE_CHEMICAL", 109, 120], ["ethanol", "SIMPLE_CHEMICAL", 133, 140], ["chloroacetamide", "TREATMENT", 40, 55], ["thiourea", "TREATMENT", 78, 86], ["acetic acid", "TREATMENT", 109, 120], ["reflux", "OBSERVATION", 167, 173]]], ["To the cold solution water (250 mL), and 10 N NaOH (80 mL) were added.", [["NaOH", "CHEMICAL", 46, 50], ["NaOH", "CHEMICAL", 46, 50], ["the cold solution water", "TREATMENT", 3, 26]]], ["The base aqueous solution was extracted with EtOAc (3 \u00c2 300 mL).", [["EtOAc", "CHEMICAL", 45, 50], ["EtOAc", "SIMPLE_CHEMICAL", 45, 50], ["The base aqueous solution", "TREATMENT", 0, 25], ["EtOAc", "TREATMENT", 45, 50], ["base", "ANATOMY_MODIFIER", 4, 8], ["aqueous", "OBSERVATION_MODIFIER", 9, 16]]], ["The combined organic extracts were dried with anhyd Na 2 SO 4 , filtered and concentrated in vacuo to give a brown oily residue (7.19 g).", [["extracts", "ANATOMY", 21, 29], ["anhyd Na 2 SO 4", "CHEMICAL", 46, 61], ["Na 2 SO 4", "CHEMICAL", 52, 61], ["extracts", "ORGANISM_SUBSTANCE", 21, 29], ["The combined organic extracts", "TREATMENT", 0, 29], ["anhyd Na", "TREATMENT", 46, 54], ["a brown oily residue", "PROBLEM", 107, 127]]], ["The residue was taken in EtOAc and the amine 3 was precipitated as its hydrochloride by adding an excess of Et 2 O\u00c1HCl (3.87 g, 62% yield).", [["amine", "CHEMICAL", 39, 44], ["Et 2 O\u00c1HCl", "CHEMICAL", 108, 118], ["EtOAc", "CHEMICAL", 25, 30], ["amine", "CHEMICAL", 39, 44], ["hydrochloride", "CHEMICAL", 71, 84], ["Et 2 O\u00c1HCl", "CHEMICAL", 108, 118], ["EtOAc", "SIMPLE_CHEMICAL", 25, 30], ["amine 3", "SIMPLE_CHEMICAL", 39, 46], ["hydrochloride", "SIMPLE_CHEMICAL", 71, 84], ["Et 2 O\u00c1HCl", "SIMPLE_CHEMICAL", 108, 118], ["The residue", "PROBLEM", 0, 11], ["its hydrochloride", "TREATMENT", 67, 84], ["an excess of Et 2 O\u00c1HCl", "TREATMENT", 95, 118]]], ["The analytical sample was obtained by crystallization from 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, 2985 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2944 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2907 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2860 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2717 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2680 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2622 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2581 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2548 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 2061 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 1606 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 1509 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 1495 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 1454 2-propanol, mp 287\u00c0288\u00b0C. IR 3499, , 1362 7, 8, 9, 10, 7 :9,11-dime thano-5H-benzocyclononen-7-amine hydrochloride, 6\u00c1HClchloroacetamide, 5To a solution of amine 3\u00c1HCl (200 mg, 0.76 mmol) in MeOH (10 mL), NaBH 3 CN (104 mg, 1.65 mmol), AcOH (0.25 mL) and benzaldehyde (80.4 mg, 0.76 mmol) were added and the mixture was stirred at room temperature for 18 h and concentrated in vacuo to dryness.", [["2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 59, 83], ["IR 3499, 2985 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 85, 123], ["IR 3499", "CHEMICAL", 125, 132], ["2944 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 136, 165], ["IR 3499", "CHEMICAL", 167, 174], ["2907 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 178, 207], ["IR 3499", "CHEMICAL", 209, 216], ["2860 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 220, 249], ["IR 3499", "CHEMICAL", 251, 258], ["2717 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 262, 291], ["IR 3499", "CHEMICAL", 293, 300], ["2680 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 304, 333], ["IR 3499", "CHEMICAL", 335, 342], ["2622 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 346, 375], ["IR 3499", "CHEMICAL", 377, 384], ["2581 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 388, 417], ["IR 3499, , 2548 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 419, 459], ["IR 3499", "CHEMICAL", 461, 468], ["2061 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 472, 501], ["IR 3499, , 1606 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 503, 543], ["IR 3499, , 1509 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 545, 585], ["IR 3499, , 1495 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 587, 627], ["IR 3499, , 1454 2-propanol, mp 287\u00c0288\u00b0C", "CHEMICAL", 629, 669], ["IR 3499", "CHEMICAL", 671, 678], ["8, 9, 10, 7 :9,11-dime thano-5H-benzocyclononen-7-amine", "CHEMICAL", 690, 745], ["6\u00c1HClchloroacetamide", "CHEMICAL", 761, 781], ["5To", "CHEMICAL", 783, 786], ["amine 3\u00c1HCl", "CHEMICAL", 801, 812], ["MeOH", "CHEMICAL", 836, 840], ["NaBH", "CHEMICAL", 850, 854], ["AcOH", "CHEMICAL", 881, 885], ["benzaldehyde", "CHEMICAL", 900, 912], ["2-propanol", "CHEMICAL", 59, 69], ["2-propanol", "CHEMICAL", 99, 109], ["2-propanol", "CHEMICAL", 141, 151], ["2-propanol", "CHEMICAL", 183, 193], ["2-propanol", "CHEMICAL", 225, 235], ["2-propanol", "CHEMICAL", 267, 277], ["2-propanol", "CHEMICAL", 309, 319], ["2-propanol", "CHEMICAL", 351, 361], ["2-propanol", "CHEMICAL", 393, 403], ["2-propanol", "CHEMICAL", 435, 445], ["2-propanol", "CHEMICAL", 477, 487], ["2-propanol", "CHEMICAL", 519, 529], ["2-propanol", "CHEMICAL", 561, 571], ["2-propanol", "CHEMICAL", 603, 613], ["2-propanol", "CHEMICAL", 645, 655], ["thano-5H-benzocyclononen-7-amine hydrochloride", "CHEMICAL", 713, 759], ["6\u00c1HClchloroacetamide", "CHEMICAL", 761, 781], ["amine 3\u00c1HCl", "CHEMICAL", 801, 812], ["MeOH", "CHEMICAL", 836, 840], ["NaBH 3 CN", "CHEMICAL", 850, 859], ["AcOH", "CHEMICAL", 881, 885], ["benzaldehyde", "CHEMICAL", 900, 912], ["2-propanol", "SIMPLE_CHEMICAL", 59, 69], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 71, 83], ["2985 2-propanol", "SIMPLE_CHEMICAL", 94, 109], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 111, 123], ["2944 2-propanol", "SIMPLE_CHEMICAL", 136, 151], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 153, 165], ["2907 2-propanol", "SIMPLE_CHEMICAL", 178, 193], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 195, 207], ["2860 2-propanol", "SIMPLE_CHEMICAL", 220, 235], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 237, 249], ["2717 2-propanol", "SIMPLE_CHEMICAL", 262, 277], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 279, 291], ["2680 2-propanol", "SIMPLE_CHEMICAL", 304, 319], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 321, 333], ["2622 2-propanol", "SIMPLE_CHEMICAL", 346, 361], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 363, 375], ["2581 2-propanol", "SIMPLE_CHEMICAL", 388, 403], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 405, 417], ["2548 2-propanol", "SIMPLE_CHEMICAL", 430, 445], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 447, 459], ["2061 2-propanol", "SIMPLE_CHEMICAL", 472, 487], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 489, 501], ["1606 2-propanol", "SIMPLE_CHEMICAL", 514, 529], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 531, 543], ["1509 2-propanol", "SIMPLE_CHEMICAL", 556, 571], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 573, 585], ["1495 2-propanol", "SIMPLE_CHEMICAL", 598, 613], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 615, 627], ["1454 2-propanol", "SIMPLE_CHEMICAL", 640, 655], ["mp 287\u00c0288\u00b0C", "SIMPLE_CHEMICAL", 657, 669], ["9,11-dime thano-5H-benzocyclononen-7-amine hydrochloride", "SIMPLE_CHEMICAL", 703, 759], ["6\u00c1HClchloroacetamide", "SIMPLE_CHEMICAL", 761, 781], ["5To", "SIMPLE_CHEMICAL", 783, 786], ["amine 3\u00c1HCl", "SIMPLE_CHEMICAL", 801, 812], ["MeOH", "SIMPLE_CHEMICAL", 836, 840], ["NaBH 3 CN", "SIMPLE_CHEMICAL", 850, 859], ["AcOH", "SIMPLE_CHEMICAL", 881, 885], ["benzaldehyde", "SIMPLE_CHEMICAL", 900, 912], ["The analytical sample", "TEST", 0, 21], ["IR", "TEST", 85, 87], ["IR", "TEST", 125, 127], ["IR", "TEST", 167, 169], ["IR", "TEST", 209, 211], ["IR", "TEST", 251, 253], ["IR", "TEST", 293, 295], ["IR", "TEST", 335, 337], ["IR", "TEST", 377, 379], ["IR", "TEST", 419, 421], ["IR", "TEST", 461, 463], ["IR", "TEST", 503, 505], ["IR", "TEST", 545, 547], ["IR", "TEST", 587, 589], ["IR", "TEST", 629, 631], ["IR", "TEST", 671, 673], ["benzocyclononen", "TREATMENT", 722, 737], ["amine hydrochloride", "TREATMENT", 740, 759], ["6\u00c1HClchloroacetamide", "TREATMENT", 761, 781], ["a solution of amine 3\u00c1HCl", "TREATMENT", 787, 812], ["AcOH", "TREATMENT", 881, 885], ["benzaldehyde", "TREATMENT", 900, 912]]], ["Water (10 mL) was added to the residue, and the mixture was extracted with Et 2 O (4 \u00c2 15 mL).", [["Et 2 O", "CHEMICAL", 75, 81], ["Et 2 O", "CHEMICAL", 75, 81], ["Et 2 O", "SIMPLE_CHEMICAL", 75, 81]]], ["The combined organic extracts were washed with 2 N NaOH (3 \u00c2 25 mL), brine (2 \u00c2 25 mL), dried with anhyd Na 2 SO 4 , filtered and concentrated in vacuo.", [["extracts", "ANATOMY", 21, 29], ["N NaOH", "CHEMICAL", 49, 55], ["anhyd Na 2 SO 4", "CHEMICAL", 99, 114], ["NaOH", "CHEMICAL", 51, 55], ["Na 2 SO 4", "CHEMICAL", 105, 114], ["extracts", "ORGANISM_SUBSTANCE", 21, 29], ["The combined organic extracts", "TREATMENT", 0, 29], ["2 N NaOH", "TREATMENT", 47, 55], ["organic extracts", "OBSERVATION", 13, 29], ["vacuo", "OBSERVATION", 146, 151]]], ["The residue was taken in EtOAc and the amine 6 was precipitated as its hydrochloride (159 mg, 68% yield) by adding an excess of Et 2 O\u00c1HCl.", [["amine 6", "CHEMICAL", 39, 46], ["Et 2 O\u00c1HCl", "CHEMICAL", 128, 138], ["EtOAc", "CHEMICAL", 25, 30], ["amine", "CHEMICAL", 39, 44], ["hydrochloride", "CHEMICAL", 71, 84], ["Et 2 O\u00c1HCl", "CHEMICAL", 128, 138], ["EtOAc", "SIMPLE_CHEMICAL", 25, 30], ["amine 6", "SIMPLE_CHEMICAL", 39, 46], ["hydrochloride", "SIMPLE_CHEMICAL", 71, 84], ["Et 2 O\u00c1HCl", "SIMPLE_CHEMICAL", 128, 138], ["its hydrochloride", "TREATMENT", 67, 84], ["an excess of Et 2 O\u00c1HCl", "TREATMENT", 115, 138]]], ["The analytical sample was obtained by crystallization from methanol/Et 2 O, mp 263\u00c0264\u00b0C. IR 3410, 2948 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 2912 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 2840 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 2733 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 2407 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1494 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1455 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1364 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1347 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1307 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1217 2 O, mp 263\u00c0264\u00b0C. IR 3410, , 1127 (11), 155 (28), 147 (16), 146 (14), 143 (18), 141 (18), 129 (18), 128 (19) , 115 (15) 11, H 7.97, N 3.86, Cl 10.74.", [["methanol/Et 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 59, 88], ["IR 3410, 2948 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 90, 121], ["2912 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 134, 156], ["IR 3410", "CHEMICAL", 158, 165], ["2840 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 169, 191], ["IR 3410, , 2733 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 193, 226], ["IR 3410", "CHEMICAL", 228, 235], ["2407 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 239, 261], ["IR 3410, , 1494 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 263, 296], ["IR 3410, , 1455 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 298, 331], ["IR 3410, , 1364 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 333, 366], ["IR 3410, , 1347 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 368, 401], ["IR 3410", "CHEMICAL", 403, 410], ["IR 3410, , 1217 2 O, mp 263\u00c0264\u00b0C", "CHEMICAL", 438, 471], ["methanol", "CHEMICAL", 59, 67], ["Et 2 O", "CHEMICAL", 68, 74], ["H", "CHEMICAL", 579, 580], ["Cl", "CHEMICAL", 595, 597], ["methanol", "SIMPLE_CHEMICAL", 59, 67], ["Et 2 O", "SIMPLE_CHEMICAL", 68, 74], ["mp 263\u00c0264\u00b0C", "SIMPLE_CHEMICAL", 76, 88], ["IR", "TEST", 90, 92], ["IR", "TEST", 123, 125], ["IR", "TEST", 193, 195], ["IR", "TEST", 228, 230], ["IR", "TEST", 263, 265], ["IR", "TEST", 333, 335], ["IR", "TEST", 368, 370], ["IR", "TEST", 438, 440], ["IR", "TEST", 473, 475], ["H", "TEST", 579, 580], ["N", "TEST", 587, 588], ["Cl", "TEST", 595, 597]]], ["Found C 76.42, H 7.65, N 3.62, 7, 8, 9, 10, 7:9, 7\u00c1HCl To a solution of 6\u00c1HCl (327 mg, 0.96 mmol) in acetonitrile (10 mL), formaldehyde (0.75 mL, 37% wt. in water solution, 9.60 mmol) and NaBH 3 CN (180 mg, 2.88 mmol) were added.", [["6\u00c1HCl", "CHEMICAL", 72, 77], ["acetonitrile", "CHEMICAL", 101, 113], ["formaldehyde", "CHEMICAL", 123, 135], ["NaBH", "CHEMICAL", 188, 192], ["H", "CHEMICAL", 15, 16], ["6\u00c1HCl", "CHEMICAL", 72, 77], ["acetonitrile", "CHEMICAL", 101, 113], ["formaldehyde", "CHEMICAL", 123, 135], ["NaBH 3 CN", "CHEMICAL", 188, 197], ["6\u00c1HCl", "SIMPLE_CHEMICAL", 72, 77], ["acetonitrile", "SIMPLE_CHEMICAL", 101, 113], ["formaldehyde", "SIMPLE_CHEMICAL", 123, 135], ["water", "SIMPLE_CHEMICAL", 157, 162], ["NaBH 3 CN", "SIMPLE_CHEMICAL", 188, 197], ["C", "TEST", 6, 7], ["H", "TEST", 15, 16], ["N", "TEST", 23, 24], ["a solution of 6\u00c1HCl", "TREATMENT", 58, 77], ["acetonitrile", "TREATMENT", 101, 113], ["water solution", "TREATMENT", 157, 171]]], ["The mixture was stirred for 30 min at room temperature, acetic acid (0.5 mL) was added and the mixture was stirred at room temperature for 2 h.", [["acetic acid", "CHEMICAL", 56, 67], ["acetic acid", "CHEMICAL", 56, 67], ["acetic acid", "SIMPLE_CHEMICAL", 56, 67], ["acetic acid", "TREATMENT", 56, 67]]], ["An additional portion of NaBH 3 CN (180 mg, 2.88 mmol) was added and the mixture was further stirred at room temperature for 2 h.", [["NaBH 3 CN", "CHEMICAL", 25, 34], ["NaBH 3 CN", "CHEMICAL", 25, 34], ["NaBH 3 CN", "SIMPLE_CHEMICAL", 25, 34], ["An additional portion of NaBH 3 CN", "TREATMENT", 0, 34]]], ["The mixture was concentrated to dryness, 2 N NaOH (10 mL) was added and the suspension was extracted with CH 2 Cl 2 (3 \u00c2 15 mL).", [["N NaOH", "CHEMICAL", 43, 49], ["CH 2 Cl", "CHEMICAL", 106, 113], ["NaOH", "CHEMICAL", 45, 49], ["CH 2 Cl 2", "CHEMICAL", 106, 115], ["dryness", "PROBLEM", 32, 39], ["2 N NaOH", "TREATMENT", 41, 49], ["the suspension", "TREATMENT", 72, 86]]], ["The combined organic phases were washed with H 2 O (2 \u00c2 10 mL), dried with anhyd Na 2 SO 4 , filtered and concentrated in vacuo to give 7 as an oil.", [["oil", "ANATOMY", 144, 147], ["H 2 O", "CHEMICAL", 45, 50], ["anhyd Na 2 SO 4", "CHEMICAL", 75, 90], ["H 2 O", "CHEMICAL", 45, 50], ["Na 2 SO 4", "CHEMICAL", 81, 90], ["H 2 O", "SIMPLE_CHEMICAL", 45, 50], ["anhyd Na 2 SO 4", "SIMPLE_CHEMICAL", 75, 90], ["oil", "ORGANISM_SUBSTANCE", 144, 147], ["anhyd Na", "TREATMENT", 75, 83], ["organic phases", "OBSERVATION", 13, 27]]], ["Its hydrochloride was obtained by adding an excess of Et 2 O\u00c1HCl to a solution of the amine in EtOAc, followed by filtration of the white solid precipitate (194 mg, 55% yield).", [["hydrochloride", "CHEMICAL", 4, 17], ["Et 2 O\u00c1HCl", "CHEMICAL", 54, 64], ["amine", "CHEMICAL", 86, 91], ["EtOAc", "CHEMICAL", 95, 100], ["hydrochloride", "CHEMICAL", 4, 17], ["Et 2 O\u00c1HCl", "CHEMICAL", 54, 64], ["amine", "CHEMICAL", 86, 91], ["EtOAc", "CHEMICAL", 95, 100], ["hydrochloride", "SIMPLE_CHEMICAL", 4, 17], ["Et 2 O\u00c1HCl", "SIMPLE_CHEMICAL", 54, 64], ["amine", "SIMPLE_CHEMICAL", 86, 91], ["EtOAc", "SIMPLE_CHEMICAL", 95, 100], ["Its hydrochloride", "TREATMENT", 0, 17], ["a solution of the amine in EtOAc", "TREATMENT", 68, 100], ["the white solid precipitate", "TREATMENT", 128, 155]]], ["The analytical sample was obtained by crystallization from methanol/ Et 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, 2963 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 2943 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 2914 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 2865 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 2844 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 2461 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 2375 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1492 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1452 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1421 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1384 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1308 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1277 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1264 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1214 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1177 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1156 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1121 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1101 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, ,1052 2 O, mp 250\u00c0251\u00b0C. IR 3411, 3016, , 1005 (12), 274 (12) , 260 (10), 246 (11) , 240 (10)NMDA receptor antagonist activityThe functional assay of antagonist activity at NMDA receptors was performed using primary cultures of cerebellar granule neurons, that were prepared according to established protocols.", [["primary cultures", "ANATOMY", 1091, 1107], ["cerebellar granule neurons", "ANATOMY", 1111, 1137], ["methanol/ Et 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 59, 89], ["3016, 2963 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 100, 128], ["3016, , 2943 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 139, 169], ["2914 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 188, 210], ["3016, , 2865 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 221, 251], ["3016, , 2844 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 262, 292], ["3016, , 2461 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 303, 333], ["3016, , 2375 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 344, 374], ["3016, , 1492 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 385, 415], ["3016, , 1452 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 426, 456], ["3016, , 1421 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 467, 497], ["3016, , 1384 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 508, 538], ["IR 3411, 3016, , 1308 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 540, 579], ["3016, , 1277 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 590, 620], ["3016, , 1264 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 631, 661], ["3016, , 1214 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 672, 702], ["IR 3411, 3016, , 1177 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 704, 743], ["3016, , 1156 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 754, 784], ["3016, , 1121 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 795, 825], ["IR 3411, 3016, , 1101 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 827, 866], ["3016, ,1052 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 877, 906], ["NMDA", "CHEMICAL", 976, 980], ["NMDA", "CHEMICAL", 1056, 1060], ["methanol", "CHEMICAL", 59, 67], ["Et 2 O, mp 250\u00c0251\u00b0C", "CHEMICAL", 69, 89], ["NMDA", "CHEMICAL", 976, 980], ["NMDA", "CHEMICAL", 1056, 1060], ["methanol", "SIMPLE_CHEMICAL", 59, 67], ["Et 2 O", "SIMPLE_CHEMICAL", 69, 75], ["mp 250\u00c0251\u00b0C", "SIMPLE_CHEMICAL", 77, 89], ["NMDA", "SIMPLE_CHEMICAL", 1056, 1060], ["cerebellar granule neurons", "CELL", 1111, 1137], ["NMDA receptors", "PROTEIN", 1056, 1070], ["primary cultures", "CELL_LINE", 1091, 1107], ["cerebellar granule neurons", "CELL_TYPE", 1111, 1137], ["IR", "TEST", 91, 93], ["IR", "TEST", 130, 132], ["IR", "TEST", 171, 173], ["IR", "TEST", 212, 214], ["IR", "TEST", 253, 255], ["IR", "TEST", 294, 296], ["IR", "TEST", 335, 337], ["IR", "TEST", 376, 378], ["IR", "TEST", 417, 419], ["IR", "TEST", 458, 460], ["IR", "TEST", 499, 501], ["IR", "TEST", 540, 542], ["IR", "TEST", 581, 583], ["IR", "TEST", 622, 624], ["IR", "TEST", 663, 665], ["IR", "TEST", 704, 706], ["IR", "TEST", 745, 747], ["IR", "TEST", 786, 788], ["IR", "TEST", 827, 829], ["IR", "TEST", 868, 870], ["IR", "TEST", 908, 910], ["NMDA receptor antagonist activity", "TREATMENT", 976, 1009], ["NMDA receptors", "TEST", 1056, 1070], ["primary cultures", "TEST", 1091, 1107], ["cerebellar granule neurons", "PROBLEM", 1111, 1137], ["cerebellar", "ANATOMY", 1111, 1121], ["granule neurons", "OBSERVATION", 1122, 1137]]], ["12 Cells were grown on 10 mm poly-L-lysine coated glass cover slips, and used for the experiments after 7-14 days in vitro.", [["Cells", "ANATOMY", 3, 8], ["poly-L-lysine", "CHEMICAL", 29, 42], ["poly-L-lysine", "CHEMICAL", 29, 42], ["Cells", "CELL", 3, 8], ["poly-L-lysine", "SIMPLE_CHEMICAL", 29, 42], ["10 mm poly-L-lysine coated glass cover slips", "TREATMENT", 23, 67]]], ["Cells were loaded with 6 lM Fura-2 AM (Invitrogen-Molecular Probes) for 45 min.NMDA receptor antagonist activityAfterwards, the coverslip was mounted on a quartz cuvette containing a Locke-Hepes buffer using a special holder.", [["Cells", "ANATOMY", 0, 5], ["Fura-2 AM", "CHEMICAL", 28, 37], ["NMDA", "CHEMICAL", 79, 83], ["NMDA", "CHEMICAL", 79, 83], ["quartz", "CHEMICAL", 155, 161], ["Cells", "CELL", 0, 5], ["Fura-2 AM", "SIMPLE_CHEMICAL", 28, 37], ["Invitrogen-Molecular Probes", "SIMPLE_CHEMICAL", 39, 66], ["NMDA", "SIMPLE_CHEMICAL", 79, 83], ["NMDA receptor", "PROTEIN", 79, 92], ["Invitrogen", "TEST", 39, 49], ["NMDA receptor antagonist activity", "TREATMENT", 79, 112], ["a quartz cuvette", "TREATMENT", 153, 169], ["a Locke-Hepes buffer", "TREATMENT", 181, 201], ["a special holder", "TREATMENT", 208, 224]]], ["Measurements were performed using a PerkinElmer LS-50B fluorometer equipped with a fast-filter accessory, under mild agitation and at 37\u00b0C. Analysis from each sample was recorded real-time during 1200 s.", [["agitation", "DISEASE", 117, 126], ["a PerkinElmer LS", "TEST", 34, 50], ["a fast-filter accessory", "TREATMENT", 81, 104], ["mild agitation", "PROBLEM", 112, 126], ["Analysis", "TEST", 140, 148], ["each sample", "TEST", 154, 165], ["mild", "OBSERVATION_MODIFIER", 112, 116], ["agitation", "OBSERVATION", 117, 126]]], ["After stimulation with NMDA or glutamate (100 lM, in the presence of 10 lM glycine), increasing cumulative concentrations of the compound to be tested were added.", [["NMDA", "CHEMICAL", 23, 27], ["glutamate", "CHEMICAL", 31, 40], ["glycine", "CHEMICAL", 75, 82], ["NMDA", "CHEMICAL", 23, 27], ["glutamate", "CHEMICAL", 31, 40], ["glycine", "CHEMICAL", 75, 82], ["NMDA", "SIMPLE_CHEMICAL", 23, 27], ["glutamate", "SIMPLE_CHEMICAL", 31, 40], ["NMDA", "TREATMENT", 23, 27], ["glutamate", "TREATMENT", 31, 40], ["increasing cumulative concentrations", "PROBLEM", 85, 121]]], ["The percentages of inhibition at every tested concentration were analyzed using a non-linear regression curve fitting (variable slope) by using the software GraphPad Prism 4.0.Antiviral evaluationThe antiviral activity of the compounds was determined in established cell culture assays using a selection of DNA and RNA viruses, including three subtypes of influenza virus [A/Puerto Rico/8/34 (H1N1); A/Hong Kong/7/87 (H3N2) and B/Hong Kong/ 5/72].", [["cell culture", "ANATOMY", 266, 278], ["influenza virus", "DISEASE", 356, 371], ["cell", "CELL", 266, 270], ["DNA", "CELLULAR_COMPONENT", 307, 310], ["influenza virus", "ORGANISM", 356, 371], ["influenza virus", "SPECIES", 356, 371], ["A/Puerto Rico/8/34 (H1N1); A/Hong Kong/7/87 (H3N2)", "SPECIES", 373, 423], ["B/Hong Kong/ 5/72", "SPECIES", 428, 445], ["a non-linear regression curve fitting", "TREATMENT", 80, 117], ["the software GraphPad Prism", "TEST", 144, 171], ["Antiviral evaluation", "TEST", 176, 196], ["established cell culture assays", "TEST", 254, 285], ["DNA", "PROBLEM", 307, 310], ["RNA viruses", "PROBLEM", 315, 326], ["influenza virus", "PROBLEM", 356, 371], ["antiviral activity", "OBSERVATION", 200, 218], ["RNA viruses", "OBSERVATION", 315, 326], ["influenza virus", "OBSERVATION", 356, 371]]], ["16 The compounds' inhibitory effect on virus replication as well as their cytotoxicity were monitored by microscopical examination, and confirmed by the colorimetric MTS cell viability assay.Plasmid, mRNA synthesis, and microinjection of oocytes.", [["cell", "ANATOMY", 170, 174], ["oocytes", "ANATOMY", 238, 245], ["cell", "CELL", 170, 174], ["oocytes", "DEVELOPING_ANATOMICAL_STRUCTURE", 238, 245], ["The compounds' inhibitory effect", "TREATMENT", 3, 35], ["virus replication", "TREATMENT", 39, 56], ["their cytotoxicity", "TEST", 68, 86], ["microscopical examination", "TEST", 105, 130], ["the colorimetric MTS cell viability assay", "TEST", 149, 190], ["Plasmid", "TREATMENT", 191, 198], ["mRNA synthesis", "TEST", 200, 214], ["microinjection of oocytes", "TREATMENT", 220, 245], ["MTS cell", "OBSERVATION", 166, 174], ["viability assay", "OBSERVATION", 175, 190]]], ["Two-electrode voltage clamp analysisThe cDNA encoding the influenza A/Udorn/72 (A/M2) was inserted into pGEM3 vector for the expression on oocyte plasma membrane.", [["oocyte plasma membrane", "ANATOMY", 139, 161], ["influenza A", "ORGANISM", 58, 69], ["Udorn/72", "ORGANISM", 70, 78], ["A", "GENE_OR_GENE_PRODUCT", 80, 81], ["M2", "GENE_OR_GENE_PRODUCT", 82, 84], ["pGEM3", "GENE_OR_GENE_PRODUCT", 104, 109], ["oocyte plasma membrane", "CELLULAR_COMPONENT", 139, 161], ["cDNA", "DNA", 40, 44], ["pGEM3 vector", "DNA", 104, 116], ["influenza A/Udorn/72", "SPECIES", 58, 78], ["Two-electrode voltage clamp analysis", "TREATMENT", 0, 36], ["A/M2)", "TREATMENT", 80, 85], ["oocyte plasma membrane", "TREATMENT", 139, 161], ["oocyte plasma membrane", "OBSERVATION", 139, 161]]], ["A/M2 S31N and A/M2 V27A mutants were generated by QuikChange site-directed mutagenesis kit (Agilent Technologies).", [["M2 S31N", "GENE_OR_GENE_PRODUCT", 2, 9], ["A", "GENE_OR_GENE_PRODUCT", 14, 15], ["M2", "GENE_OR_GENE_PRODUCT", 16, 18], ["V27A", "GENE_OR_GENE_PRODUCT", 19, 23], ["M2 S31N", "PROTEIN", 2, 9], ["M2 V27A mutants", "PROTEIN", 16, 31]]], ["The synthesis of mRNA and microinjection of oocytes have been described previously.", [["oocytes", "ANATOMY", 44, 51], ["oocytes", "CELL", 44, 51], ["mRNA", "RNA", 17, 21], ["mRNA and microinjection of oocytes", "TREATMENT", 17, 51]]], ["17 Macroscopic membrane current was recorded 48-72 h after injection as described previously.", [["membrane", "ANATOMY", 15, 23], ["membrane", "CELLULAR_COMPONENT", 15, 23]]], ["18 The tested compounds were applied at pH 5.5 at various concentrations when the inward current reaches maximum.", [["pH", "TEST", 40, 42], ["maximum", "OBSERVATION_MODIFIER", 105, 112]]], ["The compounds were applied for 2 min, and residual membrane current was compared with the membrane current before the application of compounds.", [["membrane", "ANATOMY", 51, 59], ["membrane", "ANATOMY", 90, 98], ["membrane", "CELLULAR_COMPONENT", 51, 59], ["membrane", "CELLULAR_COMPONENT", 90, 98], ["The compounds", "TREATMENT", 0, 13], ["the application of compounds", "TREATMENT", 114, 142]]], ["Membrane currents were analyzed with pCLAMP 10.0 software package (Axon Instruments, Sunnyvale, CA).T. brucei culturing and drug testingCultures of bloodstream form T. brucei (strain 427) were maintained at 37\u00b0C in modified Iscove's medium (pH 7.4).", [["Membrane", "ANATOMY", 0, 8], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["T. brucei", "ORGANISM", 100, 109], ["T. brucei", "ORGANISM", 165, 174], ["T. brucei", "SPECIES", 100, 109], ["T. brucei", "SPECIES", 165, 174], ["T. brucei", "SPECIES", 100, 109], ["T. brucei", "SPECIES", 165, 174], ["Membrane currents", "TEST", 0, 17], ["pCLAMP", "TREATMENT", 37, 43], ["Axon Instruments", "TREATMENT", 67, 83], ["T. brucei culturing", "TEST", 100, 119], ["drug testingCultures", "TEST", 124, 144], ["bloodstream", "PROBLEM", 148, 159], ["T. brucei", "PROBLEM", 165, 174], ["pH", "TEST", 241, 243], ["brucei culturing", "OBSERVATION", 103, 119], ["bloodstream", "ANATOMY", 148, 159]]], ["19 Trypanocidal activity was assessed by growing parasites for 48 h in the presence of various drug concentrations and determining the levels which inhibited growth by 50% (IC 50 ) and 90% (IC 90 ).", [["various drug concentrations", "TREATMENT", 87, 114], ["the levels", "TEST", 131, 141], ["IC", "TEST", 173, 175], ["Trypanocidal activity", "OBSERVATION", 3, 24]]], ["In the case of untreated cultures (volume 4 mL), cell densities increased from 0.25 \u00c2 10 5 to 1 \u00c2 10 6 cells mL \u00c01 over this period.", [["cultures", "ANATOMY", 25, 33], ["cell", "ANATOMY", 49, 53], ["cells", "ANATOMY", 103, 108], ["cell", "CELL", 49, 53], ["untreated cultures", "TEST", 15, 33], ["volume", "TEST", 35, 41], ["cell densities", "TEST", 49, 63], ["densities", "OBSERVATION_MODIFIER", 54, 63], ["increased", "OBSERVATION_MODIFIER", 64, 73]]], ["Cell densities at each drug concentration were determined using a hemocytometer (Weber Scientific International Ltd), and drug sensitivity was expressed as a percentage of growth of control cells.", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 190, 195], ["Cell", "CELL", 0, 4], ["cells", "CELL", 190, 195], ["control cells", "CELL_TYPE", 182, 195], ["Cell densities", "PROBLEM", 0, 14], ["a hemocytometer", "TEST", 64, 79], ["drug sensitivity", "TEST", 122, 138], ["growth of control cells", "PROBLEM", 172, 195]]]], "PMC7129164": [["Case descriptionThere has been an increase in influenza A variant detections in the US in recent years.1, 2, 3 Influenza viruses that normally circulate in swine are called \u201cvariant\u201d viruses when they are found in people.4 From December 2005 to September 21, 2012, 326 influenza A(H3N2) variant (v), 14 A(H1N1)v and 5 A(H1N2)v cases have been identified.5 In September 2012, a 37 year old male Ontario resident was diagnosed with influenza A H1N1v infection.", [["influenza", "DISEASE", 269, 278], ["influenza A H1N1v infection", "DISEASE", 430, 457], ["3", "ORGANISM", 109, 110], ["Influenza viruses", "ORGANISM", 111, 128], ["swine", "ORGANISM", 156, 161], ["people", "ORGANISM", 214, 220], ["influenza A(H3N2)", "ORGANISM", 269, 286], ["14 A(H1N1)v", "ORGANISM", 300, 311], ["5 A(H1N2)v", "ORGANISM", 316, 326], ["swine", "SPECIES", 156, 161], ["people", "SPECIES", 214, 220], ["swine", "SPECIES", 156, 161], ["influenza A variant detections", "PROBLEM", 46, 76], ["3 Influenza viruses", "PROBLEM", 109, 128], ["influenza", "PROBLEM", 269, 278], ["A(H1N1)v and 5 A(H1N2)v cases", "PROBLEM", 303, 332], ["influenza A H1N1v infection", "PROBLEM", 430, 457], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["influenza", "OBSERVATION", 46, 55], ["Influenza viruses", "OBSERVATION", 111, 128], ["influenza", "OBSERVATION", 430, 439], ["infection", "OBSERVATION", 448, 457]]], ["This was the first detection of this variant influenza strain in an individual in Canada.", [["influenza", "DISEASE", 45, 54], ["this variant influenza strain", "PROBLEM", 32, 61]]], ["The case, who has an unknown influenza immunization history, had recently traveled within Canada during which time he had close contact with swine, and to the United States where he had close contact with cattle; attendance at swine fairs could not be ascertained.", [["cattle", "SPECIES", 205, 211], ["swine", "SPECIES", 141, 146], ["cattle", "SPECIES", 205, 211], ["swine", "SPECIES", 227, 232]]], ["At the beginning of September, he became ill with gastrointestinal symptoms of unknown etiology, followed by acute respiratory symptoms and on September 9 was admitted to a local area hospital with pneumonia.", [["gastrointestinal", "ANATOMY", 50, 66], ["respiratory", "ANATOMY", 115, 126], ["gastrointestinal symptoms", "DISEASE", 50, 75], ["acute respiratory symptoms", "DISEASE", 109, 135], ["pneumonia", "DISEASE", 198, 207], ["gastrointestinal", "ORGANISM_SUBDIVISION", 50, 66], ["ill", "PROBLEM", 41, 44], ["gastrointestinal symptoms", "PROBLEM", 50, 75], ["acute respiratory symptoms", "PROBLEM", 109, 135], ["pneumonia", "PROBLEM", 198, 207], ["gastrointestinal", "ANATOMY", 50, 66], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["respiratory", "ANATOMY", 115, 126], ["pneumonia", "OBSERVATION", 198, 207]]], ["Following a 2-day admission he was discharged from hospital, but was re-admitted on September 13 with worsening respiratory symptoms, and subsequently was transferred to a tertiary care center where he required admission to an intensive care unit.", [["respiratory", "ANATOMY", 112, 123], ["respiratory symptoms", "DISEASE", 112, 132], ["worsening respiratory symptoms", "PROBLEM", 102, 132], ["respiratory", "ANATOMY", 112, 123], ["symptoms", "OBSERVATION", 124, 132]]], ["The case had two separate treatment courses of oseltamivir administered.", [["oseltamivir", "CHEMICAL", 47, 58], ["oseltamivir", "CHEMICAL", 47, 58], ["oseltamivir", "SIMPLE_CHEMICAL", 47, 58], ["oseltamivir", "TREATMENT", 47, 58]]], ["Only one close contact of the case reported symptoms of influenza-like illness (ILI); that person tested negative for influenza.Laboratory testingPHOL performs a large proportion of primary respiratory viral testing for the province of Ontario from a variety of clinical settings including ambulatory, hospital and outbreaks.", [["influenza-like illness", "DISEASE", 56, 78], ["ILI", "DISEASE", 80, 83], ["influenza", "DISEASE", 118, 127], ["person", "SPECIES", 91, 97], ["symptoms", "PROBLEM", 44, 52], ["influenza", "PROBLEM", 56, 65], ["influenza", "PROBLEM", 118, 127], ["primary respiratory viral testing", "TEST", 182, 215], ["influenza", "OBSERVATION", 56, 65], ["respiratory viral", "OBSERVATION", 190, 207]]], ["Specimens from all hospitalized and outbreak patients are tested for influenza A matrix gene and influenza B NS1 gene using CDC protocols.", [["Specimens", "ANATOMY", 0, 9], ["patients", "ORGANISM", 45, 53], ["influenza A matrix", "GENE_OR_GENE_PRODUCT", 69, 87], ["influenza B NS1", "GENE_OR_GENE_PRODUCT", 97, 112], ["influenza A matrix gene", "DNA", 69, 92], ["influenza B NS1 gene", "DNA", 97, 117], ["patients", "SPECIES", 45, 53], ["Specimens", "TEST", 0, 9], ["influenza", "PROBLEM", 69, 78], ["influenza", "PROBLEM", 97, 106], ["CDC protocols", "TREATMENT", 124, 137]]], ["If influenza A-positive, subtyping for seasonal influenza A (H3N2) HA gene (CDC assay) and influenza A (H1N1)pdm09 NA gene (in-house assay) are performed.6 Following the emergence of H3N2v infections in the US in 2011, PHOL implemented screening of a selection of influenza A-positive, H3-positive specimens with the swine NP gene PCR to screen for H3N2v.", [["specimens", "ANATOMY", 298, 307], ["influenza A-positive", "DISEASE", 3, 23], ["H3N2v infections", "DISEASE", 183, 199], ["seasonal influenza A (H3N2) HA", "ORGANISM", 39, 69], ["influenza A (H1N1)", "ORGANISM", 91, 109], ["pdm09 NA", "GENE_OR_GENE_PRODUCT", 109, 117], ["H3", "GENE_OR_GENE_PRODUCT", 286, 288], ["seasonal influenza A (H3N2) HA gene", "DNA", 39, 74], ["influenza A (H1N1)pdm09 NA gene", "DNA", 91, 122], ["swine NP gene PCR", "DNA", 317, 334], ["H3N2v", "DNA", 349, 354], ["influenza A (H1N1", "SPECIES", 91, 108], ["swine", "SPECIES", 317, 322], ["seasonal influenza A (H3N2)", "SPECIES", 39, 66], ["H3N2v", "SPECIES", 183, 188], ["swine", "SPECIES", 317, 322], ["influenza", "PROBLEM", 3, 12], ["seasonal influenza A", "PROBLEM", 39, 59], ["(H3N2) HA gene (CDC assay", "TEST", 60, 85], ["influenza", "PROBLEM", 91, 100], ["H3N2v infections", "PROBLEM", 183, 199], ["influenza", "PROBLEM", 264, 273], ["H3", "PROBLEM", 286, 288], ["positive specimens", "PROBLEM", 289, 307], ["the swine NP gene PCR", "TREATMENT", 313, 334], ["H3N2v", "TREATMENT", 349, 354], ["infections", "OBSERVATION", 189, 199]]], ["Samples that are influenza-A positive, but negative in the initial subtyping assays are designated unsubtypeable, and are investigated further including other seasonal (N2, H1, N1, pdm09H1), swine (NP) and avian (H5, H7, +/\u2212 H9) rRT-PCR subtyping targets using CDC protocols, in addition to an end-point swine influenza matrix (M) gene PCR developed by Canada's National Microbiology Laboratory (NML).", [["Samples", "ANATOMY", 0, 7], ["pdm09H1", "GENE_OR_GENE_PRODUCT", 181, 188], ["swine (NP", "ORGANISM", 191, 200], ["avian", "ORGANISM", 206, 211], ["\u2212 H9", "CELL", 223, 227], ["swine", "SPECIES", 191, 196], ["swine", "SPECIES", 191, 196], ["H5", "SPECIES", 213, 215], ["swine", "SPECIES", 304, 309], ["Samples", "TEST", 0, 7], ["influenza", "PROBLEM", 17, 26], ["A positive", "PROBLEM", 27, 37], ["other seasonal (N2, H1", "PROBLEM", 153, 175], ["H7", "TEST", 217, 219], ["rRT", "TEST", 229, 232], ["CDC protocols", "TEST", 261, 274], ["an end-point swine influenza matrix", "TREATMENT", 291, 326], ["gene PCR", "TEST", 331, 339]]], ["Influenza-negative outbreak and ICU samples are also tested using a multiplex molecular respiratory viral assay [Seeplex RV15 ACE detection kit (Seegene, Inc., Seoul, South Korea) (MRVP)].", [["samples", "ANATOMY", 36, 43], ["Influenza", "DISEASE", 0, 9], ["Influenza", "TEST", 0, 9], ["ICU samples", "TEST", 32, 43], ["a multiplex molecular respiratory viral assay", "TEST", 66, 111], ["Seeplex", "TEST", 113, 120]]], ["Assay targets include rhinovirus, enterovirus, influenza A/B, parainfluenza 1\u20134, respiratory syncytial virus A/B, adenovirus, bocavirus, human metapneumovirus, coronavirus OC43, coronavirus 229E/NL63 and bocavirus.", [["parainfluenza 1\u20134", "DISEASE", 62, 79], ["respiratory syncytial virus", "DISEASE", 81, 108], ["human metapneumovirus", "DISEASE", 137, 158], ["rhinovirus", "ORGANISM", 22, 32], ["enterovirus", "ORGANISM", 34, 45], ["influenza A/B", "ORGANISM", 47, 60], ["parainfluenza 1\u20134,", "ORGANISM", 62, 80], ["respiratory syncytial virus A/B", "ORGANISM", 81, 112], ["adenovirus", "ORGANISM", 114, 124], ["bocavirus", "ORGANISM", 126, 135], ["human", "ORGANISM", 137, 142], ["metapneumovirus", "ORGANISM", 143, 158], ["coronavirus OC43", "ORGANISM", 160, 176], ["coronavirus 229E", "ORGANISM", 178, 194], ["NL63", "GENE_OR_GENE_PRODUCT", 195, 199], ["parainfluenza", "SPECIES", 62, 75], ["respiratory syncytial virus", "SPECIES", 81, 108], ["human", "SPECIES", 137, 142], ["metapneumovirus", "SPECIES", 143, 158], ["coronavirus", "SPECIES", 160, 171], ["coronavirus", "SPECIES", 178, 189], ["respiratory syncytial virus", "SPECIES", 81, 108], ["adenovirus", "SPECIES", 114, 124], ["human metapneumovirus", "SPECIES", 137, 158], ["coronavirus 229E/NL63", "SPECIES", 178, 199], ["Assay targets", "TEST", 0, 13], ["rhinovirus", "PROBLEM", 22, 32], ["enterovirus", "PROBLEM", 34, 45], ["influenza A/B", "TEST", 47, 60], ["parainfluenza", "PROBLEM", 62, 75], ["respiratory syncytial virus", "PROBLEM", 81, 108], ["adenovirus", "PROBLEM", 114, 124], ["bocavirus", "PROBLEM", 126, 135], ["human metapneumovirus", "PROBLEM", 137, 158], ["coronavirus OC43", "PROBLEM", 160, 176], ["coronavirus", "TEST", 178, 189], ["bocavirus", "PROBLEM", 204, 213], ["rhinovirus", "OBSERVATION", 22, 32], ["respiratory syncytial", "ANATOMY", 81, 102], ["human metapneumovirus", "ANATOMY", 137, 158]]], ["Respiratory specimens from ambulatory and emergency patients not admitted to hospital are cultured for virus isolation in two cell lines.", [["Respiratory specimens", "ANATOMY", 0, 21], ["cell lines", "ANATOMY", 126, 136], ["Respiratory specimens", "CANCER", 0, 21], ["patients", "ORGANISM", 52, 60], ["cell lines", "CELL", 126, 136], ["cell lines", "CELL_LINE", 126, 136], ["patients", "SPECIES", 52, 60], ["Respiratory specimens", "TEST", 0, 21], ["virus isolation", "TREATMENT", 103, 118], ["two cell lines", "OBSERVATION", 122, 136]]], ["One line is monkey kidney cells [either Rhesus (RMK) or African green monkey kidney cells (AGMK)], and the other is WI-38 human embryonic lung fibroblast cells (Diagnostic Hybrids, Inc., Athens, OH, USA).", [["kidney cells", "ANATOMY", 19, 31], ["RMK", "ANATOMY", 48, 51], ["kidney cells", "ANATOMY", 77, 89], ["AGMK", "ANATOMY", 91, 95], ["embryonic lung fibroblast cells", "ANATOMY", 128, 159], ["monkey", "ORGANISM", 12, 18], ["kidney cells", "CELL", 19, 31], ["Rhesus", "ORGANISM", 40, 46], ["RMK", "CELL", 48, 51], ["green monkey kidney cells", "CELL", 64, 89], ["AGMK", "CELL", 91, 95], ["WI-38", "CELL", 116, 121], ["human", "ORGANISM", 122, 127], ["embryonic lung fibroblast cells", "CELL", 128, 159], ["monkey kidney cells", "CELL_TYPE", 12, 31], ["African green monkey kidney cells", "CELL_TYPE", 56, 89], ["AGMK", "CELL_TYPE", 91, 95], ["WI-38 human embryonic lung fibroblast cells", "CELL_LINE", 116, 159], ["green monkey", "SPECIES", 64, 76], ["human", "SPECIES", 122, 127], ["African green monkey", "SPECIES", 56, 76], ["human", "SPECIES", 122, 127], ["Rhesus (RMK)", "PROBLEM", 40, 52], ["African green monkey kidney cells", "PROBLEM", 56, 89], ["human embryonic lung fibroblast cells", "PROBLEM", 122, 159], ["line", "OBSERVATION", 4, 8], ["kidney cells", "OBSERVATION", 19, 31], ["kidney", "ANATOMY", 77, 83], ["lung", "ANATOMY", 138, 142], ["fibroblast cells", "OBSERVATION", 143, 159]]], ["A selection of influenza A-positive cultures are subtyped as described above.Laboratory testingA nasopharyngeal swab from the case collected on September 10 tested positive for influenza A in viral culture, and specimens collected on September 12 and 15 during a bronchoalveolar lavage was also positive for influenza A in the MRVP assay.", [["nasopharyngeal swab", "ANATOMY", 97, 116], ["specimens", "ANATOMY", 211, 220], ["bronchoalveolar lavage", "ANATOMY", 263, 285], ["nasopharyngeal swab", "CANCER", 97, 116], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 263, 285], ["influenza A-positive cultures", "CELL_LINE", 15, 44], ["A selection of influenza A-positive cultures", "TEST", 0, 44], ["Laboratory testing", "TEST", 77, 95], ["A nasopharyngeal swab", "TEST", 95, 116], ["influenza", "PROBLEM", 177, 186], ["viral culture", "TEST", 192, 205], ["specimens", "TEST", 211, 220], ["a bronchoalveolar lavage", "TEST", 261, 285], ["influenza", "PROBLEM", 308, 317], ["the MRVP assay", "TEST", 323, 337], ["influenza", "OBSERVATION", 15, 24], ["nasopharyngeal", "ANATOMY", 97, 111]]], ["A subsequent nasopharyngeal swab collected on September 17 tested negative for influenza.", [["nasopharyngeal swab", "ANATOMY", 13, 32], ["influenza", "DISEASE", 79, 88], ["nasopharyngeal swab", "CANCER", 13, 32], ["A subsequent nasopharyngeal swab", "TEST", 0, 32], ["influenza", "PROBLEM", 79, 88], ["nasopharyngeal", "ANATOMY", 13, 27]]], ["The September 10 sample was initially unsubtypeable by the influenza A subtyping assays routinely used at PHOL \u2013 influenza A(H1N1)pdm09 NA gene and seasonal HA3 gene.", [["PHOL \u2013 influenza A(H1N1)pdm09 NA", "ORGANISM", 106, 138], ["HA3", "GENE_OR_GENE_PRODUCT", 157, 160], ["PHOL \u2013 influenza A(H1N1)pdm09 NA gene", "DNA", 106, 143], ["seasonal HA3 gene", "DNA", 148, 165], ["influenza", "PROBLEM", 113, 122], ["NA gene", "TEST", 136, 143], ["seasonal HA3 gene", "PROBLEM", 148, 165]]], ["Real-time subtyping PCRs for seasonal HA1, seasonal NA1, seasonal NA2, HA5, and HA7 were all negative.", [["NA1", "GENE_OR_GENE_PRODUCT", 52, 55], ["NA2", "GENE_OR_GENE_PRODUCT", 66, 69], ["HA5", "GENE_OR_GENE_PRODUCT", 71, 74], ["HA7", "GENE_OR_GENE_PRODUCT", 80, 83], ["seasonal NA1, seasonal NA2, HA5, and HA7", "DNA", 43, 83], ["subtyping PCRs", "TEST", 10, 24], ["seasonal HA1", "PROBLEM", 29, 41], ["seasonal NA1", "TEST", 43, 55], ["seasonal NA2", "TEST", 57, 69], ["HA5", "TEST", 71, 74], ["HA7", "TEST", 80, 83], ["negative", "OBSERVATION", 93, 101]]], ["Real-time PCRs for swine nucleoprotein (NP) gene and A(H1N1)pdm09 HA1 gene were both positive, as was a PCR for swine M gene.", [["swine nucleoprotein (NP)", "GENE_OR_GENE_PRODUCT", 19, 43], ["A(H1N1)pdm09 HA1", "GENE_OR_GENE_PRODUCT", 53, 69], ["swine nucleoprotein (NP) gene and A(H1N1)pdm09 HA1 gene", "DNA", 19, 74], ["swine M gene", "DNA", 112, 124], ["swine", "SPECIES", 19, 24], ["swine", "SPECIES", 112, 117], ["swine", "SPECIES", 19, 24], ["swine", "SPECIES", 112, 117], ["swine nucleoprotein (NP) gene", "TEST", 19, 48], ["A(H1N1)pdm09 HA1 gene", "PROBLEM", 53, 74], ["a PCR", "TEST", 102, 107]]], ["These results suggested that the influenza A virus was of swine origin, and of H1 subtype.Laboratory testingWhole genome sequencing was commenced at PHOL, and sequence data shared with the National Microbiology Laboratory (NML), Canada's reference laboratory.", [["influenza A", "DISEASE", 33, 44], ["influenza A virus", "ORGANISM", 33, 50], ["PHOL", "DNA", 149, 153], ["influenza A virus", "SPECIES", 33, 50], ["swine", "SPECIES", 58, 63], ["influenza A virus", "SPECIES", 33, 50], ["swine", "SPECIES", 58, 63], ["the influenza A virus", "PROBLEM", 29, 50], ["H1 subtype", "PROBLEM", 79, 89], ["Laboratory testing", "TEST", 90, 108], ["Whole genome sequencing", "TEST", 108, 131], ["influenza", "OBSERVATION", 33, 42], ["H1 subtype", "OBSERVATION_MODIFIER", 79, 89]]], ["The NML received the primary sample and culture material for further investigation.", [["NML", "ANATOMY", 4, 7], ["primary sample", "ANATOMY", 21, 35], ["NML", "CANCER", 4, 7], ["culture material", "TEST", 40, 56], ["further investigation", "TEST", 61, 82], ["NML", "OBSERVATION", 4, 7]]], ["At NML, testing was performed on the culture material, which was negative for seasonal H3N2, pandemic NA, H3N2 variant (v), and H1N2v.", [["NML", "CANCER", 3, 6], ["H1N2v", "SPECIES", 128, 133], ["testing", "TEST", 8, 15], ["the culture material", "TEST", 33, 53], ["seasonal H3N2", "PROBLEM", 78, 91], ["pandemic NA", "PROBLEM", 93, 104], ["H1N2v", "TREATMENT", 128, 133]]], ["Antiviral susceptibility testing showed that the isolate was resistant to amantadine but sensitive to oseltamivir and zanamivir.", [["amantadine", "CHEMICAL", 74, 84], ["oseltamivir", "CHEMICAL", 102, 113], ["zanamivir", "CHEMICAL", 118, 127], ["amantadine", "CHEMICAL", 74, 84], ["oseltamivir", "CHEMICAL", 102, 113], ["zanamivir", "CHEMICAL", 118, 127], ["amantadine", "SIMPLE_CHEMICAL", 74, 84], ["oseltamivir", "SIMPLE_CHEMICAL", 102, 113], ["zanamivir", "SIMPLE_CHEMICAL", 118, 127], ["Antiviral susceptibility testing", "TEST", 0, 32], ["the isolate", "PROBLEM", 45, 56], ["amantadine", "TREATMENT", 74, 84], ["oseltamivir", "TREATMENT", 102, 113], ["zanamivir", "TREATMENT", 118, 127]]], ["Complete sequencing analysis of PB1, PB2, PA, HA, NA, and M genes on viral RNA extracted from the first passage in rhesus monkey kidney cells revealed that all sequences are very similar (between 98.9 and 99.5%) to viruses that have been found in US swine in 2011 and 2012 (Table 1).", [["kidney cells", "ANATOMY", 129, 141], ["PB1", "GENE_OR_GENE_PRODUCT", 32, 35], ["PB2", "GENE_OR_GENE_PRODUCT", 37, 40], ["PA", "GENE_OR_GENE_PRODUCT", 42, 44], ["HA", "GENE_OR_GENE_PRODUCT", 46, 48], ["NA", "GENE_OR_GENE_PRODUCT", 50, 52], ["M", "GENE_OR_GENE_PRODUCT", 58, 59], ["rhesus", "ORGANISM", 115, 121], ["monkey", "ORGANISM", 122, 128], ["kidney cells", "CELL", 129, 141], ["PB1, PB2, PA, HA, NA, and M genes", "DNA", 32, 65], ["viral RNA", "RNA", 69, 78], ["rhesus monkey kidney cells", "CELL_TYPE", 115, 141], ["rhesus monkey", "SPECIES", 115, 128], ["swine", "SPECIES", 250, 255], ["rhesus monkey", "SPECIES", 115, 128], ["swine", "SPECIES", 250, 255], ["Complete sequencing analysis", "TEST", 0, 28], ["PB1", "TEST", 32, 35], ["PB2", "TEST", 37, 40], ["PA", "TEST", 42, 44], ["HA", "PROBLEM", 46, 48], ["NA", "TEST", 50, 52], ["M genes", "PROBLEM", 58, 65], ["viral RNA", "PROBLEM", 69, 78], ["all sequences", "TEST", 156, 169], ["viruses", "PROBLEM", 215, 222], ["viral RNA", "OBSERVATION", 69, 78]]], ["Interestingly, four of the internal genes (PB1, PA, NP and NS) shared the highest homology of 99.26\u201399.64% to A/swine/Illinois/A00857318a/2012, a swine triple reassortant H3N2 isolate containing M and NP genes of pandemic H1N1.Laboratory testingThe sequences for A/Ontario/N163578/2012(H1N1v) were deposited in the GISAID database under accession numbers EPI397237\u2013EPI397244.", [["H1N1", "DISEASE", 222, 226], ["EPI397237\u2013EPI397244", "CHEMICAL", 355, 374], ["PB1", "GENE_OR_GENE_PRODUCT", 43, 46], ["PA", "GENE_OR_GENE_PRODUCT", 48, 50], ["NP", "GENE_OR_GENE_PRODUCT", 52, 54], ["swine", "ORGANISM", 112, 117], ["Illinois/A00857318a/2012", "ORGANISM", 118, 142], ["swine triple reassortant H3N2", "ORGANISM", 146, 175], ["pandemic H1N1", "ORGANISM", 213, 226], ["Ontario/N163578/2012(H1N1v", "ORGANISM", 265, 291], ["internal genes", "DNA", 27, 41], ["PB1", "DNA", 43, 46], ["PA", "DNA", 48, 50], ["NP", "DNA", 52, 54], ["NS", "DNA", 59, 61], ["M and NP genes", "DNA", 195, 209], ["swine", "SPECIES", 112, 117], ["swine", "SPECIES", 146, 151], ["reassortant H3N2", "SPECIES", 159, 175], ["pandemic H1N1", "SPECIES", 213, 226], ["A/swine/Illinois/A00857318a/2012", "SPECIES", 110, 142], ["swine triple reassortant H3N2", "SPECIES", 146, 175], ["A/Ontario/N163578/2012(H1N1v)", "SPECIES", 263, 292], ["NP and NS", "TREATMENT", 52, 61], ["a swine triple reassortant H3N2 isolate", "TREATMENT", 144, 183], ["pandemic H1N1", "PROBLEM", 213, 226], ["Laboratory testing", "TEST", 227, 245], ["internal genes", "ANATOMY", 27, 41], ["pandemic H1N1", "OBSERVATION", 213, 226]]], ["PCR and sequencing results of HA and NA showed that this virus is an H1N1 subtype, which is closely related to H1N1 swine triple reassortant viruses identified in the United States in 2011 and 2012.", [["H1N1", "ORGANISM", 111, 115], ["swine triple reassortant viruses", "ORGANISM", 116, 148], ["H1N1 swine", "SPECIES", 111, 121], ["H1N1 swine triple reassortant viruses", "SPECIES", 111, 148], ["PCR", "TEST", 0, 3], ["sequencing results", "TEST", 8, 26], ["HA", "PROBLEM", 30, 32], ["NA", "TEST", 37, 39], ["this virus", "PROBLEM", 52, 62], ["an H1N1 subtype", "PROBLEM", 66, 81], ["H1N1 swine triple reassortant viruses", "PROBLEM", 111, 148], ["H1N1", "OBSERVATION", 69, 73]]], ["Sequencing revealed that this H1N1 carries the M gene of influenza A(H1N1)pdm09, as was found in the last 2 documented cases of H1N1v infection, in Wisconsin (December 2011) and Missouri (reported September 2012).", [["influenza A", "DISEASE", 57, 68], ["H1N1v infection", "DISEASE", 128, 143], ["influenza A(H1N1)pdm09", "ORGANISM", 57, 79], ["M gene", "DNA", 47, 53], ["influenza A(H1N1", "SPECIES", 57, 73], ["H1N1v", "SPECIES", 128, 133], ["Sequencing", "TEST", 0, 10], ["this H1N1", "PROBLEM", 25, 34], ["influenza A(H1N1)pdm09", "PROBLEM", 57, 79], ["H1N1v infection", "PROBLEM", 128, 143], ["influenza", "OBSERVATION", 57, 66], ["infection", "OBSERVATION", 134, 143]]], ["The nucleotide and deduced amino acid (aa) sequences comparison of the HA gene of A/Ontario/N163578/2012 revealed 99.7% nucleotide (100% aa) and 97.1% nucleotide (97.2% aa) homologies to HAs of the two most recent H1N1v cases in Wisconsin and Missouri.", [["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 120, 130], ["nucleotide", "CHEMICAL", 151, 161], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 120, 130], ["nucleotide", "CHEMICAL", 151, 161], ["amino acid", "AMINO_ACID", 27, 37], ["H1N1v", "CANCER", 214, 219], ["HA gene", "DNA", 71, 78], ["A/Ontario/N163578/2012", "SPECIES", 82, 104], ["The nucleotide and deduced amino acid (aa) sequences", "TEST", 0, 52], ["nucleotide", "TEST", 120, 130], ["aa", "TEST", 137, 139], ["nucleotide", "TEST", 151, 161]]], ["However the HA nucleotide homology was found to be lower at 92.7% (90.8% aa homology) to A/California/7/2009 (H1N1)-like virus, the A(H1N1)pdm09 strain in the current seasonal influenza vaccine (Table 2).", [["nucleotide", "CHEMICAL", 15, 25], ["influenza", "DISEASE", 176, 185], ["nucleotide", "CHEMICAL", 15, 25], ["HA", "GENE_OR_GENE_PRODUCT", 12, 14], ["California/7/2009 (H1N1)-like virus", "ORGANISM", 91, 126], ["A(H1N1)pdm09", "ORGANISM", 132, 144], ["A/California/7/2009 (H1N1)-like virus", "SPECIES", 89, 126], ["the HA nucleotide homology", "TEST", 8, 34], ["A/California", "TEST", 89, 101], ["H1N1", "PROBLEM", 110, 114], ["like virus", "PROBLEM", 116, 126], ["the A(H1N1)pdm09 strain", "PROBLEM", 128, 151], ["the current seasonal influenza vaccine", "TREATMENT", 155, 193]]], ["The even lower nucleotide homology to A/California/7/2009 (H1N1)-like virus NA gene (79.6%) is consistent with this virus not being detected by the PHOL in-house A(H1N1)pdm09 NA gene real-time PCR due to several scattered mismatches in primer and probe binding sites.6", [["nucleotide", "CHEMICAL", 15, 25], ["nucleotide", "CHEMICAL", 15, 25], ["A/California/7/2009 (H1N1)-like virus NA", "ORGANISM", 38, 78], ["NA gene", "DNA", 76, 83], ["primer and probe binding sites", "DNA", 236, 266], ["A/California/7/2009", "SPECIES", 38, 57], ["H1N1", "PROBLEM", 59, 63], ["virus NA gene", "TEST", 70, 83], ["this virus", "PROBLEM", 111, 121], ["NA gene", "TEST", 175, 182], ["PCR", "TEST", 193, 196], ["several scattered mismatches in primer and probe binding sites", "PROBLEM", 204, 266], ["consistent with", "UNCERTAINTY", 95, 110], ["scattered", "OBSERVATION_MODIFIER", 212, 221], ["mismatches", "OBSERVATION", 222, 232]]]], "PMC3660988": [["IntroductionThe regulatory mechanisms of viral gene expression vary throughout the virus world.", [["viral gene expression", "PROBLEM", 41, 62], ["viral gene expression", "OBSERVATION", 41, 62]]], ["One widely used mechanism employed by evolutionarily divergent RNA and DNA viruses alike organizes multiple genes into a single open reading frame.", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["multiple genes", "DNA", 99, 113], ["open reading frame", "DNA", 128, 146], ["evolutionarily divergent RNA", "PROBLEM", 38, 66], ["DNA viruses", "PROBLEM", 71, 82]]], ["Most DNA viruses use extensive alternative splicing to express the viral proteins as needed; although, there are exceptions (ex.", [["DNA", "CELLULAR_COMPONENT", 5, 8], ["viral proteins", "PROTEIN", 67, 81], ["Most DNA viruses", "PROBLEM", 0, 16], ["extensive alternative splicing", "TREATMENT", 21, 51], ["the viral proteins", "PROBLEM", 63, 81]]], ["African swine fever virus [1]).", [["swine fever", "DISEASE", 8, 19], ["African swine fever virus", "ORGANISM", 0, 25], ["African swine fever virus", "SPECIES", 0, 25], ["African swine fever virus", "SPECIES", 0, 25], ["African swine fever virus", "PROBLEM", 0, 25]]], ["Almost all retroviruses and RNA viruses use the strategy of translating an open reading frame as a large, precursor polyprotein that is further cleaved by viral or cellular proteases in a highly regulated manner.IntroductionViruses that regulate gene expression by polyprotein processing represent an important group including several important human pathogens such as HIV, poliovirus, rhinovirus, Dengue virus, hepatitis C virus, West Nile virus, Chikungunya virus, and SARS coronavirus.", [["cellular", "ANATOMY", 164, 172], ["HIV, poliovirus, rhinovirus, Dengue virus, hepatitis C", "DISEASE", 369, 423], ["Chikungunya virus", "DISEASE", 448, 465], ["SARS coronavirus", "DISEASE", 471, 487], ["retroviruses", "ORGANISM", 11, 23], ["cellular", "CELL", 164, 172], ["human", "ORGANISM", 345, 350], ["HIV", "ORGANISM", 369, 372], ["poliovirus, rhinovirus", "ORGANISM", 374, 396], ["Dengue virus", "ORGANISM", 398, 410], ["hepatitis C virus", "ORGANISM", 412, 429], ["West Nile virus", "ORGANISM", 431, 446], ["Chikungunya virus", "ORGANISM", 448, 465], ["SARS coronavirus", "ORGANISM", 471, 487], ["open reading frame", "DNA", 75, 93], ["viral or cellular proteases", "PROTEIN", 155, 182], ["human", "SPECIES", 345, 350], ["HIV", "SPECIES", 369, 372], ["Dengue virus", "SPECIES", 398, 410], ["hepatitis C virus", "SPECIES", 412, 429], ["West Nile virus", "SPECIES", 431, 446], ["Chikungunya virus", "SPECIES", 448, 465], ["coronavirus", "SPECIES", 476, 487], ["human", "SPECIES", 345, 350], ["HIV", "SPECIES", 369, 372], ["Dengue virus", "SPECIES", 398, 410], ["hepatitis C virus", "SPECIES", 412, 429], ["West Nile virus", "SPECIES", 431, 446], ["Chikungunya virus", "SPECIES", 448, 465], ["SARS coronavirus", "SPECIES", 471, 487], ["RNA viruses", "PROBLEM", 28, 39], ["a large, precursor polyprotein", "PROBLEM", 97, 127], ["viral or cellular proteases", "PROBLEM", 155, 182], ["IntroductionViruses", "TREATMENT", 212, 231], ["polyprotein processing", "TREATMENT", 265, 287], ["several important human pathogens", "PROBLEM", 327, 360], ["HIV", "PROBLEM", 369, 372], ["poliovirus", "PROBLEM", 374, 384], ["rhinovirus", "PROBLEM", 386, 396], ["Dengue virus", "PROBLEM", 398, 410], ["hepatitis C virus", "PROBLEM", 412, 429], ["West Nile virus", "PROBLEM", 431, 446], ["Chikungunya virus", "PROBLEM", 448, 465], ["SARS coronavirus", "PROBLEM", 471, 487], ["retroviruses", "OBSERVATION", 11, 23], ["RNA viruses", "OBSERVATION", 28, 39], ["large", "OBSERVATION_MODIFIER", 99, 104], ["precursor polyprotein", "OBSERVATION", 106, 127], ["cellular proteases", "OBSERVATION", 164, 182]]], ["Encoding and translating large viral polyprotein precursors is a strategy with many benefits for the virus lifecycle.", [["large viral polyprotein precursors", "TREATMENT", 25, 59], ["the virus lifecycle", "TREATMENT", 97, 116], ["large", "OBSERVATION_MODIFIER", 25, 30], ["viral polyprotein precursors", "OBSERVATION", 31, 59]]], ["First, polyproteins allow for a more compact genome by eliminating additional genetic features, such as promoter or enhancer elements, that would be necessary to express each protein individually.", [["enhancer elements", "DNA", 116, 133], ["polyproteins", "TREATMENT", 7, 19], ["additional genetic features", "PROBLEM", 67, 94]]], ["Additionally, differential cleavage site usage is coordinated to regulate activity.", [["activity", "OBSERVATION_MODIFIER", 74, 82]]], ["Lastly, proteins can sometimes perform alternative functions in their precursor forms versus their mature forms.IntroductionGiven the wide prevalence of polyprotein processing in many viral families, there are surprisingly few structures of precleavage polyprotein intermediates available.", [["polyprotein processing", "TREATMENT", 153, 175], ["precleavage polyprotein intermediates", "TREATMENT", 241, 278], ["polyprotein processing", "OBSERVATION", 153, 175]]], ["Structure of viral proteins before and after cleavage is essential to provide a greater understanding of the regulation, function, and organization of the viral genome.", [["viral proteins", "PROTEIN", 13, 27], ["viral genome", "DNA", 155, 167], ["viral proteins", "PROBLEM", 13, 27], ["cleavage", "TREATMENT", 45, 53], ["the viral genome", "PROBLEM", 151, 167], ["viral proteins", "OBSERVATION", 13, 27], ["viral genome", "OBSERVATION", 155, 167]]], ["Here we review four recent atomic structures of polyprotein precursors.Alphavirus P23 ::: Precursors from viral genome replication proteinsAlphaviruses are enveloped viruses of the Togaviridae family whose genome consists of a positive-sense RNA of ~9\u201311 kb with a 5\u2032 cap structure and 3\u2032 polyadenosine tail (Figure 1a).", [["Alphaviruses", "GENE_OR_GENE_PRODUCT", 139, 151], ["Togaviridae", "GENE_OR_GENE_PRODUCT", 181, 192], ["P23", "PROTEIN", 82, 85], ["viral genome replication proteins", "PROTEIN", 106, 139], ["positive-sense RNA", "RNA", 227, 245], ["polyadenosine tail", "PROTEIN", 289, 307], ["polyprotein precursors", "PROBLEM", 48, 70], ["viral genome replication proteinsAlphaviruses", "TREATMENT", 106, 151], ["a positive-sense RNA", "PROBLEM", 225, 245], ["polyprotein precursors", "OBSERVATION", 48, 70], ["viral genome", "OBSERVATION", 106, 118]]], ["The genome contains two cistrons: the first encodes the viral replication machinery, or nonstructural proteins (nsPs), and the latter contains the structural proteins that form the virion particle.", [["nsPs", "GENE_OR_GENE_PRODUCT", 112, 116], ["cistrons", "DNA", 24, 32], ["nonstructural proteins", "PROTEIN", 88, 110], ["nsPs", "PROTEIN", 112, 116], ["structural proteins", "PROTEIN", 147, 166], ["nonstructural proteins (nsPs", "TEST", 88, 116], ["two cistrons", "OBSERVATION", 20, 32], ["viral replication", "OBSERVATION", 56, 73], ["structural proteins", "OBSERVATION", 147, 166], ["virion particle", "OBSERVATION", 181, 196]]], ["The alphavirus replication machinery is composed of four nonstructural proteins (nsP1 to nsP4), which are expressed as one of two polyproteins (P123 or P1234) caused by read through of an opal codon at the end of nsP3.", [["nsP1", "GENE_OR_GENE_PRODUCT", 81, 85], ["nsP4", "GENE_OR_GENE_PRODUCT", 89, 93], ["P123", "GENE_OR_GENE_PRODUCT", 144, 148], ["P1234", "GENE_OR_GENE_PRODUCT", 152, 157], ["nsP3", "GENE_OR_GENE_PRODUCT", 213, 217], ["nonstructural proteins", "PROTEIN", 57, 79], ["nsP1", "PROTEIN", 81, 85], ["nsP4", "PROTEIN", 89, 93], ["polyproteins", "PROTEIN", 130, 142], ["P123", "PROTEIN", 144, 148], ["P1234", "PROTEIN", 152, 157], ["opal codon", "DNA", 188, 198], ["nsP3", "PROTEIN", 213, 217], ["The alphavirus replication machinery", "TREATMENT", 0, 36], ["four nonstructural proteins (nsP1 to nsP4", "PROBLEM", 52, 93], ["an opal codon", "PROBLEM", 185, 198], ["nsP3", "PROBLEM", 213, 217], ["alphavirus replication", "OBSERVATION", 4, 26], ["opal codon", "OBSERVATION", 188, 198]]], ["The nonstructural precursor polyproteins are cleaved in a highly regulated manner by a protease at the C-terminus of nsP2 [2, 3].", [["C", "CHEMICAL", 103, 104], ["nonstructural precursor polyproteins", "PROTEIN", 4, 40], ["protease", "PROTEIN", 87, 95], ["C-terminus", "PROTEIN", 103, 113], ["nsP2", "PROTEIN", 117, 121], ["The nonstructural precursor polyproteins", "PROBLEM", 0, 40], ["a protease", "TREATMENT", 85, 95], ["nonstructural", "OBSERVATION", 4, 17], ["precursor polyproteins", "OBSERVATION", 18, 40]]], ["Shortly after translation of P1234, cleavage at the P3/4 junction occurs either in cis or trans, followed by the P1/2 junction in cis only [3, 4].", [["P1234", "GENE_OR_GENE_PRODUCT", 29, 34], ["P1234", "PROTEIN", 29, 34], ["P3/4 junction", "DNA", 52, 65], ["P1/2 junction", "DNA", 113, 126], ["cleavage at the P3/4 junction", "TREATMENT", 36, 65]]], ["Cleavage intermediates P123 + nsP4 and nsP1 + P23 + nsP4 preferentially use the genomic RNA to synthesize a negative-sense, intermediate RNA [5, 6].", [["P123", "GENE_OR_GENE_PRODUCT", 23, 27], ["nsP4", "GENE_OR_GENE_PRODUCT", 30, 34], ["nsP1", "GENE_OR_GENE_PRODUCT", 39, 43], ["P123", "PROTEIN", 23, 27], ["nsP4", "PROTEIN", 30, 34], ["nsP1", "PROTEIN", 39, 43], ["P23", "PROTEIN", 46, 49], ["nsP4", "PROTEIN", 52, 56], ["genomic RNA", "RNA", 80, 91], ["intermediate RNA", "RNA", 124, 140], ["Cleavage intermediates P123", "TEST", 0, 27], ["nsP4", "TEST", 30, 34], ["nsP1", "TEST", 39, 43], ["P23", "PROBLEM", 46, 49], ["nsP4", "PROBLEM", 52, 56]]], ["The final cleavage event between P23 yields fully mature nsPs and switches the template to the negative-sense RNA to synthesize positive-sense genomic and subgenomic RNAs.Alphavirus P23 ::: Precursors from viral genome replication proteinsThe structure of an uncleaved P23 precursor protein from Sindbis virus spanning the nsP2 protease domain through to the central, zinc-binding domain (ZBD) of nsP3 (P23pro-zbd) has been recently determined [7\u2022\u2022].", [["zinc", "CHEMICAL", 368, 372], ["zinc", "CHEMICAL", 368, 372], ["P23", "GENE_OR_GENE_PRODUCT", 33, 36], ["nsPs", "GENE_OR_GENE_PRODUCT", 57, 61], ["P23", "GENE_OR_GENE_PRODUCT", 269, 272], ["Sindbis virus", "ORGANISM", 296, 309], ["nsP2", "GENE_OR_GENE_PRODUCT", 323, 327], ["nsP3", "GENE_OR_GENE_PRODUCT", 397, 401], ["P23pro-zbd", "GENE_OR_GENE_PRODUCT", 403, 413], ["P23", "PROTEIN", 33, 36], ["nsPs", "PROTEIN", 57, 61], ["negative-sense RNA", "RNA", 95, 113], ["positive-sense genomic and subgenomic RNAs", "RNA", 128, 170], ["P23", "PROTEIN", 182, 185], ["viral genome replication proteins", "PROTEIN", 206, 239], ["uncleaved P23 precursor protein", "PROTEIN", 259, 290], ["nsP2 protease domain", "PROTEIN", 323, 343], ["central, zinc-binding domain", "PROTEIN", 359, 387], ["ZBD", "PROTEIN", 389, 392], ["nsP3", "PROTEIN", 397, 401], ["P23pro", "PROTEIN", 403, 409], ["zbd", "PROTEIN", 410, 413], ["Sindbis virus", "SPECIES", 296, 309], ["Sindbis virus", "SPECIES", 296, 309], ["sense genomic and subgenomic RNAs", "PROBLEM", 137, 170], ["viral genome replication proteins", "TREATMENT", 206, 239], ["an uncleaved P23 precursor protein", "PROBLEM", 256, 290], ["Sindbis virus", "TREATMENT", 296, 309], ["the nsP2 protease domain", "TREATMENT", 319, 343], ["nsP3", "PROBLEM", 397, 401], ["sense genomic", "OBSERVATION", 137, 150], ["subgenomic RNAs", "OBSERVATION", 155, 170], ["viral genome", "OBSERVATION", 206, 218], ["replication proteins", "OBSERVATION", 219, 239], ["P23 precursor protein", "OBSERVATION", 269, 290], ["Sindbis virus", "OBSERVATION", 296, 309], ["central", "ANATOMY_MODIFIER", 359, 366]]], ["P23pro-zbd shows a solvent exposed but inaccessible P2/3 cleavage site located at the base of an 11\u201313 \u00c5 wide cleft (Figure 1b) [7\u2022\u2022].", [["P23pro-zbd", "GENE_OR_GENE_PRODUCT", 0, 10], ["P23pro", "PROTEIN", 0, 6], ["zbd", "PROTEIN", 7, 10], ["P2/3 cleavage site", "DNA", 52, 70], ["cleavage site", "PROBLEM", 57, 70], ["base", "ANATOMY_MODIFIER", 86, 90], ["cleft", "OBSERVATION", 110, 115]]], ["The nsP2 protease active site is 40 \u00c5 away from the P2/3 cleavage site, which supports a trans only cleavage mechanism [4, 7\u2022\u2022, 8, 9].", [["nsP2 protease", "GENE_OR_GENE_PRODUCT", 4, 17], ["nsP2 protease active site", "DNA", 4, 29], ["P2/3 cleavage site", "DNA", 52, 70], ["The nsP2 protease active site", "PROBLEM", 0, 29]]], ["Attempts to model the nsP2 protease onto the P2/3 cleavage site resulted in steric clashes, indicating that accessibility of the cleavage site is highly regulated by an unknown mechanism.", [["nsP2 protease", "GENE_OR_GENE_PRODUCT", 22, 35], ["nsP2 protease", "PROTEIN", 22, 35], ["P2/3 cleavage site", "DNA", 45, 63], ["the nsP2 protease", "TREATMENT", 18, 35], ["the P2/3 cleavage site", "TREATMENT", 41, 63], ["steric clashes", "PROBLEM", 76, 90], ["the cleavage site", "PROBLEM", 125, 142], ["steric clashes", "OBSERVATION", 76, 90]]], ["P23 has an extensive buried surface area of 3000 \u00c52 due to a ring-shape structure created by nsP3, which encircles nsP2 (Figure 1c).", [["surface area", "ANATOMY", 28, 40], ["P23", "GENE_OR_GENE_PRODUCT", 0, 3], ["nsP3", "GENE_OR_GENE_PRODUCT", 93, 97], ["P23", "PROTEIN", 0, 3], ["nsP3", "PROTEIN", 93, 97], ["nsP2", "PROTEIN", 115, 119], ["Figure 1c", "PROTEIN", 121, 130], ["an extensive buried surface area", "PROBLEM", 8, 40], ["a ring-shape structure", "PROBLEM", 59, 81], ["nsP3", "PROBLEM", 93, 97], ["extensive", "OBSERVATION_MODIFIER", 11, 20], ["buried", "OBSERVATION_MODIFIER", 21, 27], ["surface", "OBSERVATION_MODIFIER", 28, 35], ["3000 \u00c52", "OBSERVATION_MODIFIER", 44, 51], ["ring", "OBSERVATION_MODIFIER", 61, 65], ["shape", "OBSERVATION_MODIFIER", 66, 71], ["nsP3", "OBSERVATION", 93, 97]]], ["Several previously described mutations in nsP2 that confer a noncytopathic phenotype [10, 11, 12, 13, 14] map to the surface of nsP2 and make contact with nsP3, implicating this interaction in viral pathogenesis.", [["surface", "ANATOMY", 117, 124], ["nsP2", "GENE_OR_GENE_PRODUCT", 42, 46], ["surface", "CELLULAR_COMPONENT", 117, 124], ["nsP2", "GENE_OR_GENE_PRODUCT", 128, 132], ["nsP3", "GENE_OR_GENE_PRODUCT", 155, 159], ["nsP2", "DNA", 42, 46], ["nsP2", "PROTEIN", 128, 132], ["nsP3", "PROTEIN", 155, 159], ["Several previously described mutations in nsP2", "PROBLEM", 0, 46], ["a noncytopathic phenotype", "PROBLEM", 59, 84], ["nsP2", "PROBLEM", 128, 132], ["viral pathogenesis", "PROBLEM", 193, 211], ["viral pathogenesis", "OBSERVATION", 193, 211]]], ["During the alphavirus lifecycle, nsP2 localizes to the nucleus; however, the mechanism by which nsP2 dissociates from nsP3 post cleavage is unknown.", [["nucleus", "ANATOMY", 55, 62], ["nsP2", "GENE_OR_GENE_PRODUCT", 33, 37], ["nucleus", "CELLULAR_COMPONENT", 55, 62], ["nsP2", "GENE_OR_GENE_PRODUCT", 96, 100], ["nsP3", "GENE_OR_GENE_PRODUCT", 118, 122], ["nsP2", "PROTEIN", 33, 37], ["nsP2", "PROTEIN", 96, 100], ["nsP3", "PROTEIN", 118, 122], ["the alphavirus lifecycle", "PROBLEM", 7, 31], ["nsP2", "PROBLEM", 33, 37], ["nsP2 dissociates", "PROBLEM", 96, 112], ["nsP3 post cleavage", "TREATMENT", 118, 136], ["nucleus", "ANATOMY", 55, 62]]], ["A potential RNA binding surface, which extends over the surface of both nsP2 and nsP3 has been proposed.", [["surface", "ANATOMY", 56, 63], ["surface", "CELLULAR_COMPONENT", 24, 31], ["surface", "CELLULAR_COMPONENT", 56, 63], ["nsP2", "GENE_OR_GENE_PRODUCT", 72, 76], ["nsP3", "GENE_OR_GENE_PRODUCT", 81, 85], ["nsP2", "PROTEIN", 72, 76], ["nsP3", "PROTEIN", 81, 85], ["A potential RNA binding surface", "PROBLEM", 0, 31], ["nsP3", "PROBLEM", 81, 85], ["RNA binding", "OBSERVATION", 12, 23], ["surface", "OBSERVATION_MODIFIER", 24, 31], ["both", "ANATOMY_MODIFIER", 67, 71], ["nsP2", "OBSERVATION", 72, 76]]], ["It is hypothesized that the RNA binding surface may be altered after cleavage, resulting in the RNA template switching that occurs after P23 cleavage.Poliovirus 3CD ::: Precursors from viral genome replication proteinsPoliovirus is a nonenveloped virus of the Picornaviridae family with a positive-sense RNA genome of ~7\u20139 kb.", [["surface", "CELLULAR_COMPONENT", 40, 47], ["P23", "GENE_OR_GENE_PRODUCT", 137, 140], ["P23", "PROTEIN", 137, 140], ["viral genome replication proteins", "PROTEIN", 185, 218], ["positive-sense RNA genome", "DNA", 289, 314], ["the RNA binding surface", "PROBLEM", 24, 47], ["the RNA template", "PROBLEM", 92, 108], ["P23 cleavage", "TREATMENT", 137, 149], ["viral genome replication proteinsPoliovirus", "PROBLEM", 185, 228], ["viral genome", "OBSERVATION", 185, 197], ["proteinsPoliovirus", "OBSERVATION", 210, 228]]], ["Poliovirus RNA lacks a 5\u2032 cap structure and uses an internal ribosomal entry site (IRES) for translation initiation [15, 16].", [["ribosomal", "ANATOMY", 61, 70], ["Poliovirus", "ORGANISM", 0, 10], ["ribosomal", "CELLULAR_COMPONENT", 61, 70], ["Poliovirus RNA", "RNA", 0, 14], ["5\u2032 cap structure", "DNA", 23, 39], ["internal ribosomal entry site", "DNA", 52, 81], ["IRES", "DNA", 83, 87], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus RNA", "PROBLEM", 0, 14], ["an internal ribosomal entry site", "TREATMENT", 49, 81]]], ["The genome contains a single, open reading frame encoding both structural and nonstructural genes as a large polyprotein [17, 18, 19] (Figure 2a).", [["open reading frame", "DNA", 30, 48], ["structural and nonstructural genes", "DNA", 63, 97], ["nonstructural genes", "OBSERVATION", 78, 97]]], ["For simplicity, the proteins are grouped into viral capsid proteins (P1), and proteins involved in viral genome replication and protein processing (P2 and P3).", [["P1", "GENE_OR_GENE_PRODUCT", 69, 71], ["viral capsid proteins", "PROTEIN", 46, 67], ["P1", "PROTEIN", 69, 71], ["P2", "DNA", 148, 150], ["P3", "DNA", 155, 157], ["the proteins", "TEST", 16, 28], ["viral capsid proteins", "TEST", 46, 67], ["proteins", "TEST", 78, 86], ["viral genome replication", "TREATMENT", 99, 123], ["protein processing", "TEST", 128, 146], ["viral capsid proteins", "OBSERVATION", 46, 67], ["viral genome replication", "OBSERVATION", 99, 123]]], ["Cleavage of the polyprotein is performed by virus-encoded proteases 2A, 3C, or 3CD precursor.", [["3C", "GENE_OR_GENE_PRODUCT", 72, 74], ["3CD", "GENE_OR_GENE_PRODUCT", 79, 82], ["virus-encoded proteases 2A, 3C, or 3CD precursor", "PROTEIN", 44, 92], ["the polyprotein", "TREATMENT", 12, 27]]], ["3CD polyprotein is made up of the 3C protease and the viral RNA polymerase (3D) that is responsible for genome replication.", [["genome", "CELLULAR_COMPONENT", 104, 110], ["3CD polyprotein", "PROTEIN", 0, 15], ["3C protease", "PROTEIN", 34, 45], ["viral RNA polymerase", "PROTEIN", 54, 74], ["3D", "PROTEIN", 76, 78], ["3CD polyprotein", "TREATMENT", 0, 15], ["the 3C protease", "TREATMENT", 30, 45], ["the viral RNA polymerase", "PROBLEM", 50, 74], ["genome replication", "PROBLEM", 104, 122], ["viral RNA", "OBSERVATION", 54, 63], ["responsible for", "UNCERTAINTY", 88, 103], ["genome replication", "OBSERVATION", 104, 122]]], ["The efficiency of 3C protease and 3D polymerase activity is altered depending on the cleavage state.", [["3C protease", "GENE_OR_GENE_PRODUCT", 18, 29], ["3D polymerase", "GENE_OR_GENE_PRODUCT", 34, 47], ["3C protease", "PROTEIN", 18, 29], ["3D polymerase", "PROTEIN", 34, 47], ["3C protease", "TREATMENT", 18, 29], ["3D polymerase activity", "TREATMENT", 34, 56], ["the cleavage state", "PROBLEM", 81, 99]]], ["The 3CD polyprotein preferentially cleaves the P1 precursor compared to mature 3C alone [20, 21] while the 3D polymerase activity is inhibited in the precursor [22].", [["3CD polyprotein", "PROTEIN", 4, 19], ["P1 precursor", "PROTEIN", 47, 59], ["The 3CD polyprotein", "TREATMENT", 0, 19], ["the 3D polymerase activity", "TEST", 103, 129]]], ["Furthermore, 3CD promotes RNA synthesis by a redistribution of cellular Arf proteins involved in membrane trafficking, an activity not triggered by the cleaved forms [23, 24\u2022].", [["cellular", "ANATOMY", 63, 71], ["membrane", "ANATOMY", 97, 105], ["3CD", "CHEMICAL", 13, 16], ["3CD", "SIMPLE_CHEMICAL", 13, 16], ["cellular", "CELL", 63, 71], ["Arf", "GENE_OR_GENE_PRODUCT", 72, 75], ["membrane", "CELLULAR_COMPONENT", 97, 105], ["3CD", "PROTEIN", 13, 16], ["cellular Arf proteins", "PROTEIN", 63, 84], ["3CD promotes RNA synthesis", "TREATMENT", 13, 39], ["a redistribution of cellular Arf proteins", "PROBLEM", 43, 84], ["redistribution", "OBSERVATION_MODIFIER", 45, 59], ["cellular", "OBSERVATION_MODIFIER", 63, 71], ["Arf proteins", "OBSERVATION", 72, 84], ["membrane trafficking", "OBSERVATION", 97, 117]]], ["These activities highlight the importance of polyprotein cleavage as a mechanism of gene regulation.Poliovirus 3CD ::: Precursors from viral genome replication proteinsThe atomic structure of 3CD resembles beads-on-a-string with 3C and 3D connected by a flexible, solvent exposed linker region containing the cleavage site [25\u2022\u2022] (Figure 2b).", [["3CD", "CHEMICAL", 192, 195], ["3CD", "CHEMICAL", 192, 195], ["3CD", "SIMPLE_CHEMICAL", 192, 195], ["viral genome replication proteins", "PROTEIN", 135, 168], ["3CD", "PROTEIN", 192, 195], ["flexible, solvent exposed linker region", "PROTEIN", 254, 293], ["cleavage site", "PROTEIN", 309, 322], ["Poliovirus", "SPECIES", 100, 110], ["polyprotein cleavage", "TREATMENT", 45, 65], ["gene regulation", "TREATMENT", 84, 99], ["Poliovirus", "PROBLEM", 100, 110], ["Precursors", "PROBLEM", 119, 129], ["viral genome replication proteins", "TREATMENT", 135, 168], ["3C and 3D", "TREATMENT", 229, 238], ["a flexible, solvent exposed linker region", "TREATMENT", 252, 293], ["the cleavage site", "PROBLEM", 305, 322], ["viral genome", "OBSERVATION", 135, 147], ["beads", "OBSERVATION_MODIFIER", 206, 211]]], ["In sharp contrast to alphavirus P23, 3C and 3D have no intramolecular contacts.", [["intramolecular contacts", "PROBLEM", 55, 78], ["no", "UNCERTAINTY", 52, 54], ["intramolecular contacts", "OBSERVATION", 55, 78]]], ["The 3CD structure supports a trans cleavage mechanism due to the location of the protease active site and the cleavage site [7\u2022\u2022, 25\u2022\u2022, 26].", [["3CD structure", "PROTEIN", 4, 17], ["protease active site", "PROTEIN", 81, 101], ["cleavage site", "PROTEIN", 110, 123], ["a trans cleavage mechanism", "TREATMENT", 27, 53], ["the protease active site", "PROBLEM", 77, 101], ["the cleavage site", "PROBLEM", 106, 123]]], ["In the post cleavage structure of 3D, the N-terminal residues fold inward and insert into a binding pocket where they participate in several hydrogen bonding interactions, while these residues are extended in the 3CD structure.", [["N", "CHEMICAL", 42, 43], ["hydrogen", "CHEMICAL", 141, 149], ["N-terminal residues", "PROTEIN", 42, 61], ["3CD structure", "PROTEIN", 213, 226], ["the N-terminal residues fold inward", "TREATMENT", 38, 73], ["a binding pocket", "PROBLEM", 90, 106], ["several hydrogen bonding interactions", "TREATMENT", 133, 170], ["hydrogen bonding", "OBSERVATION", 141, 157]]], ["The rearrangement of the N-terminal residues of 3D post cleavage is proposed to be the mechanism for activation of the 3D polymerase activity [25\u2022\u2022].Flavivirus prM-E ::: Precursors from viral structural proteinsFlaviviruses are enveloped viruses with a positive-sense RNA genome of ~11 kb.", [["N", "CHEMICAL", 25, 26], ["Flaviviruses", "GENE_OR_GENE_PRODUCT", 211, 223], ["N-terminal residues", "PROTEIN", 25, 44], ["3D polymerase", "PROTEIN", 119, 132], ["Flavivirus prM", "PROTEIN", 149, 163], ["viral structural proteins", "PROTEIN", 186, 211], ["positive-sense RNA genome", "DNA", 253, 278], ["the N-terminal residues of 3D post cleavage", "TREATMENT", 21, 64], ["viral structural proteinsFlaviviruses", "PROBLEM", 186, 223], ["enveloped viruses", "PROBLEM", 228, 245], ["viral structural", "OBSERVATION", 186, 202], ["proteinsFlaviviruses", "OBSERVATION", 203, 223]]], ["The flavivirus structural and nonstructural genes are contained within the same open reading fame and are translated as a large polyprotein (Figure 3a).", [["flavivirus structural and nonstructural genes", "DNA", 4, 49], ["The flavivirus structural and nonstructural genes", "PROBLEM", 0, 49], ["flavivirus", "OBSERVATION", 4, 14], ["nonstructural genes", "OBSERVATION", 30, 49]]], ["Both viral and cellular encoded proteases are involved in specific cleavage of the polyprotein.", [["cellular", "ANATOMY", 15, 23], ["cellular", "CELL", 15, 23], ["viral and cellular encoded proteases", "PROTEIN", 5, 41], ["Both viral and cellular encoded proteases", "PROBLEM", 0, 41], ["the polyprotein", "TREATMENT", 79, 94], ["viral", "OBSERVATION", 5, 10]]], ["The surface of the virion is composed of the envelope (E) and membrane (M) proteins [27].", [["surface", "ANATOMY", 4, 11], ["membrane", "ANATOMY", 62, 70], ["surface", "CELLULAR_COMPONENT", 4, 11], ["virion", "CELLULAR_COMPONENT", 19, 25], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["envelope (E) and membrane (M) proteins", "PROTEIN", 45, 83], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["virion", "OBSERVATION", 19, 25]]], ["E interacts with cellular receptors and contains a loop responsible for membrane fusion [27, 28].", [["cellular", "ANATOMY", 17, 25], ["membrane", "ANATOMY", 72, 80], ["cellular", "CELL", 17, 25], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["cellular receptors", "PROTEIN", 17, 35], ["a loop", "TREATMENT", 49, 55], ["membrane fusion", "TREATMENT", 72, 87]]], ["M is expressed as a precursor protein, prM, which prevents premature fusion by E and is cleaved by furin during egress to release the pr fragment, resulting in a mature particle.", [["prM", "GENE_OR_GENE_PRODUCT", 39, 42], ["E", "GENE_OR_GENE_PRODUCT", 79, 80], ["furin", "GENE_OR_GENE_PRODUCT", 99, 104], ["precursor protein", "PROTEIN", 20, 37], ["prM", "PROTEIN", 39, 42], ["E", "PROTEIN", 79, 80], ["furin", "PROTEIN", 99, 104], ["a precursor protein", "PROBLEM", 18, 37], ["premature fusion", "PROBLEM", 59, 75], ["the pr fragment", "PROBLEM", 130, 145], ["premature", "OBSERVATION_MODIFIER", 59, 68], ["fusion", "OBSERVATION", 69, 75], ["fragment", "OBSERVATION", 137, 145]]], ["In addition to its role in virion morphogenesis, the prM precursor may assist in proper folding of the E protein [29, 30].Flavivirus prM-E ::: Precursors from viral structural proteinsThe structure of a dengue virus prM-E polyprotein was published in 2008 (Figure 3b) [31\u2022\u2022].", [["dengue", "DISEASE", 203, 209], ["virion", "CELLULAR_COMPONENT", 27, 33], ["prM", "GENE_OR_GENE_PRODUCT", 53, 56], ["dengue virus", "ORGANISM", 203, 215], ["prM-E", "GENE_OR_GENE_PRODUCT", 216, 221], ["prM precursor", "PROTEIN", 53, 66], ["E protein", "PROTEIN", 103, 112], ["Flavivirus prM-E", "PROTEIN", 122, 138], ["viral structural proteins", "PROTEIN", 159, 184], ["dengue virus prM-E polyprotein", "DNA", 203, 233], ["dengue virus", "SPECIES", 203, 215], ["dengue virus", "SPECIES", 203, 215], ["virion morphogenesis", "TREATMENT", 27, 47], ["the prM precursor", "TREATMENT", 49, 66], ["the E protein", "TEST", 99, 112], ["viral structural proteins", "PROBLEM", 159, 184], ["a dengue virus prM", "PROBLEM", 201, 219], ["E polyprotein", "TREATMENT", 220, 233], ["virion morphogenesis", "OBSERVATION", 27, 47], ["viral structural proteins", "OBSERVATION", 159, 184]]], ["The construct included prM residues 1 through 91, an eight amino acid linker in place of a transmembrane region, E residues 1 through 394, and a mutated furin cleavage site between pr and M. E contains three distinct domains, termed DI, DII, and DIII, with the fusion loop located at the tip of DII [32, 33, 34, 35, 36, 37].", [["transmembrane", "ANATOMY", 91, 104], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "AMINO_ACID", 59, 69], ["furin", "GENE_OR_GENE_PRODUCT", 153, 158], ["DII", "GENE_OR_GENE_PRODUCT", 237, 240], ["DIII", "GENE_OR_GENE_PRODUCT", 246, 250], ["prM residues 1 through 91", "PROTEIN", 23, 48], ["amino acid linker", "PROTEIN", 59, 76], ["transmembrane region", "PROTEIN", 91, 111], ["E residues 1 through 394", "PROTEIN", 113, 137], ["mutated furin cleavage site", "PROTEIN", 145, 172], ["DI", "PROTEIN", 233, 235], ["DII", "PROTEIN", 237, 240], ["DIII", "PROTEIN", 246, 250], ["fusion loop", "PROTEIN", 261, 272], ["DII", "PROTEIN", 295, 298], ["prM residues", "TEST", 23, 35], ["an eight amino acid linker", "TREATMENT", 50, 76], ["a transmembrane region", "PROBLEM", 89, 111], ["a mutated furin cleavage site", "PROBLEM", 143, 172], ["termed DI, DII, and DIII", "PROBLEM", 226, 250], ["the fusion loop", "TREATMENT", 257, 272], ["acid linker", "OBSERVATION", 65, 76], ["fusion", "OBSERVATION", 261, 267], ["tip", "OBSERVATION_MODIFIER", 288, 291]]], ["The pr peptide has a novel beta barrel fold positioned at the distal end of DII, blocking the fusion loop, consistent with its role in preventing membrane fusion [31\u2022\u2022, 38].", [["membrane", "ANATOMY", 146, 154], ["pr peptide", "GENE_OR_GENE_PRODUCT", 4, 14], ["DII", "GENE_OR_GENE_PRODUCT", 76, 79], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["beta barrel fold", "PROTEIN", 27, 43], ["DII", "PROTEIN", 76, 79], ["fusion loop", "PROTEIN", 94, 105], ["The pr peptide", "TREATMENT", 0, 14], ["a novel beta barrel fold", "PROBLEM", 19, 43], ["the fusion loop", "TREATMENT", 90, 105], ["membrane fusion", "TREATMENT", 146, 161], ["distal", "ANATOMY_MODIFIER", 62, 68], ["DII", "ANATOMY_MODIFIER", 76, 79], ["fusion loop", "OBSERVATION", 94, 105], ["consistent with", "UNCERTAINTY", 107, 122], ["membrane fusion", "OBSERVATION", 146, 161]]], ["Similar inaccessibility of the fusion loop in immature virus has also been described in Chikungunya structural precursor polyprotein p62 (discussed by Vaney, Duquerroy, and Ray in current issue of Current Opinion in Virology) [39\u2022].", [["Chikungunya", "DISEASE", 88, 99], ["Chikungunya", "ORGANISM", 88, 99], ["p62", "GENE_OR_GENE_PRODUCT", 133, 136], ["Chikungunya structural precursor polyprotein p62", "PROTEIN", 88, 136], ["the fusion loop", "TREATMENT", 27, 42], ["immature virus", "PROBLEM", 46, 60], ["fusion loop", "OBSERVATION", 31, 42], ["immature virus", "OBSERVATION", 46, 60]]], ["Cryoelectron microscopy shows that immature flaviviruses at neutral pH have a \u2018spiky\u2019 appearance, while mature flaviviruses have a \u2018smooth\u2019 surface [40, 41, 42, 43].", [["smooth\u2019 surface", "ANATOMY", 132, 147], ["flaviviruses", "ORGANISM", 44, 56], ["Cryoelectron microscopy", "TEST", 0, 23], ["immature flaviviruses at neutral pH", "PROBLEM", 35, 70], ["mature flaviviruses", "PROBLEM", 104, 123], ["immature", "OBSERVATION_MODIFIER", 35, 43], ["flaviviruses", "OBSERVATION", 44, 56], ["flaviviruses", "OBSERVATION", 111, 123], ["smooth", "OBSERVATION_MODIFIER", 132, 138]]], ["These appearances are altered depending on the oligomeric state of immature prM-E or mature M and E proteins.", [["prM-E", "GENE_OR_GENE_PRODUCT", 76, 81], ["E proteins", "GENE_OR_GENE_PRODUCT", 98, 108], ["immature prM-E", "PROTEIN", 67, 81], ["mature M and E proteins", "PROTEIN", 85, 108]]], ["The hinge angle between DI and DII of E alone is very similar to the hinge angle of the prM-E heterodimer [31\u2022\u2022, 37].", [["prM-E", "GENE_OR_GENE_PRODUCT", 88, 93], ["DII", "PROTEIN", 31, 34], ["prM", "PROTEIN", 88, 91], ["E heterodimer", "PROTEIN", 92, 105]]], ["However, the difference in the angle between DI and DII in immature versus mature virus is 23\u00b0, which may determine the oligomeric state of E. Fitting the X-ray structure to cryoEM density shows that immature prM-E at neutral pH would prevent furin cleavage of prM due to steric hindrance [31\u2022\u2022].", [["DII", "GENE_OR_GENE_PRODUCT", 52, 55], ["prM-E", "SIMPLE_CHEMICAL", 209, 214], ["furin", "GENE_OR_GENE_PRODUCT", 243, 248], ["DII", "PROTEIN", 52, 55], ["prM", "PROTEIN", 209, 212], ["furin", "PROTEIN", 243, 248], ["prM", "PROTEIN", 261, 264], ["DI and DII in immature versus mature virus", "PROBLEM", 45, 87], ["immature prM", "PROBLEM", 200, 212], ["neutral pH", "TREATMENT", 218, 228], ["furin cleavage of prM", "PROBLEM", 243, 264], ["steric hindrance", "PROBLEM", 272, 288]]], ["During egress, immature virions are transported through the trans Golgi Network where exposure to more acidic conditions causes a conformational change in prM-E, allowing furin access to the cleavage site [44].HIV Gag ::: Precursors from viral structural proteinsThe Retroviridae genome consists of two copies of positive-sense RNA, which is reverse-transcribed early during infection.", [["virions", "ANATOMY", 24, 31], ["Golgi", "ANATOMY", 66, 71], ["infection", "DISEASE", 375, 384], ["prM-E", "GENE_OR_GENE_PRODUCT", 155, 160], ["furin", "GENE_OR_GENE_PRODUCT", 171, 176], ["HIV", "ORGANISM", 210, 213], ["prM", "PROTEIN", 155, 158], ["E", "PROTEIN", 159, 160], ["furin", "PROTEIN", 171, 176], ["viral structural proteins", "PROTEIN", 238, 263], ["Retroviridae genome", "DNA", 267, 286], ["positive-sense RNA", "RNA", 313, 331], ["HIV", "SPECIES", 210, 213], ["HIV", "SPECIES", 210, 213], ["immature virions", "PROBLEM", 15, 31], ["more acidic conditions", "PROBLEM", 98, 120], ["a conformational change in prM", "PROBLEM", 128, 158], ["positive-sense RNA", "PROBLEM", 313, 331], ["infection", "PROBLEM", 375, 384], ["immature virions", "OBSERVATION", 15, 31], ["viral structural proteins", "OBSERVATION", 238, 263], ["Retroviridae genome", "OBSERVATION", 267, 286], ["positive", "OBSERVATION_MODIFIER", 313, 321], ["sense RNA", "OBSERVATION", 322, 331], ["reverse", "OBSERVATION_MODIFIER", 342, 349], ["infection", "OBSERVATION", 375, 384]]], ["The resulting DNA is inserted into the host genome and used for production of viral RNA and proteins as infection progresses [45].", [["infection", "DISEASE", 104, 113], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["host genome", "DNA", 39, 50], ["viral RNA", "RNA", 78, 87], ["The resulting DNA", "PROBLEM", 0, 17], ["viral RNA", "PROBLEM", 78, 87], ["infection", "PROBLEM", 104, 113], ["DNA", "OBSERVATION", 14, 17], ["host genome", "OBSERVATION", 39, 50], ["viral RNA", "OBSERVATION", 78, 87]]], ["Retroviruses vary in the number of genes encoded, but they all have at least four open reading frames (gag, pro, pol, and env), which may or may not be in the same reading frame.", [["Retroviruses", "ORGANISM", 0, 12], ["gag", "GENE_OR_GENE_PRODUCT", 103, 106], ["pro", "GENE_OR_GENE_PRODUCT", 108, 111], ["pol", "GENE_OR_GENE_PRODUCT", 113, 116], ["env", "GENE_OR_GENE_PRODUCT", 122, 125], ["open reading frames", "DNA", 82, 101], ["gag", "DNA", 103, 106], ["pro", "DNA", 108, 111], ["pol", "DNA", 113, 116], ["env", "DNA", 122, 125], ["reading frame", "DNA", 164, 177], ["Retroviruses", "TREATMENT", 0, 12]]], ["HIV is a retrovirus whose genome encodes nine (sometimes 10) genes.", [["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3]]], ["The gag gene is located at the 5\u2032 end of all retrovirus genomes and is translated as a polyprotein precursor containing three distinct domains: matrix (MA), capsid (CA), and nucleocapsid (NC) (Figure 4a) [46].", [["gag", "GENE_OR_GENE_PRODUCT", 4, 7], ["retrovirus", "ORGANISM", 45, 55], ["matrix", "CELLULAR_COMPONENT", 144, 150], ["MA", "GENE_OR_GENE_PRODUCT", 152, 154], ["capsid", "CELLULAR_COMPONENT", 157, 163], ["CA", "GENE_OR_GENE_PRODUCT", 165, 167], ["gag gene", "DNA", 4, 12], ["5\u2032 end", "DNA", 31, 37], ["retrovirus genomes", "DNA", 45, 63], ["MA", "PROTEIN", 152, 154], ["capsid", "PROTEIN", 157, 163], ["CA", "PROTEIN", 165, 167], ["all retrovirus genomes", "PROBLEM", 41, 63], ["a polyprotein precursor", "TREATMENT", 85, 108], ["capsid (CA)", "PROBLEM", 157, 168], ["nucleocapsid (NC", "TREATMENT", 174, 190], ["gag gene", "OBSERVATION", 4, 12], ["retrovirus genomes", "OBSERVATION", 45, 63]]], ["The Gag precursor is associated with the inner surface of the cell's plasma membrane, where it participates in forming the immature virion and selectively packaging viral RNA [45, 46, 47].", [["inner surface", "ANATOMY", 41, 54], ["cell", "ANATOMY", 62, 66], ["plasma membrane", "ANATOMY", 69, 84], ["virion", "ANATOMY", 132, 138], ["Gag", "GENE_OR_GENE_PRODUCT", 4, 7], ["inner surface", "CELLULAR_COMPONENT", 41, 54], ["cell", "CELL", 62, 66], ["plasma membrane", "CELLULAR_COMPONENT", 69, 84], ["virion", "CELLULAR_COMPONENT", 132, 138], ["Gag precursor", "PROTEIN", 4, 17], ["viral RNA", "RNA", 165, 174], ["The Gag precursor", "PROBLEM", 0, 17], ["Gag precursor", "OBSERVATION", 4, 17], ["immature virion", "OBSERVATION", 123, 138]]], ["Cleavage of precursor protein causes mature CA proteins to organize into cone-like structures and ultimately leads to maturation of the virus [48\u2022\u2022].HIV Gag ::: Precursors from viral structural proteinsTo discern differences between immature and mature virion structures, the NMR structure for the N-terminal portion of immature HIV-1 Gag, including MA and the N-terminal portion of the CA domain (CAN), was determined (Figure 4b) [48\u2022\u2022].", [["cone-like structures", "ANATOMY", 73, 93], ["N", "CHEMICAL", 298, 299], ["N", "CHEMICAL", 361, 362], ["CA", "GENE_OR_GENE_PRODUCT", 44, 46], ["HIV", "ORGANISM", 149, 152], ["HIV-1 Gag", "ORGANISM", 329, 338], ["MA", "GENE_OR_GENE_PRODUCT", 350, 352], ["CA", "GENE_OR_GENE_PRODUCT", 387, 389], ["precursor protein", "PROTEIN", 12, 29], ["CA proteins", "PROTEIN", 44, 55], ["viral structural proteins", "PROTEIN", 177, 202], ["N-terminal portion", "PROTEIN", 298, 316], ["immature HIV-1 Gag", "PROTEIN", 320, 338], ["MA", "PROTEIN", 350, 352], ["N-terminal portion", "PROTEIN", 361, 379], ["CA domain", "PROTEIN", 387, 396], ["CAN", "PROTEIN", 398, 401], ["HIV", "SPECIES", 149, 152], ["HIV-1", "SPECIES", 329, 334], ["HIV", "SPECIES", 149, 152], ["HIV-1", "SPECIES", 329, 334], ["Cleavage of precursor protein", "PROBLEM", 0, 29], ["mature CA proteins", "PROBLEM", 37, 55], ["the virus", "PROBLEM", 132, 141], ["viral structural proteins", "PROBLEM", 177, 202], ["immature HIV", "PROBLEM", 320, 332], ["CA proteins", "OBSERVATION_MODIFIER", 44, 55], ["viral structural proteins", "OBSERVATION", 177, 202], ["immature", "OBSERVATION_MODIFIER", 233, 241], ["mature", "OBSERVATION_MODIFIER", 246, 252], ["virion structures", "OBSERVATION", 253, 270], ["immature", "OBSERVATION_MODIFIER", 320, 328], ["HIV", "OBSERVATION", 329, 332], ["terminal", "ANATOMY_MODIFIER", 363, 371]]], ["Structures of CAN in the immature polyprotein and mature post cleavage form demonstrate that the N-terminus undergoes a disorder to order transition upon cleavage, resulting in the formation of a \u03b2-hairpin, while immature and mature MA structures do not show significant changes.", [["disorder", "DISEASE", 120, 128], ["N", "CHEMICAL", 97, 98], ["CAN", "GENE_OR_GENE_PRODUCT", 14, 17], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 196, 205], ["MA", "GENE_OR_GENE_PRODUCT", 233, 235], ["CAN", "PROTEIN", 14, 17], ["immature polyprotein", "PROTEIN", 25, 45], ["N-terminus", "PROTEIN", 97, 107], ["\u03b2-hairpin", "PROTEIN", 196, 205], ["a disorder", "PROBLEM", 118, 128], ["a \u03b2-hairpin", "TREATMENT", 194, 205], ["significant changes", "PROBLEM", 259, 278], ["immature polyprotein", "OBSERVATION", 25, 45]]], ["Integral residues located in the CAN hairpin region have previously been shown to prevent proper capsid core formation, leading to formation of noninfectious virus [49, 50, 51].", [["CAN hairpin region", "DNA", 33, 51], ["Integral residues", "PROBLEM", 0, 17], ["proper capsid core formation", "PROBLEM", 90, 118], ["noninfectious virus", "PROBLEM", 144, 163], ["residues", "OBSERVATION", 9, 17], ["hairpin", "OBSERVATION", 37, 44], ["capsid core formation", "OBSERVATION", 97, 118], ["noninfectious", "OBSERVATION_MODIFIER", 144, 157]]], ["Therefore, cleavage triggers the formation of the \u03b2-hairpin in CAN, and may be responsible for proper capsid core particle assembly.ConclusionsPresented here are four recent atomic structures of viral polyprotein precursors.", [["CAN", "DISEASE", 63, 66], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 50, 59], ["\u03b2-hairpin", "PROTEIN", 50, 59], ["viral polyprotein precursors", "PROTEIN", 195, 223], ["viral polyprotein precursors", "PROBLEM", 195, 223], ["core particle", "OBSERVATION", 109, 122], ["viral polyprotein precursors", "OBSERVATION", 195, 223]]], ["Several underlying mechanisms for viral gene regulation can be gleaned from these structures.", [["Several underlying mechanisms", "PROBLEM", 0, 29], ["viral gene regulation", "PROBLEM", 34, 55]]], ["The first involves accessibility of the polyprotein cleavage site to control the gene's activity, function, and location at specific times post infection.", [["infection", "DISEASE", 144, 153], ["polyprotein cleavage site", "DNA", 40, 65], ["the polyprotein cleavage site", "TREATMENT", 36, 65], ["infection", "PROBLEM", 144, 153], ["polyprotein cleavage", "OBSERVATION", 40, 60], ["infection", "OBSERVATION", 144, 153]]], ["Cleavage of these polyproteins is regulated by different methods.", [["these polyproteins", "PROBLEM", 12, 30], ["polyproteins", "OBSERVATION", 18, 30]]], ["The alphavirus P2/3 cleavage site is solvent exposed but not readily accessible to the protease and the requirement for cleavage is still unknown.", [["3", "GENE_OR_GENE_PRODUCT", 18, 19], ["alphavirus P2/3 cleavage site", "DNA", 4, 33], ["protease", "PROTEIN", 87, 95], ["The alphavirus P2", "TREATMENT", 0, 17], ["the protease", "TREATMENT", 83, 95], ["cleavage", "PROBLEM", 120, 128], ["alphavirus P2", "OBSERVATION", 4, 17]]], ["Access to the Poliovirus 3CD cleavage site has been postulated to be dependent on the intermolecular scaffolding thought to form between 3CD molecules [25\u2022\u2022].", [["3CD", "CHEMICAL", 137, 140], ["Poliovirus 3CD cleavage site", "DNA", 14, 42], ["3CD molecules", "PROTEIN", 137, 150], ["the Poliovirus 3CD cleavage site", "TREATMENT", 10, 42]]], ["Cleavage of flavivirus prM-E is regulated by the low pH environment found late in viral egress, preventing immature exposure of the fusion loop.", [["flavivirus", "ORGANISM", 12, 22], ["prM-E", "GENE_OR_GENE_PRODUCT", 23, 28], ["flavivirus prM-E", "PROTEIN", 12, 28], ["Cleavage of flavivirus prM", "PROBLEM", 0, 26], ["the low pH environment", "PROBLEM", 45, 67], ["the fusion loop", "TREATMENT", 128, 143], ["flavivirus", "OBSERVATION", 12, 22], ["low pH", "OBSERVATION_MODIFIER", 49, 55], ["viral egress", "OBSERVATION", 82, 94], ["immature exposure", "OBSERVATION", 107, 124], ["fusion loop", "OBSERVATION", 132, 143]]], ["Secondly, cleavage events themselves can cause conformational changes in the newly formed termini of the mature, cleaved protein, permitting new functions post cleavage.", [["mature, cleaved protein", "PROTEIN", 105, 128], ["cleavage events", "PROBLEM", 10, 25], ["conformational changes", "PROBLEM", 47, 69]]], ["The 3D polymerase activity is initiated by inserting the N-terminus of the mature protein into a hydrophobic pocket only after cleavage.", [["N", "CHEMICAL", 57, 58], ["N-terminus", "PROTEIN", 57, 67], ["mature protein", "PROTEIN", 75, 89], ["The 3D polymerase activity", "TREATMENT", 0, 26], ["a hydrophobic pocket", "TREATMENT", 95, 115], ["activity", "OBSERVATION_MODIFIER", 18, 26], ["hydrophobic pocket", "OBSERVATION", 97, 115]]], ["The N-terminus of HIV CA undergoes the formation a \u03b2-hairpin, resulting in maturation of the core particle.", [["HIV", "ORGANISM", 18, 21], ["CA", "GENE_OR_GENE_PRODUCT", 22, 24], ["\u03b2-hairpin", "GENE_OR_GENE_PRODUCT", 51, 60], ["N-terminus", "PROTEIN", 4, 14], ["HIV CA", "PROTEIN", 18, 24], ["\u03b2-hairpin", "PROTEIN", 51, 60], ["HIV", "SPECIES", 18, 21], ["HIV CA", "PROBLEM", 18, 24], ["a \u03b2-hairpin", "TREATMENT", 49, 60], ["HIV CA", "OBSERVATION", 18, 24]]], ["Further structures regarding virus particle maturation and the involvement of precursor proteins not discussed here can be found for Chikungunya virus p62 [39\u2022], poliovirus VP0 [52\u2022], influenza HA0 [53\u2022], and human parainfluenza virus 3 fusion protein [54\u2022].ConclusionsViral polyproteins represent a largely unexplored structural aspect of the viral lifecycle, especially those involved in viral genome replication.", [["Chikungunya", "DISEASE", 133, 144], ["Chikungunya virus", "ORGANISM", 133, 150], ["p62", "GENE_OR_GENE_PRODUCT", 151, 154], ["poliovirus VP0", "ORGANISM", 162, 176], ["influenza HA0", "ORGANISM", 184, 197], ["human", "ORGANISM", 209, 214], ["parainfluenza virus 3", "ORGANISM", 215, 236], ["precursor proteins", "PROTEIN", 78, 96], ["p62", "PROTEIN", 151, 154], ["poliovirus VP0", "PROTEIN", 162, 176], ["human parainfluenza virus 3 fusion protein", "PROTEIN", 209, 251], ["Chikungunya virus", "SPECIES", 133, 150], ["human", "SPECIES", 209, 214], ["parainfluenza virus", "SPECIES", 215, 234], ["Chikungunya virus", "SPECIES", 133, 150], ["human parainfluenza virus", "SPECIES", 209, 234], ["virus particle maturation", "PROBLEM", 29, 54], ["precursor proteins", "PROBLEM", 78, 96], ["Chikungunya virus p62", "TEST", 133, 154], ["poliovirus VP0", "TEST", 162, 176], ["\u2022", "TEST", 180, 181], ["influenza HA0", "TEST", 184, 197], ["human parainfluenza virus 3 fusion protein", "TEST", 209, 251], ["Viral polyproteins", "PROBLEM", 269, 287], ["viral genome replication", "TREATMENT", 390, 414], ["virus particle", "OBSERVATION", 29, 43], ["Viral polyproteins", "OBSERVATION", 269, 287], ["viral lifecycle", "OBSERVATION", 344, 359], ["viral genome replication", "OBSERVATION", 390, 414]]], ["Despite the prevalence of these proteins throughout virus families, very few viral precursor polyprotein structures are currently available.", [["these proteins throughout virus families", "PROBLEM", 26, 66], ["very few viral precursor polyprotein structures", "PROBLEM", 68, 115], ["polyprotein structures", "OBSERVATION", 93, 115]]], ["On the basis of the diversity of the four structures and cleavage site regulation presented here, it is likely that many more regulatory mechanisms are yet to be described.", [["is likely", "UNCERTAINTY", 101, 110]]], ["Because of their regulatory roles ranging from genome replication to virion maturation, viral polyproteins will be valuable tools for the design of uniquely targeted drugs.References and recommended readingPapers of particular interest, published within the period of review, have been highlighted as:\u2022 of special interest\u2022\u2022 of outstanding interest", [["genome", "CELLULAR_COMPONENT", 47, 53], ["virion", "CELLULAR_COMPONENT", 69, 75], ["genome replication", "TREATMENT", 47, 65], ["virion maturation", "TREATMENT", 69, 86], ["viral polyproteins", "PROBLEM", 88, 106], ["virion maturation", "OBSERVATION", 69, 86]]]], "PMC7501777": [["IntroductionLeadership has received an increased profile of importance in healthcare in recent years; espoused as one of the major influences on patient safety, quality of clinical care and the shaping of healthcare culture in our society.", [["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["clinical care", "TREATMENT", 172, 185], ["healthcare culture", "TEST", 205, 223], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["[[1], [2], [3], [4]] Reports into a number of high profile cases of inadequate patient care in the UK identified failings in leaders and leadership that may have been responsible for these negative outcomes.", [["[[1], [2], [3], [4]]", "CHEMICAL", 0, 20], ["[[1], [2], [3], [4]]", "SIMPLE_CHEMICAL", 0, 20], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86]]], ["[3,[10], [11], [12], [13]] During events such as the recent covid-19 pandemic, effective leadership is reported to be needed more than ever, as we face new and difficult challenges, across healthcare professions and across the globe.IntroductionOver the last decade, leadership has become an important domain of learning in dentistry.", [["[3,[10], [11], [12], [13]", "SIMPLE_CHEMICAL", 0, 25], ["the recent covid", "TEST", 49, 65], ["pandemic", "PROBLEM", 69, 77], ["globe", "ANATOMY", 227, 232]]], ["They include the requirement that \u201cmanagement and leadership should be embedded in training from the outset of their [dental registrants\u2019] career\u201d.", [["\u201cmanagement", "TREATMENT", 34, 45]]], ["[17] However, despite widespread enthusiasm, there remains a paucity of information relating to a clear definition, theoretical model, aim or concept of leadership; making operationalisation in educational, development or training contexts highly problematic.Theoretical underpinningsLeadership is reported to be a \u201cfluid, dynamic, socially constructed and mediated concept\u2026. [whose] meaning changes over time and between cultures\u201d.", [["meaning changes", "PROBLEM", 384, 399], ["cultures", "TEST", 422, 430], ["widespread", "OBSERVATION_MODIFIER", 22, 32], ["enthusiasm", "OBSERVATION", 33, 43], ["fluid", "OBSERVATION", 316, 321]]], ["19 [p24] Multiple models and theories exist which have evolved over time.", [["Multiple models and theories exist", "PROBLEM", 9, 43]]], ["[[19], [20], [21], [22]] This trend is depicted in Fig. 1.Theoretical underpinningsThis temporal transition has not been a smooth or linear process, nor has the development of one theory necessarily negated the previous ones.", [["[[19], [20], [21], [22]]", "CHEMICAL", 0, 24], ["[[19], [20], [21], [22]]", "SIMPLE_CHEMICAL", 0, 24], ["smooth", "OBSERVATION_MODIFIER", 123, 129], ["linear", "OBSERVATION_MODIFIER", 133, 139], ["process", "OBSERVATION", 140, 147]]], ["[4,[25], [26], [27], [28]] In short, the trend is from leaders to leadership.Aims and ObjectivesThe aim of this review was to inform a PhD exploring leadership at the patient care and primary care dental practice level, in order to support authentic dental education.", [["[4,[25], [26], [27], [28]]", "SIMPLE_CHEMICAL", 0, 26], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["short", "OBSERVATION_MODIFIER", 30, 35]]], ["The search methodology can be developed easily to refine the inclusion and exclusion criteria relevant to the context of work being undertaken.", [["exclusion criteria", "TEST", 75, 93]]], ["Through this it will be possible to recognise if, how, or where, political, governance or profession level literature influences leadership at the patient-facing level.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154]]], ["The results demonstrate relevance to clinicians in all areas of practice, clinical educators, trainers and researchers across the spectrum of specialties and crossing geo-political boundaries.Aims and ObjectivesThe questions the review addresses are: \u2022What is already known about and understood by the terms \u2018management and leadership\u2019 in healthcare?\u2022Are the terms \u2018management and leadership\u2019 conceptualised in a relevant way for the dental setting?\u2022Are any accepted leadership styles, theories, skills, traits or behaviours deemed necessary to enable dentists to provide effective clinical care for their patients in primary care practice?", [["patients", "ORGANISM", 606, 614], ["patients", "SPECIES", 606, 614], ["trainers", "TREATMENT", 94, 102]]]], "6bde3798df501fc40dd89e2cff0a1a8fd2b9dd47": [["IntroductionCattle are an economically important species with a wide variety of acute and chronic diseases that significantly impact on animal production and www.elsevier.com/locate/vetimm Veterinary Immunology and Immunopathology 105 (2005) 277-287 welfare.", [["acute and chronic diseases", "PROBLEM", 80, 106], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["diseases", "OBSERVATION", 98, 106]]], ["Models have been developed for many bovine infectious diseases and these models have been used to investigate host-pathogen interactions and immune responses in cattle.", [["infectious diseases", "DISEASE", 43, 62], ["bovine", "ORGANISM", 36, 42], ["cattle", "ORGANISM", 161, 167], ["bovine", "SPECIES", 36, 42], ["cattle", "SPECIES", 161, 167], ["bovine", "SPECIES", 36, 42], ["cattle", "SPECIES", 161, 167], ["many bovine infectious diseases", "PROBLEM", 31, 62], ["bovine", "OBSERVATION_MODIFIER", 36, 42], ["infectious", "OBSERVATION", 43, 53]]], ["Many of these disease models also have substantial relevance to human infections but a paucity of research tools have limited the molecular characterization of disease pathogenesis and host responses to pathogens (Hein and Griebel, 2003) .", [["infections", "DISEASE", 70, 80], ["human", "ORGANISM", 64, 69], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["these disease models", "PROBLEM", 8, 28], ["human infections", "PROBLEM", 64, 80], ["disease pathogenesis", "PROBLEM", 160, 180], ["disease", "OBSERVATION", 14, 21], ["substantial", "OBSERVATION_MODIFIER", 39, 50], ["human", "OBSERVATION_MODIFIER", 64, 69], ["infections", "OBSERVATION", 70, 80]]], ["A variety of molecular and biological techniques now hold substantial promise for enhancing the scope of infectious disease research in cattle and providing the basis for effective interspecies comparison of disease pathogenesis.", [["infectious disease", "DISEASE", 105, 123], ["cattle", "ORGANISM", 136, 142], ["cattle", "SPECIES", 136, 142], ["cattle", "SPECIES", 136, 142], ["disease pathogenesis", "PROBLEM", 208, 228], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["infectious", "OBSERVATION", 105, 115], ["disease", "OBSERVATION", 208, 215]]], ["The present review focuses on the application of microarray technology to the investigation of disease pathogenesis in cattle.", [["cattle", "ORGANISM", 119, 125], ["cattle", "SPECIES", 119, 125], ["cattle", "SPECIES", 119, 125], ["microarray technology", "TREATMENT", 49, 70], ["disease pathogenesis", "PROBLEM", 95, 115]]], ["Future investigations with microbial microarrays will also be critical to understanding the evolutionary balance between host and pathogen.IntroductionA variety of tools have been developed over the last 10 years to facilitate large-scale analyses of gene expression at the level of individual cells, tissues, or whole organisms.", [["cells", "ANATOMY", 294, 299], ["tissues", "ANATOMY", 301, 308], ["cells", "CELL", 294, 299], ["tissues", "TISSUE", 301, 308], ["Future investigations", "TEST", 0, 21], ["microbial microarrays", "TEST", 27, 48], ["pathogen", "PROBLEM", 130, 138], ["gene expression", "PROBLEM", 251, 266], ["whole organisms", "PROBLEM", 313, 328]]], ["The most commonly used tools at the present time include oligonucleotide microarrays (Fodor et al., 1993; Southern and Maskos, 1994) , cDNA microarrays (Schena et al., 1995) , and serial analysis of gene expression (Velculescu et al., 1995) .", [["cDNA microarrays", "DNA", 135, 151], ["oligonucleotide microarrays", "TREATMENT", 57, 84], ["serial analysis", "TEST", 180, 195]]], ["Microarray technology has developed rapidly and numerous textbooks and reviews have been published addressing the critical issues of microarray experimental design (Yang et al., 2002) , data analyses (Butte, 2002) , and the application of microarray technology to investigate normal physiology (Barlow and Lockhart, 2002) and disease pathogenesis (Zamvil and Steinman, 2002) .", [["Microarray technology", "TEST", 0, 21], ["microarray technology", "TEST", 239, 260], ["disease pathogenesis", "PROBLEM", 326, 346]]], ["Microarrays have been developed for a wide variety of microbial pathogens, but the application of this technology to functional genomic studies in mammals has been limited primarily to mice and humans.", [["mice", "ORGANISM", 185, 189], ["humans", "ORGANISM", 194, 200], ["mice", "SPECIES", 185, 189], ["humans", "SPECIES", 194, 200], ["mice", "SPECIES", 185, 189], ["humans", "SPECIES", 194, 200], ["Microarrays", "TEST", 0, 11], ["microbial pathogens", "PROBLEM", 54, 73], ["this technology", "TREATMENT", 98, 113], ["functional genomic studies", "TEST", 117, 143], ["microbial pathogens", "OBSERVATION", 54, 73]]], ["A variety of commercial microarrays are now available for these two species and microarrays representing specific cell signaling pathways or biological functions are being used as routine tools to address hypotheses in basic research and clinical trials.", [["cell", "ANATOMY", 114, 118], ["cell", "CELL", 114, 118], ["commercial microarrays", "TREATMENT", 13, 35], ["these two species", "PROBLEM", 58, 75], ["microarrays", "TEST", 80, 91], ["specific cell signaling pathways", "PROBLEM", 105, 137], ["variety", "OBSERVATION_MODIFIER", 2, 9]]], ["However, there has been a substantial delay in the application of microarray technologies to the investigation of biological questions in species of veterinary importance.IntroductionA relatively small number of bovine microarray studies have been published during the last three years.IntroductionThese investigations used a variety of approaches to analyze gene expression in a wide variety of tissues, including PBMC Burton et al., 2001; Hernandez et al., 2003; Coussens et al., 2002 Coussens et al., , 2003 Coussens et al., , 2004 Tao et al., 2004) , PMN (Madsen et al., 2004) , macrophages (Weiss et al., 2004 ), spleen (Band et al., 2002 ), brain (Band et al., 2002 ), placenta (Band et al., 2002 , reproductive tissues (Robert et al., 2002; Dalbies-Tran and Mermillod, 2003; Bauersachs et al., 2003 Bauersachs et al., , 2004 Ishiwata et al., 2003; Sirard et al., 2003; Evans et al.,2004) , mammary gland (Suchyta et al., 2003a,b) , liver (Herath et al., 2004) , and muscle (Reverter et al., 2003; Sudre et al., 2003) .", [["tissues", "ANATOMY", 396, 403], ["PMN", "ANATOMY", 555, 558], ["macrophages", "ANATOMY", 583, 594], ["spleen", "ANATOMY", 618, 624], ["brain", "ANATOMY", 647, 652], ["placenta", "ANATOMY", 675, 683], ["tissues", "ANATOMY", 718, 725], ["mammary gland", "ANATOMY", 897, 910], ["liver", "ANATOMY", 939, 944], ["muscle", "ANATOMY", 973, 979], ["bovine", "ORGANISM", 212, 218], ["tissues", "TISSUE", 396, 403], ["PMN", "CELL", 555, 558], ["macrophages", "CELL", 583, 594], ["spleen", "ORGAN", 618, 624], ["brain", "ORGAN", 647, 652], ["placenta", "TISSUE", 675, 683], ["reproductive tissues", "TISSUE", 705, 725], ["mammary gland", "MULTI-TISSUE_STRUCTURE", 897, 910], ["liver", "ORGAN", 939, 944], ["muscle", "ORGAN", 973, 979], ["PBMC", "CELL_TYPE", 415, 419], ["macrophages", "CELL_TYPE", 583, 594], ["bovine", "SPECIES", 212, 218], ["microarray technologies", "TREATMENT", 66, 89], ["IntroductionA", "TREATMENT", 171, 184], ["bovine microarray studies", "TEST", 212, 237], ["These investigations", "TEST", 298, 318], ["a variety of approaches", "TREATMENT", 324, 347], ["substantial", "OBSERVATION_MODIFIER", 26, 37], ["delay", "OBSERVATION_MODIFIER", 38, 43], ["small", "OBSERVATION_MODIFIER", 196, 201], ["number", "OBSERVATION_MODIFIER", 202, 208], ["bovine microarray", "OBSERVATION", 212, 229], ["macrophages", "ANATOMY", 583, 594], ["spleen", "ANATOMY", 618, 624], ["brain", "ANATOMY", 647, 652], ["placenta", "ANATOMY", 675, 683], ["mammary gland", "ANATOMY", 897, 910], ["liver", "ANATOMY", 939, 944], ["muscle", "ANATOMY", 973, 979]]], ["Microarray analyses of gene expression were used primarily to address a variety of questions relating to normal physiological processes, such as cell differentiation, pregnancy, lactation, and parturition.", [["cell", "ANATOMY", 145, 149], ["cell", "CELL", 145, 149], ["Microarray analyses", "TEST", 0, 19], ["gene expression", "PROBLEM", 23, 38]]], ["The majority of these studies were conducted using custom designed bovine cDNA microarrays but a number investigations explored the practicality of cross-species hybridization with human micro-or macroarrays (Robert et al., 2002; Dalbies-Tran and Mermillod, 2003; Sudre et al., 2003; and Hernandez et al., 2003) .", [["bovine", "ORGANISM", 67, 73], ["human", "ORGANISM", 181, 186], ["bovine cDNA microarrays", "DNA", 67, 90], ["bovine", "SPECIES", 67, 73], ["human", "SPECIES", 181, 186], ["bovine", "SPECIES", 67, 73], ["human", "SPECIES", 181, 186], ["these studies", "TEST", 16, 29], ["custom designed bovine cDNA microarrays", "TREATMENT", 51, 90], ["a number investigations", "TEST", 95, 118]]], ["Cross-species hybridization was explored as a potential approach to circumvent a number of the problems associated with custom designed bovine cDNA microarrays, which included either relatively small numbers of wellannotated ESTs (Tao et al., 2004; Coussens et al., 2002) or much larger EST numbers with limited annotation (Ishiwata et al., 2003; Reverter et al., 2003; Bauersachs et al., 2004; Weiss et al., 2004) .", [["bovine", "ORGANISM", 136, 142], ["bovine cDNA microarrays", "DNA", 136, 159], ["bovine", "SPECIES", 136, 142], ["bovine", "SPECIES", 136, 142], ["Cross-species hybridization", "PROBLEM", 0, 27], ["the problems", "PROBLEM", 91, 103], ["custom designed bovine cDNA microarrays", "PROBLEM", 120, 159], ["small", "OBSERVATION_MODIFIER", 194, 199]]], ["Thus, there is a substantial need to develop high-density bovine cDNA or oligomicroarrays for functional genomic studies in cattle.IntroductionThe present review will focus on issues arising from the use of microarrays to characterize hostpathogen interactions.", [["bovine", "ORGANISM", 58, 64], ["cattle", "ORGANISM", 124, 130], ["bovine cDNA", "DNA", 58, 69], ["bovine", "SPECIES", 58, 64], ["cattle", "SPECIES", 124, 130], ["bovine", "SPECIES", 58, 64], ["cattle", "SPECIES", 124, 130], ["high-density bovine cDNA", "TREATMENT", 45, 69], ["functional genomic studies", "TEST", 94, 120], ["microarrays", "TREATMENT", 207, 218], ["hostpathogen interactions", "PROBLEM", 235, 260], ["substantial", "OBSERVATION_MODIFIER", 17, 28], ["density bovine cDNA", "OBSERVATION", 50, 69]]], ["Presently, few microarray studies have been published which specifically focus on bovine responses to infectious agents (Coussens et al., 2002 (Coussens et al., , 2003 Weiss et al., 2004) .", [["bovine", "ORGANISM", 82, 88], ["bovine", "SPECIES", 82, 88], ["few microarray studies", "TEST", 11, 33]]], ["Band et al. (2002) developed a 3800 gene bovine microarray which was subsequently expanded to include a total of 7884 ESTs and is commercially available (http:// www.pyxisgenomics.com).", [["bovine", "ORGANISM", 41, 47], ["bovine", "SPECIES", 41, 47], ["a 3800 gene bovine microarray", "TEST", 29, 58]]], ["The annotation available for this microarray has been substantially improved using ProbeLynx but the utility of this microarray is still limited by the presence of unannotated ESTs and while EST selection represented abroad range of cell function there was not a biased selection for genes associated with immune functions.Experimental design for microarray investigationsDisease pathogenesis reflects a complex interaction between host, pathogen, and environmental factors that influence both host and pathogen responses.", [["cell", "ANATOMY", 233, 237], ["cell", "CELL", 233, 237], ["ESTs", "DNA", 176, 180], ["this microarray", "TEST", 29, 44], ["ProbeLynx", "TREATMENT", 83, 92], ["this microarray", "TEST", 112, 127], ["unannotated ESTs", "PROBLEM", 164, 180], ["EST selection", "TEST", 191, 204], ["immune functions", "PROBLEM", 306, 322], ["microarray investigations", "TEST", 347, 372], ["Disease pathogenesis", "PROBLEM", 372, 392], ["a complex interaction between host, pathogen", "PROBLEM", 402, 446], ["improved", "OBSERVATION_MODIFIER", 68, 76], ["cell function", "OBSERVATION", 233, 246], ["complex", "OBSERVATION_MODIFIER", 404, 411]]], ["The potential for environmental factors to significantly alter host responses has always been a major concern for scientific investigators and a variety of experimental procedures have been used to control this variable.", [["environmental factors", "PROBLEM", 18, 39], ["experimental procedures", "TREATMENT", 156, 179]]], ["When using very sensitive methodology, such as microarray analyses, it is even more critical to control for the effects of experimental manipulation.", [["microarray analyses", "TEST", 47, 66], ["experimental manipulation", "TREATMENT", 123, 148]]], ["This can apply to both isolated cells and the whole animal.Cell isolationPurified cell populations provide a unique opportunity to directly correlate changes in gene expression to specific cell populations, but when isolating or purifying cell populations steps should be taken to minimize the impact on gene expression.", [["cells", "ANATOMY", 32, 37], ["Cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 82, 86], ["cell", "ANATOMY", 189, 193], ["cell", "ANATOMY", 239, 243], ["cells", "CELL", 32, 37], ["Cell", "CELL", 59, 63], ["cell populations", "CELL", 82, 98], ["cell populations", "CELL", 189, 205], ["cell", "CELL", 239, 243], ["isolated cells", "CELL_TYPE", 23, 37], ["Cell isolationPurified cell populations", "CELL_LINE", 59, 98], ["Cell isolationPurified cell populations", "TREATMENT", 59, 98], ["specific cell populations", "PROBLEM", 180, 205], ["purifying cell populations steps", "TREATMENT", 229, 261], ["cell populations", "OBSERVATION", 82, 98], ["cell populations", "OBSERVATION", 189, 205]]], ["For example, culturing cells for 24-36 h prior to conducting an experiment will equilibrate gene expression (Lafleur et al., 2001) .", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28], ["culturing cells", "CELL_LINE", 13, 28], ["culturing cells", "TEST", 13, 28]]], ["To understand the effects of cell isolation, bovine primary monocytes were purified by using anti-CD14 or anti-CD172a monoclonal antibodies (mAb) combined with magnetic activated cell sorting (MACS).", [["cell", "ANATOMY", 29, 33], ["monocytes", "ANATOMY", 60, 69], ["cell", "ANATOMY", 179, 183], ["cell", "CELL", 29, 33], ["bovine", "ORGANISM", 45, 51], ["monocytes", "CELL", 60, 69], ["anti-CD14", "GENE_OR_GENE_PRODUCT", 93, 102], ["anti-CD172a", "GENE_OR_GENE_PRODUCT", 106, 117], ["cell", "CELL", 179, 183], ["bovine primary monocytes", "CELL_TYPE", 45, 69], ["anti-CD14", "PROTEIN", 93, 102], ["anti-CD172a monoclonal antibodies", "PROTEIN", 106, 139], ["mAb", "PROTEIN", 141, 144], ["MACS", "CELL_TYPE", 193, 197], ["bovine", "SPECIES", 45, 51], ["bovine", "SPECIES", 45, 51], ["cell isolation", "TREATMENT", 29, 43], ["bovine primary monocytes", "TREATMENT", 45, 69], ["anti-CD14", "TREATMENT", 93, 102], ["anti-CD172a monoclonal antibodies", "TREATMENT", 106, 139]]], ["This isolation methodology was selected since it provides rapid isolation of highly purified monocytes (>99.5%) and cell function and viability are reportedly preserved (Miltenyi Biotech, Instructions for Use: MiniMACS and MidiMACS).", [["monocytes", "ANATOMY", 93, 102], ["cell", "ANATOMY", 116, 120], ["monocytes", "CELL", 93, 102], ["cell", "CELL", 116, 120], ["highly purified monocytes", "CELL_TYPE", 77, 102], ["This isolation methodology", "TREATMENT", 0, 26], ["monocytes", "TEST", 93, 102], ["cell function", "TEST", 116, 129], ["MiniMACS and MidiMACS", "TREATMENT", 210, 231]]], ["CD14 was selected as a target molecule because it lacks a transmembrane domain and mAb binding should not initiate cell signaling.", [["transmembrane", "ANATOMY", 58, 71], ["cell", "ANATOMY", 115, 119], ["CD14", "GENE_OR_GENE_PRODUCT", 0, 4], ["mAb", "GENE_OR_GENE_PRODUCT", 83, 86], ["cell", "CELL", 115, 119], ["CD14", "PROTEIN", 0, 4], ["transmembrane domain", "PROTEIN", 58, 78], ["mAb", "PROTEIN", 83, 86], ["CD14", "TEST", 0, 4], ["a transmembrane domain and mAb binding", "PROBLEM", 56, 94], ["cell signaling", "PROBLEM", 115, 129]]], ["In contrast, the CD172a molecule is an integral membrane protein, but it has been used extensively as a target for bovine monocyte isolation.Cell isolationRNA was extracted from MACS purified monocytes immediately following isolation (Time 0) and after culture in medium (Aim-V + 2% FBS) for 4, 12, and 36 h.", [["membrane", "ANATOMY", 48, 56], ["monocyte", "ANATOMY", 122, 130], ["Cell", "ANATOMY", 141, 145], ["monocytes", "ANATOMY", 192, 201], ["FBS", "ANATOMY", 283, 286], ["CD172a", "GENE_OR_GENE_PRODUCT", 17, 23], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["bovine", "ORGANISM", 115, 121], ["monocyte", "CELL", 122, 130], ["Cell", "CELL", 141, 145], ["monocytes", "CELL", 192, 201], ["FBS", "ORGANISM_SUBSTANCE", 283, 286], ["CD172a molecule", "PROTEIN", 17, 32], ["integral membrane protein", "PROTEIN", 39, 64], ["MACS purified monocytes", "CELL_TYPE", 178, 201], ["bovine", "SPECIES", 115, 121], ["an integral membrane protein", "PROBLEM", 36, 64], ["bovine monocyte isolation", "TREATMENT", 115, 140], ["Cell isolationRNA", "PROBLEM", 141, 158], ["culture", "TEST", 253, 260], ["Aim", "TEST", 272, 275], ["FBS", "TEST", 283, 286], ["membrane protein", "OBSERVATION", 48, 64], ["bovine monocyte isolation", "OBSERVATION", 115, 140]]], ["Microarray analysis (three biological and two technical replicates) was performed for each culture interval relative to Time 0.", [["Microarray analysis", "TEST", 0, 19], ["each culture interval", "TEST", 86, 107]]], ["Bovine monocytes isolated with anti-CD172a or anti-CD14 showed extensive gene activation after 4 h in culture, but gene expression decreased sharply over time (Table 1) .", [["monocytes", "ANATOMY", 7, 16], ["Bovine", "ORGANISM", 0, 6], ["monocytes", "CELL", 7, 16], ["anti-CD172a", "GENE_OR_GENE_PRODUCT", 31, 42], ["anti-CD14", "GENE_OR_GENE_PRODUCT", 46, 55], ["Bovine monocytes", "CELL_TYPE", 0, 16], ["anti-CD172a", "PROTEIN", 31, 42], ["anti-CD14", "PROTEIN", 46, 55], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine monocytes", "TEST", 0, 16], ["anti-CD172a", "TREATMENT", 31, 42], ["anti-CD14", "TREATMENT", 46, 55], ["extensive gene activation", "PROBLEM", 63, 88], ["culture", "TEST", 102, 109], ["gene expression", "PROBLEM", 115, 130], ["decreased", "OBSERVATION_MODIFIER", 131, 140], ["sharply", "OBSERVATION_MODIFIER", 141, 148]]], ["Monocytes isolated with anti-CD14 had 30% less gene activation at 4 h, but the number of differentially expressed genes did not decline to the same level as observed with CD172a selected monocytes cultured for 24 and 36 h.", [["Monocytes", "ANATOMY", 0, 9], ["monocytes", "ANATOMY", 187, 196], ["Monocytes", "CELL", 0, 9], ["anti-CD14", "GENE_OR_GENE_PRODUCT", 24, 33], ["CD172a", "GENE_OR_GENE_PRODUCT", 171, 177], ["monocytes", "CELL", 187, 196], ["Monocytes", "CELL_TYPE", 0, 9], ["anti-CD14", "PROTEIN", 24, 33], ["CD172a", "PROTEIN", 171, 177], ["monocytes", "CELL_TYPE", 187, 196], ["Monocytes", "TEST", 0, 9], ["anti-CD14", "TREATMENT", 24, 33]]], ["Thus, MACS isolation had a significant impact on monocyte gene expression and this effect was not eliminated by changing the surface molecule used for cell selection.", [["monocyte", "ANATOMY", 49, 57], ["surface", "ANATOMY", 125, 132], ["cell", "ANATOMY", 151, 155], ["monocyte", "CELL", 49, 57], ["cell", "CELL", 151, 155], ["surface molecule", "PROTEIN", 125, 141], ["MACS isolation", "TREATMENT", 6, 20], ["monocyte gene expression", "TREATMENT", 49, 73], ["the surface molecule", "TREATMENT", 121, 141], ["cell selection", "TREATMENT", 151, 165], ["significant", "OBSERVATION_MODIFIER", 27, 38]]], ["Furthermore, a comparison of differentially expressed genes (Table 1) revealed no over-lap in the gene expression patterns for CD14 + and CD172A + cells.", [["CD172A + cells", "ANATOMY", 138, 152], ["CD14", "GENE_OR_GENE_PRODUCT", 127, 131], ["differentially expressed genes", "DNA", 29, 59], ["CD14", "PROTEIN", 127, 131], ["CD14", "TEST", 127, 131], ["no", "UNCERTAINTY", 79, 81], ["lap", "OBSERVATION", 87, 90]]], ["This observation indicates that time-matched and cell specific controls may be advisable within each experiment.Animal models and commensal microfloraThe surgical preparation of multiple, sterile intestinal ''loops'' has been used as a model for the analysis of mucosal immune responses (Gerdts et al., 2001) and to analyze differential gene expression induced by bovine rotavirus infection (Tatlow et al., 2000) .", [["cell", "ANATOMY", 49, 53], ["intestinal", "ANATOMY", 196, 206], ["mucosal", "ANATOMY", 262, 269], ["rotavirus infection", "DISEASE", 371, 390], ["cell", "CELL", 49, 53], ["intestinal", "ORGAN", 196, 206], ["mucosal", "MULTI-TISSUE_STRUCTURE", 262, 269], ["bovine", "ORGANISM", 364, 370], ["rotavirus", "ORGANISM", 371, 380], ["bovine", "SPECIES", 364, 370], ["bovine", "SPECIES", 364, 370], ["This observation", "TEST", 0, 16], ["cell specific controls", "TREATMENT", 49, 71], ["Animal models", "PROBLEM", 112, 125], ["commensal microflora", "PROBLEM", 130, 150], ["The surgical preparation", "TREATMENT", 150, 174], ["multiple, sterile intestinal ''loops''", "TREATMENT", 178, 216], ["the analysis", "TEST", 246, 258], ["bovine rotavirus infection", "PROBLEM", 364, 390], ["commensal microflora", "OBSERVATION_MODIFIER", 130, 150], ["surgical", "OBSERVATION", 154, 162], ["multiple", "OBSERVATION_MODIFIER", 178, 186], ["intestinal", "ANATOMY", 196, 206], ["bovine rotavirus infection", "OBSERVATION", 364, 390]]], ["Inflammation associated with the surgical creation of intestinal ''loops'' is expected to have a significant impact on gene expression.", [["intestinal", "ANATOMY", 54, 64], ["Inflammation", "DISEASE", 0, 12], ["intestinal", "ORGAN", 54, 64], ["Inflammation", "PROBLEM", 0, 12], ["surgical", "OBSERVATION", 33, 41], ["intestinal", "ANATOMY", 54, 64], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["impact", "OBSERVATION", 109, 115], ["gene expression", "OBSERVATION", 119, 134]]], ["Furthermore, removal of microflora during ''loop'' preparation may also have an impact on host gene transcription.", [["removal", "TREATMENT", 13, 20], ["microflora", "TREATMENT", 24, 34], ["''loop'' preparation", "TREATMENT", 42, 62], ["host gene transcription", "TREATMENT", 90, 113]]], ["There is increasing evidence that both the mucosal immune 153 79 a RNA collected from monocytes following culture for 0, 4, 12, and 36 h. b Differentially expressed genes (p < 0.05 and 2.0-fold change) were identified with a bovine microarray (7884 ESTs) relative to time 0. c MACS purified monocytes (>99.5% CD14 + or CD172a + ) were isolated from the blood of three 6-8-month-old castrated male calves. system and mucosal epithelial cells have evolved in response to the presence of commensal microflora (Cummings et al., 2003; de Vrese and Schrezenmeir, 2002; Macpherson and Uhr, 2004) and these interactions may influence inflammation and disease in the gastrointestinal tract (Macpherson and Uhr, 2004; Miniello et al., 2003) .Animal models and commensal microfloraBefore using the intestinal ''loop'' model for functional genomic analyses of host responses to enteric pathogens, we investigated the effects of surgical manipulation and the elimination of commensal microflora.", [["mucosal", "ANATOMY", 43, 50], ["monocytes", "ANATOMY", 86, 95], ["monocytes", "ANATOMY", 291, 300], ["CD172a +", "ANATOMY", 319, 327], ["blood", "ANATOMY", 353, 358], ["system", "ANATOMY", 405, 411], ["mucosal epithelial cells", "ANATOMY", 416, 440], ["gastrointestinal tract", "ANATOMY", 658, 680], ["intestinal", "ANATOMY", 787, 797], ["inflammation and disease in the gastrointestinal tract", "DISEASE", 626, 680], ["monocytes", "CELL", 86, 95], ["bovine", "ORGANISM", 225, 231], ["c MACS", "GENE_OR_GENE_PRODUCT", 275, 281], ["monocytes", "CELL", 291, 300], ["CD14", "GENE_OR_GENE_PRODUCT", 309, 313], ["CD172a", "GENE_OR_GENE_PRODUCT", 319, 325], ["blood", "ORGANISM_SUBSTANCE", 353, 358], ["calves", "ORGANISM", 397, 403], ["mucosal epithelial cells", "CELL", 416, 440], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 658, 680], ["intestinal", "ORGAN", 787, 797], ["mucosal immune 153 79 a RNA", "RNA", 43, 70], ["monocytes", "CELL_TYPE", 86, 95], ["c MACS purified monocytes", "CELL_TYPE", 275, 300], ["CD14", "PROTEIN", 309, 313], ["CD172a", "PROTEIN", 319, 325], ["mucosal epithelial cells", "CELL_TYPE", 416, 440], ["bovine", "SPECIES", 225, 231], ["calves", "SPECIES", 397, 403], ["the mucosal immune", "TEST", 39, 57], ["a RNA", "TEST", 65, 70], ["monocytes", "TEST", 86, 95], ["culture", "TEST", 106, 113], ["a bovine microarray", "TEST", 223, 242], ["monocytes", "TEST", 291, 300], ["CD14", "TEST", 309, 313], ["CD172a", "TEST", 319, 325], ["mucosal epithelial cells", "PROBLEM", 416, 440], ["commensal microflora", "PROBLEM", 485, 505], ["influence inflammation", "PROBLEM", 616, 638], ["disease in the gastrointestinal tract", "PROBLEM", 643, 680], ["commensal microfloraBefore", "TREATMENT", 750, 776], ["the intestinal ''loop'' model", "TREATMENT", 783, 812], ["enteric pathogens", "PROBLEM", 866, 883], ["surgical manipulation", "TREATMENT", 916, 937], ["commensal microflora", "PROBLEM", 961, 981], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["mucosal", "ANATOMY", 43, 50], ["monocytes", "ANATOMY", 291, 300], ["calves", "ANATOMY", 397, 403], ["mucosal", "ANATOMY", 416, 423], ["epithelial cells", "OBSERVATION", 424, 440], ["inflammation", "OBSERVATION", 626, 638], ["gastrointestinal tract", "ANATOMY", 658, 680], ["intestinal", "ANATOMY", 787, 797]]], ["RNA was isolated from intestinal ''loop'' tissue (Sample) and adjacent, intact intestine (Control) at 48 h (n = 3) and 12 days (n = 3) postsurgery.", [["intestinal ''loop'' tissue", "ANATOMY", 22, 48], ["intestine", "ANATOMY", 79, 88], ["intestinal ''loop'' tissue", "TISSUE", 22, 48], ["intestine", "ORGAN", 79, 88], ["RNA", "RNA", 0, 3], ["intestinal ''loop'' tissue", "PROBLEM", 22, 48], ["intestinal", "ANATOMY", 22, 32], ["intact", "OBSERVATION", 72, 78], ["intestine", "ANATOMY", 79, 88]]], ["These within animal comparisons revealed that 2.3% (180/7884) of ESTs were significantly ( p < 0.05 and 1.5-fold change) altered in expression levels at 48 h post-surgery and approximately 80% (143/180) of these genes were up-regulated (Aich et al., 2005) .", [["ESTs", "TEST", 65, 69], ["altered in expression levels", "PROBLEM", 121, 149], ["surgery", "TREATMENT", 163, 170]]], ["Differential gene expression revealed that a variety of cell processes, including apoptosis, cell cycle, and cell differentiation, had been significantly changed.", [["cell", "ANATOMY", 56, 60], ["cell", "ANATOMY", 93, 97], ["cell", "ANATOMY", 109, 113], ["cell", "CELL", 56, 60], ["cell", "CELL", 93, 97], ["cell", "CELL", 109, 113], ["Differential gene expression", "TEST", 0, 28], ["cell processes", "PROBLEM", 56, 70], ["apoptosis", "PROBLEM", 82, 91], ["cell cycle", "TEST", 93, 103], ["variety of cell processes", "OBSERVATION", 45, 70], ["cell cycle", "OBSERVATION", 93, 103], ["cell differentiation", "OBSERVATION", 109, 129], ["significantly", "OBSERVATION_MODIFIER", 140, 153], ["changed", "OBSERVATION_MODIFIER", 154, 161]]], ["The absence of genes involved in inflammation and cell recruitment may reflect the low abundance of relevant immune genes on the Pyxis microarray and, consequently, the effects of surgery on host gene expression may be under-estimated for the small intestine.", [["cell", "ANATOMY", 50, 54], ["small intestine", "ANATOMY", 243, 258], ["inflammation", "DISEASE", 33, 45], ["cell", "CELL", 50, 54], ["small intestine", "ORGAN", 243, 258], ["immune genes", "DNA", 109, 121], ["Pyxis", "DNA", 129, 134], ["inflammation", "PROBLEM", 33, 45], ["cell recruitment", "TREATMENT", 50, 66], ["surgery", "TREATMENT", 180, 187], ["host gene expression", "TREATMENT", 191, 211], ["inflammation", "OBSERVATION", 33, 45], ["cell recruitment", "OBSERVATION", 50, 66], ["low abundance", "OBSERVATION_MODIFIER", 83, 96], ["immune genes", "OBSERVATION", 109, 121], ["small intestine", "ANATOMY", 243, 258]]], ["Therefore, a similar experiment was repeated in young calves (n = 3) but this time the intestinal ''loops'' were either flushed with saline containing antibiotics (\u00c0microflora) or left intact (+microflora) and tissues were collected 24 h later.", [["intestinal", "ANATOMY", 87, 97], ["microflora", "ANATOMY", 194, 204], ["tissues", "ANATOMY", 210, 217], ["calves", "ORGANISM", 54, 60], ["intestinal", "ORGAN", 87, 97], ["saline", "SIMPLE_CHEMICAL", 133, 139], ["tissues", "TISSUE", 210, 217], ["calves", "SPECIES", 54, 60], ["the intestinal ''loops''", "TREATMENT", 83, 107], ["saline containing antibiotics", "TREATMENT", 133, 162], ["\u00c0microflora", "TREATMENT", 164, 175], ["intestinal", "ANATOMY", 87, 97], ["left", "ANATOMY_MODIFIER", 180, 184], ["tissues", "ANATOMY", 210, 217]]], ["Microarray analyses of these paired tissue samples identified 5.1% (406/7884) genes with altered expression ( p < 0.05 and 1.5-fold change) following antibiotic treatment to eliminate microflora.", [["tissue samples", "ANATOMY", 36, 50], ["tissue samples", "CANCER", 36, 50], ["Microarray analyses", "TEST", 0, 19], ["these paired tissue samples", "TEST", 23, 50], ["altered expression", "PROBLEM", 89, 107], ["antibiotic treatment", "TREATMENT", 150, 170], ["microflora", "PROBLEM", 184, 194]]], ["Thus, each experimental manipulation significantly altered host gene expression, confirming the importance of within animal controls.Animal models and commensal microfloraThe importance of commensal microflora for normal development and function of the mucosal epithelium and immune system was further investigated.", [["mucosal epithelium", "ANATOMY", 253, 271], ["immune system", "ANATOMY", 276, 289], ["commensal microflora", "MULTI-TISSUE_STRUCTURE", 189, 209], ["mucosal epithelium", "TISSUE", 253, 271], ["immune system", "ANATOMICAL_SYSTEM", 276, 289], ["Animal models", "PROBLEM", 133, 146], ["commensal microflora", "PROBLEM", 151, 171], ["commensal microflora", "TREATMENT", 189, 209], ["commensal microflora", "OBSERVATION_MODIFIER", 151, 171], ["mucosal epithelium", "ANATOMY", 253, 271]]], ["To address this question, host responses to an enteric viral infection was analyzed in the presence or absence of commensal microflora.", [["viral infection", "DISEASE", 55, 70], ["an enteric viral infection", "PROBLEM", 44, 70], ["commensal microflora", "PROBLEM", 114, 134], ["infection", "OBSERVATION", 61, 70], ["commensal microflora", "OBSERVATION", 114, 134]]], ["Again, paired intestinal ''loops'' (\u00c0microflora and +microflora) were prepared in young calves (n = 3) and both ''loops'' were injected with bovine coronavirus.Animal models and commensal microfloraMicroarray analyses revealed that removal of ingesta and commensal microflora had a marked impact on host responses at 24 h post-infection (Fig. 1A) .", [["intestinal", "ANATOMY", 14, 24], ["\u00c0microflora", "ANATOMY", 36, 47], ["infection", "DISEASE", 327, 336], ["intestinal", "ORGAN", 14, 24], ["calves", "ORGANISM", 88, 94], ["bovine", "ORGANISM", 141, 147], ["coronavirus", "ORGANISM", 148, 159], ["calves", "SPECIES", 88, 94], ["bovine", "SPECIES", 141, 147], ["bovine coronavirus", "SPECIES", 141, 159], ["paired intestinal ''loops''", "PROBLEM", 7, 34], ["\u00c0microflora and +microflora", "TREATMENT", 36, 63], ["both ''loops''", "TREATMENT", 107, 121], ["bovine coronavirus", "PROBLEM", 141, 159], ["Animal models", "TEST", 160, 173], ["commensal microfloraMicroarray analyses", "TEST", 178, 217], ["removal", "TREATMENT", 232, 239], ["ingesta", "TREATMENT", 243, 250], ["commensal microflora", "TREATMENT", 255, 275], ["infection", "PROBLEM", 327, 336], ["intestinal", "ANATOMY", 14, 24], ["marked", "OBSERVATION_MODIFIER", 282, 288], ["infection", "OBSERVATION", 327, 336]]], ["Only 196 of the differentially expressed genes ( p < 0.2) were common to both experimental systems and a more stringent analysis ( p < 0.05) of the data reduced this number to 63.", [["a more stringent analysis", "TEST", 103, 128], ["the data", "TEST", 144, 152]]], ["Furthermore, over 4-fold more genes were differentially expressed in the small intestine when coronavirus infection occurred in the presence of ingesta and commensal microflora.", [["small intestine", "ANATOMY", 73, 88], ["coronavirus infection", "DISEASE", 94, 115], ["small intestine", "ORGAN", 73, 88], ["coronavirus", "ORGANISM", 94, 105], ["coronavirus infection", "PROBLEM", 94, 115], ["ingesta", "PROBLEM", 144, 151], ["commensal microflora", "PROBLEM", 156, 176], ["small intestine", "ANATOMY", 73, 88], ["coronavirus", "OBSERVATION_MODIFIER", 94, 105], ["infection", "OBSERVATION", 106, 115], ["commensal microflora", "OBSERVATION", 156, 176]]], ["These observations provide substantial evidence for a significant interaction between intestinal microflora and the mucosal epithelium and immune system.", [["intestinal microflora", "ANATOMY", 86, 107], ["mucosal epithelium", "ANATOMY", 116, 134], ["immune system", "ANATOMY", 139, 152], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 86, 107], ["mucosal epithelium", "TISSUE", 116, 134], ["immune system", "ANATOMICAL_SYSTEM", 139, 152], ["a significant interaction between intestinal microflora", "PROBLEM", 52, 107], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["interaction", "OBSERVATION", 66, 77], ["intestinal microflora", "ANATOMY", 86, 107], ["mucosal epithelium", "ANATOMY", 116, 134], ["immune system", "OBSERVATION", 139, 152]]], ["Thus, surgical manipulations and microflora must be carefully considered when designing and performing functional genomic analyses of host-pathogen interactions at mucosal surfaces.Enteric infectionsOver 90% of all bovine pathogens invade through mucosal surfaces and the immune responses that contribute to either pathology or protection are unknown for most diseases.", [["mucosal", "ANATOMY", 164, 171], ["mucosal surfaces", "ANATOMY", 247, 263], ["Enteric infections", "DISEASE", 181, 199], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 164, 180], ["bovine", "ORGANISM", 215, 221], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 247, 263], ["bovine", "SPECIES", 215, 221], ["bovine", "SPECIES", 215, 221], ["surgical manipulations", "TREATMENT", 6, 28], ["microflora", "TREATMENT", 33, 43], ["Enteric infections", "PROBLEM", 181, 199], ["all bovine pathogens", "TREATMENT", 211, 231], ["pathology", "PROBLEM", 315, 324], ["most diseases", "PROBLEM", 355, 368], ["infections", "OBSERVATION", 189, 199], ["mucosal", "ANATOMY", 247, 254]]], ["Tools, such as microarrays, have the potential to provide significant insight into the molecules that regulate the induction and differentiation of mucosal immune responses.", [["mucosal", "ANATOMY", 148, 155], ["mucosal", "ANATOMICAL_SYSTEM", 148, 155], ["the induction", "TREATMENT", 111, 124]]], ["Microarrays should facilitate the identification of host responses that are conserved among pathogens and help identify those responses unique to each pathogen.Enteric infectionsThis strategy was used to identify host immune responses to bovine rotaviruses and coronaviruses using the intestinal ''loop'' model.", [["intestinal", "ANATOMY", 285, 295], ["Enteric infections", "DISEASE", 160, 178], ["bovine", "ORGANISM", 238, 244], ["rotaviruses", "ORGANISM", 245, 256], ["coronaviruses", "ORGANISM", 261, 274], ["intestinal", "ORGAN", 285, 295], ["bovine", "SPECIES", 238, 244], ["Microarrays", "TREATMENT", 0, 11], ["Enteric infections", "PROBLEM", 160, 178], ["This strategy", "TREATMENT", 178, 191], ["bovine rotaviruses", "TREATMENT", 238, 256], ["coronaviruses", "PROBLEM", 261, 274], ["the intestinal ''loop'' model", "TREATMENT", 281, 310], ["infections", "OBSERVATION", 168, 178], ["intestinal", "ANATOMY", 285, 295]]], ["This model system can minimize effects due to genetic variability within an outbred population by comparing uninfected and infected intestinal tissues collected from the same animal.", [["intestinal tissues", "ANATOMY", 132, 150], ["intestinal tissues", "TISSUE", 132, 150], ["genetic variability", "PROBLEM", 46, 65], ["an outbred population", "PROBLEM", 73, 94], ["uninfected and infected intestinal tissues", "PROBLEM", 108, 150], ["infected", "OBSERVATION", 123, 131], ["intestinal tissues", "ANATOMY", 132, 150]]], ["Data presented in Fig. 1B indicates that both RNA viruses induce differential expression of approximately 13% of the genes on the array, but even with lenient stringency ( p < 0.2 and 1.2-fold change) over 90% of the differentially expressed genes were unique to each pathogen.", [["1B", "GENE_OR_GENE_PRODUCT", 23, 25], ["both RNA viruses", "PROBLEM", 41, 57], ["lenient stringency", "PROBLEM", 151, 169], ["RNA viruses", "OBSERVATION", 46, 57]]], ["Preliminary validation studies of these genes using quantitative real-time PCR (Table 2) indicate that approximately 75% of the genes tested by PCR concur with the microarray results and this validation efficiency remains relatively constant despite reducing the stringency of the significance cutoffs used for microarray analysis.", [["Preliminary validation studies", "TEST", 0, 30], ["PCR", "TEST", 144, 147], ["the microarray", "TEST", 160, 174], ["this validation efficiency", "PROBLEM", 187, 213], ["microarray analysis", "TEST", 311, 330]]], ["This suggests that using a reduced stringency for initial microarray analysis may be an advantageous approach to maximize the identification of potential gene targets for further biological investigation.Enteric infectionsThe relation of microarray data to biology is complicated when using RNA isolated from tissues.", [["tissues", "ANATOMY", 309, 316], ["Enteric infections", "DISEASE", 204, 222], ["tissues", "TISSUE", 309, 316], ["a reduced stringency", "PROBLEM", 25, 45], ["initial microarray analysis", "TEST", 50, 77], ["further biological investigation", "TEST", 171, 203], ["Enteric infections", "PROBLEM", 204, 222], ["microarray data", "TEST", 238, 253], ["RNA isolated from tissues", "PROBLEM", 291, 316], ["infections", "OBSERVATION", 212, 222]]], ["For example, both rotavirus and coronavirus infection result in substantial destruction of mucosal epithelial cells.", [["mucosal epithelial cells", "ANATOMY", 91, 115], ["coronavirus infection", "DISEASE", 32, 53], ["rotavirus", "ORGANISM", 18, 27], ["coronavirus", "ORGANISM", 32, 43], ["mucosal epithelial cells", "CELL", 91, 115], ["mucosal epithelial cells", "CELL_TYPE", 91, 115], ["coronavirus", "SPECIES", 32, 43], ["rotavirus", "SPECIES", 18, 27], ["both rotavirus", "PROBLEM", 13, 27], ["coronavirus infection", "PROBLEM", 32, 53], ["substantial destruction of mucosal epithelial cells", "PROBLEM", 64, 115], ["both", "OBSERVATION_MODIFIER", 13, 17], ["rotavirus", "OBSERVATION", 18, 27], ["coronavirus", "OBSERVATION_MODIFIER", 32, 43], ["infection", "OBSERVATION", 44, 53], ["substantial", "OBSERVATION_MODIFIER", 64, 75], ["destruction", "OBSERVATION", 76, 87], ["mucosal epithelial cells", "OBSERVATION", 91, 115]]], ["In addition, the immune cell populations in the intestine can change rapidly in response to infection.", [["immune cell", "ANATOMY", 17, 28], ["intestine", "ANATOMY", 48, 57], ["infection", "DISEASE", 92, 101], ["immune cell populations", "CELL", 17, 40], ["intestine", "ORGAN", 48, 57], ["immune cell populations", "CELL_TYPE", 17, 40], ["the immune cell populations", "TREATMENT", 13, 40], ["infection", "PROBLEM", 92, 101], ["immune cell populations", "OBSERVATION", 17, 40], ["intestine", "ANATOMY", 48, 57], ["infection", "OBSERVATION", 92, 101]]], ["Thus, apparent changes in gene expression may simply reflect the altered abundance of mucosal epithelial cells or changes in the relative cellular composition of the mucosal immune system.", [["mucosal epithelial cells", "ANATOMY", 86, 110], ["cellular", "ANATOMY", 138, 146], ["mucosal", "ANATOMY", 166, 173], ["mucosal epithelial cells", "CELL", 86, 110], ["cellular", "CELL", 138, 146], ["mucosal immune system", "ANATOMICAL_SYSTEM", 166, 187], ["mucosal epithelial cells", "CELL_TYPE", 86, 110], ["apparent changes in gene expression", "PROBLEM", 6, 41], ["mucosal epithelial cells", "PROBLEM", 86, 110], ["gene expression", "OBSERVATION", 26, 41], ["may simply reflect", "UNCERTAINTY", 42, 60], ["altered", "OBSERVATION_MODIFIER", 65, 72], ["abundance", "OBSERVATION_MODIFIER", 73, 82], ["mucosal epithelial cells", "OBSERVATION", 86, 110], ["cellular composition", "OBSERVATION", 138, 158], ["mucosal immune system", "OBSERVATION", 166, 187]]], ["One approach to tackling the limitations of studying gene expression in complex tissues is to study in parallel differential gene expression in a specific cell population in an in vitro model.", [["tissues", "ANATOMY", 80, 87], ["cell", "ANATOMY", 155, 159], ["tissues", "TISSUE", 80, 87], ["cell", "CELL", 155, 159], ["a specific cell population", "TREATMENT", 144, 170], ["specific cell", "OBSERVATION_MODIFIER", 146, 159]]], ["Using this combined approach, a primary bovine intestinal epithelial cell line was developed to assess bovine rotavirus infection.", [["intestinal epithelial cell line", "ANATOMY", 47, 78], ["rotavirus infection", "DISEASE", 110, 129], ["bovine", "ORGANISM", 40, 46], ["intestinal epithelial cell line", "CELL", 47, 78], ["bovine", "ORGANISM", 103, 109], ["rotavirus", "ORGANISM", 110, 119], ["primary bovine intestinal epithelial cell line", "CELL_LINE", 32, 78], ["bovine", "SPECIES", 40, 46], ["bovine", "SPECIES", 103, 109], ["bovine", "SPECIES", 40, 46], ["bovine", "SPECIES", 103, 109], ["rotavirus", "SPECIES", 110, 119], ["this combined approach", "TREATMENT", 6, 28], ["a primary bovine intestinal epithelial cell line", "TREATMENT", 30, 78], ["bovine rotavirus infection", "PROBLEM", 103, 129], ["intestinal", "ANATOMY", 47, 57], ["epithelial cell line", "OBSERVATION", 58, 78], ["rotavirus", "OBSERVATION_MODIFIER", 110, 119], ["infection", "OBSERVATION", 120, 129]]], ["Primary jejunal epithelial cell cultures were infected with bovine rotavirus and RNA was isolated at 16 h post-infection.", [["jejunal epithelial cell cultures", "ANATOMY", 8, 40], ["infection", "DISEASE", 111, 120], ["jejunal epithelial cell cultures", "CELL", 8, 40], ["bovine", "ORGANISM", 60, 66], ["rotavirus", "ORGANISM", 67, 76], ["Primary jejunal epithelial cell cultures", "CELL_LINE", 0, 40], ["bovine", "SPECIES", 60, 66], ["bovine", "SPECIES", 60, 66], ["rotavirus", "SPECIES", 67, 76], ["Primary jejunal epithelial cell cultures", "TEST", 0, 40], ["bovine rotavirus and RNA", "PROBLEM", 60, 84], ["infection", "PROBLEM", 111, 120], ["jejunal", "ANATOMY", 8, 15], ["epithelial cell", "OBSERVATION", 16, 31], ["infection", "OBSERVATION", 111, 120]]], ["Microarray analyses revealed that a total of 1914 genes were differentially expressed ( p < 0.2 and 1.2-fold change) in the epithelial cells following viral infection ( Fig. 1C ; in vitro).", [["epithelial cells", "ANATOMY", 124, 140], ["viral infection", "DISEASE", 151, 166], ["epithelial cells", "CELL", 124, 140], ["1914 genes", "DNA", 45, 55], ["epithelial cells", "CELL_TYPE", 124, 140], ["Microarray analyses", "TEST", 0, 19], ["the epithelial cells", "PROBLEM", 120, 140], ["viral infection", "PROBLEM", 151, 166], ["epithelial cells", "ANATOMY", 124, 140], ["viral infection", "OBSERVATION", 151, 166]]], ["More importantly, 279 of the differentially expressed genes were common to the set of genes identified in bovine rotavirus infected intestinal ''loops'' (Fig. 1C; in vivo) .", [["intestinal ''loops", "ANATOMY", 132, 150], ["rotavirus infected", "DISEASE", 113, 131], ["bovine", "ORGANISM", 106, 112], ["rotavirus", "ORGANISM", 113, 122], ["intestinal", "ORGAN", 132, 142], ["bovine", "SPECIES", 106, 112], ["rotavirus", "SPECIES", 113, 122], ["bovine rotavirus infected intestinal ''loops''", "PROBLEM", 106, 152], ["bovine rotavirus", "OBSERVATION", 106, 122]]], ["This is important since the in vitro model not only provides independent confirmation of the in vivo observations, but also provides evidence to link expression of specific genes to mucosal epithelial cells.", [["mucosal epithelial cells", "ANATOMY", 182, 206], ["mucosal epithelial cells", "CELL", 182, 206], ["mucosal epithelial cells", "CELL_TYPE", 182, 206], ["mucosal epithelial cells", "OBSERVATION", 182, 206]]], ["Thus, a combination of in vitro and in vivo models can provide powerful tools to enhance functional genomic analyses and associate gene expression with specific cell types.", [["cell", "ANATOMY", 161, 165], ["cell", "CELL", 161, 165], ["functional genomic analyses", "PROBLEM", 89, 116]]], ["Furthermore, the comparative analysis of gene expression induced by two or more enteric pathogens provides a strategy for the identification of conserved mucosal responses that may be of broad relevance to disease protection.", [["mucosal", "ANATOMY", 154, 161], ["mucosal", "MULTI-TISSUE_STRUCTURE", 154, 161], ["the comparative analysis", "TEST", 13, 37], ["gene expression", "PROBLEM", 41, 56], ["disease protection", "TREATMENT", 206, 224]]], ["These analyses should also reveal innate immune responses that play a pivotal role in determining the outcome of host-pathogen interactions.Respiratory infectionsA diverse number of viral and bacterial pathogens have been associated with bovine respiratory disease.", [["respiratory", "ANATOMY", 245, 256], ["Respiratory infections", "DISEASE", 140, 162], ["bovine respiratory disease", "DISEASE", 238, 264], ["bovine", "ORGANISM", 238, 244], ["bovine", "SPECIES", 238, 244], ["bovine", "SPECIES", 238, 244], ["These analyses", "TEST", 0, 14], ["Respiratory infections", "PROBLEM", 140, 162], ["viral and bacterial pathogens", "PROBLEM", 182, 211], ["bovine respiratory disease", "PROBLEM", 238, 264], ["infections", "OBSERVATION", 152, 162], ["diverse", "OBSERVATION_MODIFIER", 164, 171], ["number", "OBSERVATION_MODIFIER", 172, 178], ["viral", "OBSERVATION_MODIFIER", 182, 187], ["bacterial pathogens", "OBSERVATION", 192, 211], ["associated with", "UNCERTAINTY", 222, 237], ["bovine", "OBSERVATION_MODIFIER", 238, 244], ["respiratory disease", "OBSERVATION", 245, 264]]], ["Furthermore, the epidemiology of bovine respiratory disease in North America has been linked to environmental and nutritional changes, as well as husbandry procedures, with an increased incidence of respiratory disease at the time of weaning.", [["respiratory", "ANATOMY", 40, 51], ["respiratory", "ANATOMY", 199, 210], ["respiratory disease", "DISEASE", 40, 59], ["respiratory disease", "DISEASE", 199, 218], ["bovine", "ORGANISM", 33, 39], ["bovine", "SPECIES", 33, 39], ["bovine", "SPECIES", 33, 39], ["bovine respiratory disease", "PROBLEM", 33, 59], ["husbandry procedures", "TREATMENT", 146, 166], ["respiratory disease", "PROBLEM", 199, 218], ["bovine", "OBSERVATION_MODIFIER", 33, 39], ["respiratory disease", "OBSERVATION", 40, 59], ["increased", "OBSERVATION_MODIFIER", 176, 185], ["respiratory disease", "OBSERVATION", 199, 218]]], ["These observations have implicated stress as a significant factor that can compromise host defenses and increase disease susceptibility.", [["stress", "PROBLEM", 35, 41], ["a significant factor", "PROBLEM", 45, 65], ["increase disease susceptibility", "PROBLEM", 104, 135], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["disease", "OBSERVATION", 113, 120]]], ["To date, it has been difficult to quantify stress responses and determine what adaptation period is required to eliminate the effects of stress when studying host responses to infectious disease.", [["infectious disease", "DISEASE", 176, 194], ["infectious disease", "PROBLEM", 176, 194]]], ["Microarray analyses, however, may be able to provide a more global view of the physiological responses influenced by stress.Respiratory infectionsThe interplay between stress and disease resistance was investigated by using microarray analyses to profile gene expression in peripheral blood mononuclear cells (PBMC).", [["peripheral blood mononuclear cells", "ANATOMY", 274, 308], ["PBMC", "ANATOMY", 310, 314], ["Respiratory infections", "DISEASE", 124, 146], ["peripheral blood mononuclear cells", "CELL", 274, 308], ["PBMC", "CELL", 310, 314], ["peripheral blood mononuclear cells", "CELL_TYPE", 274, 308], ["PBMC", "CELL_TYPE", 310, 314], ["Microarray analyses", "TEST", 0, 19], ["Respiratory infections", "PROBLEM", 124, 146], ["stress and disease resistance", "PROBLEM", 168, 197], ["microarray analyses", "TEST", 224, 243], ["peripheral blood mononuclear cells", "TEST", 274, 308], ["infections", "OBSERVATION", 136, 146], ["disease resistance", "OBSERVATION", 179, 197], ["peripheral", "ANATOMY_MODIFIER", 274, 284], ["blood", "ANATOMY", 285, 290], ["mononuclear cells", "OBSERVATION", 291, 308]]], ["Two groups of calves were housed in a single pen with one group of suckling calves (n = 8) removed from their dams 24 h prior to bovine herpesvirus-1 (BHV-1) infection (abrupt weaning) and a second group removed from their dams and fed hay and grain for 2 weeks prior to viral challenge (pre-conditioned).", [["calves", "ANATOMY", 76, 82], ["infection", "DISEASE", 158, 167], ["calves", "ORGANISM", 14, 20], ["calves", "ORGANISM", 76, 82], ["bovine herpesvirus-1", "ORGANISM", 129, 149], ["BHV-1", "ORGANISM", 151, 156], ["dams", "ORGANISM", 223, 227], ["grain", "ORGANISM_SUBDIVISION", 244, 249], ["calves", "SPECIES", 14, 20], ["calves", "SPECIES", 76, 82], ["bovine", "SPECIES", 129, 135], ["herpesvirus-1", "SPECIES", 136, 149], ["BHV-1", "SPECIES", 151, 156], ["bovine herpesvirus-1 (BHV-1", "SPECIES", 129, 156], ["bovine herpesvirus", "PROBLEM", 129, 147], ["infection", "PROBLEM", 158, 167], ["abrupt weaning", "TREATMENT", 169, 183], ["viral challenge", "TREATMENT", 271, 286], ["calves", "ANATOMY", 14, 20], ["infection", "OBSERVATION", 158, 167]]], ["RNA was extracted from PBMC collected prior to infection and 4 days following BHV-1 respiratory infection and microarray analysis performed relative to a reference RNA (5 mg RNA aliquots pooled from all PBMC samples).", [["PBMC", "ANATOMY", 23, 27], ["PBMC samples", "ANATOMY", 203, 215], ["infection", "DISEASE", 47, 56], ["respiratory infection", "DISEASE", 84, 105], ["PBMC", "CELL", 23, 27], ["BHV-1", "ORGANISM", 78, 83], ["RNA", "RNA", 0, 3], ["PBMC", "CELL_TYPE", 23, 27], ["reference RNA", "RNA", 154, 167], ["PBMC", "CELL_TYPE", 203, 207], ["BHV-1", "SPECIES", 78, 83], ["PBMC", "TREATMENT", 23, 27], ["infection", "PROBLEM", 47, 56], ["BHV-1 respiratory infection", "PROBLEM", 78, 105], ["microarray analysis", "TEST", 110, 129], ["a reference RNA", "TREATMENT", 152, 167], ["RNA aliquots", "TEST", 174, 186], ["all PBMC samples", "TEST", 199, 215], ["infection", "OBSERVATION", 47, 56], ["respiratory", "ANATOMY", 84, 95], ["infection", "OBSERVATION", 96, 105]]], ["Microarray analyses revealed that both groups of calves shared common transcriptional responses (22 ESTs; p < 0.05 and 1.5-fold change) on day 4 postinfection but. it was also apparent that abrupt weaning and pre-conditioning had a marked effect on host responses to a respiratory infection.", [["respiratory", "ANATOMY", 269, 280], ["respiratory infection", "DISEASE", 269, 290], ["calves", "ORGANISM", 49, 55], ["calves", "SPECIES", 49, 55], ["Microarray analyses", "TEST", 0, 19], ["ESTs", "TEST", 100, 104], ["p", "TEST", 106, 107], ["abrupt weaning", "TREATMENT", 190, 204], ["pre-conditioning", "TREATMENT", 209, 225], ["a respiratory infection", "PROBLEM", 267, 290], ["calves", "ANATOMY", 49, 55], ["abrupt", "OBSERVATION_MODIFIER", 190, 196], ["weaning", "OBSERVATION", 197, 204], ["respiratory", "ANATOMY", 269, 280], ["infection", "OBSERVATION", 281, 290]]], ["There was almost 3-fold more changes in gene expression (39 ESTs) ( p < 0.05 and 1.5-fold change) in calves that experienced the stress of abrupt weaning and transport immediately prior to infection.", [["infection", "DISEASE", 189, 198], ["calves", "ORGANISM", 101, 107], ["calves", "SPECIES", 101, 107], ["gene expression", "TEST", 40, 55], ["1.5-fold change) in calves", "PROBLEM", 81, 107], ["abrupt weaning", "TREATMENT", 139, 153], ["infection", "PROBLEM", 189, 198], ["3-fold", "OBSERVATION_MODIFIER", 17, 23], ["infection", "OBSERVATION", 189, 198]]], ["Thus, to minimize variability in gene expression it is critical that changes in management or diet be carefully controlled when performing functional genomic experiments.", [["variability in gene expression", "PROBLEM", 18, 48], ["changes in management", "TREATMENT", 69, 90]]], ["It is also apparent that microarray analyses may provide a powerful tool to determine how stress can compromise innate immunity and disease resistance.Host responses to pathogen-associated moleculesInnate immunity plays a critical role in host responses to infectious disease and there is increasing evidence that innate immunity also influences adaptive immune responses.", [["infectious disease", "DISEASE", 257, 275], ["pathogen-associated molecules", "PROTEIN", 169, 198], ["microarray analyses", "TEST", 25, 44], ["disease resistance", "PROBLEM", 132, 150], ["associated molecules", "PROBLEM", 178, 198], ["infectious disease", "PROBLEM", 257, 275]]], ["Furthermore, it has become apparent that the activation of many innate immune responses is regulated by pattern recognition receptors (PRR) that recognize specific structural motifs of pathogen-associated molecules.", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 104, 133], ["PRR", "GENE_OR_GENE_PRODUCT", 135, 138], ["pattern recognition receptors", "PROTEIN", 104, 133], ["PRR", "PROTEIN", 135, 138], ["pathogen-associated molecules", "PROTEIN", 185, 214], ["pathogen-associated molecules", "PROBLEM", 185, 214], ["pathogen", "OBSERVATION", 185, 193]]], ["An important family of PRR is the toll-like receptors (TLR) which recognize a wide variety of viral, bacterial and fungal molecules.", [["PRR", "GENE_OR_GENE_PRODUCT", 23, 26], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 34, 53], ["TLR", "GENE_OR_GENE_PRODUCT", 55, 58], ["PRR", "PROTEIN", 23, 26], ["toll-like receptors", "PROTEIN", 34, 53], ["TLR", "PROTEIN", 55, 58], ["viral, bacterial and fungal molecules", "PROTEIN", 94, 131], ["viral, bacterial and fungal molecules", "PROBLEM", 94, 131], ["viral", "OBSERVATION", 94, 99], ["fungal molecules", "OBSERVATION", 115, 131]]], ["Understanding the role of TLR in the regulation of innate immunity is critical for a full understanding of host responses to infectious disease.", [["infectious disease", "DISEASE", 125, 143], ["TLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["TLR", "PROTEIN", 26, 29], ["infectious disease", "PROBLEM", 125, 143]]], ["Microarray analysis of differential gene expression following exposure of dendritic cells to specific pathogens and pathogen-associated molecules has been an effective approach to understanding the induction of both innate and adaptive immune responses (Huang et al., 2001) .Host responses to pathogen-associated moleculesLipopolysaccharide (LPS) and non-methylated CpG motifs in bacterial DNA are pathogen-associated molecules which activate innate immune responses through interactions with TLR4 and TLR9, respectively.", [["dendritic cells", "ANATOMY", 74, 89], ["Lipopolysaccharide", "CHEMICAL", 322, 340], ["LPS", "CHEMICAL", 342, 345], ["CpG", "CHEMICAL", 366, 369], ["dendritic cells", "CELL", 74, 89], ["pathogen-associated molecules", "GENE_OR_GENE_PRODUCT", 293, 322], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 322, 340], ["LPS", "SIMPLE_CHEMICAL", 342, 345], ["DNA", "CELLULAR_COMPONENT", 390, 393], ["TLR4", "GENE_OR_GENE_PRODUCT", 493, 497], ["TLR9", "GENE_OR_GENE_PRODUCT", 502, 506], ["dendritic cells", "CELL_TYPE", 74, 89], ["pathogen-associated molecules", "PROTEIN", 116, 145], ["pathogen-associated molecules", "PROTEIN", 293, 322], ["non-methylated CpG motifs", "DNA", 351, 376], ["bacterial DNA", "DNA", 380, 393], ["pathogen-associated molecules", "PROTEIN", 398, 427], ["TLR4", "PROTEIN", 493, 497], ["TLR9", "PROTEIN", 502, 506], ["Microarray analysis", "TEST", 0, 19], ["dendritic cells", "PROBLEM", 74, 89], ["specific pathogens", "PROBLEM", 93, 111], ["pathogen", "PROBLEM", 116, 124], ["pathogen", "PROBLEM", 293, 301], ["Lipopolysaccharide (LPS)", "TREATMENT", 322, 346], ["non-methylated CpG motifs", "TREATMENT", 351, 376], ["bacterial DNA", "PROBLEM", 380, 393], ["pathogen", "PROBLEM", 398, 406], ["associated molecules", "PROBLEM", 407, 427], ["TLR4 and TLR9", "TREATMENT", 493, 506], ["dendritic cells", "OBSERVATION", 74, 89], ["bacterial DNA", "OBSERVATION", 380, 393]]], ["LPS triggers monocyte activation by binding to LPS-binding protein (LBP) and this complex associates with CD14.", [["monocyte", "ANATOMY", 13, 21], ["LPS", "CHEMICAL", 0, 3], ["LPS", "CHEMICAL", 47, 50], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["monocyte", "CELL", 13, 21], ["LPS-binding protein", "GENE_OR_GENE_PRODUCT", 47, 66], ["LBP", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD14", "GENE_OR_GENE_PRODUCT", 106, 110], ["LPS-binding protein", "PROTEIN", 47, 66], ["LBP", "PROTEIN", 68, 71], ["CD14", "PROTEIN", 106, 110], ["LPS", "TEST", 0, 3], ["monocyte activation", "TEST", 13, 32], ["LPS", "TEST", 47, 50], ["binding protein", "TEST", 51, 66], ["LBP", "PROBLEM", 68, 71], ["CD14", "PROBLEM", 106, 110], ["monocyte activation", "OBSERVATION", 13, 32]]], ["The LPS-CD14 complex then binds to TLR4 which initiates the intracellular signaling that leads to an inflammatory response (Hemmi et al., 2000) .", [["intracellular", "ANATOMY", 60, 73], ["LPS", "CHEMICAL", 4, 7], ["LPS-CD14", "GENE_OR_GENE_PRODUCT", 4, 12], ["TLR4", "GENE_OR_GENE_PRODUCT", 35, 39], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["CD14 complex", "PROTEIN", 8, 20], ["TLR4", "PROTEIN", 35, 39], ["The LPS", "TEST", 0, 7], ["TLR4", "TEST", 35, 39], ["the intracellular signaling", "PROBLEM", 56, 83], ["an inflammatory response", "PROBLEM", 98, 122], ["inflammatory", "OBSERVATION_MODIFIER", 101, 113]]], ["Synthetic CpG oligodeoxynucleotides (CpG ODN) can be used as TLR9 ligands to activate immune cells, including NK cells, monocytes, macrophages, dendritic cells and B cells (Krieg et al., 1995; Takeshita et al., 2001) .", [["immune cells", "ANATOMY", 86, 98], ["NK cells", "ANATOMY", 110, 118], ["monocytes", "ANATOMY", 120, 129], ["macrophages", "ANATOMY", 131, 142], ["dendritic cells", "ANATOMY", 144, 159], ["B cells", "ANATOMY", 164, 171], ["CpG oligodeoxynucleotides", "CHEMICAL", 10, 35], ["CpG ODN", "CHEMICAL", 37, 44], ["CpG", "CHEMICAL", 10, 13], ["CpG oligodeoxynucleotides", "SIMPLE_CHEMICAL", 10, 35], ["CpG ODN", "SIMPLE_CHEMICAL", 37, 44], ["TLR9", "GENE_OR_GENE_PRODUCT", 61, 65], ["immune cells", "CELL", 86, 98], ["NK cells", "CELL", 110, 118], ["monocytes", "CELL", 120, 129], ["macrophages", "CELL", 131, 142], ["dendritic cells", "CELL", 144, 159], ["B cells", "CELL", 164, 171], ["TLR9", "PROTEIN", 61, 65], ["immune cells", "CELL_TYPE", 86, 98], ["NK cells", "CELL_TYPE", 110, 118], ["monocytes", "CELL_TYPE", 120, 129], ["macrophages", "CELL_TYPE", 131, 142], ["dendritic cells", "CELL_TYPE", 144, 159], ["B cells", "CELL_TYPE", 164, 171], ["Synthetic CpG oligodeoxynucleotides (CpG ODN)", "TREATMENT", 0, 45], ["TLR9 ligands", "TREATMENT", 61, 73], ["immune cells", "TEST", 86, 98], ["NK cells", "TEST", 110, 118], ["monocytes", "TEST", 120, 129], ["macrophages", "TEST", 131, 142], ["monocytes", "ANATOMY", 120, 129], ["macrophages", "ANATOMY", 131, 142], ["dendritic cells", "OBSERVATION", 144, 159]]], ["To determine how these cells contribute to the induction of innate immunity it is important to understand the consequences of TLR signaling for each leukocyte population.Host responses to pathogen-associated moleculesTo identify common and unique TLR signaling pathways that may result in the activation of unique cellular functions we used bovine microarrays to profile gene expression in bovine monocytes following LPS (TLR4) and class B CpG ODN (TLR9) stimulation.", [["cells", "ANATOMY", 23, 28], ["leukocyte", "ANATOMY", 149, 158], ["cellular", "ANATOMY", 314, 322], ["monocytes", "ANATOMY", 397, 406], ["LPS", "CHEMICAL", 417, 420], ["cells", "CELL", 23, 28], ["TLR", "GENE_OR_GENE_PRODUCT", 126, 129], ["leukocyte", "CELL", 149, 158], ["TLR", "GENE_OR_GENE_PRODUCT", 247, 250], ["cellular", "CELL", 314, 322], ["bovine", "ORGANISM", 341, 347], ["bovine", "ORGANISM", 390, 396], ["monocytes", "CELL", 397, 406], ["LPS", "GENE_OR_GENE_PRODUCT", 417, 420], ["TLR4", "GENE_OR_GENE_PRODUCT", 422, 426], ["class B CpG ODN", "GENE_OR_GENE_PRODUCT", 432, 447], ["TLR9", "GENE_OR_GENE_PRODUCT", 449, 453], ["TLR", "PROTEIN", 126, 129], ["leukocyte population", "CELL_TYPE", 149, 169], ["pathogen-associated molecules", "PROTEIN", 188, 217], ["TLR", "PROTEIN", 247, 250], ["bovine monocytes", "CELL_TYPE", 390, 406], ["TLR4", "PROTEIN", 422, 426], ["TLR9", "PROTEIN", 449, 453], ["bovine", "SPECIES", 341, 347], ["bovine", "SPECIES", 390, 396], ["bovine", "SPECIES", 390, 396], ["TLR signaling", "TREATMENT", 126, 139], ["each leukocyte population", "PROBLEM", 144, 169], ["associated molecules", "PROBLEM", 197, 217], ["unique cellular functions", "PROBLEM", 307, 332], ["bovine microarrays", "TREATMENT", 341, 359], ["bovine monocytes", "TREATMENT", 390, 406], ["LPS (TLR4)", "TREATMENT", 417, 427], ["class B CpG ODN (TLR9) stimulation", "TREATMENT", 432, 466], ["bovine monocytes", "OBSERVATION", 390, 406]]], ["Microarray analyses identified a large number of transcriptionally activated genes following LPS or CpG ODN stimulation.", [["LPS", "CHEMICAL", 93, 96], ["ODN", "CHEMICAL", 104, 107], ["CpG", "CHEMICAL", 100, 103], ["LPS", "SIMPLE_CHEMICAL", 93, 96], ["CpG ODN", "SIMPLE_CHEMICAL", 100, 107], ["transcriptionally activated genes", "DNA", 49, 82], ["Microarray analyses", "TEST", 0, 19], ["LPS", "TREATMENT", 93, 96], ["CpG ODN stimulation", "TREATMENT", 100, 119], ["large", "OBSERVATION_MODIFIER", 33, 38]]], ["Approximately 30 common genes were up-regulated in the presence of LPS or CpG ODN but the majority of the differentially expressed genes were unique to each of the stimuli.", [["LPS", "CHEMICAL", 67, 70], ["ODN", "CHEMICAL", 78, 81], ["CpG", "CHEMICAL", 74, 77], ["LPS", "SIMPLE_CHEMICAL", 67, 70], ["CpG ODN", "SIMPLE_CHEMICAL", 74, 81], ["LPS", "TREATMENT", 67, 70], ["CpG ODN", "TREATMENT", 74, 81]]], ["Thus, microarrays provide an effective tool to analyze cell signaling in response to specific ligands and to determine how families of related molecules can induce distinct cellular responses.Future analyses of disease pathogenesisThe advent of the microarray, with its high throughput analyses has revolutionized the analysis of whole cell gene expression and disease studies (Ball et al., 2002; DeRisi et al., 1996 DeRisi et al., , 2000 McKendry et al., 2002; Schena, 1996; Schena et al., 1996 Schena et al., , 1998 Stears et al., 2003) .", [["cell", "ANATOMY", 55, 59], ["cellular", "ANATOMY", 173, 181], ["whole cell", "ANATOMY", 330, 340], ["cell", "CELL", 55, 59], ["cellular", "CELL", 173, 181], ["cell", "CELL", 336, 340], ["microarrays", "TREATMENT", 6, 17], ["disease pathogenesis", "PROBLEM", 211, 231], ["the microarray", "TEST", 245, 259], ["the analysis", "TEST", 314, 326], ["whole cell gene expression", "PROBLEM", 330, 356], ["disease studies", "TEST", 361, 376], ["disease", "OBSERVATION", 211, 218], ["whole cell", "OBSERVATION", 330, 340]]], ["Traditional microarray hybridization techniques are based on fluorescence, but this technique is limited by low sensitivity, high background signal, quenching, and photobleaching (Ball et al., 2002; Pan et al., 2002; Wang et al., 2002) .", [["Traditional microarray hybridization techniques", "TREATMENT", 0, 47], ["fluorescence", "TEST", 61, 73], ["this technique", "TEST", 79, 93], ["low sensitivity", "PROBLEM", 108, 123], ["low sensitivity", "OBSERVATION_MODIFIER", 108, 123]]], ["Emerging techniques such as Resonance Light Scattering (RLS) and Near Infrared Imaging are gaining popularity in both research and clinical application of microarray detection due to increased sensitivity and robustness of data (Bao et al., 2002; Waddell et al., 2000) .", [["Near Infrared Imaging", "TEST", 65, 86], ["microarray detection", "TEST", 155, 175], ["increased sensitivity", "PROBLEM", 183, 204]]], ["The RLS technique has several advantages over fluorescence based techniques for microarray studies, including increased sensitivity, better signal to noise ratio, no photobleaching (so arrays can be repeatedly scanned), and no need for dye swapping.", [["RLS", "DISEASE", 4, 7], ["fluorescence based techniques", "TEST", 46, 75], ["microarray studies", "TEST", 80, 98], ["increased sensitivity", "PROBLEM", 110, 131], ["noise ratio", "TEST", 150, 161], ["photobleaching", "PROBLEM", 166, 180], ["dye swapping", "TREATMENT", 236, 248]]], ["RLS was used throughout our microarray analyses and resulted in a substantially increased detection of differentially expressed genes when compared to fluorescence (Fig. 2) .", [["RLS", "DISEASE", 0, 3], ["differentially expressed genes", "DNA", 103, 133], ["RLS", "PROBLEM", 0, 3], ["our microarray analyses", "TEST", 24, 47], ["increased", "OBSERVATION_MODIFIER", 80, 89]]], ["Thus, there is substantial capacity to improve functional genomic analyses at the level of microarray detection of differentially expressed genes, especially when RNA is of limited quantity.Future analyses of disease pathogenesisMolecular diagnostic tests typically analyze key protein, DNA, or RNA markers to identify specific diseases.", [["DNA", "CELLULAR_COMPONENT", 287, 290], ["differentially expressed genes", "DNA", 115, 145], ["substantial capacity", "PROBLEM", 15, 35], ["functional genomic analyses", "PROBLEM", 47, 74], ["microarray detection", "TEST", 91, 111], ["disease pathogenesis", "PROBLEM", 209, 229], ["Molecular diagnostic tests", "TEST", 229, 255], ["DNA", "PROBLEM", 287, 290], ["RNA markers", "TEST", 295, 306], ["specific diseases", "PROBLEM", 319, 336], ["substantial", "OBSERVATION_MODIFIER", 15, 26], ["capacity", "OBSERVATION_MODIFIER", 27, 35]]], ["Immunohistochemistry, Western blotting, DNA sequencing, Southern and Northern blotting, and (quantitative) polymerase chain reaction are molecular techniques that have been effectively used in clinical diagnostic laboratories.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["Immunohistochemistry", "TEST", 0, 20], ["DNA sequencing", "TEST", 40, 54], ["Northern blotting", "TEST", 69, 86], ["(quantitative) polymerase chain reaction", "PROBLEM", 92, 132]]], ["However, molecular tests that involve the simultaneous analysis of tens to hundreds of markers within a clinical sample will soon Fluorescence scanned arrays were hybridized with Cy3/Cy5 dye labeled 'control' and 'sample' cDNA, respectively (left panel) and RLS scanned arrays were hybridized with silver/gold labeled 'control' and 'sample' cDNA, respectively (right panel).", [["silver", "CHEMICAL", 298, 304], ["silver", "CHEMICAL", 298, 304], ["Cy3", "SIMPLE_CHEMICAL", 179, 182], ["Cy5 dye", "SIMPLE_CHEMICAL", 183, 190], ["silver", "SIMPLE_CHEMICAL", 298, 304], ["Cy3/Cy5 dye labeled 'control' and 'sample' cDNA", "DNA", 179, 226], ["silver/gold labeled 'control' and 'sample' cDNA", "DNA", 298, 345], ["molecular tests", "TEST", 9, 24], ["the simultaneous analysis", "TEST", 38, 63], ["Fluorescence scanned arrays", "TEST", 130, 157], ["Cy3/Cy5 dye labeled 'control'", "TREATMENT", 179, 208], ["'sample' cDNA", "TEST", 213, 226], ["left panel", "TEST", 242, 252], ["RLS scanned arrays", "TREATMENT", 258, 276], ["silver/gold labeled 'control'", "TREATMENT", 298, 327], ["'sample' cDNA", "TREATMENT", 332, 345], ["right", "ANATOMY_MODIFIER", 361, 366]]], ["The amount of total RNA used for fluorescence and RLS techniques was 5 and 1 mg, respectively.", [["RLS", "DISEASE", 50, 53], ["total RNA", "RNA", 14, 23], ["total RNA", "TREATMENT", 14, 23], ["fluorescence and RLS techniques", "TREATMENT", 33, 64], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["(B) Scatter plot of processed and normalized intensities for gene expression as observed in fluorescence (left panel) and RLS analysis (right panel).", [["Scatter plot", "TEST", 4, 16], ["normalized intensities", "PROBLEM", 34, 56], ["gene expression", "PROBLEM", 61, 76], ["fluorescence (left panel", "TEST", 92, 116], ["RLS analysis", "TEST", 122, 134], ["right panel", "TEST", 136, 147], ["right", "ANATOMY_MODIFIER", 136, 141]]], ["Lines above and below the center line denote the limits for 2-fold up or down regulation of gene expression and points between these lines are considered unchanged between 'Control' and 'Sample'. be required to allow maximum translation of postgenomic research to patient care.", [["patient", "ORGANISM", 264, 271], ["patient", "SPECIES", 264, 271], ["Lines", "TREATMENT", 0, 5], ["gene expression", "TREATMENT", 92, 107], ["these lines", "TREATMENT", 127, 138], ["postgenomic research to patient care", "TREATMENT", 240, 276], ["center", "OBSERVATION_MODIFIER", 26, 32], ["line", "OBSERVATION", 33, 37], ["unchanged", "OBSERVATION_MODIFIER", 154, 163]]], ["This is particularly important today for the rapid identification of biomarkers and potential therapeutic targets for emerging diseases such as SARS and West Nile.", [["SARS", "DISEASE", 144, 148], ["biomarkers", "TEST", 69, 79], ["emerging diseases", "PROBLEM", 118, 135], ["SARS", "PROBLEM", 144, 148]]], ["However, because of the inherent variability in microarray technologies a global standard may be needed to facilitate the comparison of results among laboratories.", [["the inherent variability", "PROBLEM", 20, 44]]], ["This will also be critical if we are to realize the huge biological potential of performing interspecies comparative functional genomics.Future analyses of disease pathogenesisWhile microarrays represent a powerful technology to interrogate bovine gene expression in response to disease pathogenesis, the quality of the microarray analysis depends heavily upon accurate, high quality annotation of the array probes.", [["bovine", "ORGANISM", 241, 247], ["bovine", "SPECIES", 241, 247], ["disease pathogenesis", "PROBLEM", 156, 176], ["bovine gene expression", "TREATMENT", 241, 263], ["disease pathogenesis", "PROBLEM", 279, 299], ["the microarray analysis", "TEST", 316, 339], ["disease", "OBSERVATION", 156, 163]]], ["Annotation should include both assessment of the specificity of a given probe sequence for a given transcript (to detect cases of cross-hybridization), as well as high quality information about the transcripts themselves.", [["both assessment", "TEST", 26, 41]]], ["This annotation is critical in order to extract meaningful biological data from microarray signal intensity measurements.", [["microarray signal intensity measurements", "TEST", 80, 120]]], ["However, in the absence of a complete bovine genome sequence, the availability of accurate gene prediction and annotation data is limited.Future analyses of disease pathogenesisProbeLynx is one bioinformatics tool that has been developed to tackle the need for improved annotation.", [["bovine", "ORGANISM", 38, 44], ["bovine genome sequence", "DNA", 38, 60], ["bovine", "SPECIES", 38, 44], ["a complete bovine genome sequence", "TEST", 27, 60], ["annotation data", "TEST", 111, 126], ["disease pathogenesis", "PROBLEM", 157, 177], ["disease", "OBSERVATION", 157, 164]]], ["ProbeLynx is a microarray annotation update tool which allows researchers to continuously assess the specificity of their probes and ensure up-to-date gene annotations by using the latest sequence and annotation data available for a particular species.", [["ProbeLynx", "DNA", 0, 9], ["the latest sequence", "TEST", 177, 196], ["annotation data", "TEST", 201, 216], ["a particular species", "PROBLEM", 231, 251]]], ["By exploiting the TIGR Gene Index and Eukaryotic Gene Orthologs (EGO) databases (Quackenbush et al., 2001) , ProbeLynx allows users to map their probe sequences to predicted bovine transcript sequences and use interspecies information to link putative orthologs to uncharacterized transcript sequences for inference of gene function.", [["bovine", "ORGANISM", 174, 180], ["Eukaryotic Gene Orthologs", "DNA", 38, 63], ["EGO", "DNA", 65, 68], ["ProbeLynx", "DNA", 109, 118], ["probe sequences", "DNA", 145, 160], ["bovine transcript sequences", "DNA", 174, 201], ["bovine", "SPECIES", 174, 180], ["the TIGR Gene Index", "TEST", 14, 33], ["bovine transcript sequences", "TREATMENT", 174, 201], ["transcript sequences", "TEST", 281, 301]]], ["This integration of resources makes ProbeLynx a powerful tool for bovine microarray researchers, as it ensures up-to-date, accurate links between probe sequences and the latest, enhanced gene annotation information for biological interpretation.", [["bovine", "ORGANISM", 66, 72], ["probe sequences", "DNA", 146, 161], ["bovine", "SPECIES", 66, 72], ["probe sequences", "TEST", 146, 161], ["biological interpretation", "TEST", 219, 244]]], ["In the future, additional integration of meta-data in probe annotations including protein subcellular localization predictions or pathway information (for both signaling and metabolic networks), will enable improved higher order bioinformatics analyses.", [["subcellular", "ANATOMY", 90, 101], ["meta-data", "TREATMENT", 41, 50], ["probe annotations", "TEST", 54, 71], ["bioinformatics analyses", "TEST", 229, 252]]], ["Furthermore, a complete bovine genome sequence will be critical to future bioinformatic and laboratory studies in the identification of gene regulatory sequences.", [["bovine", "ORGANISM", 24, 30], ["bovine genome sequence", "DNA", 24, 46], ["gene regulatory sequences", "DNA", 136, 161], ["bovine", "SPECIES", 24, 30], ["a complete bovine genome sequence", "TEST", 13, 46], ["laboratory studies", "TEST", 92, 110], ["gene regulatory sequences", "TEST", 136, 161]]], ["The integrated use of high-throughput analyses of protein and metabolite profiles may also provide an effective approach to accelerate validation of gene prediction and gene expression as well as to predict the dynamics of systems in a more definitive way.Future analyses of disease pathogenesisThe continuous development of bioinformatics approaches for improved array annotation combined with new data analysis tools that enable cross-species comparisons will greatly enhance the extraction of biological information from bovine microarrays and advance our understanding of disease pathogenesis in cattle.", [["bovine", "ORGANISM", 524, 530], ["cattle", "ORGANISM", 600, 606], ["bovine", "SPECIES", 524, 530], ["cattle", "SPECIES", 600, 606], ["bovine", "SPECIES", 524, 530], ["cattle", "SPECIES", 600, 606], ["metabolite profiles", "TEST", 62, 81], ["gene prediction", "TREATMENT", 149, 164], ["disease pathogenesis", "PROBLEM", 275, 295], ["bioinformatics approaches", "TREATMENT", 325, 350], ["new data analysis", "TEST", 395, 412], ["the extraction", "TREATMENT", 478, 492], ["bovine microarrays", "TREATMENT", 524, 542], ["disease pathogenesis", "PROBLEM", 576, 596], ["disease", "OBSERVATION", 275, 282]]]], "PMC5587294": [["IntroductionThe One Health concept is not new [1, 2] perhaps dating back to the late nineteenth century when medical observations were made that human and animal health were closely linked [3, 4].", [["human", "ORGANISM", 145, 150], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150]]], ["Often human health, animal health and environmental health are examined as closely linked.", [["human", "ORGANISM", 6, 11], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11]]], ["Examples of such complex problems include emerging infectious diseases, food safety, and selection of antimicrobial resistant pathogens.", [["infectious diseases", "DISEASE", 51, 70], ["such complex problems", "PROBLEM", 12, 33], ["emerging infectious diseases", "PROBLEM", 42, 70], ["antimicrobial resistant pathogens", "PROBLEM", 102, 135], ["infectious", "OBSERVATION", 51, 61], ["antimicrobial resistant", "OBSERVATION", 102, 125]]], ["In particular, emerging zoonotic disease problems are now remarkable common [5] and very complex.", [["zoonotic disease problems", "DISEASE", 24, 49], ["emerging zoonotic disease problems", "PROBLEM", 15, 49], ["zoonotic", "OBSERVATION_MODIFIER", 24, 32]]], ["Controlling these complex problems often requires interdisciplinary approaches such as One Health [6, 7].", [["these complex problems", "PROBLEM", 12, 34], ["interdisciplinary approaches", "TREATMENT", 50, 78], ["complex", "OBSERVATION_MODIFIER", 18, 25], ["problems", "OBSERVATION", 26, 34]]], ["For example, One Health has been variously defined as an initiative [8], a movement [9], a strategy [10], a framework [11], an agenda [12, 13], an approach, a collaborative effort, among others.", [["an agenda", "TEST", 124, 133], ["an approach", "TEST", 144, 155]]], ["As a milestone in the history of One Health, the symbolic \u2018umbrella\u2019, developed by One Health Sweden in cooperation with the One Health Initiative Autonomous Pro Bono Team, illustrates the broad One Health scope.", [["\u2018umbrella\u2019", "DISEASE", 58, 68]]], ["According to the \u2018umbrella\u2019, the goal of One Heath is to promote a worldwide strategy for the well-being in all aspects of health of people, animals and the environment [2, 14].", [["\u2018umbrella\u2019", "DISEASE", 17, 27], ["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139], ["a worldwide strategy", "TREATMENT", 65, 85]]], ["Yet, the internal relationships of these disciplines remain a bit amorphous.", [["internal", "ANATOMY_MODIFIER", 9, 17]]], ["Or alternatively stated, thoroughly understanding a complex problem involves discovering the system\u2019s structure, which often involves feedback connections between interdependent components.", [["a complex problem", "PROBLEM", 50, 67], ["interdependent", "OBSERVATION_MODIFIER", 163, 177], ["components", "OBSERVATION_MODIFIER", 178, 188]]], ["This approach has also been successfully used to enhance the development of health policies and programs [17, 18], enable modeling of health care systems [19], and guide chronic disease prevention and interventions [20\u201322].System dynamics ::: Materials and methodsA system dynamics theoretical model can be constructed using the following series of steps:Systematic literature search for One Health articles ::: Materials and methodsTo identify scientific articles pertaining to the One Health concept, we performed searches in multiple abstract databases, including PubMed, Web of Science, and ProQuest, in February and March 2017.", [["guide chronic disease prevention", "TREATMENT", 164, 196], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["disease", "OBSERVATION", 178, 185]]], ["All references were extracted into a reference manager\u2014EndNote (version X7.4, Bld 8818) and screened independently by two researchers (TX and WL).", [["Bld", "TEST", 78, 81]]], ["In full test screening, the exclusion criteria were: 1) One Health practice in a particular disease or district; 2) One Health concept or approach mentioned in limited sentences.Systematic literature search for One Health articles ::: Materials and methodsTo ensure that we did not omit important literature using the aforementioned search strategy, we also used the HistCite\u00ae tool to identify significant articles in One Health.", [["full test screening", "TEST", 3, 22], ["a particular disease", "PROBLEM", 79, 99]]], ["HistCite\u00ae is a science tool that visualizes the citation relationships between papers to identify key publications in the results returned by a Web of Science search.", [["HistCite\u00ae", "CHEMICAL", 0, 9]]], ["The results were analyzed with HistCite\u00ae software version 12.3.17 (Thomson Reuters, New York City, NY, USA).", [["HistCite\u00ae software version", "TEST", 31, 57]]], ["The default setting for searched articles in the HistCite\u00ae software is 30 but we increased this default number to 100 articles.Problem Identification (Step 1) ::: ResultsFrom the articles identified by the literature review, it was difficult to determine a generally accepted definition for the One Health concept, including the scope and breadth of its practice.", [["the HistCite\u00ae software", "TEST", 45, 67]]], ["This concept of One Health served as the root or first level of the theoretical model.Behavior Analysis (Step 2) ::: ResultsAll 19 analyzed reports agreed that the One Health concept contained at least three primary domains\u2014human, animal, and environment/ecosystem.", [["root", "ANATOMY", 41, 45], ["root", "ANATOMY_MODIFIER", 41, 45]]], ["These three domains were added as the second level of the theoretical model.", [["theoretical model", "OBSERVATION", 58, 75]]], ["This discrepancy is likely due to the ongoing rapid development of One Health and the addition of new disciplines that are embracing it as a way forward [23].", [["likely due to", "UNCERTAINTY", 20, 33], ["new", "OBSERVATION_MODIFIER", 98, 101]]], ["Table 1 summarizes the various and diverse disciplines or scopes mentioned in each of the 19 publications, which highlights the broad interpretation that could result in defining the One Health concept.", [["scopes", "TREATMENT", 58, 64]]], ["These disciplines and scopes were included as the third level of the theoretical model.Model Hypothesis (Step 3) ::: ResultsIn the theoretical model, the direction of influence is indicated by the polarity of a causal loop, represented by connecting arrows, which may be positive (\u201c+\u201d) or negative (\u201c-\u201d).", [["scopes", "TEST", 22, 28], ["theoretical model", "OBSERVATION", 69, 86]]], ["A positive causal link indicates that both the causative and the resultant factors increase or decrease in the same direction.", [["A positive causal link", "PROBLEM", 0, 22], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["decrease", "OBSERVATION_MODIFIER", 95, 103]]], ["A negative causal link indicates that the two linked factors change in opposite directions.", [["negative", "OBSERVATION", 2, 10]]], ["We then added the human, animal, and ecosystem domains (second level) to the model.", [["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23]]], ["These terms are represented by the red squares which are used to denote stock elements.", [["stock elements", "DNA", 72, 86], ["the red squares", "PROBLEM", 31, 46], ["red squares", "OBSERVATION", 35, 46], ["stock elements", "OBSERVATION", 72, 86]]], ["Next, the third level elements were added, denoted by squares with grey color, which were also derived from the reviewed articles.", [["grey color", "TEST", 67, 77]]], ["Then, variable elements associated with each of the three One Health domains were added, denoted by circular shapes.", [["Health domains", "DNA", 62, 76], ["circular shapes", "OBSERVATION", 100, 115]]], ["This model (we have learned the \u201cOne Health Cosmos\u201d, Fig 2) was constructed using AnyLogic\u00ae PLE software, version 7.3.4 (AnyLogic North America, LLC, Chicago, IL, USA).Model Evaluation (Step 4) ::: ResultsOur analysis focused upon peer-reviewed articles specifically discussing the One Health concept, which were selected as described by the search criteria.", [["Model Evaluation", "TEST", 168, 184], ["Our analysis", "TEST", 205, 217], ["LLC", "ANATOMY", 145, 148]]], ["While these papers may have been excluded, it is important to note that many of the specific topics they discuss, such as zoonoses and food safety, in the context of One Health practice, are still accounted for in our model.", [["zoonoses", "DISEASE", 122, 130]]], ["Thus, the model likely benefits from the removal of those reports so that the conceptual framework is centered on more specific interpretations of the One Health concept.Model Evaluation (Step 4) ::: ResultsA term that has been used synonymously to One Health is comparative/translational medicine, which in fact was used before the One Health term was introduced [2, 3, 6, 25].", [["the removal", "TREATMENT", 37, 48], ["Model Evaluation", "TEST", 170, 186], ["comparative/translational medicine", "TREATMENT", 263, 297]]], ["Furthermore, compared to comparative/translational medicine, One Health has a broader application in scope [15].DiscussionFrom our analysis of the One Health literature and through the construction of the One Health Cosmos using a system dynamics theoretical model, we were able to derive multiple inferences.DiscussionOur results make it clear that One Health represents a wide-ranging synergistic field that is rapidly growing.", [["rapidly", "OBSERVATION_MODIFIER", 413, 420], ["growing", "OBSERVATION_MODIFIER", 421, 428]]], ["This is reflected in the number of One Health articles that have been published in the past 25 years, which has seen an average publication increase of 14.6% per year during this time [23].", [["average", "OBSERVATION_MODIFIER", 120, 127], ["increase", "OBSERVATION_MODIFIER", 140, 148]]], ["As a result, the interpretation of the One Health concept remains unclear because its internal relationships between this growing list of various components have not been systematically described.DiscussionOur model indicates that humans and animals are closely connected by zoonoses and the food supply chain [34, 35].", [["zoonoses", "DISEASE", 275, 283], ["humans", "ORGANISM", 231, 237], ["humans", "SPECIES", 231, 237], ["humans", "SPECIES", 231, 237]]], ["Some common zoonoses include avian influenza [36, 37], leishmaniasis [38], Middle East respiratory syndrome coronavirus prevention [39], rabies [40, 41] etc. Additionally, the rising demand for animal protein for human consumption, resulting in a shift towards larger, more complex animal production operations, has spurred the increased use of antimicrobials.", [["zoonoses", "DISEASE", 12, 20], ["avian influenza", "DISEASE", 29, 44], ["leishmaniasis", "DISEASE", 55, 68], ["Middle East respiratory syndrome coronavirus", "DISEASE", 75, 119], ["rabies", "DISEASE", 137, 143], ["avian influenza", "ORGANISM", 29, 44], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 75, 119], ["human", "ORGANISM", 213, 218], ["avian influenza", "SPECIES", 29, 44], ["human", "SPECIES", 213, 218], ["Middle East respiratory syndrome coronavirus", "SPECIES", 75, 119], ["human", "SPECIES", 213, 218], ["Some common zoonoses", "PROBLEM", 0, 20], ["avian influenza", "PROBLEM", 29, 44], ["leishmaniasis", "PROBLEM", 55, 68], ["Middle East respiratory syndrome coronavirus prevention", "PROBLEM", 75, 130], ["the rising demand", "PROBLEM", 172, 189], ["human consumption", "TREATMENT", 213, 230], ["animal production operations", "TREATMENT", 282, 310], ["antimicrobials", "TREATMENT", 345, 359], ["respiratory syndrome", "OBSERVATION", 87, 107], ["larger", "OBSERVATION_MODIFIER", 261, 267], ["complex", "OBSERVATION_MODIFIER", 274, 281], ["animal", "OBSERVATION_MODIFIER", 282, 288], ["production operations", "OBSERVATION", 289, 310], ["increased", "OBSERVATION_MODIFIER", 328, 337]]], ["In fact, experts estimate that from 2010 and 2030, the global consumption of antimicrobials will increase by 67% [42].", [["antimicrobials", "TREATMENT", 77, 91]]], ["As such, investing more resources into the research and control of zoonotic diseases and complex food production systems could be an effective strategy for improving the overall health of humans and animals.DiscussionOur model also shows that zoonoses are closely associated with the economy, and can result in extensive economic losses when large zoonotic diseases outbreaks among humans and animals occur.", [["zoonotic diseases", "DISEASE", 67, 84], ["zoonoses", "DISEASE", 243, 251], ["zoonotic diseases", "DISEASE", 348, 365], ["humans", "ORGANISM", 188, 194], ["humans", "ORGANISM", 382, 388], ["humans", "SPECIES", 188, 194], ["humans", "SPECIES", 382, 388], ["humans", "SPECIES", 188, 194], ["humans", "SPECIES", 382, 388], ["zoonotic diseases", "PROBLEM", 67, 84], ["complex food production systems", "PROBLEM", 89, 120], ["zoonoses", "PROBLEM", 243, 251], ["extensive economic losses", "PROBLEM", 311, 336], ["large zoonotic diseases outbreaks", "PROBLEM", 342, 375], ["zoonotic diseases", "OBSERVATION", 67, 84], ["zoonoses", "OBSERVATION", 243, 251], ["extensive", "OBSERVATION_MODIFIER", 311, 320], ["large", "OBSERVATION_MODIFIER", 342, 347], ["zoonotic", "OBSERVATION_MODIFIER", 348, 356], ["diseases", "OBSERVATION", 357, 365]]], ["For example, after the 2014 outbreak of Ebola virus, it was estimated that the affected countries of Guinea, Liberia, and Sierra Leone alone lost $2.2 billion in gross domestic product (GDP) the following year [43].", [["Ebola virus", "DISEASE", 40, 51], ["Ebola virus", "ORGANISM", 40, 51], ["Ebola virus", "SPECIES", 40, 51], ["Ebola virus", "SPECIES", 40, 51], ["Ebola virus", "PROBLEM", 40, 51], ["Ebola virus", "OBSERVATION", 40, 51]]], ["Additionally, the 2014 highly pathogenic avian influenza (HPAI) H5N2 outbreak in the United States, resulted in an estimated economic loss of $3.3 billion [44].", [["avian influenza (HPAI) H5N2 outbreak", "DISEASE", 41, 77], ["avian influenza", "ORGANISM", 41, 56], ["avian influenza", "SPECIES", 41, 56], ["HPAI", "SPECIES", 58, 62], ["influenza", "PROBLEM", 47, 56], ["an estimated economic loss", "PROBLEM", 112, 138], ["economic loss", "OBSERVATION", 125, 138]]], ["Hence, given the strength of association between zoonoses and the economy as demonstrate by the model, investing in prevention measures could result in an overall cost savings as new potential outbreaks are avoided [45].DiscussionAlso, the health of companion animals is a growing concern.", [["zoonoses", "DISEASE", 49, 57]]], ["Pets could also bring disease to pet owners or non-pet owners who lives in close with them [46], such as echinococcosis, toxocarosis [47\u201349].", [["echinococcosis", "DISEASE", 105, 119], ["toxocarosis", "DISEASE", 121, 132], ["echinococcosis", "PATHOLOGICAL_FORMATION", 105, 119], ["echinococcosis", "OBSERVATION", 105, 119]]], ["Our model currently links education to epidemiology, human medicine, veterinary medicine, ecology, microbiology, and biomedicine.", [["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58]]], ["However, the depth of current education in One Health is unknown.", [["depth", "OBSERVATION_MODIFIER", 13, 18]]], ["Likewise, we may have failed to identify some important factors or components engaged in One Health activities.DiscussionTo date, our analyses is the first to apply a system dynamics approach to understanding the One Health concept.", [["a system dynamics approach", "TREATMENT", 165, 191]]], ["By showing the inter-relationships between the various components of One Health, offering a visual example of the conceptual framework, the One Health Cosmos can help facilitate a more concise interpretation of the One Health concept for the development of future research and training programs.", [["training programs", "TREATMENT", 277, 294]]]]}